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Abstract 
    
Campylobacter jejuni is the leading bacterial cause of foodborne human gastroenteritis 
worldwide. The first C. jejuni genome (strain NCTC11168) was sequenced in 2000. This 
original annotation was a milestone in Campylobacter research, but soon became 
outdated. A re-annotation and re-analysis of this genome sequence was performed 
resulting in updates to over 90% of coding sequences (CDSs) and modification of 18.2% 
of CDS product functions (Gundogdu et al., 2007). Following this re-annotation, 15 
uncharacterised CDSs with revised functions relating to virulence, signal transduction or 
regulation of gene expression were selected for further investigation. Defined isogenic C. 
jejuni 11168H mutants were constructed and after preliminary analysis, the Cj1556 and 
Cj0248 mutants were selected for further characterisation. Cj1556 was originally 
annotated as a hypothetical protein and was updated to a MarR family transcriptional 
regulator. Further bioinformatic analysis indicated a putative role in regulating the 
oxidative stress response. A C. jejuni 11168H Cj1556 mutant exhibited increased 
sensitivity to oxidative and aerobic (O2) stress, decreased ability for intracellular survival 
in both Caco-2 intestinal epithelial cells (IECs) and J774A.1 mouse macrophages and a 
reduction in virulence in the Galleria mellonella infection model. Microarray analysis of 
gene expression changes in the Cj1556 mutant compared to the wild-type strain indicated 
negative autoregulation of Cj1556 expression and down-regulation of genes associated 
with oxidative and aerobic (O2) stress responses. Cj0248 was originally annotated as a 
hypothetical protein however the re-annotation identified a HD domain linked to a 
superfamily of metal-dependent phosphohydrolases with roles in signal transduction in 
bacteria. Previously a C. jejuni 81-176 Cj0248 mutant was shown to be deficient for 
motility and chick colonisation, however the exact function of Cj0248 was not 
investigated. The C. jejuni 11168H Cj0248 mutant also possessed a reduced motility 
phenotype and exhibited reduced interaction and invasion when co-cultured with Caco-2 
IECs compared to the wild-type strain. However the Cj0248 mutant showed no 
difference in autoagglutination compared to the wild-type strain and TEM analysis 
indicated the mutant possessed intact flagella. Higher magnification TEM indicated the 
possibility of an altered flagella basal body region in the Cj0248 mutant. Secretion 
profile analysis identified no differences in the protein profile of the Cj0248 mutant 
compared to the wild-type strain. The exact function of Cj0248 remains unclear.  
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Chapter 1: Introduction 
 
1.1 Campylobacter jejuni 
The human intestinal pathogen C. jejuni is a microaerophilic bacterium which grows 
optimally in a 12% CO2 and 5% O2
 atmosphere between 37°C and 42°C (Garenaux et 
al., 2008, Park, 2002). C. jejuni has the general characteristics of being Gram-negative, 
curved rod-shaped or spiral, with an approximate size of 0.2 – 0.8 μm wide and 0.5 – 5.0 
μm long. The bacterium is motile via uni- or bi-polar flagella (Figure 1.1).  
 
 
   
(A)       (B) 
 
Figure 1.1. TEM of a C. jejuni cell from individual colonies grown on blood plates 
resuspended in a 1.5 ml microcentrifuge tube containing 2.5% (v/v) glutaraldehyde, 
2.5% (v/v) paraformaldehyde and 0.1 M sodium cacodylate buffer (pH 7.4) (A). 
Scanning electron micrograph of C. jejuni (B). Image obtained from the Agricultural 
Research Service – United States Department of Agriculture 
(http://www.ars.usda.gov/main/main.htm). Magnification = 250,000x. Size bar = 100 
nm.  
 
C. jejuni is capable of growth at temperatures ranging from 30°C to 47°C and therefore 
is capable of growth at the body temperatures of human and avian hosts, 37°C and 42°C 
respectively (Blaser et al., 1983, Garenaux et al., 2008). Traditionally, several problems 
have hindered the study of Campylobacter species compared to other enteric bacteria 
such as E. coli and Salmonella species. In particular, for decade’s scientists did not have 
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the appropriate conditions to culture the bacterium and were unknown until microaerobic 
growth conditions for bacteria were established. In the last two decades microaerobic 
cabinets have greatly assisted in the routine growth and study of Campylobacter species. 
The bacterium is oxidase-positive and unable to ferment or oxidise sugars. Energy is 
obtained from amino acids or tricarboxylic acid cycle intermediates rather than 
utilisation of carbohydrates (Debruyne et al., 2008). C. jejuni has two sub-species, C. 
jejuni subsp. jejuni and C. jejuni subsp. doylei which are distinguished by biochemical 
testing with the latter characterised by the absence of nitrate reduction and susceptibility 
to cephalothin (Debruyne et al., 2008).    
  
1.2 Campylobacter species 
It is believed that the earliest description of Campylobacter was by Theodor Escherich in 
1886, followed by the 1913 publication describing the isolation of Vibrio-like organisms 
from aborted ovine foetuses by McFadyean and Stockman (Escherich, 1886, McFadyean 
and Stockman, 1913). In later years, several novel “Vibrio” species in a range of animals 
with and without clinical symptoms were identified. In 1963, Sebald and Véron 
transferred two of these Vibrio species into the new genus Campylobacter due to low 
DNA base composition, microaerophilic growth requirements and non-fermentative 
metabolism (Sebald and Veron, 1963). In 1973 Veron and Chatelain outlined four 
distinct species in the genus Campylobacter (Véron and Chatelain, 1973, Debruyne et 
al., 2008). Improved isolation, growth and incubation methods have allowed further 
species to be identified (Figure 1.2). There are currently 23 Campylobacter species and 
21 different C. jejuni strains (July 2010). Campylobacter species are generally motile, 
typically microaerophilic, have a low G + C content and do not form spores. Strict 
anaerobiosis is a stress condition for C. jejuni, however alternative respiratory pathways 
can contribute significantly to energy conservation under oxygen-limited conditions 
(Sellars et al., 2002). Anaerobic growth can occur with fumarate or nitrate as an electron 
acceptor, whereas microaerobic growth will occur with hydrogen, formate or succinate 
used as the electron source (Debruyne et al., 2008). 
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Figure 1.2. Phylogenetic tree of the relatedness of Campylobacter species to other 
bacteria as inferred by comparison of 16S rRNA gene sequences. The scale bar indicates 
1% distance for the dendogram. Image obtained from Debruyne, et al., 2008.         
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1.3 Pathology of C. jejuni infection 
C. jejuni infection is one of the leading bacterial causes of gastroenteritis in humans and 
is the leading foodborne cause of gastroenteritis worldwide (Allos, 2001). 
Campylobacter species such as C. fetus have long been recognised as a cause of 
diarrhoea in cattle and of septic abortion in both cattle and sheep (Jerrett et al., 1984, 
Sauerwein et al., 1993). The identification of C. jejuni as a causative agent of human 
gastroenteritis became apparent in 1977 due to improved selective and transport media 
for the isolation of the organism from clinical specimens (Skirrow, 1977). Historically, 
more than 95% of Campylobacter strains isolated and identified in cases of human 
disease have been C. jejuni and C. coli (Lastovica and Allos, 2008). Thus, the clinical 
aspects described in this section are mainly attributed to C. jejuni and C. coli. The 
essential lesion in Campylobacter enteritis is an acute inflammatory enteritis which 
commonly extends down the intestine to affect the colon and rectum (Blaser and 
Engberg, 2008). Terminal ileitis and cecitis with inflammation of the mesentery is also 
common (Blaser and Engberg, 2008). In terms of disease symptoms, there does not seem 
to be any clear difference between infections caused by C. jejuni and C. coli when 
assessed by frequency of diarrhoea, blood in stool, abdominal pain, fever, vomiting, 
mean duration of illness or admission to hospitals (Blaser and Engberg, 2008). One other 
Campylobacter species of significance is C. fetus which is of particular economic 
importance as this species can cause sterility and abortion in cattle and sheep (Bergen et 
al., 2008).   
  
1.3.1 Gastroenteritis 
The most common clinical symptom observed in humans infected with C. jejuni is 
gastroenteritis (Figure 1.3) (Blaser, 1997). C. jejuni causes acute inflammatory enteritis, 
affecting the intestine down to the colon and rectum (Blaser and Engberg, 2008). 
Symptoms vary based on the individual infected, however following an incubation 
period of 24-72 hours, acute diarrhoea usually occurs (Young and Mansfield, 2005). This 
may be followed or preceded by non-specific syndrome of fever, chills, myalgia, 
headache and can lead to abdominal cramps. The illness typically lasts for 5 - 10 days 
and is self-limiting (Blaser, 1997). However extended illness can also occur, specifically 
in immunocompromised individuals such as elderly or human immunodeficiency 
syndrome (HIV) patients (Sorvillo et al., 1991). Presentation of clinical symptoms in 
humans from C. jejuni infection has been noted to vary between developed and 
developing countries. Clinical symptoms of humans in developed countries infected by 
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C. jejuni typically results in inflammatory bloody diarrhoea and abdominal pain (Black 
et al., 1988, Karmali and Fleming, 1979, Ketley et al., 1996, Richard and David, 2000). 
Occasionally, intestinal complications, extra-intestinal infections and late onset 
complications can follow initial gastroenteritis (Figure 1.3). 
 
 
 
Figure 1.3. Overview of illnesses caused by C. jejuni. Image adapted from Blaser and 
Engberg., 2008. 
 
Campylobacter enteritis in developing countries is low frequency in adults (Blaser and 
Engberg, 2008) yet it has been noted from a study in Egypt that C. jejuni shedding can 
occur from adults (Pazzaglia et al., 1991). In developing countries, infection rates 
decline with age with fewer infections being associated with diarrhoea (Blaser and 
Engberg, 2008). The clinical symptoms for humans in developing countries infected by 
C. jejuni are generally non-inflammatory watery diarrhoea (Richard and David, 2000). 
The differences observed in clinical symptoms after C. jejuni infection between patients 
from developed and developing countries have been linked to pre-exposure of the 
developing country population to the bacterium at not only an earlier stage in life, which 
allows immunity to develop, but from probable multiple re-exposure to the bacterium 
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(Calva et al., 1988, Richardson et al., 1981, Taylor et al., 1988). In addition, factors such 
as diet, lifestyle, common exposure to parasitic infections and even strain differences 
may explain the reported differences in clinical outcomes between C. jejuni infection in 
developed and developing countries. 
 
Bacteraemia has been observed rarely following C. jejuni infection (Crushell et al., 
2004) and is believed to occur as a transient event in the early stages of infection, 
especially in patients with high fever (Blaser and Engberg, 2008). C. jejuni bacteraemia 
is difficult to detect because of the lack of blood samples taken in the early stages of 
disease presentation and not all methods of detecting bacteraemia are equally sensitive 
for Campylobacter species (Wang and Blaser, 1986). In a recent study in Denmark, the 
highest frequency of bacteraemia associated with Campylobacter species was 2.9 per 
1,000,000 persons (Nielsen et al., 2010). 
 
1.3.2 Post-infectious sequelae 
Even though gastroenteritis is the most common clinical symptom observed in humans 
infected with C. jejuni, on rare occasions a number of post-infectious sequelae such as 
Guillain-Barré syndrome (GBS), Miller Fisher syndrome (MFS), endocarditis, 
meningitis, post-dysenteric irritable bowel syndrome (PD-IBS) and reactive arthritis 
(ReA) can develop (Kuroki et al., 1993, Skirrow, 1991). Current evidence suggests C. 
jejuni as the predominant preceding infection in GBS and that this infection triggers the 
production of cross-reactive antibodies to human gangliosides that damage peripheral 
nerve tissue (Jacobs et al., 2008). GBS is characterised by an acute progressive and 
symmetrical motor weakness of limbs with loss of tendon reflexes (Asbury and 
Cornblath, 1990). GBS is believed to occur in between 0.6-1.9 cases for every 100,000 
people infected with Campylobacter (Schonberger et al., 1981). The mortality rate is less 
than 5-10% and is mainly the result of respiratory or autonomic nervous system 
complications (Ropper et al., 1991).  
  
MFS is a sub-form of GBS that is characterised by areflexia, ataxia, and ophthalmoplegia 
(Fisher, 1956). C. jejuni is also the predominant type of preceding infection in patients 
with MFS (Koga et al., 2005). PD-IBS causes continued diarrhoeal complications and 
the prevalence of such cases are believed to be far higher than observed (5-20%) 
(Thornley et al., 2001, Marshall et al., 2006, Dunlop et al., 2003). ReA typically affects 
ankles, knees, wrists and the small joints of the hands and feet (Schaad, 1982, Peterson, 
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1994). The prevalence of ReA is believed to be 1-5% of those previously infected with 
Campylobacter species (Pope et al., 2007). Little is known about the mechanism(s) of 
how Campylobacter infection causes ReA.  
 
1.3.3 Epidemiology 
Most illnesses caused by Campylobacter species occur sporadically, however the 
bacterium can still be associated with large outbreaks affecting thousands of people 
(Miller and Mandrell, 2005, Clark et al., 2003). Infection from Campylobacter species is 
estimated to cause 5–14% of diarrhoea worldwide (Coker et al., 2002). Each year 
Campylobacter is responsible for an estimated 400 million human cases of gastroenteritis 
worldwide, making this the leading cause of bacterial food borne disease and a major 
causative agent of traveller's disease (Walker, 2005, Friedman et al., 2000). Herein, lies a 
peculiarity often referred to as the “Campylobacter conundrum” (Jones, 2001) – how can 
a bacterium that rarely causes outbreaks be responsible for such large numbers of 
infection? This may be because the organism is omnipresent in the environment and 
probably survives better in the oxidative stress of the environment than traditionally 
thought. The number of cases of Campylobacter species reported in England and Wales 
over the last 20 years is illustrated in Figure 1.4. However, the actual numbers are 
estimated to be nearer half a million per year due to lack of reporting by patients with 
less severe clinical symptoms (Wheeler et al., 1999).  
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Figure 1.4. Laboratory cases of Campylobacter reported to the Health Protection Agency 
Centre for Infections England and Wales, 1989-2009. Data shown is human 
Campylobacter cases reported from diagnostic laboratories to the HPA’s local and 
national surveillance. It includes patients with enteric and non-enteric infections. Data 
obtained from http://www.hpa.org.uk/infections/topics_az/campy/data_ew.htm. 
 
Many countries in temperate zones observe a sharp increase in the isolation of 
Campylobacter species infections in the spring, a well-defined summer peak and a 
gradual decrease in the autumn or winter (Skirrow, 1987, Kovats et al., 2005, Miller et 
al., 2004, Olson et al., 2008). Human behaviour has been suggested as a possible reason 
for the summer peak with the increased barbecuing of meat and water-associated 
recreational activities (Olson et al., 2008). Investigation into the age distribution of 
humans infected with Campylobacter species in the U.S.A has identified children 
younger than 12 months of having the highest rate of Campylobacter species infection at 
27 per 100,000 cases. Other notable peaks occurred at 1-4 and 40-49 years of age in 
males, and 1-4 and 20-29 years of age in females (Tauxe et al., 1988). This bimodal age 
distribution has also been described in other European countries (Olson et al., 2008).  
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1.3.4 Sources of C. jejuni infection 
Campylobacter infection is most commonly associated with the consumption of 
contaminated poultry or meat products (MacKichan et al., 2004). Potential sources and 
routes of human infection by C. jejuni are shown in Figure 1.5. Campylobacter species 
are a typical commensal microorganism of the gastrointestinal tract of many birds and 
animals (Altekruse et al., 1999). Studies have shown the bacterium to be maintained 
asymptomatically at levels of 106 to 108 CFU per gram of caecal contents within poultry 
(Stern, 2008). Other reported sources of infection include untreated water, raw or 
unpasteurized milk, vegetables and transmission from pets (Crushell et al., 2004, Olson 
et al., 2008, Harris et al., 1987, Friedman et al., 2004, Miller and Mandrell, 2005).  
 
 
 
Figure 1.5. Potential environmental reservoirs of C. jejuni leading to human infection. 
The bacterium colonises the chicken gastrointestinal tract and is passed between chicks 
within a flock through the faecal-oral route. C. jejuni can enter the water supply, where it 
can associate with protozoans, such as freshwater amoebae. C. jejuni can also infect 
humans directly through the drinking water or through the consumption of animal 
products. Image from Young et al. 2007. 
 
1.3.5 Diagnosis and Treatment 
Accurate diagnosis requires the isolation of bacteria from patient stools and performing 
growth-dependent tests, immunological assays or a Gram-stain. Stool antigen tests for 
Campylobacter species have also been developed (Fitzgerald et al., 2008). Sensitivity is 
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believed to vary between 80-96% compared with culture and has specificity greater than 
97% (Dediste et al., 2003, Hindiyeh et al., 2000, Tolcin et al., 2000). Currently there is a 
lack of reliable molecular-based assays to detect Campylobacter species in stool samples 
(Dediste et al., 2003, Hindiyeh et al., 2000, Tolcin et al., 2000). Molecular based 
techniques have advantages over culturing including same-day detection, additional data 
regarding mixed infections, automation and identification of uncommon species (Dediste 
et al., 2003, Hindiyeh et al., 2000, Tolcin et al., 2000).   
  
Antibiotics are not typically administered as Campylobacter infections are generally self-
limiting. Where antibiotics have been administered, notable differences in resistance 
rates have been identified between countries (Blaser and Engberg, 2008). Treatment 
consists principally of oral replacement of fluid and electrolytes lost through diarrhoea 
and vomiting (Taylor and Tracz, 2005). However for severe cases, antibiotics from the 
fluoroquinolone class such as ciprofloxacin are administered which function by 
inhibiting bacterial DNA gyrase activity and thus inhibiting DNA unwinding and 
replication. However resistance to ciprofloxacin and other fluoroquinolones have been 
shown for Campylobacter strains isolated from humans (Blaser and Engberg, 2008). Up 
to 20% of patients treated with a fluoroquinolone for a Campylobacter infection will 
develop resistance (Wistrom and Norrby, 1995, Fitzgerald et al., 2008). Gentamicin has 
also been recommended for the treatment of campylobacteriosis, particularly in patients 
with systemic infection (Skirrow and Blaser, 2002). Resistance to antibiotics for 
Campylobacter strains is believed to have developed as a result of fluoroquinolones 
being used in veterinary medicine and the resulting resistance developing in livestock 
animals (Blaser and Engberg, 2008).   
 
1.4 Virulence determinants 
The four major virulence determinants in C. jejuni were identified before, during and 
after the publication of the original genome sequenced strain NCTC11168 (Parkhill et 
al., 2000) and are shown in Figure 1.6. A virulence determinant is a feature of the 
bacterium (in this case sugar structures) that allows for colonisation (by adhesion and/or 
invasion), immune evasion, immune suppression and/or generally assisting the 
persistence of the bacterium in a host. In C. jejuni these include flagella, 
lipooligosaccharide (LOS), N-linked glycoproteins, O-linked glycosylated flagella, 
capsular polysaccharide (CPS), cytolethal distending toxin (CDT) and also adhesins.  
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Figure 1.6. Potential glyco-based virulence determinants in C. jejuni. These include 
LOS, N-linked glycoproteins, O-linked glycosylated flagella and CPS. Image obtained 
from Young et al. 2007.  
 
1.4.1 Flagella 
The flagellum is a key virulence factor for C. jejuni enabling motility and intestinal 
colonisation (Hendrixson, 2006, Hendrixson and DiRita, 2004). Motility via functional 
flagella is not only important for colonisation, but studies have demonstrated that the 
flagella can also secrete important virulence factors that enable the bacterium to invade 
human intestinal cells (Black et al., 1988, Grant et al., 1993, Hendrixson, 2008). Flagella 
allow the bacterium to penetrate, colonize and persist in the thick mucus lining the 
intestinal surface and crypts (Guerry, 2007, Hendrixson, 2008).   
 
1.4.1.1 Biosynthesis of flagella 
Up to 50 genes have been implicated in the biosynthesis of the C. jejuni flagella 
requiring a finely tuned regulatory system to control the biosynthesis of the organelle 
(Hendrixson, 2008). The flagella rod links the flagella export apparatus to the flagella 
hook, which connects to the major and minor flagellins where FlaA is the predominant 
flagellin, whereas FlaB appears to be sparse, contributing to less than 20% of the flagella 
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filament (Guerry et al., 1991) (Figure 1.7). The flagella basal body proteins (FlgABC, 
FlgFGHIJ and FliE), the ring structures in the peptidoglycan and outer membrane 
(FliFHI, FlhAB and FliOPQR) and rod proteins (FlgDE and FlgKL) are all present in C. 
jejuni. Key components of the flagella include cytoplasmic flagella motor switch 
complex proteins, inner-membrane-localised export apparatus and a cytoplasmic ATPase 
which together form a secretion system for flagella proteins. Regulation of the 
expression of these genes is controlled by RpoN (σ54), FliA (σ28) and the two-component 
regulatory system FlgSR (Hendrixson, 2008). Studies have shown that site directed 
mutagenesis of rpoN and fliA result in non-motile mutants (Hendrixson et al., 2001, 
Jagannathan et al., 2001). RpoN regulates expression of flaB along with the hook and 
basal-body genes, whereas FliA regulates expression of flaA. Recent studies have also 
identified FlhF to be necessary for flagella organelle development and also required for 
σ54-dependent flagella expression (Balaban et al., 2009). In addition, until the flagella 
secretory system has formed, FlgM can inhibit the activity of σ28. Once the secretory 
system is formed, FlgM is transported out of the cytoplasm and σ28 can initiate the 
expression of genes such as flaA encoding the major flagellin (Hendrixson and DiRita, 
2003, Wosten et al., 2004). 
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Figure 1.7. Biosynthesis of C. jejuni flagella. Image obtained from Wosten, et al. 2004. 
 
Much of the early understanding of flagella biosynthesis and regulation has developed 
from mutagenesis studies on Salmonella and Vibrio species (Hughes et al., 1993, 
Karlinsey et al., 2000, Klose and Mekalanos, 1998). Many of the orthologous genes have 
been identified in C. jejuni, however important differences exist between the flagella 
biosynthesis mechanisms in these microorganisms when compared to C. jejuni. Analysis 
of different Campylobacter species has shown that flagella genes are not organised into 
one big operon, but are dispersed throughout the genome (Fouts et al., 2005, Chilcott and 
Hughes, 2000, Liu and Ochman, 2007, Parkhill et al., 2000). This is in contrast to other 
bacteria which typically have one operon for flagella genes allowing expression to be 
controlled from a single promoter. Formation of flagella within Campylobacter species is 
considered to be a three stage process. Initial steps include the formation of export 
apparatus, the expression of regulatory genes encoding RpoN, FliA, FlgM, FlgS, FlgR 
and FlhF. Unlike C. jejuni, other motile bacteria contain a master regulator for 
controlling flagella formation; FlhDC in Salmonella species, FlrA for Vibrio species and 
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FleQ for Pseudomonas species (Klose and Mekalanos, 1998, Arora et al., 1997, 
Karlinsey et al., 2000, Kutsukake et al., 1990). After formation of the flagella export 
apparatus, FlgS may sense an undetermined signal to autophosphorylate and begin a 
signal transduction cascade, terminating in activation of FlgR and expressing σ54-
dependent flagella genes (Hendrixson, 2008). Differences exist in the flagella 
biosynthesis process when compared to Salmonella species where three classes of genes 
exist; class I encodes the master regulator FlhDC, class II genes encode FliA, FlgM, 
export apparatus, basal body and hook components and class III genes encode flagellins 
(Hughes et al., 1993, Karlinsey et al., 2000, Kutsukake et al., 1990). In the case of Vibrio 
species there exists four classes of genes for flagella biosynthesis; class I encodes the 
master regulator FlrA and in conjunction with RpoD activates class II genes. These 
activate FliA, export genes, a two component regulatory system and a σ54-dependent 
response regulator (Arora et al., 1997, Dasgupta et al., 2000). The response regulator 
FlrB for Vibrio species allows RpoD to initiate expression of hook and basal genes. Only 
one class III gene encodes the flagellin and this is followed by class IV genes encoding 
further flagellins and motor proteins (Dasgupta et al., 2003, Prouty et al., 2001, Klose 
and Mekalanos, 1998). 
 
1.4.1.2 Flagella and chemotaxis  
A key element in flagella motility is chemotaxis which enables bacteria to move towards 
nutrient and away from noxious agents (Hendrixson, 2008). Extracellular signals, often 
sugars or amino acids, are sensed by chemoreceptors called methyl-accepting chemotaxis 
proteins (MCPs) which typically contain a periplasmic domain that binds to the signal. 
C. jejuni contains approximately 10 chemoreceptor proteins involved in this process of 
sensing. CheAY is a two-component regulatory system which controls chemotaxis in 
response to environmental stimuli. The binding of the signal ligand is relayed by the 
MCP to CheA, a histidine kinase that forms a complex with the MCP in conjunction with 
CheW. CheA autophosphorylates and subsequently phosphorylates CheY, the response 
regulator (Young et al., 2007). Phosphorylated CheY interacts with the FliM of the 
flagella motor to initiate movement (Yao et al., 1997). C. jejuni lacks a homologue of 
CheZ, a phosphatase which dephosphorylates CheY, but does possess a homologue of 
the poorly understood protein CheV (Marchant et al., 2002, Young et al., 2007, Parkhill 
et al., 2000). CheV has an amino terminal CheW-like domain and a carboxyl terminal 
CheY-like domain, so has been hypothesised to act as a phosphate sink for the 
chemotaxis signal-transduction machinery (Young et al., 2007, Marchant et al., 2002, 
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Pittman et al., 2001). It is believed this may ameliorate the effect of the absence of a 
CheZ phosphatase on phosphate flow through this signal-transduction pathway (Young 
et al., 2007, Marchant et al., 2002). Another type of taxis, called energy taxis, is a 
response to an intracellular signal, such as the proton motive force or the redox state of 
the electron-transport system (Young et al., 2007). Sequence and genetic analyses 
indicate that C. jejuni transduces an energy taxis (or aerotaxis) signal using two proteins, 
CetA and CetB, in place of the single protein (Aer) that is used by E. coli and other 
species (Hendrixson et al., 2001, Young et al., 2007).  
 
Based on E. coli studies, the bacterial chemotaxis signal transduction pathway is 
considered a model for bacterial two-component regulatory systems and specifically for 
chemotaxis signal transduction (Eisenbach, 1996, Falke et al., 1997). Movement is either 
based on a tumbling mode induced by clockwise-rotating dissociated flagella or a 
smooth, straight swimming mode induced by anti-clockwise flagella rotation (Korolik 
and Ketley, 2008). Tumbling motion is performed to allow reorientation, whereas the 
straight motion is used by the bacterium to swim to a specific concentration gradient 
(Korolik and Ketley, 2008). Importantly, in the absence of chemoattractants, 
autophosphorylation of CheA is inhibited and CheY is not phosphorylated (Korolik and 
Ketley, 2008). The signal transduction pathway is initiated by the MCP sensory receptors 
described above. The interaction between CheY and FliM determines the type of 
movement, as studies in E. coli have shown phosphorylated CheY need to occupy at 
least 70% of the available FliM molecules in the basal body for a change of rotational 
direction to occur (Bren and Eisenbach, 2001). It is predicted that when CheY binds to 
FliM in the flagella motor complex, this leads to a clockwise rotation, resulting in 
tumbling of the cell (Falke et al., 1997, Korolik and Ketley, 2008, Bren and Eisenbach, 
2001, Spohn and Scarlato, 2001). In contrast, if a chemoattractant is bound to the MCP, 
this leads to suppression of CheA activity which in turn leads to less CheY binding to 
FliM and hence a return to anti-clockwise rotation leading to swimming (Falke et al., 
1997, Korolik and Ketley, 2008, Bren and Eisenbach, 2001).  
 
1.4.1.3 Flagella and secretion  
In addition to providing motility, it has been proposed that flagella can act as a secretory 
channel in C. jejuni. C. jejuni lack classical type III and IV secretion systems used by 
many bacteria to secrete a range of determinants important in survival and pathogenesis 
(Parkhill et al., 2000). However, C. jejuni 81-176 has been noted to contain a pVIR 
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plasmid containing homologues of CDSs matching components of the type IV secretion 
system (Bacon et al., 2000). Studies have described the identification of at least eight 
proteins from the culture supernatant when C. jejuni was grown in the presence of INT 
407 IECs (Konkel et al., 2004, Konkel et al., 1999b, Young et al., 1999). Protein 
secretion was not detected when C. jejuni was incubated in the absence of IECs. These 
proteins, termed Cia (Campylobacter Invasion Antigen) proteins are further stimulated in 
the presence of other factors such as serum and bile salts (Guerry, 2007, Konkel et al., 
1999b, Rivera-Amill et al., 2001, Malik-Kale et al., 2008). A ciaB mutant was shown to 
be 50- fold less invasive compared to the C. jejuni F38011 wild-type strain (Konkel et 
al., 1999b). The secretion of Cia proteins is dependent on a functional flagellum, 
indicating that this organelle has a dual function in motility and as a type III secretion 
system (Konkel et al., 2004). Secretion of Cia proteins was not detected in a flhB mutant 
(defective in export), or in flgB, flgC and flgE mutants (defective for the basal body and 
hook) (Larson et al., 2008). Secretion of Cia proteins occurred in both flaA and flaB 
single mutants, but not a double flaA flaB mutant that lacked the filament (Konkel et al., 
2004).  
 
The putative role of flagella as secretory tools is controversial. Watson and Galan 
suggest that there is little evidence that any component of the flagella apparatus is 
directly secreting proteins involved in invasion when in contact with IECs (Watson and 
Galán, 2008). The authors argue that previous research shows that gene mutations 
causing a reduced motility phenotype, but not affecting the structure of the flagella 
apparatus show reduced invasion into host IECs (Yao et al., 1994). The argument is that 
these mutants, though non-motile, still harbour secretion positive flagella and so should 
be able to secrete the proposed virulence proteins. Watson and Galan argue that it is 
motility that is essential for invasion (Watson and Galán, 2008). Recent studies by this 
group have also shown that a flaA mutant (lacking the major flagellin filament subunit) 
and a motA mutant (lacking rotation), both have severely reduced ability to invade IECs 
even though both mutants should still harbour a functional secreting flagella structure 
(Novik et al., 2010). 
 
1.4.2 Lipooligosaccharide  
Gram-negative bacteria contain lipopolysaccharide (LPS) or LOS in the outer membrane 
which are important variable cell surface structures playing a key role in virulence 
(Moran et al., 1996). LPS is made up of an O-polysaccharide chain, core oligosaccharide 
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and a lipid A component in the outer membrane. LOS lacks an O-polysaccharide 
repeating structure and exhibits greater structural diversity in the outer core than LPS 
(Gilbert et al., 2008, Moran and Penner, 1999). LPSs and LOSs are families of 
phosphorylated lipoglycans and glycolipids that are considered toxic with potent 
immunomodulating and immune stimulating properties.   
 
Analysis of the LOS from different C. jejuni strains have shown lipid A to have an 
unusual mixed lipid A containing D-glucosamine (GlcN) and 2,3-diamino-2,3-dideoxy-
D-glucose (GlcN3N) (Gilbert et al., 2008). The LOS outer core of many species is 
characterised by the presence of sugars such as D-glucose (Glc), D-galactose (Gal), N-
acetyl-D-glucosamine (GlcNAc), and N-acetyl-D-galactosamine (GalNAc), whereas the 
inner core contains 2-keto-3-deosyoctulosonic acid (Kdo) and the heptose sugars, L-
glycero-D-manno-heptose (L,D-Hep) and D-glycero-D-manno-heptose (D,D-Hep) 
(Rietschel et al., 1993). C. jejuni LOS inner cores contain the trisaccharide L,D-Hep-
α(1,3)-L,D-hep-α(1,5)-Kdo (Moran, 1997). Another feature is that the heptose adjacent 
to Kdo (HepI) is substituted by D-glucose in a β(1→4) linkage, hence producing a 
common tetrasaccharide (Moran, 1997) (Figure 1.8). The genetic locus responsible for 
the biosynthesis of LOS in C. jejuni NCTC11168 is Cj1131c - Cj1152c.  
 
 
 
  
 
 
Figure 1.8. The proposed complete LOS core structure of C. jejuni NCTC11168. Kdo, 2-
keto-3-deosyoctulosonic acid, Hep, L-glycero-D-manno-heptose. glc, Glucose. Gal, 
galactose. NeuAc, N-acetylneuraminic acid. GalNAc, N-acetyl-D-galactosamine. PEA, 
phosphoethanolamine. Image obtained from Gilbert et al. 2005. 
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Much of the interest in the structure and biosynthesis of the core LOS of C. jejuni 
resulted from the ganglioside-like structures in the outer core of C. jejuni LOSs that may 
be responsible for inducing autoimmune neurological disorders such as GBS and MFS. 
Outer core structures of many C. jejuni strains mimic the saccharide portion of certain 
human gangliosides. LOS locus classes A, B, C, M and R encode genes responsible for 
the production of sialylated LOS that are human ganglioside mimics, while LOS locus 
classes such as D, F and G lack a cst gene that encodes a sialic acid transferase (Parker et 
al., 2008). Different C. jejuni serotypes have shown varying LOS structures (Gilbert et 
al., 2008). C. jejuni HS:19 serostrain expresses a heterogeneous outer core composed of 
a mixture of GM1a and GD1a ganglioside mimics (Aspinall et al., 1994). In parallel, 
studies have shown that C. jejuni HS:19 isolates from GBS patients and enteritis patients 
produce LOS that contain terminal tetra- and pentasaccharide moieties identical to those 
of GM1a and GD1a gangliosides (Yuki et al., 1993, Moran and O'Malley, 1995). C. 
jejuni NCTC11168 (HS:2) exhibits GM2 and GM1a mimicry over tri- and 
tetrasaccharides (Oldfield et al., 2002, Prendergast and Moran, 2000, St Michael et al., 
2002).  
 
There exists great variation in LOS between Campylobacter strains and species. A 
number of genetic mechanisms exist to induce this diversity, namely genetic differences 
in gene content and organisation. Studies have shown that introduction of a complete 
new class of LOS biosynthesis loci can occur between strains by horizontal transfer 
(Phongsisay et al., 2006, Gilbert et al., 2004). There are at least four genetic mechanisms 
that affect glycosyltransferase activity and hence vary the LOS outer core structures; i) 
phase variation of certain genes due to homopolymeric tracts, ii) gene inactivation by 
deletion of insertion of single or multiple bases, but without phase variation, iii) amino 
acid substitution resulting in an inactive variant of the glycosyltransferase and, iv) single 
or multiple mutations leading to variant glycosyltransferases with different acceptor 
specificities. The huge variation in LOS structures generated by the mechanisms outlined 
above allow C. jejuni to modulate the structure of this cell-surface carbohydrate (Gilbert 
et al., 2008).  
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1.4.3 Capsular polysaccharide 
The belated discovery that C. jejuni has a CPS was an important step in our 
understanding of C. jejuni pathogenesis (Karlyshev et al., 2005b). CPS consists of 
repeating oligosaccharide units attached to a phospholipid and is not chemically linked to 
LOS. The variability in CPS composition is the main determinant exploited by the 
Penner serotyping system (Penner and Hennessy, 1980, Moran and Penner, 1999). Great 
variety exists in the make-up of CPS due to the phospholipid chain containing different 
numbers of repeating sugar units (Karlyshev et al., 2005a). Diversity in CPS between C. 
jejuni strains can occur by multiple mechanisms such as exchange of capsular genes and 
gene clusters by horizontal transfer, gene duplication, phase, variation, deletion and 
fusion (Karlyshev et al., 2005a). CPS is believed to be an important factor protecting the 
bacterium against environmental conditions and also plays a role in pathogenesis 
(Karlyshev et al., 2008). CPS has been shown to be required for biofilm formation which 
contributes to virulence of the bacteria infecting the gastrointestinal tract and survival 
within environments that are not ideal. However, some studies have demonstrated that 
the presence of CPS may actually hinder the formation of biofilms in certain strains, and 
also mask bacterial adhesins required for interaction with host cells (Karlyshev et al., 
2008). In addition, a recent study demonstrated that C. jejuni alters its surface 
polysaccharides when co-cultured with IECs suggesting the existence of cross talk 
mechanism(s) that modulate CPS expression during infection (Corcionivoschi et al., 
2009). C. jejuni grown in conditioned medium taken from co-culture experiments after a 
single passage showed no loss of CPS. However, C. jejuni grown in conditioned medium 
taken from co-culture experiments after two rounds of passaging showed reduced CPS. 
In contrast, there was no change in CPS profile for bacteria grown in conditioned 
medium taken from HCT-8 cells alone or in medium conditioned by bacteria alone. 
These results suggested that a soluble factor present in the conditioned medium from 
HCT-8 cells co-cultured with C. jejuni was responsible for CPS alteration. The alteration 
in CPS appears to be dependent on a soluble factor that is both heat labile and proteinase 
K sensitive. CPS depletion occurred when C. jejuni organisms were exposed to 
conditioned media from a different C. jejuni strain, but not when exposed to conditioned 
media from other bacterial species. Thus, C. jejuni alters its surface polysaccharides 
when co-cultured with IECs. The genetic locus responsible for the biosynthesis of CPS 
in C. jejuni NCTC11168 is between Cj1413c - Cj1448c. 
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There are currently four different classifications of CPS (I-IV) (Whitfield, 2006, 
Whitfield and Roberts, 1999). These classifications are not based on antigenic or 
structural differences of the phospholipid chain, but on mechanisms of biosynthesis, 
assembly, genetic regulation, and sequence similarity (Whitfield, 2006, Whitfield and 
Roberts, 1999). C. jejuni CPSs fall in groups II and III which are typically characterised 
by organisation of the respective gene clusters containing a major internal biosynthetic 
region flanked by two groups of genes involved in CPS transport and assembly (kps 
genes). These CPSs contain a phospholipid moiety attached to a repeating unit either 
with or without a relatively labile linkage involving the sugar Kdo.  
 
There remains unanswered questions as to the specific role of C. jejuni CPS structures in 
bacteria-host interactions and gastroenteritis development  and there is a significant gap 
in our knowledge as to the regulation of CPS expression in C. jejuni (Karlyshev et al., 
2008).   
 
1.4.4 Glycosylation 
Glycosylation of proteins is important for biological activity (Nothaft et al., 2008). 
Although it has been predicted that bacteria synthesize at least six-fold more sugar 
building blocks compared to eukaryotes, it was previously assumed prokaryotes were 
incapable of modifying proteins with sugars (Nothaft et al., 2008). This was due to lack 
of reagents and sensitive techniques capable of detecting these unusual sugars.  
 
1.4.4.1 O-linked glycosylation  
Bacteria can attach sugars via the hydroxyl groups of Ser and Thr in an O-linkage 
(Thibault et al., 2001, Logan et al., 2002). O-linked glycosylation of C. jejuni appears to 
be a specific process where only the flagellin subunits of the flagella become 
glycosylated (Logan et al., 2008). O-linked glycosylation is integral to the flagella 
assembly process in Campylobacter and prevention of glycosylation leads to an inability 
to assemble the flagella filament leading to a non-motile phenotype (Logan et al., 2008). 
Unlike other prokaryotic glycosylation systems which occur in association with the cell 
membrane, flagellin monomers are secreted through the flagella apparatus and are 
therefore not found in the periplasm (Aas et al., 2007, Chaban et al., 2006). Hence, 
glycosylation takes place either in the cytoplasm, possibly in close proximity to the 
flagella machinery, or in the basal body compartment (Logan et al., 2008). There is no 
specific consensus sequence for the addition of O-linked glycosylated proteins on 
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flagellin (Logan et al., 2008). The C. jejuni O-linked glycosylation locus encompasses 
Cj1293 - Cj1342c.   
 
Structural and metabolomics studies have elucidated the O-linked glycosylation pathway 
to produce Pse5Ac7Ac (pseudaminic acid) (Thibault et al., 2001, Logan et al., 2002, 
Schoenhofen et al., 2006a, Schoenhofen et al., 2006b). The pathway commences from 
UDP-GlcNAc and evolves to UDP-2 acetamido-2,6-dideoxy-β-L-arabino-hexos-4-ulose 
via PseB. PseC further converts this to UDP-4-amino-4,6-dideoxy-β-L-AltNAc. PseH 
converts this to UDP-2,4-diacetamido-2,3,6-trideoxy-β-L-altropyranose. PseG acts as a 
sugar hydrolase resulting in the release of 2,4-diacetamido-2,4,6-trideoxy-L-altro-
pyranose. This is then converted by PseI to the nine-carbon structure Pse5Ac7Ac 
(pseudaminic acid). PseF allows CMP activation of Pse5Ac7Ac (Logan et al., 2008) 
(Figure 1.9). 
 
 
 
 
 
Figure 1.9. O-linked glycosylation of flagellin monomers is proposed to occur in the 
cytoplasmic inner membrane where nucleotide-activated sugars are individually added to 
serine or threonine residues that are surface exposed. Pse, 5,7-diamino-3,5,7,9-
tetradeoxynon-2-ulosonic acid (Pse5Ac7Ac); PseAm, 5-acetamidino analogue of Pse 
(Pse5Am7Ac); MATDH, monoacetamido-trideoxyhexose; NeuAc, N-acetylneuraminic 
acid; DATDH, diacetamido-trideoxyhexose; UDP, uridine diphosphate; CMP, cytidine 
monophosphate. Image obtained from Young et al. 2007. 
 
The requirement that flagellin proteins are glycosylated for filament assembly illustrates 
the biological significance of glycosylation (Logan et al., 2008). The function of 
modifications to flagella structure by O-linked glycosylation is still not fully understood. 
Mutation of genes involved in O-linked glycosylation generally do not result in loss of 
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motility (Logan, 2006). C. jejuni 81-176 has been shown to require glycosylation to 
assemble a flagella filament (Ewing et al., 2009, Goon et al., 2003). However O-linked 
glycosylation can occur in the absence of a functional flagella (Ewing et al., 2009). Loss 
of flagella and changes in sugars attached to flagellin have been shown to affect 
autoagglutination in C. jejuni (Ewing et al., 2009).  
 
1.4.4.2 N-linked glycosylation  
C. jejuni was the first bacterium identified to be capable of attaching sugars to proteins 
via the amide group of Asn in an N-linkage (Szymanski et al., 1999). The identification 
of N-linked glycosylation within bacteria was a breakthrough in glycobiology as it was 
initially considered that this glycosylation pathway was only present in eukaryotes. The 
field of functional glycomics has received a large amount of interest due to the fact that 
in eukaryotes, up to 90% of all proteins are modified with sugars. Disruption of these 
sugar pathways has been implicated in multiple disease states ranging from congenital 
disorders of glycosylation to autoimmune disease and cancer (Nothaft et al., 2008). The 
N-linked glycosylation system in C. jejuni has been exploited as an ubiquitous toolbox 
for understanding the pathway, developing new techniques for glycobiology and to 
exploit novel diagnostics and therapeutics strategies (Nothaft et al., 2008, Karlyshev et 
al., 2004, Langdon et al., 2009). 
 
Disruption of the N-glycosylation system within C. jejuni is believed to have pleiotropic 
effects affecting iron transport (Palyada et al., 2004), amino acid transport (Nothaft et 
al., 2008), induction of the host-immune response (Nothaft et al., 2008), chicken 
colonisation (Jones et al., 2004, Szymanski and Wren, 2005, Kelly et al., 2006), 
adhesion/invasion (Szymanski et al., 2002), mouse colonisation (Szymanski et al., 2002) 
and even the O-linked glycosylation pathway (Schoenhofen et al., 2006b). Previously, it 
has been shown that glycans play an important role in immunity during infection by 
masking the primary amino acid epitopes (Szymanski et al., 1999). N-linked 
glycosylation also plays an important role in C. jejuni-host cell interactions where C. 
jejuni 81-176 mutants in the pgl pathway showed reduced levels of adherence to and 
invasion of INT 407 cells and colonisation of the intestinal tracts of mice (Szymanski et 
al., 2002, Karlyshev et al., 2004). A number of glycoproteins have been identified with a 
virulence related role e.g. PEB3, VirB10 and Cj1496c (Young et al., 2002, Kowarik et 
al., 2006, Nothaft et al., 2008, Scott et al., 2010). For example, Cj1496c has been shown 
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to be required for efficient cell invasion and chick gastrointestinal colonisation (Kakuda 
and DiRita, 2006).  
 
The process of N-linked glycosylation starts with the synthesis of a heptasaccharide as 
the final product on the lipid bactoprenylpyrophosphate at the cytoplasmic side of the 
inner membrane. Initially UDP-GlcNAc is converted to UDP-bacillosamine by PglD, 
PglE and PglF proteins. The glycosyltransferases PglC, PglA, PglI, PglH and PglJ are 
involved in the formation of the heptasaccharide (Figure 1.10). The PglK flippase allows 
the translocation of the lipid-linked heptasaccharide across the inner membrane. The 
oligosaccharyltransferase PglB catalyses the transfer of the heptasaccharide from the 
lipid carrier to selected asparagine residues on nascent polypeptide chains. N-linked 
protein glycosylation takes place in the periplasmic space with the PglB requiring the 
extended consensus sequence Asp/Glu-X-Asn-Z-Ser/Thr (D/E-X-N-Z-S/T; X, Z ≠ P) 
(Kowarik et al., 2006) for transfer of oligosaccharides to protein. The C. jejuni N-linked 
glycosylation locus is between Cj1119c - Cj1130c.  
 
 
 
 
 
Figure 1.10. N-linked glycosylation is proposed to proceed through the sequential edition 
of nucleotide-activated sugars onto a lipid carrier, resulting in the formation of a 
branched heptasaccharide. The glycan is then ‘flipped’ across the inner membrane into 
the periplasm by a ATP-binding cassette (ABC) transporter. Bac, 2,4-diacetamido-2,4,6-
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trideoxyglucose; GalNAc, N-acetylgalactosamine; HexNAc, N-acetylhexosamine; Glc, 
glucose; UDP, uridine diphosphate. Image obtained from Young et al. 2007.  
 
Recently, studies have demonstrated that C. jejuni also produces free heptasaccharides 
derived from the N-glycan pathway reminiscent of the free oligosaccharides (fOS) 
produced by eukaryotes (Nothaft et al., 2009). It has been shown that C. jejuni produces 
fOS in response to changes in the osmolarity of the environment and bacterial growth 
phase (Nothaft et al., 2009). This study showed the conserved WWDYG motif of the 
oligosaccharyltransferase PglB is necessary for fOS release into the periplasm and the 
work demonstrates that fOS from an N-glycosylation pathway in bacteria are potentially 
equivalent to osmoregulated periplasmic glucans in other Gram-negative bacteria 
(Nothaft et al., 2009, Nothaft et al., 2010). Thus, C. jejuni heptasaccharides play a dual 
role in the periplasm being involved in the post-translational modification of proteins as 
well as potentially existing in the free with a role in osmotic control (Nothaft et al., 
2010). 
 
1.4.5 Cytolethal distending toxin  
C. jejuni has been reported to produce CDT encoded by the genes cdtA, cdtB and cdtC 
(Whitehouse et al., 1998). Not all strains of C. jejuni contain the complete cdt operon 
(Engberg et al., 2005). Studies have shown CDT to irreversibly block eukaryotic cells in 
the G2 phase of the cell cycle (Whitehouse et al., 1998, Lara-Tejero and Galan, 2001). 
CDT has also been shown to cause progressive cellular distension, chromatic 
fragmentation and apoptotic cell death (Frisan et al., 2002, Lara-Tejero and Galan, 
2001). The active subunit CdtB, a type I deoxyribonuclease, enters the nucleus resulting 
in DNA double-strand breaks causing cell arrest (Lara-Tejero and Galan, 2001). Studies 
using E. coli have shown the eukaryotic cell responds to the DNA double-strand breaks 
by initiating a regulatory cascade that results in cell cycle arrest, cellular distension and 
cell death (Smith and Bayles, 2006, Bielaszewska et al., 2005). CDT contributes to 
pathogenesis by inhibiting both cellular and humoral immunity via apoptosis of immune 
response cells and also by generating necrosis of epithelial-type cells and fibroblasts 
involved in the repair of lesions produced by pathogens (Smith and Bayles, 2006, 
Bielaszewska et al., 2005). This results in slow healing and production of disease 
symptoms (Smith and Bayles, 2006, Bielaszewska et al., 2005). C. jejuni co-cultured 
with INT 407 IECs has been shown to induce IL-8 secretion (Hickey et al., 2000), 
however CDT has not been shown to play a role in colonisation of chickens (Hu and 
 36 
Kopecko, 2008). cdtB mutants have been shown to exhibit impaired ability to cause 
disease in immunodeficient mice (Fox et al., 2004, Purdy et al., 2000). Studies have also 
shown cdt mutants to have normal levels of adhesion to HeLa and HD-11 cells, but to 
have a 10- fold decrease in the level of invasion (Biswas et al., 2006). The role of 
cytotoxin or enterotoxin during C. jejuni infection in initiating inflammation or diarrhoea 
remains unclear (Florin and Antillon, 1992, Ketley, 1997, Wassenaar and Blaser, 1999). 
It has been hypothesised that CDT may promote epithelial cell death at a quicker rate and 
thus allow further C. jejuni to translocate across the mucosa (Hu and Kopecko, 2008). 
Alternatively, diarrhoeal symptoms may result from C. jejuni induced epithelial cell 
death or translocation across the epithelium which has been noted to loosening of tight 
junctions leading to compromised mucosal barrier function.  
 
1.4.6 Adhesins 
One of the major adhesins of C. jejuni to IECs is the flagella (Hu et al., 2008). 
Disruption of flagella functionality results in a reduction of C. jejuni binding to host cells 
(Konkel and Joens, 1989, Konkel et al., 2004, Carrillo et al., 2004). Major adhesins 
involved in C. jejuni adhering to IECs include PEB1, a conserved antigen proposed to be 
an adhesin (Pei and Blaser, 1993, Pei et al., 1991). PEB1 shares homology with a 
periplasmic binding protein involved in nutrient acquisition (Pei and Blaser, 1993, 
Garvis et al., 1996). A peb1A mutant demonstrates a 50- to 100- fold reduction in 
adherence to HeLa cells (Pei and Blaser, 1993, Pei et al., 1998). C. jejuni has been noted 
to bind to components of the extracellular matrix such as fibronectin, laminin, vitronectin 
and collagen (Hu and Kopecko, 2008). CadF (Campylobacter adhesion to fibronectin) 
has been identified as an adhesin to fibronectin and is conserved among C. jejuni strains 
(Konkel et al., 1999a). Studies have shown that anti-CadF antibodies have reduced the 
binding of C. jejuni clinical isolates to immobilised fibronectin by greater than 50% 
(Monteville et al., 2003). Another adhesin identified for C. jejuni was the surface-
exposed lipoprotein JlpA (Jin et al., 2001) which acts by binding to Hsp90-alpha on the 
surface of Hep-2 epithelial cells (Jin et al., 2003). Both LOS and CPS have important 
roles to play in adherence. It has also been reported that N-linked glycosylation proteins 
on the cell surface have a role to play in adhesion and even invasion of Caco-2 cells 
(Karlyshev et al., 2004, Hu and Kopecko, 2008).  
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1.5 Host-pathogen interactions 
C. jejuni is a pathogen that has established a close association with a variety of vertebrate 
hosts and thus has evolved specific adaptations to modulate cellular functions (Watson 
and Galán, 2008). Studies have shown that C. jejuni can gain intracellular access to 
nonphagocytic IECs (Konkel and Joens, 1989, Ketley, 1997, De Melo et al., 1989). In 
humans, C. jejuni typically colonises the ileum and colon, where bacteria interfere with 
the absorptive capacity of the intestine (MacCallum et al., 2005b). C. jejuni has evolved 
mechanisms such as attachment to and invasion of IECs to combat the defensive 
mechanisms posed by the host such as the mucous layer, epithelial barrier and innate 
immune response. C. jejuni, like other pathogenic bacteria, adhere to colonic epithelial 
cells and trigger signal transduction events that induce host cytoskeletal rearrangements, 
bacterial internalisation and translocation across IECs (Hu and Kopecko, 2008). During 
mucosal penetration, different bacteria-host cell interactions induce interleukin and 
chemokine production, the recruitment of inflammatory cells, host cell death and cause 
diarrhoea, colitis, or both (Hu and Kopecko, 2008). C. jejuni does not contain 
homologues of classical bacterial enterotoxins, adhesins, invasins or type III protein 
secretion systems or even pathogenicity islands (Fouts et al., 2005, Parkhill et al., 2000). 
The presence of a type IV secretion system has been noted in certain C. jejuni strains; in 
particular on the pVIR plasmid of C. jejuni 81-176 (Bacon et al., 2000, Bacon et al., 
2002), however the role in disease is uncertain. A recent study identified pVIR in 17 of 
104 (16.3%) clinical C. jejuni isolates and found that these particular isolates were 
associated with the presence of a tetracycline resistance plasmid (Tracz et al., 2005).  
 
1.5.1 C. jejuni adhesion to host intestinal epithelial cells 
C. jejuni adherence, as in other bacteria, is typically due to specific interactions between 
molecules on the surface (adhesins) and molecules on the host surface (receptors). 
Putative adhesins for C. jejuni attachment to IECs have been described in Section 1.4.6. 
The mechanisms of binding and attachment are still largely uncharacterised, though it is 
clear that attachment is a prerequisite to adhesion (Hu and Kopecko, 2008).  
 
1.5.2 C. jejuni invasion of host intestinal epithelial cells 
C. jejuni transcytose host IECs to emerge in the lamina propria resulting in an 
inflammatory response (Everest et al., 1992, Konkel et al., 1992b, Harvey et al., 1999, 
MacCallum et al., 2005a) (Figure 1.11). The two main mechanisms by which C. jejuni 
passes through the impermeable epithelial layer is via transcellular methods whereby 
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bacteria pass through the absorptive enterocytes or M cells, or paracellular where 
bacteria pass between adjacent epithelial cells (Hu and Kopecko, 2008). Polarized cell 
lines such as Caco-2 (human colonic carcinoma) have provided a simple and alternative 
method to study host-pathogen interactions without using animal models (Hu and 
Kopecko, 2008). C. jejuni invasion into the epithelial mucosa is an essential process to 
forming colitis (Allos, 1997, Russell and Blake, 1994). C. jejuni interacts with the 
intestinal mucosal surface, triggering host signal transduction events that lead to host 
cytoskeletal rearrangements, resulting in bacterial uptake (Hu and Kopecko, 2008). 
There remains confusion as to the exact mechanism for Campylobacter entering and 
crossing the intestinal mucosa. Bacterial internalisation into IECs has typically been 
linked to involve pathogen-induced rearrangement of host cytoskeletal structures, 
resulting in endocytosis of the pathogen (Hu and Kopecko, 2008). These structures 
comprise microfilaments (MFs) and microtubules (MTs), which are made up of actin and 
tubulin respectively. The structures are involved in both cellular and subcellular 
movements and along with intermediate filaments help determine cell shape (Hu and 
Kopecko, 2008). Internalisation of C. jejuni has been reported to be MF-dependent (De 
Melo et al., 1989, Konkel and Joens, 1989), MT-dependent (Hu and Kopecko, 1999, 
Oelschlaeger et al., 1993), both MF- and MT-dependent (Biswas et al., 2003, Monteville 
et al., 2003), or neither (Russell and Blake, 1994). There is evidence that suggests C. 
jejuni may encode separate MF-dependent (Konkel et al., 1992a, Konkel and Joens, 
1989) and MT-dependent (Hu and Kopecko, 1999, Oelschlaeger et al., 1993) pathways 
for host invasion. A number of explanations have been put forward as to why such 
differences in host cell cytoskeletal requirements for C. jejuni invasion occur. These 
including experimental techniques, cell lines used and strains used (Hu and Kopecko, 
2008). It is believed that the MT-dependent pathway is observed at the apical host cell 
surface, whereas MF-dependent invasion occurs mainly at the basolateral surface (Hu 
and Kopecko, 2008).  
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Figure 1.11. C. jejuni evades the mucus layer in humans and interacts with the IECs 
causing IL-8 production. C. jejuni binds to, and is internalised by epithelial cells. This 
leads to interaction with dendritic cells, macrophages and neutrophils, which further 
leads to a pro-inflammatory response and increase in cytokines production. C. jejuni 
resides primarily in the mucosal layer in chicken intestines. In vitro studies have shown 
that C. jejuni can stimulate the production of IL-1, IL-6 and intracellular nitric oxide 
synthase from IECs and macrophages, but importantly the resulting host response does 
not typically lead to inflammatory diarrhoea in chickens. Image obtained from Young et 
al. 2007. 
 
Invasion and translocation are important steps in the survival and persistence of C. jejuni. 
An important factor for C. jejuni invasion is the disruption of tight junctions as a route 
for translocation, which was shown using Caco-2 cell monolayers (MacCallum et al., 
2005b). Polarized Caco-2 cells with differentiated apical and basolateral surfaces are 
separated by tight junctions, express several markers characteristic of normal small 
intestinal cells and have a well-defined brush border (Everest et al., 1992, Finlay and 
Falkow, 1990). Studies have demonstrated that C. jejuni translocate tight polarized 
epithelial monolayers (Bras and Ketley, 1999, Everest et al., 1992, Grant et al., 1993). A 
putative paracellular pathway of C. jejuni mucosal translocation termed subvasion has 
also been described (van Alphen et al., 2008). The findings suggest that subvasion does 
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not occur in polarized IECs, and is only observed in cultured IECs maintained under 
nutrient-limiting conditions, raising the relevance of this process is for C. jejuni 
pathogenesis (Hu and Kopecko, 2008). In addition, infection of polarised Caco-2 cells 
with high multiplicities of infection (MOI 10,000:1) were found to cause loss of 
transepithelial electrical resistance (TEER) by 24 h after infection (MacCallum et al., 
2005b). This loss of TEER was accompanied by a rearrangement of the tight junction 
protein occludin (MacCallum et al., 2005b). Loss of tight junctions, electrolyte and fluid 
absorption are likely to be compromised and this may likely contribute to the clinical 
manifestations of diarrhoea (MacCallum et al., 2005b) 
 
In addition to host cytoskeletal requirements during C. jejuni adhesion and invasion, 
signal transduction events are also important where pathogens modulate host signalling 
systems both to allow for invasion and to trigger disease pathogenesis (Hu and Kopecko, 
2008). The divalent calcium cation Ca2+ plays a role in host signal transduction and other 
cellular processes (Clapham, 1995, Jacob, 1990, Marks and Maxfield, 1990a, Marks and 
Maxfield, 1990b). Increased free intracellular Ca2+ has been demonstrated to link cell 
surface receptor stimulation via signalling pathways with intracellular effectors and to 
modulate cytoskeletal structure, chemotaxis, membrane fluidity, chromosome 
segregation, cell cycle transition, enzyme activity, transmembrane ion fluxes, proteolysis 
and other functions (Clapham, 1995, Jacob, 1990, Marks and Maxfield, 1990a, Marks 
and Maxfield, 1990b). Although many signalling events have been found to affect C. 
jejuni invasion there still remains gaps in our knowledge of the signal transduction 
pathway involvement in bacterial internalisation (Hu and Kopecko, 2008).  
  
A key bacterial factor for invasion is motility as non-motile mutants are non-invasive 
(Watson and Galán, 2008, Yao et al., 1994). Non-flagella proteins secreted through the 
flagella (e.g. Cia proteins) have been shown to trigger internalisation (Konkel et al., 
2004). However, this hypothesis is controversial, as mutants defective in motility but 
with an intact flagella structure should still be invasive as secretion is possible. However, 
these mutants were non-invasive (Yao et al., 1994). Mutations affecting protein 
glycosylation or capsular synthesis also affect bacterial entry, thus there exists mixed 
data as to what is exactly required for invasion (Bachtiar et al., 2007, Bacon et al., 2001, 
Guerry et al., 2006, Kakuda and DiRita, 2006, Karlyshev et al., 2004, Szymanski et al., 
2002, Vijayakumar et al., 2006).  
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1.5.3 C. jejuni internalisation and survival 
An important factor involved in C. jejuni internalisation are lipid rafts or caveolae which 
are microdomains within plasma membranes enriched for cholesterol, glycolipids, 
sphingolipids and signalling molecules such as receptor tyrosine kinases (Hu et al., 2006, 
Wooldridge et al., 1996). C. jejuni are believed to exploit these areas to gain entry into 
the cell and importantly avoid delivery to lysosomes (Watson and Galan, 2008). It is 
therefore possible that in order to survive within cells, C. jejuni has evolved specific 
adaptations to survive within lysosomes or to modulate host cellular trafficking events to 
avoid fusion with lysosomes (Watson and Galan, 2008). Once internalised into IECs, C. 
jejuni is believed to reside within a vacuole (Campylobacter Containing Vacuole - CCV). 
Characterisation of this compartment indicates that it is functionally distinct from 
lysosomes (Watson and Galan, 2008). Studies have shown that the CCV acquires lipid 
raft or caveolae markers at early time points during infection and that a functional 
caveolin-1 is required for efficient C. jejuni entry (Watson and Galan, 2008). Even 
though C. jejuni internalisation into IECs requires caveolae, bacterial internalisation has 
been shown to not require dynamin, which is an essential component of the endocytic 
machinery associated with caveolae (Watson and Galán, 2008). Thus, it is possible that 
caveolae may be required for the assembly of signalling molecules used for the signal 
transduction pathways that leads to C. jejuni entry rather than to allow bacterial entry 
through its associated endocytic machinery (Watson and Galán, 2008). The CCV is not 
part of the canonical endocytic pathway and studies have demonstrated C. jejuni does not 
survive within lysosomes (Watson and Galan, 2008). C. jejuni has been identified in 
macrophages, but long term survival is not feasible within this cell type due to oxidative 
stress (Watson and Galan, 2008, Sikic Pogacar et al., 2009). There has also been some 
data demonstrating the potential importance of cellular processes in C. jejuni 
internalisation e.g. tyrosine kinase inhibitors have been noted to inhibit bacterial 
internalisation into cultured IECs (Woolcock et al., 1996, Biswas et al., 2003). The 
identity of the tyrosine kinase or kinases required for bacterial entry or the specific role 
that they may play in the entry process is currently unknown (Watson and Galán, 2008). 
  
C. jejuni utilises a number of different mechanisms to survive and replicate within host 
cells. In general, intracellular C. jejuni lose viability within IECs over 24 hours, with no 
evidence of replication (Day et al., 2000, Candon et al., 2007, Konkel et al., 1992a). 
Recent studies have demonstrated not only that intracellular C. jejuni remains viable for 
up to 24 hours, but also that it shifts to a physiological state where it can only be initially 
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cultured under anaerobic conditions (Watson and Galan, 2008). This is believed to be a 
mechanism of survivability in low oxygen environments.  
 
It is noteworthy that not only different species, but different strains of C. jejuni have 
varying abilities to adhere, invade and survive within IECs. Even though a great deal has 
been elucidated in the past decade, there are still major gaps in our knowledge of the 
cellular mechanisms that lead to internalisation (Hu and Kopecko, 2008).   
 
1.6 C. jejuni genome sequences 
Given the socioeconomic importance of this pathogen, it is surprising that the ecology, 
epidemiology and, in particular, the pathogenesis are still so poorly understood. The lack 
of information on this problematic pathogen was the driving force for the original C. 
jejuni NCTC11168 genome sequencing project (Parkhill et al., 2000). C. jejuni 
NCTC11168 was selected for sequencing as it is genetically tractable and widely 
available. This strain was isolated in 1977 from a U.K. patient with severe gastroenteritis 
(Skirrow, 1977). The sequencing process involved the construction of seven libraries in 
pUC18 using size fractions ranging from 1.0 kb to 2.2 kb (Parkhill et al., 2000). 
Approximately 19,400 pUC clones were sequenced using Dye-terminator chemistry on 
ABI 373 and 377 sequencing machines. The sequencing project was initiated in 1997 
and completed in 1999 (Parkhill et al., 2000). Initial annotation was performed at the 
WTSI and the genome was published in 2000 (Parkhill et al., 2000).  
 
1.6.1 Key features of C. jejuni genome sequences  
Key features identified in the original annotation of the C. jejuni NCTC11168 genome 
were CPS (surface polysaccharide at the time), flagella modification and LOS loci 
(Figure 1.12). There was a notable lack of insertion or phage-associated sequences and 
very few repeat sequences within the genome. Hypervariable sequences allowing phase 
variation were identified in genes encoding proteins involved in the biosynthesis or 
modification of surface structures (Parkhill et al., 2000). Initially these were considered 
sequencing errors, but closer inspection revealed that these were genuine and were on 
surface polysaccharide structures that had been previously shown to phase vary (De 
Bolle et al., 2000, Saunders et al., 1998). A number of known and potential 
pathogenicity factors were identified including genes encoding for CDT, haemolysin-like 
toxins, putative type II export and chemotaxis genes. The C. jejuni genome was shown to 
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be highly compact (1654 CDSs representing 94.3% of the genome), with a relatively low 
G/C percentage at 30.55%. 
 
 
 
 
 
Figure 1.12. Schematic diagram of the C. jejuni NCTC11168 genome. Green circular 
rings show CDSs transcribed in forward (dark green) and reverse (light green) 
orientation. Black lines indicate locations of hypervariable sequences. Pink lines indicate 
locations of surface structures. The innermost histogram shows the similarity of each 
CDS to its H. pylori orthologue where present; height of the bar and the intensity of the 
colour are proportional to the degree of similarity. Figure reproduced from NCTC11168 
original genome sequence project where ‘surface polysaccharide’ was later noted as 
CPS. Image obtained from Parkhill et al. 2000. 
 
Since this work was published in 2000, there has been continued interest in this 
important human pathogen. A consequence of this has been significant revisions of the 
genetic loci that code for important surface structures on C. jejuni strains. The surface 
polysaccharide region (Cj1413c – Cj1448c) has been renamed as the capsule locus 
(Karlyshev et al., 2005a, Karlyshev et al., 2000, Karlyshev et al., 2001). The flagella 
modification locus (Cj1293 – Cj1342c) has been confirmed as an O-linked glycosylation 
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pathway which is responsible for glycosylation of the flagellin structural proteins FlaA 
and FlaB (Thibault et al., 2001, Szymanski et al., 2003a, Liu and Tanner, 2006, 
Karlyshev et al., 2002). Progress has also been made in our understanding of the LOS 
locus (Cj1131c - Cj1152c) (Guerry et al., 2000, Valvano et al., 2002, Gilbert et al., 2002, 
Linton et al., 2000). In addition, the N-linked glycosylation pathway (Cj1119c – 
Cj1130c) was identified before the original genome annotation (though was not 
mentioned) and this locus was further characterised in due course (Linton et al., 2005, 
Glover et al., 2005, Kelly et al., 2006, Szymanski et al., 2003a). To date, up to 81 C. 
jejuni proteins modified with the same N-linked heptasaccharide glycan structure have 
been identified (Schoenhofen et al., 2006b, Nothaft et al., 2008, Scott et al., 2010).  
 
1.6.2 Further C. jejuni genome sequences  
Further strains and species isolated from different environmental sources have since been 
sequenced (Tables 1.1 and 1.2). These include C. jejuni RM1221, isolated in 2000 from a 
chicken carcass in the U.S.A (Miller et al., 2000), C. jejuni 81-176, a highly pathogenic 
clinical strain originally isolated from a patient during an outbreak of C. jejuni 
campylobacteriosis (Korlath et al., 1985) isolated from a milk outbreak in the US 
(Hofreuter et al., 2006), a genetically stable C. jejuni 81116 strain originally isolated 
from a case of campylobacteriosis associated with a human waterborne outbreak 
(Pearson et al., 2007) and CG8486 which was isolated from a patient with inflammatory 
diarrhoea in Thailand (Poly et al., 2007). In addition, a number of different 
Campylobacter species have been sequenced and annotated such as C. lari, C. 
upsaliensis and C. coli (Fouts et al., 2005). 
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Table 1.1. C. jejuni sequencing projects at July 2010 with sequence characteristics. 
  
C. jejuni strain Source a 
State of 
genome 
sequence 
project 
Genome 
size (Mb)b 
GC 
content 
(%) 
Number 
of 
plasmids 
GenBank 
Accession 
number 
Sequencing 
centre c 
Publication 
C. jejuni subsp. jejuni 
NCTC11168 
Clinical isolate / 
faeces of a diarrheic 
patient in 1977 
Completed 1.60 30.6 0 AL111168.1 Sanger 
Parkhill et al., 
2000 
Campylobacter jejuni 
RM1221 
Skin of a retail 
chicken in 2000 
Completed 1.80 30.3 0 CP000025.1 JCVI 
Fouts et al. 
2005 
Campylobacter jejuni 
subsp. jejuni 81116 
(NCTC11828) 
Clinical isolate / 
waterborne outbreak 
in 1983 
Completed 1.60 30.3 0 CP000814.1 BBSRC IFR 
Pearson et al., 
2007 
Campylobacter jejuni 
subsp. jejuni 81-176 
Clinical isolate / 
Campylobacteriosis 
Outbreak in 1985 
Completed 1.68 30.5 2 CP000538.1 JCVI 
Hofreuter et 
al., 2006 
Campylobacter jejuni 
subsp. doylei 269.97 
Isolated from human 
bacteraemia 
Completed 1.8 30.6 0 CP000768 TIGR Unpublished 
Campylobacter jejuni 
subsp. jejuni IA3902 
Causes abortion in 
sheep  
Completed 1.64 30.5 0 CP001876 
Iowa State 
University 
Unpublished 
Campylobacter jejuni 
subsp. jejuni CG8486 
Clinical isolate / 
faeces of a diarrheic 
patient in 1999 
In progress ** 30.4 ** AASY00000000 NMRC 
Poly et al., 
2007 
Campylobacter jejuni 
subsp. jejuni 260.94 
Clinical isolate (GBS 
associated) 
In progress ** 30.5 ** AANK00000000 JCVI Unpublished 
Campylobacter jejuni 
subsp. jejuni 84-25 
Child cerebrospinal 
fluid  
In progress ** 30.4 ** AANT00000000 JCVI Unpublished 
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6
 
 
Campylobacter jejuni 
subsp. jejuni CF93-6 
Clinical isolate 
(MFS) 
In progress ** 30.5 ** AANJ00000000 JCVI Unpublished 
Campylobacter jejuni 
subsp. jejuni HB93-13 
Child faeces (GBS) In progress ** 30.6 ** AANQ00000000 JCVI Unpublished 
Campylobacter jejuni 
subsp. jejuni 1336 
** In progress 1.70 29.7 **  ADGL00000000 
University of 
Liverpool 
Unpublished 
Campylobacter jejuni 
subsp. jejuni 305 
Turkey isolate In progress ** ** ** ** 
University of 
Copenhagen 
Unpublished 
Campylobacter jejuni 
subsp. jejuni 327 
Turkey isolate In progress ** ** ** ** 
University of 
Copenhagen 
Unpublished 
Campylobacter jejuni 
subsp. jejuni 414 
** In progress 1.70 29.6 ** ADGM00000000 
University of 
Liverpool 
Unpublished 
Campylobacter jejuni 
subsp. jejuni BH-01-
0142 
Clinical isolate from 
patient with 
gastroenteritis 
In progress ** 27.7 ** ABKD00000000 
Naval Medical 
Research 
Center 
Poly, F et al, 
2008  
Campylobacter jejuni 
subsp. jejuni CG8421 
Clinical isolate from 
patient with 
gastroenteritis 
In progress ** 30.4 ** ABGQ00000000 
Naval Medical 
Research 
Center 
Poly, F et al, 
2008  
Campylobacter jejuni 
subsp. jejuni DFVF1099 
** In progress ** ** ** ** 
University of 
Copenhagen 
Unpublished 
Campylobacter jejuni 
subsp. jejuni 
ICDCCJ07001 
** In progress ** ** ** ** 
Dept. of 
Diagnosis for 
Infectious 
Disease 
Unpublished 
Campylobacter jejuni 
subsp. jejuni M1 
** In progress ** ** ** ** 
Danish 
Technical 
University 
Unpublished 
  
  
4
7
 
 
Campylobacter jejuni 
subsp. jejuni S3 
Poultry isolate In progress 1.70 ** ** ** 
University of 
Arizona 
Unpublished 
 
Data obtained from NCBI website (http://www.ncbi.nlm.nih.gov/).** Denotes information not yet available. a Source abbreviations: GBS, Guillain 
Barré syndrome; MFS, Miller Fisher syndrome. b Denotes genome is estimated. c Institute abbreviations: JCVI, J. Craig Venter Institute; BBSRC IFR. 
BBSRC Institute of Food Research; NMRC, Naval Medical Research Centre.  
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Table 1.2. Features of five selected C. jejuni genomes.  
 
Trait Strains 
 
Strain 
 
NCTC11168 RM1221 81-176 81116 CG8486 
Serotype HS:2 HS:53 HS:23/36 HS:6 HS:4 
MLSTa ST-21 (43) ST-354 (354) ST-42 (913) ST-283 (267) unknown 
Origin Clinical Chicken Clinical Clinical Clinical 
Genome size 
(Mb) b 
1.64 1.77 1.62 1.63 1.60 
GC content 
(%) 
30.55 30.31 30.62 30.54 30.43 
Predicted 
CDS numbers 
1654 (1643)e 1835 1568 1626 1588 
Pseudogenes 20(19)e 47 0c 1c 3c 
Poly G/C 
tractsd 
29 (22) 25 (8) 19 17 23 
Plasmids 0 0 2 0 0 
References 
(Parkhill et 
al., 2000) 
(Fouts et al., 
2005) 
(Hofreuter et 
al., 2006) 
(Pearson et 
al., 2007) 
(Poly et al., 
2007) 
 
 
Legend. a ST represents clonal complex. () indicates sequence type. b indicates genome 
size made by approximation. CG8486 genome sequence is currently in 19 contigs. c 
indicates approximate number of pseudogenes. d Poly G/C tracts represent total found. () 
indicate tracts greater than seven or more nucleotides in length and have been shown to 
vary during sequencing project. e () indicates number after NCTC11168 re-annotation.  
 
The first Campylobacter genome sequence was completed in 2000 and allowed 
researchers to partially identify the genetic makeup of this microaerophilic organism. 
This genomic data provided renewed impetus for Campylobacter research. Multiple 
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strains and species have since been sequenced and have led to greater insights into the 
organism. However, somewhat surprisingly, the ecology, epidemiology and in particular, 
the pathogenesis of C. jejuni are still poorly understood. Even a basic question, such as 
how this microaerophilic organism can persist in the natural environment yet for many 
years prove difficult to grow in laboratories, remains unanswered. Genome sequence 
data from all sequenced Campylobacter strains have identified a large number of CDSs 
still denoted as hypothetical proteins with no designated function. Characterising such 
CDSs should help further our understanding of this unique human pathogen. 
 
1.7 Aims of study 
The initial aim of this study was to undertake a comprehensive, up-to-date re-annotation 
of the C. jejuni NCTC11168 genome sequence. From this re-annotation, CDSs with a 
putative role in virulence, signal transduction or regulation of gene expression were 
selected for further investigation.  
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Chapter 2: Materials and Methods 
 
2.1 Re-annotation of C. jejuni NCTC11168 genome sequence 
A manual re-annotation of the C. jejuni NCTC11168 genome sequence was performed at 
the WTSI using the methodology outlined below.  
 
2.1.1 Sequence searches for re-annotation 
A manual re-annotation of the C. jejuni NCTC11168 genome sequence was performed 
using Artemis software release 8 (Rutherford et al., 2000). BLASTP (Altschul et al., 
1990) and FASTA (Pearson and Lipman, 1988) sequence comparisons from non-
redundant databases were performed for every CDS. Re-annotation was based, wherever 
possible on characterised genes/proteins (Parkhill et al., 2000). Re-annotation also used 
information generated from PFAM (Sonnhammer et al., 1997), PROSITE (Falquet et al., 
2002), RFAM (Griffiths-Jones et al., 2003), TMHMM (Sonnhammer et al., 1998b) and 
SIGNALP (Nielsen et al., 1997) databases search results. These databases are described 
in Table 2.1. 
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Table 2.1. Databases with corresponding search methodology used in this re-annotation. 
 
Database 
Name 
Database description 
BlastP 
Database of protein sequences used to identify similar matches to a 
query sequence via a heuristic algorithm 
FASTA 
Database of protein sequences used to identify similar matches to a 
query sequence via a local sequence alignment algorithm  
PFAM 
Database of protein families that includes their annotations and 
multiple sequence alignments generated using Hidden Markov 
Models 
PROSITE 
Database of protein domains, families and functional sites as well 
as amino acid patterns, signatures, and profiles 
RFAM Database containing non-coding RNA (ncRNA) families 
TMHMM Database predicting transmembrane helices in proteins 
SIGNALP 
 
Database predicting the presence and location of signal peptide 
cleavage sites in amino acid sequences  
 
 
 
2.1.2 Literature and additional searches for re-annotation 
Literature searches with CDS numbers and gene names was performed using PubMed 
(Entrez Pubmed), HighWire Press (HighWire Press), Scirus (Scirus - for scientific 
information only) and Google Scholar (Scholar). Updated ‘note’, ‘product’ and ‘gene’ 
qualifiers were added to each CDS in the EMBL (European Molecular Biology 
Laboratory) file. The original ‘note’ qualifier was retained for reference. Gene Ontology 
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(GO) annotation of the NCTC11168 genome sequence was performed automatically on 
submission to EMBL (accessed via the Gene Ontology Annotations link at EBI 
(European Bioinformatics Institute) (http://www.ebi.ac.uk/GOA/proteomes.html). GO 
annotation was also performed within GeneDB by performing a reciprocal FASTA 
comparison with C. jejuni RM1221 and adopting the GO annotation from orthologous 
CDSs. 
 
2.1.3 Product designation 
Results from the methods detailed in 2.1.1 and 2.1.2 were added to the ‘updated’ note 
qualifier. This data was used to evaluate whether the product function was to be updated. 
In this study, a sequence similarity of 35% was used as a benchmark for updating the 
product function. The decision to update product function was greatly aided by using 
supporting motif and characterisation data from the searches performed in 2.1.1 and 
2.1.2. Importantly, any update based on alignment data was assessed in terms of 
coverage, as partial matches without key motifs may provide inaccurate designations. 
 
2.1.4 Re-designation of pseudogenes  
Pseudogene updates were performed with the aid of TBLASTX results. A complete re-
analysis of all pseudogenes was performed using two alternative techniques. Two or 
more adjacent, in frame CDSs (previously annotated as separate pseudogene CDSs) were 
merged to create a single pseudogene containing internal stop codons. Alternatively, 
pseudogenes were modified by inserting multiple CDSs on different frames representing 
one or more frameshift in the full CDS.  
 
2.1.5 Re-designation of CDSs with an intersecting homopolymeric tract 
CDSs containing an intersecting homopolymeric tract (phase-variable CDSs) were 
merged to reflect the complete amino acid sequence, irrespective of whether the genome 
sequence indicated the CDS was in or out of phase. The result of this modification was to 
better illustrate a complete encoding of the CDS as opposed to a partial encoding 
represented by two separate CDSs. 
 
2.1.6 Genome submission   
The re-annotated genome was submitted to EMBL which acts as a database for genome 
sequences. The re-annotation can be accessed through - 
http://www.ncbi.nlm.nih.gov/nuccore/AL111168. 
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2.2 Microbiological and molecular biology techniques  
 
2.2.1 Chemicals and reagents 
Chemicals were purchased from Sigma-Aldrich (Poole, U.K), VWR/BDH/Merck (Poole, 
U.K), Fisher Scientific (Loughborough, U.K) or Invitrogen/Gibco (Paisley, U.K), unless 
stated otherwise (Appendix 1). All buffers and solutions were prepared as indicated in 
Sambrook and Russell unless otherwise stated (Sambrook and Russell, 2001). All media 
and reagent compositions not defined in the text are listed in Appendix 2. 
 
2.2.2 Sterilisation 
Solutions and buffers were sterilised either by autoclaving (Touchclave System PL, LTE 
Scientific, Oldham, U.K) or filtration. Wet steam sterilisation was performed at 121°C 
for 20 minutes. Dry steam sterilisation was performed at 134°C for 15 minutes. Filter 
sterilisation was performed using a 10 ml syringe (BD Plastipak, Oxford, U.K) and a 0.2 
µm (32 mm) Acrodisc Syringe Filter with Supor Membrane (Pall Life Sciences, 
Portsmouth, U.K). All molecular reactions used filter sterilised Milli-Q grade water 
(Millipore, Billerica, U.S.A). All other solutions and buffers were prepared using Milli-
RO (Reverse Osmosis) grade water (Millipore).  
 
2.2.3 Bacterial strains 
C. jejuni strains used in this study are described in Table 2.2. 
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Table 2.2. C. jejuni strains used in this study. 
 
C. jejuni strains Description References 
11168H 
A hypermotile derivative of the original 
sequence strain NCTC11168 that shows 
higher levels of caecal colonisation in a 
chick colonisation model 
(Karlyshev et al., 
2002, Jones et al., 
2004) 
11168H Cj1556 
mutant 
 
Isogenic mutant of Cj1556 with the 
insertion of a 1.4 kb KmR cassette at 
position 202 of the Cj1556 nucleotide 
sequence 
 
This study 
11168H Cj1556 
complement 
 
Cj1556 complement constructed with the 
insertion of Cj1556 (0.33 kb) into the 
Cj0233 pseudogene, in the Cj1556 mutant 
chromosome 
 
This study 
11168H Cj0248 
mutant 
Isogenic mutant of Cj0248 with the 
insertion of a 1.4 kb KmR cassette at 
position 454 of the Cj0248 nucleotide 
sequence 
This study 
 
 
E. coli strains used in this study are described in Table 2.3. 
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Table 2.3. E. coli strains used in this study. 
 
E. coli strains Description Reference 
XL2-Blue MRF strain 
Epicurian coli XL2 Blue 
MRF’ Competent cells 
Stratagene 
SCS110 
E. coli competent cells - DAM 
methylase negative. 
Stratagene 
  
 
2.2.4 Plasmids 
Plasmids used in this study are described in Table 2.4. 
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Table 2.4. Plasmids used in this study. 
 
 Plasmids Description Reference 
pGEM-T Easy PCR cloning vector, ampicillin resistant Promega 
pUC-Cj1556 
pUC library clone (cam25a2 
(1489074..1490567)) used for the C. jejuni 
NCTC11168 genome sequencing project. A 
1.49 kb insert containing the CDSs Cj1555c – 
Cj1560 including Cj1556 (0.33 kb). 
(Parkhill et 
al., 2000) 
pGEM-Cj0248 
pGEM-T Easy vector containing Cj0248 CDS 
fragment (0.84 kb) 
This study 
pUC-Cj1556-KmR 
pUC-Cj1556 containing Cj1556 with a 1.4 kb 
KmR inserted at position 202 of the Cj1556 
nucleotide sequence 
This study 
pGEM-Cj0248-KmR 
pGEM-T Easy containing Cj0248 with a 1.4 
kb KmR inserted at position 454 of the Cj0248 
nucleotide sequence 
This study 
 
 
2.2.5 Primers 
Primers used in this study are described in Table 2.5. 
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Table 2.5. Primers used in this study. 
 
Primer Name Sequence 
Cj1556-F ATCATTCTCTTTGTCCTAT 
Cj1556-R TAAGATGGATTCTAAACTATTG 
Comp-Cj1556-F 
CCCCCATGGATAAGGATTTATAATGAAAAAATATCAT
TCTCT 
Comp-Cj1556-R CCCGCTAGCTTAAACGATATTTTTATAGCTAT 
Cj0248-F ATGATTGGAGATATGAATGA 
Cj0248-R TTTCCTTAGCTTTGTTAGGA 
Cj0248-IPCR-F GGGAGATCTTCTTATACAAAATC 
Cj0248-IPCR-R GGAGATCTTAACAATACCAAGCC 
Comp-Cj0248-F 
CCCCCATGGATTAAGGATAAATTAAATATGATTGGAG
ATATGAATG 
Comp-Cj0248-R CCCGCTAGCTTAATCTTCTTTGTTTAAATTT 
KmR forward-out TGGGTTTCAAGCATTAGTCCATGCAAG 
KmR reverse-out GTGGTATGACATTGCCTTCTGCG 
 
 
2.2.6 Statistical analysis 
All experimental data is represented using the average of at least three biological 
replicates performed in triplicate. Error bars represent the standard error of mean. 
Statistical analyses were performed using GraphPad Prism software (v4.02). Variables 
  
  58 
were compared for significance using a student’s t-test with one star (*) indicating p = 
0.01 - 0.05, two stars (**) indicating p = 0.001- 0.01 and three stars (***) p < 0.001. 
  
2.2.7 Bacterial growth and storage 
All media and reagents not defined in this text are described in Appendix 2. C. jejuni 
cells were resuscitated from glycerol stocks by plating onto blood agar plates and 
incubated at 37°C under microaerobic conditions (85% Nitrogen, 10% Carbon dioxide 
and 5% Oxygen) in a variable atmospheric incubator (VAIN) (Don Whitley Scientific, 
Shipley, U.K). C. jejuni restreaks were performed every 3 or 4 days up to a maximum of 
10 passages. Overnight cultures of C. jejuni were prepared by adding an appropriate 
quantity of a bacterial suspension (see Section 2.2.8) to 10 ml Brucella broth (Sigma-
Aldrich) in a 50 ml flask (Thermo Scientific, Massachusetts, U.S.A). Cultures were 
incubated at 37°C under microaerobic conditions on a shaker (75 rpm) (Platform Shaker 
STR6, VWR-Jencons, East Grinstead, U.K). Escherichia coli cells were resuscitated 
from glycerol stocks and plated onto Luria-Bertani (LB) agar plates and were incubated 
at 37°C under aerobic conditions in an incubator (Sanyo, Loughborough, U.K). LB 
plates with E. coli grown overnight were sealed with Parafilm M (Neenah, U.S.A) and 
stored at 4°C for 2-3 weeks. Overnight cultures of E. coli were prepared by adding a 
single colony to 10 ml LB broth in a 30 ml universal. Cultures were grown at 37°C under 
aerobic conditions in an incubator shaking at 200 rpm (Weiss Gallenkamp, 
Loughborough, U.K). Appropriate antibiotics were added at the following 
concentrations; ampicillin (100 μg/ml), kanamycin (50 μg/ml), chloramphenicol for E. 
coli growth (50 μg/ml) or for C. jejuni growth (10 μg/ml). Glycerol stocks were prepared 
for C. jejuni (from an overnight plate) and E. coli (from an overnight liquid culture) cells 
using 10% (v/v) glycerol, 10% (v/v) Foetal Calf Serum (FCS) (Sigma-Aldrich) and 80% 
(v/v) Mueller-Hinton broth mixture (C. jejuni) or 15% (v/v) glycerol in LB broth (E. 
coli). 500 μl aliquots were snap-frozen using dry ice in 100% (v/v) ethanol and stored in 
a -80°C freezer (New Brunswick Scientific, St. Albans, U.K).   
 
2.2.8 Preparation of a specific OD600 C. jejuni suspension   
15 ml Brucella broth was preincubated in a 50 ml flask at 37°C under microaerobic 
conditions for 24 h. C. jejuni were grown on blood agar plates for 24 h. C. jejuni were 
collected using a sterile swab and resuspended in 1 ml Brucella broth. 100 µl of this 
suspension was resuspended in 900 µl Brucella broth in a 1.5 ml microcentrifuge tube. 
This diluted suspension was vortexed, transferred to a 1 ml spectrophotometer cuvette 
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and the OD600 recorded using a spectrophotometer (S2000 UV/Vis Spectrophotometer, 
VWR-Jencons, Leighton Buzzard, U.K). 1 ml Brucella broth was used as a blank. The 
volume of the original C. jejuni suspension to be added to the 15 ml of equilibrated 
Brucella broth to produce an initial inoculum with an OD600 of 0.1 was calculated as 
follows:- 
 
 
 
 
2.2.9 Isolation of genomic DNA 
Bacterial genomic DNA was isolated using the Gentra – Puregene DNA Purification Kit 
(Gentra Systems Inc, Flowgene, Lichfield, U.K). C. jejuni cells were collected from a 24 
h blood agar plate using a sterile swab and resuspended in 0.75 ml Phosphate Buffered 
Saline (PBS) in a 1.5 ml microcentrifuge tube and centrifuged at 13,000 rpm for 5 
seconds. The supernatant was removed and 300 μl Cell Lysis Solution was added to the 
sample tube and mixed until the bacterial pellet was thoroughly resuspended. The 
suspension was incubated at 80°C for 5 minutes. 1.5 μl RNase A Solution (80 U/ml) was 
then added to the cell lysate. The tube was mixed by inverting 25 times and incubated at 
37°C for 45 minutes. Once cooled to room temperature, 100 μl Protein Precipitation 
Solution was added to the RNase A-treated cell lysate, vortexed for 20 seconds and then 
0.1 
OD600 Reading x 10 
= 
Volume of cells (µl) 
to add from original 
bacterial suspension 
x x 1000 15 
Required OD600 
in final solution 
Initial OD600 reading 
of diluted bacterial 
suspension  
Dilution factor  
Final volume (ml)  
Conversion 
from ml to µl 
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centrifuged at 13,000 rpm for 3 minutes. The process of vortexing and centrifugation was 
repeated to achieve greater separation of DNA from protein. The supernatant containing 
the DNA was transferred into a 1.5 ml microcentrifuge tube containing 300 μl 100% 
(v/v) isopropanol and mixed by inverting 50 times. The resulting suspension was 
centrifuged at 13,000 rpm for 1 minute at which point the DNA was usually visible as a 
small white pellet. The supernatant was carefully removed and the microcentrifuge tube 
inverted and drained on absorbent paper for 20 minutes. 300 μl of 70% (v/v) ethanol was 
then added and the DNA pellet was rinsed by inverting the tube several times. This tube 
was centrifuged at 13,000 rpm for 1 minute. The remaining ethanol was poured off and 
the tube was air dried for 15 minutes. 50 μl DNA Hydration Solution was added to the 
sample tube and the DNA rehydrated by incubating the sample for 1 h at 65°C. Genomic 
DNA concentrations were quantified using a NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies, Wilmington, U.S.A). Genomic DNA was stored at -20°C. 
 
2.2.10 RNA Extraction  
10 ml Brucella broth was preincubated in a 50 ml flask at 37°C under microaerobic 
conditions for 24 h. A C. jejuni suspension was prepared and used to inoculate this broth 
to a starting OD600 of 0.1 (see Section 2.2.8). C. jejuni cultures were grown for 16 h. 
RNA extraction was performed using the Qiagen RNeasy kit and RNAprotect Bacteria 
Reagent (Qiagen) as follows. 8 ml RNAprotect Bacteria Reagent was added to a 30 ml 
universal. 4 ml of the 16 h C. jejuni culture was added to this universal and briefly 
vortexed. This mixture was incubated for 5 minutes at room temperature, then 
centrifuged at 4,000 rpm for 10 minutes followed by the removal of the resulting 
supernatant. 200 µl TE buffer/lysozyme mix (950 µl TE (pH 8.0) + 50 µl lysozyme (1 
mg/ml)) was added and mixed to resuspend the pellet using a P1000 Gilson pipette for 1 
minute. This suspension was then incubated for 10 minutes at room temperature, 
vortexing every 2 minutes. 700 µl buffer RLT mix (10 µl β-mercaptoethanol (14.3 M) 
(Stratagene, Amsterdam, Holland) + 1 ml buffer RLT) was added to the mix and 
vortexed vigorously. 500 µl 100% (v/v) ethanol was then added and mixed by pipetting. 
700 µl of this suspension was added to an RNeasy Mini spin column and centrifuged for 
15 seconds at 10,000 rpm. The flow through was discarded. The above procedure was 
repeated for any remaining suspension to further increase RNA yield. 350 µl of buffer 
RW1 was added to the spin column and centrifuged for 15 seconds at 10,000 rpm. The 
resulting flow through was discarded. 80 µl DNaseI/buffer RDD mix (Qiagen) (10 µl 
DNaseI stock solution + 70 µl Buffer RDD) was added directly onto the membrane and 
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incubated at room temperature for 15 minutes. 350 µl Buffer RW1 was added to the spin 
column and centrifuged for 15 seconds at 10,000 rpm. The spin column was then 
transferred to a fresh 2 ml collection tube. 500 µl Buffer RPE was added to the spin 
column and centrifuged for 15 seconds at 10,000 rpm. The flow through was discarded. 
Another 500 µl Buffer RPE was added to the spin column and centrifuged for 2 minutes 
at 10,000 rpm. The column was then placed in a new 2 ml collection tube and 
centrifuged for a further 1 minute at 13,000 rpm to allow removal of any Buffer RPE 
carryover. The spin column was then removed from the collection tube and placed into a 
new 1.5 ml microcentrifuge tube. 50 µl RNase-free water was added directly onto the 
RNeasy silica membrane in the spin column and then centrifuged for 1 minute at 10,000 
rpm to allow elution. The elution was reapplied to the membrane and centrifugation was 
repeated for 1 minute at 10,000 rpm. RNA concentrations were quantified using a 
NanoDrop ND-1000 spectrophotometer. RNA was stored at -80°C.   
  
2.2.11 Polymerase Chain Reaction 
Oligonucleotide primers (Sigma-Aldrich) were designed manually or using the web 
program Primer3 (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Primers 
were checked for ‘self-dimers’ and ‘hairpins’ using the web program IDT SciTools – 
OligoAnalyzer 3.0 
(http://www.idtdna.com/analyzer/Applications/OligoAnalyzer/Default.aspx). Primers 
were resuspended in sterilised Milli-Q water and diluted to a final concentration of 100 
pmol/μl.  
 
A dNTP stock solution containing 1.25 mM of dATP, dTTP, dCTP and dCTP was 
prepared as follows:- 
 
dNTP 1.25 mM Stock  
dATP (100mM)  - 12.5 μl 
dTTP (100mM)  - 12.5 μl 
dGTP (100mM)  - 12.5 μl  
dCTP (100mM)  - 12.5 μl 
Sterilised Milli-Q water - to 1000 μl 
 
Standard polymerase chain reaction (PCR) pre-mix was prepared as follows:- 
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10X Buffer     - 100 μl 
dNTPs (1.25mM)    - 168 μl 
MgCl2 (25 mM)   - 60 μl 
Taq polymerase (5 U/μl)   - 6 μl 
Sterilised Milli-Q water  - to 1000 μl 
 
Standard PCR pre-mix was mixed using a P100 Gilson pipette and stored at -20°C. 
 
Typical PCR reactions were performed as follows:- 
 
Forward primer (100 pmol/μl) - 0.075 μl*  
Reverse primer (100 pmol/μl) - 0.075 μl 
Genomic DNA (10 – 100 ng/ /μl) - 1 μl 
Standard PCR pre-mix  - to 20 μl 
* A 10 reaction volume was typically used to allow greater accuracy during pipetting e.g. 
0.75 μl forward and reverse primer.  
 
Standard PCR programme 
Step 1 – Denature at 94°C for 15 seconds 
Step 2 – Anneal at 50°C for 1 minute 
Step 3 – Extension at 72°C for 1 minute 
Repeat steps 1-3 34 times 
Step 4 – End cycle with 72°C for 7 minutes 
 
Steps 2 or 3 were varied to optimise PCR amplification or to amplify larger products 
where each minute for extension amplified approximately 1.5 kb. PCR amplification was 
performed using an MJ Research PTC-225 Peltier Thermal Cycler (GRI, Braintree, 
U.K). 
 
2.2.12 Agarose gel electrophoresis  
0.7% (w/v) TAE agarose gels were prepared as described in Appendix 2. The agarose 
suspension was heated in a microwave until molten and allowed to cool to approximately 
50°C. Ethidium bromide (10 mg/ml / Promega) was added to the agarose to a final 
concentration of 0.5 μg/μl. The agarose was poured into a sealed gel tray (Scie-Plas, 
Southam, U.K) with appropriate combs in place and allowed to gel. The well combs 
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were then removed. The gel was then placed into a gel tank (Scie-Plas) and fully 
immersed in 1X TAE buffer. 20 μl of PCR reactions were mixed with 5 μl gel loading 
buffer (Appendix 2) then loaded into individual wells. A 1-10 kb ladder (HyperLadder 1 
– Bioline, London, U.K) was run parallel to the samples to allow PCR product sizes to be 
ascertained. Electrophoresis was performed using a Hybaid PS250 (Hybaid Ltd, 
Middlesex, U.K) with settings of 120V and 500mA. Running time was approximately 45 
minutes. Gels were visualised using a GeneGenius Gel-Documentation System 
(SynGene, Cambridge, U.K).  
 
2.2.13 PCR product purification 
PCR products and also restriction endonuclease reactions (see Section 2.2.11 and 2.2.19) 
were purified using the QIAquick PCR Purification kit (Qiagen). 5 volumes of buffer PB 
was added to 1 volume of PCR reaction. This mixture was transferred onto a QIAquick 
spin column in a 2 ml collection tube and centrifuged at 13,000 rpm for 1 minute. The 
flow-through was discarded and the QIAquick column was placed back into the same 2 
ml collection tube. 0.75 ml buffer PE was applied to the QIAquick column and 
centrifuged for 1 minute at 13,000 rpm. The flow-through was discarded and the 
QIAquick column was placed back into the 2 ml collection tube and centrifuged at 
13,000 rpm for an additional minute. The QIAquick column was transferred to a new 1.5 
ml microcentrifuge tube and 50 μl sterilised Milli-Q water was applied to the centre of 
the QIAquick membrane. This was allowed to fully absorb for 1 minute at room 
temperature and then centrifuged at 13,000 rpm for an additional minute. Sample 
concentrations were recorded using a NanoDrop ND-1000 spectrophotometer. Purified 
PCR products were stored at -20°C. 
 
2.2.14 Gel fragment purification  
Purification of PCR products from agarose gels was performed using the GenElute Gel 
Extraction Kit (Sigma-Aldrich). Samples to be purified were separated on a 0.7% (w/v) 
TAE agarose gel (see Section 2.2.12). Gels were visualised using near-UV light (365 
nm) on a TM-20 transilluminator (UVP, Cambridge, U.K) in a dark room under red 
light. The appropriate band was excised from the agarose gel with a sterile scalpel and 
placed into a 1.5 ml microcentrifuge tube. The excised agarose sample was weighed and 
3 gel volumes of Gel Solubilization Solution was added to the 1.5 ml microcentrifuge 
tube containing the gel fragment then heated at 55°C for 10 minutes with brief vortexing 
every 2-3 minutes to ensure the gel was fully dissolved. A GenElute Binding Column G 
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was placed into a 2 ml collection tube. 500 μl of Column Preparation Solution was 
applied to the column and centrifuged at 13,000 rpm for 1 minute. The flow through was 
discarded. 1 gel volume of 100% (v/v) isopropanol was added to the solubilized gel and 
mixed until homogenous. The solubilized gel solution was then loaded onto the prepared 
binding column and centrifuged at 13,000 rpm for 1 minute. The flow-through was 
discarded. 700 μl of Wash Solution was applied to the binding column and centrifuged 
for 1 minute at 13,000 rpm. The flow through was discarded and the column was placed 
back into the same 2 ml collection tube and centrifuged for an additional minute at 
13,000 rpm. DNA elution was performed by transferring the binding column to a fresh 
collection tube and applying 50 μl Elution Solution to the centre of the binding column. 
This was allowed to absorb for 1 minute before centrifuging for 1 minute at 13,000 rpm. 
Sample concentrations were recorded using a NanoDrop ND-1000 spectrophotometer. 
Purified DNA fragments were stored at -20°C. 
 
2.2.15 DNA ligation 
Ligation reactions were performed using the pGEM-T Easy kit (Promega). The amount 
of PCR product to be ligated into the pGEM-T Easy vector was calculated using the 
equation below.  
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    e.g. 
  
 
 
Molar ratios of 3:1 for insert:vector were recommended by the manufacturer, however 
ratios down to 1:8 were also successfully used. The ligation reaction was set up as 
follows:- 
 
2X Rapid Ligation Buffer    - 5 μl 
pGEM-T Easy Vector (50 ng/μl)    - 1 μl 
PCR product      - X μl 
T4 DNA Ligase (3 Weiss units/μl)   - 1 μl 
Sterilised Milli-Q water    - to 10 μl 
 
The reaction mixture was mixed gently by pipetting and incubated overnight at 4°C. 
 
2.2.16 Transformation of E. coli cells  
The DNA ligation mixture (see Section 2.2.15) was briefly centrifuged. 2 μl ligation mix 
was added to a 1.5 ml microcentrifuge tube and incubated on ice. A separate 1.5 ml tube 
ng of vector x kb size of insert 
insert 
kb size of vector  
ng of insert insert:vector 
molar ratio 
= x 
50 ng x 1.3 kb 
3.0 kb 
= 173.3 ng 1:8 x 
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was incubated on ice and 2 µl of β-mercaptoethanol (14.3 M) added. To this tube, 100 μl 
Epicurian coli XL2 Blue MRF’ Competent cells (Stratagene) was added, mixed and 
incubated on ice for 5-10 minutes. The cells were mixed by gently tapping the tubes 
every 2/3 minutes. 50 μl of these competent cells were transferred into the tube 
containing the 2 μl ligation mix. This tube was gently tapped to mix and then incubated 
on ice for 20 minutes. The cells were heat-shocked in a 42°C water bath for 45-50 
seconds and then incubated on ice for 2 minutes. 950 μl SOC media (at room 
temperature) was then added to the transformation reaction and incubated for 1.5 h at 
37°C with shaking at 200 rpm. 100 μl of the transformation culture was plated onto 
LB/ampicillin/IPTG/X-Gal plates (Appendix 2). The plates were incubated for 12 - 16 h 
at 37°C. White colony transformants were selected for further study. 
 
2.2.17 Screening by vector primer PCR / insert specific PCR  
White colony transformants were restreaked onto LB plates and incubated overnight at 
37°C. A single colony from the restreaked plate was selected and resuspended in 100 μl 
sterilised Milli-Q water, briefly vortexed and heated at 95°C for 10 minutes followed by 
centrifuging at 13,000 rpm for 5 minutes. Vector primer PCR (VPPCR) reactions were 
set up as follows:- 
 
Forward T7 primer (100 pmol/μl)  - 0.075 μl 
Reverse SP6 primer (100 pmol/μl)  - 0.075 μl 
Boilate supernatant     - 1 μl 
VPPCR pre-mix    - to 25 μl 
 
Standard PCR programmes were performed (see Section 2.2.11). PCR reactions were 
analysed on a 0.7% (w/v) TAE agarose gel (see Section 2.2.12). A variation of VPPCR 
was to use insert specific primers (ISPCR) using the original primers used for 
amplification of the CDS of interest (see Section 2.2.11) to test for positive 
transformants.  
  
2.2.18 Isolation of plasmid DNA 
Plasmid minipreps were performed using QIAprep Miniprep Kits (Qiagen). An overnight 
culture of E. coli was prepared by adding a single colony to 10 ml LB broth in a 30 ml 
universal, then incubated at 37°C in an incubator shaking at 200 rpm. The overnight 
bacterial suspension was centrifuged at 4,000 rpm for 10 minutes. The supernatant was 
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discarded. The pellet of bacterial cells was resuspended in 250 μl buffer P1 and 
transferred to a 1.5 ml microcentrifuge tube. 250 μl buffer P2 was added and mixed by 
inverting 4-6 times. This was followed by adding 350 μl buffer N3 and mixing 
immediately by inverting the tube 4-6 times. The mixture was then centrifuged at 13,000 
rpm for 10 minutes. The supernatant was transferred to a QIAprep spin column and 
centrifuged for 1 minute. The resulting flow-through was discarded. 0.5 ml buffer PB 
was added to the column and this was centrifuged for 1 minute. The flow-through was 
discarded and 0.75 ml buffer PE was added to the column. The column was then 
centrifuged at 13,000 rpm for 1 minute. The flow-through was discarded and centrifuged 
again for 1 minute at 13,000 rpm to remove residual wash buffer. Finally, the QIAprep 
column was transferred to a clean 1.5 ml microcentrifuge tube and 50 μl buffer EB was 
applied to the centre of the column. This was allowed to absorb for 1 minute before 
centrifuging for 1 minute at 13,000 rpm. Plasmid DNA concentrations were recorded 
using a NanoDrop ND-1000 spectrophotometer. Plasmid DNA samples were stored at -
20°C. 
 
2.2.19 Restriction endonuclease digests 
Standard restriction digests were prepared using a final volume of 20 μl. 0.5 – 1.0 μg 
plasmid DNA was digested with 10 U of the appropriate restriction endonuclease and 
buffer (New England Biolabs, Hitchin, U.K). Reactions were prepared in 1.5 ml 
microcentrifuge tubes and incubated at the appropriate temperature and time duration 
recommended by the manufacturer. Digests were purified using the QIAquick PCR 
Purification kit (see Section 2.2.13). 
 
2.2.20 DNA sequencing 
Sequencing of plasmid DNA was performed using ABI Prism Terminator Ready 
Reaction Mix (Applied Biosystems, Warrington, U.K). Sequencing reactions were also 
performed on genomic DNA (see Section 2.2.9) using similar concentrations as for 
plasmid DNA. 
 
ABI Reaction Mix       - 8 μl 
Plasmid or genomic DNA (200 – 500 ng)    - 1 μl 
Forward or reverse CDS specific primer* (1 pmol/μl)  - 4 μl 
Sterilised Milli-Q water      - to 20 μl 
*Sequencing reactions were also performed using a vector specific primer. 
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PCR cycle 
Step 1 – Denature at 96°C for 10 seconds 
Step 2 – Anneal at 50°C for 5 seconds 
Step 3 – Extension at 60°C for 4 minutes 
Repeat steps 1-3 25 times 
 
Sequencing reactions were performed on a GeneAmp 9600 thermal cycler (Perkin-
Elmer, Beaconsfield, U.K). The entire sequencing reaction was then transferred to a 1.5 
ml microcentrifuge tube containing 80 μl 75% (v/v) isopropanol. The sample was briefly 
vortexed and incubated at -20°C for 1 h. The sample was then centrifuged at 13,000 rpm 
for 30 minutes and the supernatant discarded. 400 μl of 75% (v/v) isopropanol was added 
to the pellet and briefly vortexed before centrifuging at 13,000 rpm for 5 minutes. The 
supernatant was removed using a pipette. The pellet was dried at room temperature for 
approximately 20 minutes. 10 μl HiDi solution (Applied Biosystems) was applied to the 
pellet and the reaction mixture sequenced using the ITD Faculty facilities. Analysis of 
sequence data was performed using Chromas v1.61 software (Technelysium Pty. Ltd). 
  
2.2.21 Mutagenesis strategy  
Defined isogenic C. jejuni mutants were constructed in this study as follows. Before 
designing amplifying primers, the CDS of interest was checked for the presence of 
BamHI, BclI or BglII restriction sites. If any of these restriction sites were present in the 
CDS of interest, the mutagenesis strategy would not require inverse PCR mutagenesis 
(IPCRM) (see Section 2.2.23). Primers for the CDS of interest were designed (see 
Section 2.2.11) and the CDS/CDS fragment was PCR amplified (see Section 2.2.11). 
After confirmation of PCR product size and purification (see Section 2.2.13), the PCR 
product was cloned into the pGEM-T Easy vector followed by transformation into E.coli 
XL2 cells (or E. coli SCS110 cells if the unique restriction site was BclI) (see Sections 
2.2.15 and 2.2.16). Isolation of plasmid DNA was followed by checking for positive 
transformants and glycerol stock preparation (see Sections 2.2.7, 2.2.17, 2.2.19 and 
2.2.20).  
 
The second stage was to incorporate a KmR cassette into the CDS of interest. IPCRM 
was performed at this stage if required (see Section 2.2.23). Restriction digests were 
performed to allow the ligation of BamHI digested KmR cassette into the centre of the 
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cloned CDS/CDS fragment (see Sections 2.2.19) followed by transformation into E.coli 
XL2 cells (see Sections 2.2.15 and 2.2.16). Isolation of plasmid DNA was followed by 
checking for correct sized insert, correct orientation of the KmR cassette and glycerol 
stock preparation (see Sections 2.2.7, 2.2.17, 2.2.19 and 2.2.20).  
 
The final stage was to transform this plasmid construct by electroporation into C. jejuni 
11168H wild-type strain (see Section 2.2.24) followed by screening for positive mutants 
(see Section 2.2.25). 
 
2.2.22 Mutation of individual C. jejuni CDSs 
A KmR cassette (aphA-3 (Trieu-Cuot et al., 1985)) was isolated from pJMK30 (van Vliet 
et al., 1998) following a BamHI restriction digest. The C. jejuni CDS to be mutated was 
analysed for the presence of a single BamHI, BclI or BglII site within the sequence using 
NEBcutter v2.0 (http://tools.neb.com/NEBcutter2/index.php). The unique restriction site 
should ideally be located near the centre of the amplified CDS/CDS fragment to improve 
efficiency of recombination. All three restriction sites are complementary to BamHI. 
When using BclI, the original plasmid and CDS of interest transformation was performed 
using SCS110 E. coli competent cells (Stratagene), rather than Epicurian coli XL2 Blue 
MRF’ Competent cells (Stratagene), due to the BclI restriction site exhibiting DAM 
methylase sensitivity. It would not be possible to BclI digest plasmid DNA from XL2 
cells which are DAM methylase positive. SCS110 cells are DAM methylase negative. 
 
To allow insertion of the KmR cassette, 2 μg plasmid DNA containing the cloned CDS of 
interest was digested with approximately 20 units restriction enzyme (BamHI, BclI or 
BglII) (see Section 2.2.19). The digest were purified using the QIAquick PCR 
Purification kit (see Section 2.2.13) and sample concentrations were recorded using a 
NanoDrop ND-1000 spectrophotometer. The following ligation reaction was then set 
up:-  
 
Plasmid DNA digested with unique restriction enzyme (≈ 250 ng/μl)  - 2 μl  
KmR cassette digested with BamHI (≈ 20 ng/μl)     - 5 μl  
10X Ligase buffer         - 1 μl 
T4 DNA Ligase (3 Weiss units/μl)       - 2 μl 
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Reactions were incubated overnight at 4°C. Transformation of the reaction mixture into 
XL2 or SCS110 cells was performed as described in Section 2.2.16. Transformants were 
selected on LB/ampicillin/kanamycin plates and incubated overnight at 37°C. Colonies 
were restreaked onto LB/ampicillin/kanamycin plates and checked for the insertion of a 
KmR cassette by carrying out ISPCR (see Section 2.2.17). Plasmid DNA was isolated 
from positive clones as described in Section 2.2.18. The orientation of the KmR cassette 
was determined by performing multiple combinations of CDS specific and kanamycin 
specific primer PCR reactions (Appendix 3 and 4). 
 
2.2.23 Inverse PCR mutagenesis 
IPCRM was performed when the CDS to be mutated did not contain a BamHI, BclI or 
BglII restriction site. IPCRM primers were designed by selecting 15-20 nucleotides in 
the centre of the CDS to be mutated with an interspacing region of 10-15 nucleotides 
(Figure 2.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  71 
ATGATTGGAGATATGAATGAGCTTTTATTAAAAAGCGTTGAAGTATTGCCACCTTTACCTGATAC
TGTAAGTAAGTTAAGAAAATATGTGAGCGAGGCTAATTCAAATATAGAAACTATGAAAGTTGCTG
AAATCATTTCAAGCGATCCGTTGATGACGGCTAAGCTTTTGCAATTAGCAAATTCTCCTTATTAT
GGTTTTACAAGAGAAATTACAACCATAAATCAAGTGATTACTTTATTAGGCGTTGGTAATATCAT
CAATATAGTTATGGCTGACTCCATTAGAGATAATTTTAAAATAGACGTTTCACCTTATGGTTTAA
ATACTCAAAATTTTTTAAAAACGTGCAATGAAGAGGCAACTTTTATCGCAAATTGGCTTAATGAT
GAAGATAAAAAACTTTCTCATCTTTTAGTTCCTTGTGCAATGCTTTTAAGGCTTGGTATTGTTAT
TTTTTCAAATTTTCTTATACAAAATCATAAGGATAAGGATTTTTTAGCTTTTTTAAATAAAAATG
AAAATCTTGCTTTAGCGGAGAATGAATTTTTAGGCGTAGATCATATTTCTTTCTTGGGATTTTTG
TTACATCGTTGGAATTTTGATGATGTTTTGATTGAAAGTATATGTTTTGTTCGCACTCCTCATGC
TGCTCGCGAAAAAGTGAAAAAATCCGCTTATGCTTTAGCAATAACAGATCATCTTTTTGCTCCGC
ATGATGGTTCTTCTCCATTTAACGCAAAAGCTGCAGTTGCTTTACTTAAAGAGGCAAAAACTCAA
GGAATTAATTTTGATTTAAACAATCTTTTATCTAAGCTTCCTAACAAAGCTAAGGAAAATTTAAA
CAAAGAAGATTAA 
 
Cj0248-IPCRM–F = 5’ GGGAGATCTTCTTATACAAAATC 3’   
 
Cj0248-IPCRM–R = 5’ GGGAGATCTTAACAATACCAAGCC 3’ 
 
 
 
Figure 2.1. IPCRM primers designed for Cj0248. The 5’-end of the IPCRM primers 
contained three guanine residues to allow efficient functionality of the BamHI restriction 
site. This was followed by the BamHI complementary sequence – AGATCT.  
 
IPCRM reactions were performed using cloned CDS fragments at a diluted concentration 
of approximately 0.1-10 ng. The reduced concentration of template DNA was used to 
minimise the number of false positives after transformation into XL2 cells (described 
below). 
 
The following reactions were prepared:- 
 
IPCRM Pre-Mix  
Buffer I (10X)         - 10 μl 
AccuPrime Taq DNA high fidelity polymerase* (5 U/μl) (Invitrogen)  - 0.4 μl 
Milli-Q water          - 89.6 μl 
*dNTPs are present in Buffer I at a concentration of 400 μM. 
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IPCRM reaction  
IPCRM Pre-mix  - 98.4 μl 
DNA (0.1 – 10 ng)  - 1.0 μl  
IPCRM primers* - 0.6 μl 
*IPCRM primers were resuspended in sterilised Milli-Q water and diluted to a final 
concentration of 100 pmol/μl. A 1:1 mix of both primers was prepared giving a working 
concentration of each primer of 50 pmol/μl.  
 
IPCRM reaction conditions 
Step 1 – 94°C for 2 minutes 
Step 2 – Denature at 94°C for 1 minute 
Step 3 – Anneal at 45°C for 1 minute 
Step 4 – Extension at 72°C for X minutes (X = size of plasmid in kb x 1.5 minutes) 
Repeat steps 2-4 40 times 
Step 5 – 72°C for 7 minutes 
 
15 μl of the PCR reaction was analyzed on an agarose gel (see Section 2.2.12). The 
amplified IPCRM product was purified using the QIAquick PCR Purification kit (see 
Section 2.2.13). Sample concentrations were recorded using a NanoDrop ND-1000 
spectrophotometer. The amplified IPCRM product was then digested with BglII and 
DpnI for 3 h at 37°C. Digestion using DpnI was performed to ensure the 
reduction/elimination of methylated template DNA that would lead to false positive 
transformation (Shenoy and Visweswariah, 2003). Digestion volumes were as follows:-  
   
Amplified IPCRM product (10-500 ng/μl)  - 20 μl  
BglII (20 units)     - 2 μl 
DpnI (20 units)      - 2 μl 
NEBuffer 2      - 10 μl 
Milli-Q water       - to 100 μl  
 
Restriction endonuclease reactions were purified using the QIAquick PCR Purification 
kit as described in Section 2.2.13. Sample concentrations were again recorded using a 
NanoDrop ND-1000 spectrophotometer. To perform the insertion of the KmR cassette 
and re-ligation of the digested IPCRM product, the following reaction was set up:- 
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Amplified IPCRM product digested with BglII and DpnI (≈ 250 ng/μl) - 2 μl  
KmR cassette digested with BamHI (≈ 20 ng/μl)     - 5 μl  
10X Ligase buffer           - 1 μl 
T4 DNA Ligase (3 Weiss units/μl)        - 2 μl  
 
The reaction was incubated overnight at 4°C. The ligation reactions were then 
transformed into XL2 E. coli cells (see Section 2.2.16). Transformants were selected on 
LB/ampicillin/kanamycin plates. Colonies were screened using ISPCR (see Section 
2.2.17). Positive colonies were re-streaked onto LB/ampicillin/kanamycin plates and 
plasmid DNA isolated (see Section 2.2.18).  
  
2.2.24 Transformation of C. jejuni cells by electroporation 
Bacterial cells from a 24 h plate of C. jejuni 11168H were collected using a sterile loop 
and resuspended in 10 ml ice cold EBF buffer (Appendix 2) in a universal container. The 
suspension was centrifuged at 4,000 rpm for 10 minutes and the supernatant discarded. 
The pellet was then resuspended in 1 ml ice cold EBF buffer, transferred to a 1.5 ml 
microcentrifuge tube and centrifuged at 13,000 rpm for 2 minutes. This process was 
repeated before resuspending the pellet in 250 μl ice cold EBF buffer. 5 μl ice-cold 
plasmid DNA (1-5 μg) was then added to 50 μl C. jejuni 11168H suspension and mixed 
by pipetting. This reaction was incubated on ice for 5-10 minutes. The mixture was then 
transferred to a cold electroporation 2 mm gap cuvette (Bio-Rad Laboratories, Hemel 
Hempstead, U.K). The cuvette was gently tapped to ensure no bubbles were present. 
Electroporation was performed using a GenePulser Xcell (Bio-Rad) using 2.5 kV, 25 
μFD and 200 Ω settings. Immediately after electroporation, 100 μl pre-warmed SOC 
media was added to the cuvette to aid bacterial recovery. The bacterial cells were then 
plated onto blood agar plates and incubated at 37°C under microaerobic conditions for 2 
days. After 2 days, bacterial cells were harvested using a sterile swab and resuspended in 
0.5 ml PBS solution. 100 - 200 μl aliquots were then pipetted onto blood agar plates 
containing 50 μg/ml kanamycin. The bacterial cells were spread across the plate surface 
using a sterile spreader. Plates were incubated for up to 5-7 days at 37°C under 
microaerobic conditions.  
 
2.2.25 Screening C. jejuni clones for positive mutants 
Kanamycin resistant colonies were restreaked onto blood agar plates containing 
kanamycin. A single loop of this putative kanamycin resistant colony was resuspended in 
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100 μl sterilised Milli-Q water, briefly vortexed and heated at 95°C for 10 minutes 
followed by centrifuging at 13,000 rpm for 5 minutes. PCR screening was performed 
using CDS specific primers as described in Section 2.2.17. Glycerol stocks were 
prepared and genomic DNA isolation was performed on positive mutants. 
 
2.2.26 Complementation of C. jejuni 11168H mutants 
Complementation constructs were produced using the Campylobacter complementation 
vector (named pDENNIS in this study) (Hitchen et al., 2010). The forward complement 
primer was designed by incorporating three cytosine residues, an NcoI restriction site, 
approximately 15 bps upstream of the intended CDS start codon (allowing incorporation 
of the ribosome binding site), followed by 15-20 bps of the 5’ end of the CDS sequence 
(Figure 2.2). 
 
 
 
Figure 2.2. Forward complement primer incorporating three cytosine residues, an NcoI 
restriction site, approximately 15 bps upstream of the intended CDS (allowing 
incorporation of the ribosome binding site) followed by 15-20 bps of the 5’ end of the 
CDS sequence. 
  
The reverse complement primer was designed by incorporating three cytosine residues, 
an NheI restriction site, a stop codon (TTA), followed by 15-20 bps of the 3’ end of the 
CDS sequence (Figure 2.3). 
Included 
for 
efficient 
digestion 
NcoI 
restriction 
site 
15 bp 
upstream of 
CDS of 
interest 
Start of 
CDS of 
interest 
5’ - CCCCCATGGataaggatttataATGAAAAAATATCATTCTCT - 3’ 
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Figure 2.3. Reverse complement primer incorporating three cytosine residues, an NheI 
restriction site, a stop codon (TTA), followed by 15-20 bps of the 3’ end of the CDS 
sequence. 
 
The CDS of interest was amplified using AccuPrime™ Taq DNA Polymerase High 
Fidelity (Invitrogen) to ensure nucleotide modifications did not occur during PCR 
amplification (see Section 2.2.11). PCR products were analysed on an agarose gel (see 
Section 2.2.12). Both the amplified PCR product and the pDENNIS vector were digested 
with NheI and NcoI (see Section 2.2.19), followed by ligation and subsequent 
transformation into XL2 cells and selection on LB agar plates containing ampicillin and 
chloramphenicol (see Sections 2.2.15 and 2.2.16). Transformants were screened using 
ISPCR (see Section 2.2.17) and positive clones sequenced (see Section 2.2.20). 
Electroporation of constructs into C. jejuni mutant strains was performed and screened as 
described previously with kanamycin and chloramphenicol respectively (see Sections 
2.2.24 and 2.2.25). Complemented C. jejuni mutants were checked for the presence of 
the non-disrupted CDS and the CDS containing the KmR cassette using ISPCR and by 
sequencing (see Sections 2.2.17 and 2.2.20). 
 
 
 
 
Included 
for 
efficient 
digestion 
 
NheI 
restriction 
site 
Stop 
codon 
Final 15-20 
bps of CDS 
sequence 
5’ – CCCGCTAGCTTAaacgatatttttatagctat – 3’         
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2.2.27 RT-PCR 
RNA was isolated as described in Section 2.2.10. DNA contamination of the RNA 
sample was removed using the TURBO DNA-free kit (Ambion, Austin, U.S.A) using the 
following protocol:- 
 
10X TURBO DNase buffer    - 5 μl 
TURBO DNase (2 U/μl)   - 1 μl   
RNA (0.2 – 1.0 μg/μl)    - 44 μl  
  
The reaction mixture was gently vortexed and incubated at 37°C for 30 minutes. 5 μl 
DNase Inactivation Reagent was added and mixed. The reaction was kept at room 
temperature for 5 minutes with occasional mixing followed by centrifugation for 90 
seconds at 10,000 rpm. The supernatant containing the RNA was transferred to a fresh 
tube and used for cDNA synthesis by RT-PCR. 
 
cDNA synthesis was performed using SuperScript III first-strand synthesis system for 
RT-PCR (Invitrogen). The following reaction was initially set up:- 
 
Random hexamers (50 ng/μl)  - 1 μl 
dNTP mix (10 mM)   - 1 μl 
RNA (1 pg - 5 μg)   - 7 μl 
 
The reaction was incubated at 65°C for 5 minutes and immediately transformed onto ice 
for a further minute. 10 μl of cDNA synthesis mix (see below) was added to each 
RNA/primer mixture and incubated for 10 minutes at 25°C, followed by 50 minutes at 
50°C. 
 
cDNA synthesis mixture 
10X RT buffer   - 2 μl 
MgCl2 (25 mM)   - 4 μl 
DTT (0.1 M)    - 2 μl   
RNaseOUT (40 U/μl)    - 1 μl 
SuperScript III RT (200 U/μl)  - 1 μl 
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The reaction was terminated by incubating at 85°C for 5 minutes, followed by incubating 
on ice for 1 minute. The reaction was briefly centrifuged and 1 μl RNase H (2 U/µl) 
(Invitrogen) was added and incubated for 20 minutes at 37°C. Introduction of RNase H 
after first strand synthesis can increase the sensitivity of the PCR step by removing the 
RNA template from the cDNA-RNA hybrid molecule by digestion (Invitrogen). PCR 
reactions were performed and analysed as described in Section 2.2.11. 
 
2.2.28 Designing 6XHis-tagged complementation primer  
To allow protein purification and further studies of the CDS of interest, a 6XHis-tagged 
protein sequence was cloned into the complementation construct for detection purposes. 
Primers were designed as in Section 2.2.26, however the reverse primer contained a 
6XHis-tag in between the CDS sequence and the stop codon (Figure 2.4). 
 
 
 
 
Figure 2.4. Reverse complement primer incorporating three cytosine residues, an NheI 
restriction site, a stop codon (TTA), 6XHis-tag, followed by 15-20 bps of the 3’ end of 
the CDS sequence. 
 
2.2.29 Protein sample preparation 
 
2.2.29.1 Whole-cell lysate preparation 
Whole-cell lysates of C. jejuni or E. coli strains were prepared from either a plate grown 
for 24 h or a 20 ml culture grown for 16 h (see Section 2.2.7 for C. jejuni and E. coli 
5’ - CCCGCTAGCTTAATGATGATGATGATGATGAACGATATTTTTATAGCTAT -3’ 
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respectively). Bacteria from a plate were resuspended in 1 ml PBS. This suspension (or 
culture) was then spun at 4,000 rpm for 10 minutes at 4°C. The supernatant was 
discarded and the bacterial pellet was resuspended with 100 µl 1X Laemmli buffer 
(Sigma-Aldrich), then boiled for 10 minutes and spun at 13,000 rpm for 5 minutes. For 
experiments requiring normalisation of protein content between different strains, bacteria 
were resuspended in 1X Laemmli buffer at a ratio of 2 OD600/100 µl. Protein samples 
were stored at -20°C.  
 
2.2.29.2 Whole-cell lysate preparation using sonication 
Bacterial pellets obtained from the method described in Section 2.2.29.1 and were 
resuspended in 1 ml PBS. Bacterial samples were sonicated for 10 minutes (1 min on / 
30 seconds off) using setting H (High) (Diagenode, Liege, Belgium). Samples were 
centrifuged after sonication for 5 minutes at 13,000 rpm. The supernatant containing 
lysed cell content was poured into a new 1.5 ml microcentrifuge tube. The samples were 
concentrated using a centrifugal filter column with a 10 kDa cut-off. Equal volume of 2X 
Laemmli buffer was added and samples were boiled for 10 minutes to ensure denaturing 
of proteins. Samples were centrifuged after sonication for 5 minutes at 13,000 rpm and 
were stored at -20°C.  
 
2.2.29.3 Purification of 6XHis-tagged proteins  
Bacterial pellets were obtained from the method described in 2.2.29.1 and were 
resuspended in 1 ml equilibration buffer (Appendix 2). Lysed cells were obtained using 
the sonication method described in Section 2.2.29.2 were incubated with Ni-NTA 
(binding capacity up to 50 mg/ml) (Qiagen) for 1 h at 4°C on a rotator. Liquid 
chromatography (Pierce Biotechnology, Inc, Rockport, U.S.A) was performed using a 
His-Select spin column (Sigma-Aldrich). Equilibration, Wash and Elution buffers 
(Appendix 2) were used to elute the His-tagged protein. Three 2 ml aliquots were 
prepared and samples were concentrated using a centrifugal filter column with a 10 kDa 
cut-off. Equal volume of 2X Laemmli buffer was added and samples were boiled for 10 
minutes to ensure denaturing of proteins. Samples were centrifuged for 5 minutes at 
13,000 rpm and were stored at -20°C.   
 
2.2.30 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
Protein samples were loaded onto 16% (w/v) Tris-Glycine gels (Invitrogen) and set-up in 
a Novex EI9001-XCell II Mini Cell (Invitrogen) and loaded with 1X running buffer 
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(Appendix 2). 20 µl of protein sample (prepared as described in 2.2.29) was loaded into 
each well. For elucidation of band sizes during sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis (SDS-PAGE) and subsequent transfer to nitrocellulose membranes, a 
Spectra BR marker (Fermentas, Ontario, Canada) was used. Gels were run at 150 V for 
approximately 1 h.  
 
2.2.31 Coomassie staining of SDS-PAGE gels 
Coomassie staining was performed when analysing protein sample content. For staining, 
0.125% (w/v) coomassie stain (see Appendix 2) (Amresco, Ohio, U.S.A) was used to 
stain the gel for 1 h shaking at 75 rpm, followed by destaining overnight. Destain 
solution (Appendix 2) was re-applied three times. Coomassie gels were visualised on a 
GeneGenius Gel-Documentation System (SynGene).  
 
2.2.32 Western blots 
Protein samples were loaded onto SDS-PAGE gels and were separated as described in 
2.3.30. For elucidation of band sizes after transfer onto Hyperfilm ECL (GE Healthcare, 
Buckinghamshire, U.K), MagicMark XP (Invitrogen) was used. Whatman paper 3MM 
(Scientific Lab Supplies, Nottingham, U.K) and nitrocellulose Hybond-C extra (GE 
Healthcare) were cut into gel shapes and incubated in transfer buffer (Appendix 2). 
Completion of the SDS-PAGE was followed by transfer of the proteins from the gel to 
the nitrocellulose membrane, performed using a Hoefer SemiPhor System (GE 
Healthcare) set at 45 mA for 1.5 h (or 90 mA for two gels). A 1.5 kg weight was placed 
onto the transfer apparatus to ensure efficient transfer.  
 
2.2.33.1 Western blot 6XHis-tag detection 
The following methodology was used for detection of 6XHis-tagged proteins. All stages 
were performed at room temperature unless stated otherwise. Whilst performing the 
transfer stage, blocking reagent was prepared. Blocking reagent was provided as part of 
the Penta-His HRP Conjugate kit (Qiagen) used for the detection of HIS-tagged proteins. 
Blocking reagent was prepared by adding 0.1 g of blocking reagent to 20 ml PBS 
containing 0.05% (v/v) Tween-20 and 0.2% (v/v) Triton X-100 (Sigma-Aldrich). 
Blocking was performed for either 1 h shaking at 75 rpm (Platform Shaker STR6, VWR-
Jencons) or overnight at 4°C without shaking. Once blocking was completed, the Penta-
His HRP conjugate antibody (Qiagen) was added at a dilution of 1:5000 (1 µl in 5 ml 
blocking reagent solution). The nitrocellulose membrane was incubated for 1 h with 
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shaking with the Penta-His HRP conjugate antibody in a square petri dish. The 
nitrocellulose membrane was then washed twice with PBS containing 0.05% (v/v) 
Tween-20 and 0.2% (v/v) Triton X-100 for 10 minutes, followed by PBS alone for 10 
minutes. Detection was performed by chemoluminescence using ECL Plus Western 
blotting reagent pack (GE Healthcare) in a Hypercassette case (GE Healthcare). 
Chemiluminescent detection was performed using Hyperfilm ECL (GE Healthcare). 
Detection was performed after placing the Hyperfilm ECL on top of the nitrocellulose 
membrane inside the Hypercassette case for 1 minute and also for longer time points as 
required.  
 
2.2.33.2 Western blot polyclonal antibody detection 
The following methodology was used for detection of proteins using a primary antibody. 
All stages were performed at room temperature unless stated otherwise. Whilst 
performing the transfer stage, blocking reagent was prepared. Blocking reagent was 
made up of 10% (w/v) dried skimmed milk (Tesco, Cheshunt, U.K) in PBS containing 
0.05% (v/v) Tween-20. Blocking was performed for either 1 h shaking at 75 rpm or 
overnight at 4°C without shaking. Once blocking was completed, the primary antibody 
was added at a dilution of 1:5000 (1 µl in 5 ml blocking reagent solution). The dilution 
was prepared using PBS with 5% (w/v) skimmed milk and 0.05% (v/v) Tween-20. The 
nitrocellulose membrane was incubated with the primary antibody for 1 h with shaking 
in a square petri dish. The nitrocellulose membrane was then washed twice with PBS 
containing 0.05% (v/v) Tween-20 and 0.2% (v/v) Triton X-100 for 10 minutes. The 
secondary antibody (anti-rabbit IgG - whole molecule / peroxidase antibody produced in 
goat (Sigma-Aldrich)) was added at a dilution of 1:5000 (1 µl in 5 ml blocking reagent 
solution). The dilution was prepared using PBS with 5% (w/v) skimmed milk and 0.05% 
(v/v) Tween-20. The nitrocellulose membrane was incubated with the secondary 
antibody for 1 h shaking in a square petri dish. The nitrocellulose membrane was then 
washed twice with PBS containing 0.05% (v/v) Tween-20 and 0.2% (v/v) Triton X-100 
for 10 minutes. The nitrocellulose membrane was finally washed with PBS for 10 
minutes. Detection was performed by chemoluminescence using ECL Plus Western 
blotting reagent pack (GE Healthcare) in a Hypercassette case (GE Healthcare). 
Developing and detection was as described in Section 2.2.33.1.  
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2.2.35 Protein quantification 
Protein concentrations were analyzed using a BCA assay (Thermo Scientific) following 
the manufacturers guidelines. 
 
2.2.36 Gram stains 
Gram stains were performed using a Diagnostics Kit (Sigma-Aldrich). A blank glass 
slide was spotted with Milli-Q water. A single colony was selected from an agar plate 
and smeared onto the spotted Milli-Q water on the slide and left to dry. The smear was 
heat fixed by passing the slide over a blue flame. The slide was then immersed in Crystal 
Violet for 45 seconds then rinsed with tap water. The slide was immersed in iodine for 
45 seconds then rinsed again with tap water. 3 drops of decolouriser were added onto the 
stained section of the slide and then rinsed with water. Finally, Safranin O solution 
(counter-wash) was added onto the slide for 45 seconds. This was rinsed off with tap 
water and the slide dried. The slide was viewed using a Laborlux K microscope (Leica, 
Milton Keynes, U.K). 
 
2.3 Assays 
 
2.3.1 Primary culture growth kinetics  
15 ml Brucella broth was preincubated in a 50 ml flask at 37°C under microaerobic 
conditions for 24 h, shaking at 75 rpm. A bacterial suspension was prepared and the 
volume to inoculate the 15 ml Brucella broth to a starting OD600 of 0.1 was calculated as 
described in Section 2.2.8. The calculated volume was removed from the pre-incubated 
Brucella broth. This volume of cells from the original bacterial cell suspension was then 
added to produce a final volume of 15 ml. Flasks were incubated at 37°C under 
microaerobic conditions, shaking at 75 rpm. OD600 readings were performed at selected 
time points. 
  
2.3.2 Secondary culture growth kinetics 
15 ml Brucella broth was preincubated in a 50 ml flask at 37°C under microaerobic 
conditions for 24 h, shaking at 75 rpm. A bacterial suspension was prepared and the 
volume to inoculate the 15 ml Brucella broth to a starting OD600 of 0.1 was calculated as 
described in Section 2.2.8. This primary culture was grown for 16 h at 37°C under 
microaerobic conditions, shaking at 75 rpm. 15 ml Brucella broth was preincubated in a 
50 ml flask at 37°C under microaerobic conditions for 24 h. The primary culture was 
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used to inoculate the preincubated broth to a starting OD600 of 0.1. Flasks were incubated 
at 37°C under microaerobic conditions, shaking at 75 rpm. OD600 readings were 
performed at selected time points. 
   
2.3.3 Motility assay 
Brucella motility plates were prepared as described in Appendix 2. A bacterial 
suspension with an OD600 of 1.0 was prepared as described in Section 2.2.8. The 
suspension was briefly vortexed and 5 µl of this suspension pipetted into the centre of 
the motility plate using a P10 tip. Plates were incubated at 37°C under microaerobic 
conditions. Plate images were recorded at 24, 48 and 72 h using a GeneGenius Gel-
Documentation System (SynGene). Motility was quantified by measuring the diameter of 
the halo on the plate. 
 
2.3.4 Oxidative stress assay  
A stock of 100 mM H2O2 was prepared by performing a 1/10 dilution with Milli-Q water 
from 1 M H2O2 (Sigma-Aldrich). Serial dilution tubes were also prepared up to 10
-6 with 
900 µl PBS in each tube. C. jejuni were grown on blood agar plates for 24 h. Bacteria 
were collected using a sterile swab and resuspended in 1 ml PBS. A bacterial suspension 
was prepared and the volume to inoculate into 900 µl broth to produce a starting OD600 
of 1.0 was calculated as described in Section 2.2.8. The suspension was briefly vortexed. 
100 µl of 100 mM H2O2 was added to the test sample to produce a final concentration of 
10 mM H2O2 and 100 µl Brucella broth added to the control sample. Both test and 
control tubes were incubated at 37°C under microaerobic conditions for 15 minutes with 
the caps open. Tubes were briefly vortexed and serial dilutions were performed down to 
10-6. A 10 µl volume of each dilution was pipetted onto blood agar plate(s) and incubated 
uninverted at 37°C under microaerobic conditions for 48 h. Plate images were taken after 
48 h using a GeneGenius Gel-Documentation System. The level of sensitivity was 
measured as log survival based on the serial dilutions.  
 
2.3.5 Acidified nitrite assay  
A stock of 100 mM sodium nitrite (NaNo2) at pH 5 was prepared by performing 1/10 
dilution with Milli-Q water from 1 M NaNo2 (Sigma-Aldrich). The assay method used 
was as described in Section 2.3.4, with a final concentration of 10 mM NaNo2 used. Both 
test and control tubes were incubated at 37°C under microaerobic conditions for 75 
minutes. Further assays using a final concentration of 100 mM NaNo2 with a 30 minute 
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incubation time at 37°C under microaerobic conditions were performed. The level of 
sensitivity was measured as log survival based on the serial dilutions.  
 
2.3.6 Oxidative growth inhibition assay 
10 ml Brucella broth was preincubated in a 50 ml flask at 37°C under microaerobic 
conditions for 24 h. A bacterial suspension was prepared as described in Section 2.2.8 
and used to inoculate the 10 ml Brucella broth to a starting OD600 of 0.1. Control flasks 
had the calculated volume of Brucella broth removed and the same volume of C. jejuni 
added. Test flasks had the calculated volume of Brucella broth removed, in addition to 
another 500 µl Brucella broth. 500 µl of 20 mM H2O2 was added to the flask followed by 
the calculated cell volume. This gave a final concentration of 1 mM H2O2. Flasks were 
incubated at 37°C under microaerobic conditions, shaking at 75 rpm. OD600 readings 
were recorded at 6, 24 and 48 h.  
  
2.3.7 Acidified nitrite growth inhibition assay 
Acidified nitrite growth inhibition assays were performed basically as described in 
Section 2.3.6 with the modification that a 2 mM stock of NaNo2 at pH 5 was prepared 
and added to the test flask containing Brucella broth with C. jejuni at a starting OD600 of 
0.1 to produce a final concentration of 0.1 mM NaNo2.  
 
2.3.8 Sodium deoxycholate growth inhibition assay 
Sodium deoxycholate (sDOC) growth inhibition assays were performed basically as 
described in Section 2.3.6 with the modification that a 2% (w/v) sDOC stock was 
prepared and added to the test flask containing Brucella broth with C. jejuni at a starting 
OD600 of 0.1 to produce a final concentration of 0.1% (w/v) sDOC.   
 
2.3.9 Iron chelating (deferoxamine) growth inhibition assay 
Iron chelating (deferoxamine) growth inhibition assays were performed basically as 
described in Section 2.3.6 with the following modifications. Stocks of deferoxamine at 
1M, 100mM and 10mM were prepared and added to the flask containing Brucella broth 
with C. jejuni at a starting OD600 of 0.1 to produce a final concentration of 0.01, 0.1 and 
1 mM deferoxamine respectively.   
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2.3.10 Microarray experimental design, template labelling and hybridisation 
Gene expression profiling of C. jejuni 11168H during the late log phase of growth (16 h) 
was performed using an indirect comparison method or type 2 experimental design 
(Kamal et al., 2007). In this experimental design, replicate test sets of Cy5-labelled C. 
jejuni 11168H total RNA samples were combined with a common reference sample 
(Cy3-labelled C. jejuni 11168H genomic DNA). The microarrays used in this study were 
whole genome C. jejuni NCTC11168 arrays printed on Ultragaps glass slides (Corning, 
NY, U.S.A), produced by the BµG@S Group (www.bugs.sghms.ac.uk). 
 
The procedures for the Cy3-labelling of 11168H genomic DNA and Cy5-labelling of 
total RNA samples are detailed below. Initially, 50 ml pre-hybridisation solution was 
prepared and placed into a Coplin jar (Fisher). Reagents were added in the following 
order:- 
 
SDS 20% (v/v)     - 250 l 
Milli-Q water      - 36.0 ml 
20X saline sodium citrate (SSC)    - 8.75 ml 
Bovine serum albumin (BSA) (100 mg/ml)   - 5.0 ml 
  
The pre-hybridisation solution was incubated at 65°C for 1 h before commencing the 
labelling reactions.  
 
The following reaction was set up for labelling of control genomic DNA:-  
 
Genomic DNA     ≈ 2 g 
Random primers (3 g/l) (Invitrogen) - 1 l
Milli-Q water      to 41.5 l

Reactions were heated at 95°C for 5 minutes followed by snap cooling on ice and brief 
pulse centrifugation. Control Cy3 DNA labelling reactions were prepared as follows, 
adding reagents in the following order:- 
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10xREact 2 buffer (Invitrogen)     - 5 l
dNTP’s (5 mM each dATP, dGTP and dTTP, 2 mM dCTP)  - 1 l
Cy3-labelled dCTP (25 mmol) (GE healthcare)   - 1.5 l
Klenow fragment (10 U/l) (Invitrogen)    - 1 l

The control reaction was incubated at 37°C for 90 minutes.  
 
The following reaction was set up for labelling of test Cy5 total RNA:- 
 
Total RNA      ≈ 10 g 
Random primers (3 g/l) (Invitrogen) - 1 l
Milli-Q water      - to 11 l
  
Reactions were heated at 95°C for 5 minutes followed by snap cooling on ice and brief 
pulse centrifugation. Test reactions were prepared, adding reagents in the following 
order:- 
  
5X first strand buffer (Invitrogen)     - 5 l
DTT (100mM)        - 2.5 l
dNTP’s (5 mM each dATP, dGTP and dTTP, 2 mM dCTP)  - 2.3 l
Cy5-labelled dCTP (25 mmol) (GE Healthcare)    - 1.7 l
Reverse transcriptase (Superscript II 200 U/l) (Invitrogen)  - 2.5 l
 
The Test Cy5-labelled reaction was incubated at 25°C for 10 minutes, followed by 
incubating at 42°C for 90 minutes. 20 minutes prior to completion of this incubation 
period, microarray slide(s) were placed into the pre-hybridisation solution in the Coplin 
jar and incubated at 65°C. Both control and test reactions were then combined in a 1.5 ml 
microcentrifuge tube. The reaction was purified using a MinElute PCR purification kit 
(Qiagen). 500 l buffer PB was added to the combined reaction and centrifuged using a 2 
ml MinElute column for 1 minute at 13,000 rpm. 250 l buffer PE was added to the 
column and centrifuged for 1 minute at 13,000 rpm. The cDNA was eluted from the 
column by adding 14 l Milli-Q water. Samples were incubated on ice. Pre-hybridised 
microarray slides were rinsed in water for 1 minute using a trough and slide holder 
(Raymond A. Lamb, Eastbourne, U.K). Slides were then rinsed in 100% isopropanol for 
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1 minute. Slides were dried by placing into 50 ml Falcon tubes (Fisher) and centrifuging 
at 1500 rpm for 5 minutes. The Hybridisation solution was prepared as follows in a 1.5 
ml microcentrifuge:- 
 
Eluted sample  - 13 l
Milli-Q water   - l
20X SSC  - 12 l 
2% (v/v) SDS  - 9 l 
 
This hybridisation solution was then heated at 95ºC for 2 minutes and allowed to cool at 
room temperature. The reaction was briefly pulse centrifuged.  
 
Microarray slide(s) were placed in a humidified hybridisation cassette (Telechem 
International, Sunnyvale, U.S.A) and covered with a LifterSlip™ (Erie Scientific, 
Portsmouth, U.S.A) glass coverslip (22 mm x 25 mm) over the array section. The 
hybridisation solution was carefully pipetted under the coverslip. The microarray 
chamber was sealed and incubated in a water bath at 65°C overnight without shaking. 
Wash A and B solutions were prepared as below:- 
 
Wash A  
20X SSC   - 20 ml 
20% (v/v) SDS  - 1 ml
Milli-Q water   - ml 
  
Wash B  
20X SSC  - 2.4 ml
Milli-Q water  - ml
 
Wash A solution was incubated overnight at 65°C. Prior to performing the wash 
protocol, Wash A solution was dispensed into a pre-rinsed single trough. Wash B was 
dispensed into two troughs. The microarray slides were removed from the chambers and 
placed into the slide holder in Wash A. This was gently agitated for 5 minutes. The slides 
were transferred to a clean slide holder and rinsed with gentle agitation in Wash B for 2 
minutes. This was followed by another 2 minutes in the second Wash B trough. 
Microarray slides were placed into 50 ml Falcon tubes (label away from lid), and 
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centrifuged at 1500 rpm for 5 minutes to dry. Microarray experiments were performed 
with three biological replicates, each with one technical replicate. 
 
2.3.11 Data acquisition and microarray data analysis 
The microarray slides were scanned with an Affymetrix 418 array scanner (MWG 
Biotech) according to the manufacturer's guidelines. Signal and local background 
intensity readings for each spot were quantified using ImaGene software v8.0 
(BioDiscovery, El Segundo, U.S.A). Quantified data were analysed using GeneSpring 
GX software v7.2 (Agilent, Santa Clara, U.S.A). Expression analysis was performed 
using a DNA versus RNA experimental set-up. Statistically significant up- and down-
regulated genes were selected when comparing gene expression from mutant test arrays 
against 11168H control arrays using ANOVA (ANalysis Of VAriance) (Bacon et al., 
2004, Corcionivoschi et al., 2009). ANOVA was performed using a Benjamini and 
Hochberg False Discovery Rate as the Multiple Testing Correction within the 
GeneSpring software. All microarray data was deposited into ArrayExpress. 
 
2.3.12 C. jejuni co-culture studies 
Co-culture experiments were set-up in a sterile hood (Envair, Haslingden, U.K). The 
Caco-2 human intestinal epithelial and J774A.1 mouse macrophage cell lines were 
maintained using the following media:-  
 
Dulbecco’s Modified Eagle's Medium (DMEM)     - 500 ml 
FCS           - 50 ml 
Non-essential amino acids         - 5 ml 
Penicillin (100 U/ml) / Streptomycin (100 μg/ml) solution    - 5 ml 
 
The T84 human colonic epithelial cell line was maintained using the following media:- 
 
1:1 mixture of DMEM and Ham's F-12 medium containing Glutamax®, 2.5 mM l-
glutamine, 15 mM HEPES, and 0.5 mM sodium pyruvate (Gibco)  - 500 ml 
FCS          - 50 ml 
Penicillin (100 U/ml) / Streptomycin (100 μg/ml) solution   - 5 ml 
 
Cells were maintained in a CO2 incubator (Sanyo). For Caco-2 cell co-culture 
experiments, cells were seeded at ≈ 1 x 105 cells/ml and grown in 24-well plates to >90% 
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confluence (≈ 1 x 106 cells/ml). For T84 cell co-culture experiments, cells were seeded at 
≈ 5 x 105 cells/ml and grown in 24-well plates to >90% confluence (≈ 5 x 106 cells/ml). 
For co-culture experiments involving J774A.1 mouse macrophage, cells were seeded at ≈ 
5 x 105 cells/ml and grown in 24-well plates for 24 h. For ELISA experiments, T84 cells 
were maintained in low serum 1% (v/v) and antibiotic-free media overnight prior to co-
culture. Supernatants for ELISA experiments were stored at -80°C until required.    
 
Caco-2, T84 and J774A.1 cells reaching a confluent state were split and/or seeded for 
future experiments. Cells were washed three times with 10 ml PBS. 5 ml 0.25% (v/v) 
Trypsin-EDTA solution was added to the flask containing cells and incubated in a 37°C 
CO2 incubator for approximately 7 minutes to allow removal of cells (20 minutes for 
J774A.1 cells). 20 ml culture media was added to the cells and pipetted vigorously. 
Media containing cells was added to a 50 ml Falcon with culture media added to make a 
final volume of 50 mls. Cells were centrifuged at 1500 rpm for 10 minutes. The 
supernatant was decanted and cells were resuspended in 1 ml culture media. 9 ml culture 
media was added to complete a 10- fold dilution. 3 ml of this suspension was mixed with 
27 ml culture media in a new 50 ml Falcon, giving ≈ 1 x 105 cells/ml. All 30 mls were 
pipetted into a new 75 cm2 flask (Corning) and incubated at 37°C in a CO2 incubator. 
Dilutions were adjusted for different cell lines. 
  
To calculate the required cells for interaction, invasion, intracellular survival and 
macrophage survival assays, seeding was prepared at ≈ 1 x 105 cells/ml (e.g. for Caco-2 
cells). 800 µl DMEM, 100 µl Trypan Blue (Sigma-Aldrich) solution and 100 µl cells 
from the cell suspension (≈ 1 x 106 cells/ml) were briefly mixed in a 1.5 ml 
microcentrifuge tube. This suspension was added to a Neubauer cell counter (Weber, 
Hamilton New Jersey, US) and covered with a slide (VWR). Cells were counted on a 
light microscope (DM1000 Leica, Milton Keynes, U.K) and calculated as follows:- 
 
Number of cells in total area within cell counter x dilution factor (1000) x dilution (10) = 
approximate number of cells 
 
Appropriate dilutions were performed to obtain ≈ 1 x 105 cells/ml. 1 ml volumes were 
seeded onto 24 well plates (Corning) and were incubated at 37°C in a CO2 incubator. All 
reagents were obtained from Invitrogen unless otherwise stated.   
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2.3.13 Interaction, invasion and intracellular survival assays 
Interaction (adhesion and invasion), invasion and intracellular survival assays were 
performed using Caco-2 cells. All assays used the following media:- 
 
DMEM      - 500 ml 
FCS       - 5 ml   
Non-essential amino acids    - 5 ml 
  
C. jejuni cells from a 24 h grown bacteria plate were collected using a sterile swab and 
resuspended in a 1.5 ml microcentrifuge tube containing 1 ml DMEM. A bacterial 
suspension with an OD600 of 1.0 was prepared as described in Section 2.2.8 using 
DMEM as the blank. The volume was made up with DMEM to 2 ml. 1 ml of this 
mixture was added to a 30 ml universal and 9 ml DMEM was added, to produce a final 
OD600 of 0.1 (≈ 1 x 108 cells). 100 µl of this suspension was taken and serial dilutions 
performed by resuspending in a 1.5 ml microcentrifuge tube containing 900 µl PBS. 
Serial dilutions were performed down to 10-6. 200 µl volume from the final tube was 
pipetted and spread onto three dried blood agar plates. Plates were incubated at 37°C 
under microaerobic conditions for 72 h. Plates were inverted after 24 h. Colonies were 
counted on each plate and this data was used to calculate the initial inoculum (CFU/ml). 
C. jejuni cells (≈ 1 x 108 cells) in DMEM were added to a monolayer of ≈ 1 x 106 Caco-2 
cells (MOI 100:1) and incubated for 3, 6 or 24 h. The number of interacting bacteria was 
determined by washing the monolayers three times with PBS then lysing the cells by 
addition of 0.2% (v/v) Triton X-100 in PBS. The number of intracellular bacteria was 
determined by further incubating the monolayers after the initial interaction time point 
with 150 µg/ml gentamicin in DMEM for 2 h at 37°C to allow killing of extracellular 
bacteria. Monolayers were then washed three times in PBS and the epithelial cells lysed 
as above. For intracellular survival assays, bacterial cells were co-cultured with a 
monolayer of Caco-2 cells for 3 h following by washing the monolayers three times with 
PBS. The monolayers were then incubated in DMEM containing gentamicin (150 µg/ml) 
for 2 h and then incubated in DMEM containing a reduced concentration of gentamicin 
(10 µg/ml) for 19 h (Naito et al., 2010). Monolayers were then washed three times in 
PBS and the epithelial cells lysed as above. Bacterial survival in the tissue culture 
medium during co-culture experiments was also investigated after 24 h co-culture, the 
tissue culture medium alone was removed followed by plating of serial dilutions to 
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determine the CFU/ml. In all cases, serial dilutions, plating and enumeration of bacterial 
numbers were performed as stated above. 
 
2.3.14 Macrophage survival assays 
Macrophage survival assays were performed using J774A.1 mouse macrophages. A 
bacterial suspension with an OD600 of 0.1 was prepared in DMEM as described in 
Section 2.3.13. C. jejuni cells (≈ 1 x 108 cells) were added to a culture of ≈ 5 x 105 
J774A.1 mouse macrophage cells (MOI 200:1) and incubated for 3 h. Cells were washed 
three times in PBS followed by incubation in DMEM containing gentamicin (150 µg/ml) 
for 2 h to allow killing of extracellular bacteria. The macrophages were then incubated in 
DMEM containing a reduced concentration of gentamicin (10 µg/ml) and bacterial 
survival determined at 0, 4 and 16 h. At each time point, the macrophages were washed 
three times with PBS and lysed by adding 0.2% (v/v) Triton X-100. Serial dilutions, 
plating and enumeration of bacterial numbers were performed as stated in Section 2.3.13. 
 
2.3.15 ELISA 
Levels of IL-8 and IL-6 secreted from T84 cells during co-culture with C. jejuni were 
quantified using a human IL-8 and IL-6 ELISA development kit (Peprotech, New Jersey, 
U.K). For ELISA experiments, T84 cells were maintained in antibiotic-free media with 
1% (v/v) FCS overnight prior to co-culture. A bacterial suspension with an OD600 of 2 
was prepared as described in Section 2.3.13. 50 µl of this suspension was added to each 
well of the prepared T84 cells and incubated in a 37°C CO2 incubator (Sanyo). This 
ensured a dilution of 1:20 and produced a working OD600 of 0.1 (≈ 1 x 108 CFU/ml). 
Supernatants from uninfected T84 cells and T84 cells infected with C. jejuni (MOI of 
20:1) for 24 h were removed and placed into 1.5 ml microcentrifuge tubes and spun for 1 
minute at 13,000 rpm. The prepared samples were stored at -80°C and used for ELISA.    
 
ELISA 96 well microplates were used during the assay (Nunc, Roskilde, Denmark). 
ELISA assays were performed following the manufacturer’s instructions. Briefly, 100 µl 
capture antibody (0.5 µg/ml) was added to each well, plates were sealed, then incubated 
overnight at room temperature. The wells were aspirated four times with 300 µl wash 
buffer (0.05% (v/v) Tween-20 in PBS). 300 µl block buffer (1% (w/v) BSA in PBS) was 
added to each well and incubated for 1 h at room temperature. Wells were aspirated four 
times with 300 µl wash buffer. Human IL-8 Standard (1 µg/ml) was diluted to 2 ng/ml 
using diluent (0.05% (v/v) Tween-20, 0.1% (w/v) BSA in PBS). Serial dilutions of this 2 
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ng/ml standard were performed using a 1:2 dilution to 0 using diluent. 100 µl of each 
standard and samples were added to duplicate wells. The plates were incubated at room 
temperature for 2 h. Wells were then aspirated four times with wash buffer. 100 µl 
detection antibody (0.25 µg/ml) was added to each well. The plate was incubated at room 
temperature for 2 h. Wells were then aspirated four times with wash buffer. 100 µl 
avidin-HRP conjugate was added at a dilution of 1:2000 using diluent and incubated at 
room temperature for 30 minutes. Wells were aspirated four times with PBS and 100 µl 
2,2'-azino-bis-(3-benzthiazoline-6-sulfonic acid) (ABTS) substrate solution (Sigma) was 
added to each well. Plates were incubated at room temperature for 10 minutes. Detection 
was performed using a Dynex MRX II 96 well plate reader (Dynex, Chantilly, U.S.A) at 
an absorbance of 405 nm (A405) and analysed on Revelation software (Dynex, Chantilly, 
U.S.A).   
  
2.3.16 Galleria mellonella model of infection  
G. mellonella larvae (LiveFoods Direct, Sheffield, U.K) were kept on wood chips at 
room temperature. A 16 h secondary culture was prepared as described in Section 2.2.8, 
and adjusted to OD600 of 0.1. Larvae were injected with a 10 l inoculum of the C. jejuni 
culture by micro-injection (Hamilton, Switzerland) in the right foremost leg, giving an 
infectious dose of ≈ 106 CFU. Larvae were incubated at 37oC with survival and 
appearance recorded at 24 h intervals. Brucella broth injection and no injection controls 
were also prepared. For each experiment, 10 G. mellonella larvae were infected and 
experiments were repeated three times. G. mellonella larvae were scored as alive if able 
to rotate fully onto front when placed onto their back and also when demonstrating 
sufficient twitching in the presence of contact. 
 
2.3.17 Biofilm formation assay 
10 ml Brucella broth was preincubated in a 50 ml flask at 37°C under microaerobic 
conditions for 24 h. A bacterial suspension with an OD600 of 0.1 was prepared as 
described in Section 2.2.8. 1 ml of this suspension was added to 24 well plates (Corning) 
and plates were incubated at 37°C under microaerobic conditions with shaking at 75 rpm 
for 3 days. Wells were washed three times with PBS, followed by addition of 1 ml 0.2% 
(w/v) crystal violet for 10 minutes. Wells were then washed with PBS three times 
followed by dissolving the crystal violet stain with 1:4 acetone/ethanol (v/v) followed by 
recording the absorbance at 595 nm using a ELx800 Absorbance Microplate Reader 
(BioTek, Winooski, U.S.A).  
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2.3.18 Secretion profile analysis of C. jejuni 
30 ml Brucella broth was preincubated in a 150 ml flask at 37°C under microaerobic 
conditions for 24 h. C. jejuni were grown on blood agar plates for 24 h. A bacterial 
suspension was prepared as described in Section 2.2.8 and used to inoculate the 30 ml 
Brucella broth to a starting OD600 of 0.1. The culture was incubated for 16 h with 
shaking at 75 rpm, followed by centrifuged for 1 h at 6,000 rpm. Filter sterilisation was 
performed using 0.2 µm Supor Acrodisc, 32 mm filter (Pall Life Sciences). Samples 
were concentrated using a centrifugal filter column with a 10 kDa cut-off. 0.1% (v/v) 
FCS serum and/or 0.1% (w/v) sDOC were also used to supplement the culture media at 
the point of inoculation. Negative controls contained no bacteria. Protein samples were 
mixed with equal volume of 2X Laemmli buffer, then boiled for 10 minutes and spun at 
13,000 rpm for 5 minutes. In order to semi-quantify any differences in protein secretion 
between strains, the starting OD600 and growth conditions were standardized. 30 l of 
final sample were analysed by SDS-PAGE as described in Sections 2.2.30.  
 
2.3.19 Transmission Electron Microscopy 
Samples for TEM were prepared from both solid and liquid media. C. jejuni were grown 
on blood agar plates for 24 h at 37°C under microaerobic conditions. Alternatively, 10 
ml Brucella broth was preincubated in a 50 ml flask at 37°C under microaerobic 
conditions for 24 h. C. jejuni grown on blood agar plates for 24 h at 37°C under 
microaerobic conditions was used to prepare a bacterial suspension with an OD600 of 0.1. 
This bacterial culture was prepared as described in Section 2.2.8. Flasks were incubated 
at 37°C under microaerobic conditions, shaking at 75 rpm for 24 h. Individual colonies 
of C. jejuni from blood agar plates or 10 μl of C. jejuni culture were resuspended in a 1.5 
ml microcentrifuge tube containing 2.5% (v/v) glutaraldehyde / 2.5% (v/v) 
paraformaldehyde / 0.1 M sodium cacodylate buffer pH 7.4. TEM was performed by an 
in-house technician (Maria McCrossan).  
  
2.3.20 Autoagglutination ability of C. jejuni  
C. jejuni from a 24 h grown blood agar plate were collected using a sterile swab and 
resuspended in a 1.5 ml microcentrifuge tube containing 1 ml PBS. A bacterial 
suspension with an OD600 of 1.0 was prepared as described in Section 2.2.8. The 
appropriate volume was made up with PBS to 10 ml in glass tubes. Cultures were 
incubated for 24 h at 37°C under microaerobic conditions. 1 ml of the suspension (taken 
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from approximately the 5 ml mark of the glass tube) was measured using OD600 after 24 
h.    
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Chapter 3: Re-annotation and re-analysis of the C. jejuni 
NCTC11168 genome sequence 
 
3.1 Introduction 
 
3.1.1 Aims 
Since the publication of the Haemophilus influenzae strain Rd KW20 genome sequence 
in 1995 (Fleischmann et al., 1995), the availability of genome sequence data has 
increased at an exponential rate. To date (July 2010), there have been 12,567 genomes 
sequenced, however only a handful of these have had re-annotations performed 
(http://www.ncbi.nlm.nih.gov/sites/genome). Genomes which are not re-annotated can 
start to hinder research as scientists may rely on out of date information. Re-annotation is 
required as new methods for gene analysis become available and as our knowledge of 
gene function increases over time. The C. jejuni strain NCTC11168 was the second 
genome to be completely sequenced and annotated at the WTSI after Mycobacterium 
tuberculosis strain H37Rv. The aims of this work were to perform a complete re-
annotation of the C. jejuni NCTC11168 genome sequence and to use this new 
information to select and characterise CDSs with an uncertain function, but a possible 
role in virulence, signal transduction or regulation of gene expression. The original 
genome sequencing project of C. jejuni strain NCTC11168 was published in 2000 
(Parkhill et al., 2000) and since this time considerable research has been undertaken on 
C. jejuni and other bacteria. Re-annotation of C. jejuni NCTC11168 was undertaken in 
collaboration with Stephen Bentley, Matt Holden and Julian Parkhill in accordance with 
WTSI annotation guidelines.  
 
3.1.2 Genome annotations and re-annotations 
Once a genome sequence has been generated, the primary aim is to identify potential 
open reading frames (ORFs) and annotate each ORF accordingly as a predicted CDS. 
The annotation process has traditionally been performed manually whereby similarity 
searches, motif searches and also literature searches are performed by dedicated 
scientists (annotators). However the recent scale of genome sequence generation has now 
made it near impossible to undertake manual annotation as the time required to generate 
a genome sequence has decreased so rapidly that there is insufficient resources to 
perform manual annotations. The problem has become even more acute with the advent 
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of next-generation sequencing technology and is likely to continue for the foreseeable 
future. As a result, automated annotation procedures are increasingly used (Friedberg, 
2006, Stothard and Wishart, 2006, Brent, 2008). 
 
Re-annotation is defined as the process of re-analysis of a previously annotated genome 
(Ouzounis and Karp, 2002). A re-annotation is performed to allow incorporation of data 
generated since the original annotation was produced. Examples of re-annotated 
genomes are rare compared to the number of sequenced genomes (Camus et al., 2002, 
Dandekar et al., 2000). Re-annotation projects are typically performed as a result of large 
amounts of new information becoming available since the original annotation was 
produced and as such rendering the original annotation a less useful resource. An 
example is the Mycobacterium tuberculosis H37Rv genome (the first genome to be 
completed at the WTSI) where a re-annotation was performed four years after the 
original annotation, leading to updates on 300 CDSs. Currently, new sequenced genomes 
receive priority when annotation resources are available. However due to the number of 
genome sequences currently being generated, the resources simply do not exist for all 
these new genome sequences to be annotated manually. Manual annotation is time 
consuming and costly, however automated techniques do not yet provide the level of 
detail and accuracy that manual techniques provide. Thus, it is no surprise that re-
annotations of existing genomes are so rare. Re-annotation of genome sequences can 
significantly reduce the time spent on misdirected research. For example, attempts at 
characterising a specific CDS may be wasteful on time and resources if the CDS had 
already been studied, but not updated in terms of annotation, or if the original annotation 
was incorrect. An outdated annotation can lead to gaps in our knowledge, particularly if 
genome information is already available. Hence, there is a need for a research review and 
regular update of the genome annotation of any given organism. 
 
3.1.3 Methods available for annotating genomes 
Newly sequenced genomes have ORF prediction performed using automated programs 
such as ORPHEUS (Frishman 1998) or Glimmer (Delcher, 2007), followed by sequence 
and additional motif searches. Most sequenced genomes will have an automated 
annotation performed that uses genome wide comparison searches such as BLAST 
(Altschul et al., 1990) or FASTA (Pearson and Lipman, 1988) to find characterised 
orthologues. This can be a quick and efficient way of providing a basic annotation for a 
genome sequence. The incorporation of additional specialist searches and specific tools 
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can further enhance the annotation process, such as running motif databases like PFAM 
(Sonnhammer et al., 1998a) or PROSITE (Falquet et al., 2002). The more up-to-date the 
genome, the more useful the annotation is for researchers utilising this resource. 
 
3.1.4 Comparison of manual and automated annotation methods 
The process of manual annotation takes far longer to perform than automated annotation, 
however there are a number of advantages in a manual approach. Manual annotation 
allows the incorporation of knowledge from experts on the organism of interest. In 
particular, it is often the case that annotators have actually worked on the organism. The 
annotator will be able to use multiple sources of information and resources for the 
annotation process that will not be possible with an automated process. One such 
example demonstrating the importance of manual annotation is from the original C. 
jejuni NCTC11168 genome sequencing project. The original annotation identified a 
number of hypervariable sequences that encoded phase-variable CDSs (Parkhill et al., 
2000). Until then, such homopolymeric tracts were assumed to be a result of sequencing 
errors (Saunders et al., 1998). This manual identification of phase-variable CDSs has 
also been performed for a number of Helicobacter pylori genome sequences whereby a 
re-analysis of the genomes altered the number of phase-variable CDSs from 36 to 46 
(Salaun et al., 2004).  
 
The majority of genome annotations are currently performed by automated methods, 
however the accuracy of these approaches has been questioned since the beginning of the 
sequencing era (Poptsova and Gogarten, 2010). Automated annotation methods also rely 
on genome-wide searches. However, based on information from additional searches and 
programs, a more informative decision can be made in the designation of product 
function during a manual annotation. Indeed, it is exactly this point which is often 
debated during the annotation process. When does a CDS become a fully characterised 
gene considering all the annotation information? In some cases, CDSs that have been 
characterised as genes will have a definitive product function. However this is often not 
the case, so many CDSs have a ‘putative’ designation as the annotator cannot be 100% 
sure of the product function. The annotator must rely on a wide range of sources to 
finally make an informed decision on the designation of the product function, especially 
if they have research experience with the particular organism. In addition, manual 
annotators can take advantage of additional resources such as recent characterisation 
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papers. This advanced level of data integration will have far greater benefits for 
downstream research (Smith and Zhang, 1997).  
 
Annotation can be performed at different levels of specificity. Different annotators will 
use different thresholds for deciding whether the acquired information is worthy of 
designating a product function to a CDS and also whether a ‘putative’ designation is 
more appropriate. The ‘putative’ designation applies to a CDS when evidence is present 
to support the product function, but this evidence is inconclusive. The majority of 
product function designations are made using similarity search results. An accepted 
criteria is to use 35% sequence similarity as a benchmark for naming a putative product 
function and then to use supplementary data to ascertain an unanimous designation 
(Sander and Schneider, 1991). Errors exist in the assignment of CDS function mainly 
due to use of databases that are still of insufficient quality (Bork, 2000). Problems can 
also exist with product function assignment where low similarity search results are used 
to incorrectly assign function (Bork, 2000). 
 
In summary, automated annotation methods can save time and resources, but will not 
incorporate the maximum information available from experienced manual annotators, 
leading to incomplete or even false designations. The main drawbacks of manual 
annotation or re-annotation are that they are subjective, costly (in terms of curator 
wages) and time consuming.  
 
3.1.5 Sequencing of the C. jejuni NCTC11168 genome  
C. jejuni NCTC11168 was selected for sequencing as it is genetically tractable and 
widely available. This strain was isolated in 1977 from a U.K patient with severe 
gastroenteritis (Skirrow, 1977). The sequencing process involved construction of seven 
libraries in pUC18 using size fractions ranging from 1.0 kb to 2.2 kb (Parkhill et al., 
2000). Approximately 19,400 pUC clones were sequenced using Dye-terminator 
chemistry on ABI 373 and 377 sequencing machines. The sequencing project was 
initiated in 1997 and completed in 1999 (Parkhill et al., 2000). Annotation was 
performed at the WTSI and the genome was published in 2000 (Parkhill et al., 2000).   
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3.2 Results 
 
3.2.1 Re-annotation overview of the C. jejuni NCTC11168 genome sequence 
A complete re-annotation of the C. jejuni NCTC11168 genome was performed according 
to WTSI guidelines and submitted to EBI. The updated EMBL file (AL111168) is 
publicly available (http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AL111168.1). 
The re-annotation has been acknowledged on the WTSI website 
(http://www.sanger.ac.uk/Projects/C_jejuni/). This re-annotation resulted in a reduction 
in the total number of CDSs in the NCTC11168 genome sequence from 1654 to 1643. 
The reduction in the number of CDSs was due to either the merging of adjacent CDSs or 
the removal of CDSs. Based on the annotation criteria, a re-analysis of pseudogenes was 
performed on the C. jejuni NCTC11168 genome (see Section 3.2.3). CDSs designated as 
pseudogenes were updated to reflect the complete amino acid sequence for the encoded 
protein regardless of the number of multiple reading frames represented in the genome 
sequence. The implication for this type of designation is that CDSs from multiple 
reading frames can be joined to represent one single pseudogene or CDS. For example, 
Cj0290c, Cj0291c and Cj0292c were merged to represent a single CDS on multiple 
frames denoting a pseudogene and re-annotated as Cj0292c (putative glycerol-3-
phosphate transporter). Cj0968 and Cj0969 were also merged to represent a single CDS 
on multiple frames denoting a pseudogene and re-annotated as Cj0969 (putative 
periplasmic protein). All merged CDSs representing pseudogenes were named after the 
most downstream CDS (e.g. the new name for Cj0290c, Cj0291c and Cj0292c is now 
Cj0292c). Phase-variable CDSs that contained an intersecting homopolymeric region 
between adjacent CDSs on separate frames were also merged (see Section 3.2.4). This 
allowed the complete amino acid sequence for newly merged adjacent CDSs to be 
represented, regardless of possible variation in the size of the homopolymeric region. Re-
interpretation of phase-variable CDSs resulted in removal of seven CDSs. All merged 
CDSs representing phase-variable CDSs linked by a homopolymeric region were named 
after the upstream CDS. For example, the new name for Cj0031 and Cj0032 is Cj0031 
(see Section 3.2.4). The Cj1520 CDS was removed because of the identification of 
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) structural 
moieties (Schouls et al., 2003) (see Section 3.2.5). In total, 11 CDSs were removed from 
the re-annotated sequence and are listed in Table 3.1. 
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Table 3.1. CDSs from the original C. jejuni NCTC11168 annotation that were merged or removed during re-annotation.  
 
Original 
CDS 
Number 
Original Annotation Type/Description 
New CDS 
Number 
Updated Annotation 
Cj0031 
probable DNA restriction/modification 
enzyme, N-terminal half 
Cj0031/Cj0032 - Phase-variable Cj0031 
putative type IIS 
restriction/modification enzyme 
Cj0032 
probable DNA restriction/modification 
enzyme, C-terminal half 
Cj0031/Cj0032 - Phase-variable Cj0031 
putative type IIS 
restriction/modification enzyme 
Cj0170 unknown Cj0170/Cj0171 - Phase-variable Cj0170 hypothetical protein Cj0170 
Cj0171 unknown Cj0170/Cj0171 - Phase-variable Cj0170 hypothetical protein Cj0170 
Cj0290c 
probable pseudogene representing the C-
terminus of Cj0291c (glpT') 
Cj0290c/Cj0291c/Cj0292c - 
Pseudogenes 
Cj0292c 
pseudogene (putative glycerol-3-
phosphate transporter) 
Cj0291c 
glycerol-3-phosphate transporter, 
possible pseudogene 
Cj0290c/Cj0291c/Cj0292c - 
Pseudogenes 
Cj0292c 
pseudogene (putative glycerol-3-
phosphate transporter) 
  
  
1
0
0
 
 
Cj0292c 
probable pseudogene representing the N-
terminus of Cj0291c (glpT') 
Cj0290c/Cj0291c/Cj0292c - 
Pseudogenes 
Cj0292c 
pseudogene (putative glycerol-3-
phosphate transporter) 
Cj0628 probable lipoprotein Cj0628/Cj0629 - Phase-variable Cj0628 putative lipoprotein 
Cj0629 possible lipoprotein Cj0628/Cj0629 - Phase-variable Cj0628 putative lipoprotein 
Cj0968 probable periplasmic protein Cj0968/Cj0969 - Pseudogenes Cj0969 
pseudogene (putative periplasmic 
protein) 
Cj0969 probable pseudogene Cj0968/Cj0969 - Pseudogenes Cj0969 
pseudogene (putative periplasmic 
protein) 
Cj1144c unknown Cj1144c/Cj1145c - Phase-variable Cj1144c hypothetical protein Cj1144c 
Cj1145c unknown Cj1144c/Cj1145c - Phase-variable Cj1144c hypothetical protein Cj1144c 
Cj1325 unknown Cj1325/Cj1326 - Phase-variable Cj1325 putative methyltransferase 
Cj1326 unknown Cj1325/Cj1326 - Phase-variable Cj1325 putative methyltransferase 
  
  
1
0
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Cj1335 unknown Cj1335/Cj1336 - Phase-variable Cj1335 
motility accessory factor (function 
unknown) 
Cj1336 unknown Cj1335/Cj1336 - Phase-variable Cj1335 
motility accessory factor (function 
unknown) 
Cj1520 hypothetical protein Cj1520 - removed 
CRISPR 
region 
identified 
CRISPR 
Cj1677 probable lipoprotein Cj1677/Cj1678 - Phase-variable Cj1677 putative lipoprotein 
Cj1678 possible lipoprotein Cj1677/Cj1678 - Phase-variable Cj1677 putative lipoprotein 
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3.2.2 Re-annotation of CDS function 
A systematic re-annotation of all 1654 CDSs in the original annotation of the 
NCTC11168 genome sequence was performed. As a result of this re-annotation, all 
CDSs with additional new information have had an ‘updated’ note qualifier attached to 
the published EMBL file (Figure 3.1). Qualifiers are the different categories for 
describing each CDS. The ‘colour’ and ‘literature’ qualifiers were only displayed in the 
EMBL file deposited at the WTSI and GeneDB (analysis website of WTSI genomes - 
http://www.genedb.org) due to EMBL restrictions at EBI. A ‘colour’ qualifier refers to 
the colouring scheme adopted by the WTSI – Pathogen Genomics Department 
(http://www.sanger.ac.uk/Projects/Microbes/) to allow classification of functionality for 
each CDS. The colour qualifier is used in the genome viewing software Artemis 
produced by the WTSI (Rutherford et al., 2000). Importantly, the ‘colour’ qualifier 
adopted by the WTSI does not correlate with the more detailed functional classification 
system defined by the ‘class’ qualifier (Appendix 5 – Additional File 1). The six broad 
category headings of this ‘class’ qualifier are:-  
 
1. Small molecule metabolism 
2. Broad regulatory 
3. Macromolecule metabolism  
4. Cell processes 
5. Other 
6. Miscellaneous  
 
The ‘literature’ qualifier refers to a new qualifier adopted in this particular re-annotation 
whereby relevant literature was attached to each individual CDS (Figure 3.1). The 
‘updated’ note qualifier contains consistent free-hand descriptions on recently identified 
motifs, relevant similarity search results and any published characterisation work 
performed in Campylobacter species/strains or any orthologues in related organisms. 
Additionally, the ‘updated’ note qualifier also contains reasoning for designating a 
product function for a CDS as putative or definitive. Putative designations infer an 
accepted product function without definitive evidence. For each CDS, a full literature 
search was performed. Detailed statistics on genome modifications are given in Table 
3.2. The product functions of 299 (18.2% CDSs) were updated (Appendix 5 – Additional 
File 5). The classification of each CDS into a ‘functional classification’ was adopted 
using WTSI classification guidelines (Appendix 5 – Additional File 4). Out of the 299 
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CDSs with an updated product function, 181 (60.5% CDSs) now have a different 
functional classification. One example is Cj1546, where this CDS was originally 
annotated as a ‘hypothetical protein’. The re-annotation changed the product function to 
a ‘putative transcriptional regulator’. This change has also altered the functional 
classification from ‘5.H - Conserved hypothetical protein’ to ‘2 - Broad regulatory 
functions’. A different ‘functional classification’ may or may not be within the same 
broad category of functional classifications (outlined as 1-6 above). Of the 181 CDSs 
with new product functions AND a new functional classification, 177 were moved into a 
new broad category of functional classification (as was the case for Cj1546). This was 
originally in the functional classification ‘5.I - Unknown’, which is in broad category 5. 
The re-annotation has moved the functional classification to ‘2 - Broad regulatory 
functions’, which is in broad category 2. One example of a CDS that had a new 
functional classification, but remained in the same broad category was Cj1317, where the 
CDS was originally annotated as a ‘N-acetylneuraminic acid synthetase’ in the functional 
classification ‘3.C.2 - Surface polysaccharides, lipopolysaccharide and antigens’. The re-
annotation changed the product function to ‘Pse synthetase’. This CDS is part of the 
pseudaminic acid biosynthesis pathway of the O-linked glycosylation pathway that 
modifies the flagellin protein. The functional classification was altered to ‘3.C.3 - 
Surface structures’. As such, Cj1317 has a new product name, a different functional 
classification, but still within the same broad category of functional classification (in this 
case, category 3). 
 
Appendix 5 – Additional Files 2 & 3 display in-depth data on the change and distribution 
of CDSs within these functional categories. Importantly, the number of CDSs in the 
‘Unknown and other’ category was reduced from 389 to 267 (a reduction of 122). This 
category includes functional classifications such as ‘IS elements’, ‘plasmid related 
functions’, ‘antibiotic resistance’, ‘conserved hypothetical proteins’ and ‘unknown’ 
(where no motifs were identified). The reduction in this category demonstrates the 
significant number of CDSs with new information relating to product function. However 
it is also clear that there remain a large number of CDSs yet to be characterised. Also the 
number of CDSs in the ‘Miscellaneous’ category increased from 75 to 152 (an increase 
of 77). CDSs were designated as miscellaneous when a motif was present, but there was 
no clear indication as to what functional classification the CDS belonged to. The increase 
in ‘miscellaneous’ numbers was due to the identification of new motifs not present 
during the original annotation, such as an ATP/GTP-binding site motif A (P-loop) in 
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Cj0096. Sequence comparisons and structural data have shown that proteins containing 
this motif have a role in ATP or GTP binding (Saraste et al., 1990). The fact that a 
number of CDSs have new information relating to a product function from such motifs, 
has led to an increase in CDSs within this particular category. This motif identification 
may not provide the full functional characterisation, however the designation of such 
motifs will aid in the future characterisation of the CDS in question. 
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Figure 3.1. An example of a re-annotated CDS (Cj0238) displayed in Artemis. Highlighted is the ‘original’ and ‘updated’ annotations along with a 
new ‘literature’ qualifier, which was added in the re-annotation and details relevant publications related to the CDS. This CDS shows the different 
qualifiers used in the re-annotation. 
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Table 3.2. Statistics on CDSs from the C. jejuni NCTC11168 re-annotation. 
 
Categories Number of CDS 
Percentage 
change 
CDSs with new motifs identified 743 +44.9% 
CDSs with new literature qualifier 1067 +64.5% 
CDSs with new updated note qualifier 1489 +90.0% 
CDSs with hypothetical designations in 
product function 
124 -7.5% 
CDSs with conserved hypothetical in product 
function 
62 +3.7% 
CDSs with putative designation in product 
function 
98 +5.9% 
CDSs with new gene qualifier 105 +6.3% 
CDSs with new product function 299 +18.2% 
CDSs with new product function and with a 
new functional classification 
181 +60.5% 
CDSs with new product function and a new 
functional classification with a different broad 
category 
177 +97.8% 
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Since the original annotation was published in 2000, significant new information has 
been generated about the genetic loci encoding the four main C. jejuni surface structures. 
The C. jejuni N-linked glycosylation pathway (Cj1119c – Cj1130c) was not described in 
the original annotation, but has been studied extensively since the original annotation 
(Linton et al., 2005, Glover et al., 2005, Kelly et al., 2006, Szymanski et al., 2003a). 
This re-annotation includes the nomenclature for the pglA-K (protein glycosylation) 
genes and has updated all the product functions for each gene within this locus. The LOS 
locus (Cj1131c - Cj1152c) described in the original annotation was updated to include 
product functions for genes identified since the original annotation such as neuA1, 
neuB1, neuC1 and hldDE (Guerry et al., 2000, Valvano et al., 2002, Linton et al., 2000, 
Gilbert et al., 2002). The O-linked glycosylation loci (Cj1293 - Cj1342) which is 
responsible for glycosylation of the flagellin structural proteins, has been updated to 
include the neu, pse and maf genes (Thibault et al., 2001, Szymanski et al., 2003a, Liu 
and Tanner, 2006, Karlyshev et al., 2002). Finally, the CPS locus (Cj1413c - Cj1448c) 
has now been updated to include kps and hdd genes (Karlyshev et al., 2000, Karlyshev et 
al., 2001, Karlyshev et al., 2005a). The new product designations made to these four loci 
in the C. jejuni NCTC11168 genome are shown in Tables 3.3-3.6.  
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Table 3.3. Re-annotation updates for the C. jejuni NCTC11168 N-glycosylation locus. 
 
CDS Number Gene Name Original Annotation Re-annotation 
Cj1119c pglG probable integral membrane protein putative integral membrane protein 
Cj1120c pglF possible sugar epimerase/dehydratase UDP-GlcNAc C4,6 dehydratase 
Cj1121c pglE possible aminotransferase UDP-4-keto-6-deoxy-GlcNAc C4 aminotransferase 
Cj1122c  possible integral membrane protein putative integral membrane protein 
Cj1123c pglD possible transferase acetyltransferase 
Cj1124c pglC probable galactosyltransferase galactosyltransferase 
Cj1125c pglA probable galactosyltransferase GalNAc transferase 
Cj1126c pglB probable integral membrane protein oligosaccharide transferase to N-glycosylate proteins 
Cj1127c pglJ probable glycosyltransferase GalNAc transferase 
Cj1128c pglI probable glycosyltransferase glucosyl transferase 
Cj1129c pglH probable glycosyltransferase GalNAc transferase/polymerase 
Cj1130c pglK ABC-type transport protein flippase 
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Table 3.4. Re-annotation updates for the C. jejuni NCTC11168 LOS locus.  
 
CDS Number Gene Name Original Annotation Re-annotation 
Cj1131c gne probable UDP-glucose 4-epimerase UDP-GlcNAc/Glc 4-epimerase 
Cj1132c  unknown conserved hypothetical protein 
Cj1133 waaC probable lipopolysaccharide heptosyltransferase heptosyltransferase I 
Cj1134 htrB probable lipid A biosynthesis lauroyl acyltransferase putative lipid A biosynthesis lauroyl acyltransferase 
Cj1135  probable two-domain glycosyltransferase putative two-domain glucosyltransferase 
Cj1136  probable galactosyltransferase putative glycosyltransferase 
Cj1137c  unknown putative glycosyltransferase 
Cj1138  probable galactosyltransferase putative glycosyltransferase 
Cj1139c wlaN probable galactosyltransferase beta-1,3 galactosyltransferase 
Cj1140 cstIII unknown alpha-2,3 sialyltransferase 
Cj1141 neuB1 probable N-acetylneuraminic acid synthetase 
sialic acid synthase (N-acetylneuraminic acid 
synthetase) 
Cj1142 neuC1 probable N-acetylglucosamine-6-phosphate 2- putative UDP-N-acetylglucosamine 2-epimerase 
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epimerase/N-acetylglucosamine-6-phosphatase 
Cj1143 neuA1/cgtA 
probable acylneuraminate cytidylyltransferase (CMP-
N-acetylneuraminic acid synthetase) 
two-domain bifunctional protein (beta-1,4-N-
acetylgalactosaminyltransferase/CMP-Neu5Ac 
synthase) 
Cj1144c  unknown hypothetical protein 
Cj1146c waaV possible glucosyltransferase putative glucosyltransferase 
Cj1148 waaF probable ADP-heptose--LPS heptosyltransferase heptosyltransferase II 
Cj1149c gmhA probable phosphoheptose isomerase sedoheptulose 7-phosphate isomerase 
Cj1150c hldE possible ADP-heptose synthase 
D-beta-D-heptose 7-phosphate kinase/D-beta-D-
heptose 1-phosphate adenylyltransferase 
Cj1151c hldD 
probable ADP-L-glycero-D-manno-heptose-6-
epimerase 
ADP-glyceromanno-heptose 6-epimerase 
Cj1152c gmhB possible phosphatase D,D-heptose 1,7-bisphosphate phosphatase 
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Table 3.5. Re-annotation updates for the C. jejuni NCTC11168 O-glycosylation locus. 
 
CDS Number Gene Name Original Annotation Re-annotation 
Cj1293 pseB possible sugar nucleotide epimerase/dehydratase UDP-GlcNAc-specific C4,6 dehydratase/C5 epimerase 
Cj1294 pseC probable aminotransferase C4 aminotransferase specific for PseB product 
Cj1295  unknown conserved hypothetical protein 
Cj1296  unknown hypothetical protein 
Cj1297  unknown hypothetical protein 
Cj1298  unknown putative N-acetyltransferase 
Cj1299 acpP2 probable acyl carrier protein putative acyl carrier protein 
Cj1300  unknown putative SAM domain containing methyltransferase 
Cj1301  unknown hypothetical protein 
Cj1302  unknown putative HAD-superfamily phosphatase, subfamily IIIC 
Cj1303 fabH2 probable 3-oxoacyl-[acyl-carrier-protein] synthase putative 3-oxoacyl-[acyl-carrier-protein] synthase 
Cj1304 acpP3 probable acyl carrier protein putative acyl carrier protein 
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Cj1305c  unknown hypothetical protein 
Cj1306c  unknown hypothetical protein 
Cj1307  possible amino acid activating enzyme putative amino acid activating enzyme 
Cj1308  possible acyl carrier protein putative acyl carrier protein 
Cj1309c  unknown hypothetical protein 
Cj1310c  unknown hypothetical protein 
Cj1311 pseF 
probable acylneuraminate cytidylyltransferase (CMP-
N-acetylneuraminic acid synthetase) 
putative acylneuraminate cytidylyltransferase 
Cj1312 pseG possible flagella protein 
nucleotidase specific for PseC product, UDP-4-amino-
4,6-dideoxy-beta-L-AltNAc 
Cj1313 pseH possible flagella protein 
N-acetyltransferase specific for PseC product, UDP-4-
amino-4,6-dideoxy-beta-L-AltNAc 
Cj1314c hisF probable cyclase imidazole glycerol phosphate synthase subunit 
Cj1315c hisH probable amidotransferase imidazole glycerol phosphate synthase subunit 
Cj1316c pseA unknown pseudaminic acid biosynthesis PseA protein 
Cj1317 pseI N-acetylneuraminic acid synthetase Pse synthetase 
  
  
1
1
3
 
 
Cj1318 maf1 unknown motility accessory factor (function unknown) 
Cj1319  probable nucleotide sugar dehydratase putative nucleotide sugar dehydratase 
Cj1320  probable aminotransferase putative aminotransferase (degT family) 
Cj1321  probable transferase putative transferase 
Cj1322  unknown hypothetical protein 
Cj1323  unknown hypothetical protein 
Cj1324  unknown hypothetical protein 
Cj1325  unknown putative methyltransferase 
Cj1327 neuB2 N-acetylneuraminic acid synthetase N-acetylneuraminic acid synthetase 
Cj1328 neuC2 
probable N-acetylglucosamine-6-phosphate 2-
epimerase/N-acetylglucosamine-6-phosphatase 
putative UDP-N-acetylglucosamine 2-epimerase 
Cj1329  probable sugar-phosphate nucleotide transferase putative sugar-phosphate nucleotide transferase 
Cj1330  unknown hypothetical protein 
Cj1331 ptmB 
probable acylneuraminate cytidylyltransferase (CMP-
N-acetylneuraminic acid synthetase) 
acylneuraminate cytidylyltransferase (flagellin 
modification) 
Cj1332 ptmA probable oxidoreductase putative oxidoreductase (flagellin modification) 
  
  
1
1
4
 
 
Cj1333 pseD unknown PseD protein 
Cj1334 maf3 unknown motility accessory factor (function unknown) 
Cj1335 maf4 unknown motility accessory factor (function unknown) 
Cj1337 pseE unknown PseE protein 
Cj1338c flaB flagellin B flagellin 
Cj1339c flaA flagellin A flagellin 
Cj1340c  unknown conserved hypothetical protein 
Cj1341c maf6 unknown motility accessory factor (function unknown) 
Cj1342c maf7 unknown motility accessory factor (function unknown) 
  
  
1
1
5
 
 
Table 3.6. Re-annotation updates for the C. jejuni NCTC11168 CPS biosynthesis locus.  
 
CDS Number Gene Name Original Annotation Re-annotation 
Cj1413c kpsS possible polysaccharide modification protein capsule polysaccharide modification protein 
Cj1414c kpsC possible polysaccharide modification protein capsule polysaccharide modification protein 
Cj1415c cysC possible adenylylsulfate kinase putative adenylylsulfate kinase 
Cj1416c  probable sugar nucleotidyltransferase putative sugar nucleotidyltransferase 
Cj1417c  unknown putative amidotransferase 
Cj1418c  unknown putative transferase 
Cj1419c  possible methyltransferase putative methyltransferase 
Cj1420c  unknown putative methyltransferase 
Cj1421c  possible sugar transferase putative sugar transferase 
Cj1422c  possible sugar transferase putative sugar transferase 
Cj1423c hddC possible sugar-phosphate nucleotidyltransferase 
putative D-glycero-D-manno-heptose 1-phosphate 
guanosyltransferase 
Cj1424c gmhA2 probable phosphoheptose isomerase phosphoheptose isomerase 
  
  
1
1
6
 
 
Cj1425c hddA possible sugar kinase 
putative D-glycero-D-manno-heptose 7-phosphate 
kinase 
Cj1426c  unknown putative methyltransferase family protein 
Cj1427c  probable sugar-nucleotide epimerase/dehydratease putative sugar-nucleotide epimerase/dehydratease 
Cj1428c fcl probable fucose synthetase GDP-L-fucose synthetase 
Cj1429c  unknown hypothetical protein 
Cj1430c rfbC probable nucleotide-sugar epimerase/dehydratase putative dTDP-4-dehydrorhamnose 3,5-epimerase 
Cj1431c hddC unknown capsular polysaccharide heptosyltransferase 
Cj1432c  possible sugar transferase putative sugar transferase 
Cj1433c  unknown hypothetical protein 
Cj1434c  probable sugar transferase putative sugar transferase 
Cj1435c  unknown putative phosphatase 
Cj1436c  probable aminotransferase aminotransferase 
Cj1437c  probable aminotransferase aminotransferase 
Cj1438c  probable sugar transferase putative sugar transferase 
Cj1439c glf probable UDP-galactopyranose mutase UDP-galactopyranose mutase 
  
  
1
1
7
 
 
Cj1440c  probable sugar transferase putative sugar transferase 
Cj1441c kfiD probable UDP-glucose 6-dehydrogenase UDP-glucose 6-dehydrogenase 
Cj1442c  unknown putative sugar transferase 
Cj1443c kpsF unknown D-arabinose 5-phosphate isomerase 
Cj1444c kpsD 
probable capsule polysaccharide export system 
periplasmic protein 
capsule polysaccharide export system periplasmic 
protein 
Cj1445c kpsE 
probable capsule polysaccharide export system inner 
membrane protein 
capsule polysaccharide export system inner membrane 
protein 
Cj1447c kpsT 
probable capsule polysaccharide export ATP-binding 
protein 
capsule polysaccharide export ATP-binding protein 
Cj1448c kpsM 
probable capsule polysaccharide export system inner 
membrane protein 
capsule polysaccharide export system inner membrane 
protein 
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Additional genome-wide updates were performed of which a large proportion entailed 
adding specificity to existing product function. For example, the identification of a new 
PFAM or PROSITE motif for the CDS Cj1556 has allowed the product function to 
become further specified. In this example, a hypothetical protein was re-annotated as a 
putative transcriptional regulator. A complete list of changes throughout the C. jejuni 
NCTC11168 genome is provided in Appendix 5 – Additional Files 4 & 5.  
 
3.2.3 Modifications to pseudogene annotations 
Pseudogene identification is a challenging process with discrepancies existing between 
the methods used for assignment of pseudogenes (Lerat and Ochman, 2005). Methods 
include detection of ORFs belonging to a single CDS on multiple frames, the presence of 
one or more stop codons within a CDS and extra information from the biology of the 
organism. More recently, comparative genomics have been used as a technique for 
pseudogene identification where alignment to a fully functional version of the CDS from 
a different strain/species has assisted in the annotation of pseudogenes (Lerat and 
Ochman, 2004). The driving force for these studies is that the identification of such 
mutations aids in determining the phylogenetic relatedness and evolution of bacterial 
strains. A full re-analysis of all pseudogenes in the NCTC11168 genome was performed 
as part of this re-annotation (Table 3.7). The original annotation had only displayed a 
pseudogene on a single frame so did not reflect the true position of the mutated CDS. 
This process of identifying pseudogenes is difficult and support from homologues 
identified using FASTA and TBLASTX search results were used. The majority of 
revisions in this re-annotation incorporated multiple features created from different co-
ordinates on more than one reading frame. This full re-analysis of all pseudogenes 
resulted in the adjustment of 19 out of 20 pseudogenes by introducing multiple CDSs on 
different reading frames representing the hypothetical fully functional original single 
CDS. The final pseudogene number was reduced to 19 due to the merging of two CDSs 
(Cj0290c and Cj0292c) designated as pseudogenes along with an intermediate CDS 
Cj0291c, which had been originally annotated as a glycerol-3-phosphate transporter and 
had been noted as a possible pseudogene (Figure 3.2). 
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Table 3.7. Re-annotated pseudogenes in C. jejuni NCTC11168 with modifications. 
 
CDS Number Product function Modification 
Cj0046 
pseudogene (putative 
sodium:sulfate transmembrane 
transport protein) 
CDS split into multiple frames 
Cj0072c 
pseudogene (putative iron-binding 
protein) 
CDS split into multiple frames 
Cj0223 
pseudogene (putative IgA protease 
family protein) 
CDS split into multiple frames 
Cj0292c 
pseudogene (putative glycerol-3-
phosphate transporter) 
Merging of multiple CDS 
Cj0444 
pseudogene (putative TonB-
denpendent outer membrane 
receptor) 
CDS split into multiple frames 
Cj0501 
pseudogene (ammonium 
transporter) 
CDS split into multiple frames 
Cj0565 
pseudogene (conserved 
hypothetical protein) 
CDS split into multiple frames 
Cj0654c 
pseudogene (putative 
transmembrane transport protein) 
CDS split into multiple frames 
Cj0676 
pseudogene (potassium-
transporting ATPase A chain) 
CDS split into multiple frames 
Cj0678 
pseudogene (potassium-
transporting ATPase C chain) 
CDS split into multiple frames 
Cj0742 
pseudogene (putative outer 
membrane protein) 
CDS split into multiple frames 
Cj0752 
pseudogene (IS element 
transposase) 
CDS split into multiple frames 
Cj0866 pseudogene (arylsulfatase) CDS split into multiple frames 
Cj0969 
pseudogene (putative periplasmic 
protein) 
Merging of multiple CDS 
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Cj1064 pseudogene (nitroreductase) CDS split into multiple frames 
Cj1389 
pseudogene (putative C4-
dicarboxylate anaerobic carrier) 
CDS split into multiple frames 
Cj1395 
pseudogene (putative MmgE/PrpD 
family protein) 
Unmodified 
Cj1395 
pseudogene (putative MmgE/PrpD 
family protein) 
Unmodified 
Cj1470c 
pseudogene (type II protein 
secretion system F protein) 
CDS split into multiple frames 
Cj1528 
pseudogene (putative C4-
dicarboxylate anaerobic carrier) 
CDS split into multiple frames 
  
  
1
2
1
 
 
     
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
Figure 3.2. Artemis genome viewer illustrating CDSs Cj0290c, Cj0291c and Cj0292c. Upper panel illustrates CDS layout from the original annotation. 
Lower panel illustrates CDS layout from the re-annotation. The two pseudogenes along with Cj0291c, which had originally been annotated as a 
‘glycerol-3-phosphate transporter – putative pseudogene’ were all merged together. Pseudogenes are illustrated in brown. The result of this 
modification was the removal of one of the two original pseudogenes Cj0290c and Cj0292c). 
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3.2.4 Modifications to phase-variable CDS annotations 
Predicted phase-variable CDSs containing an intersecting homopolymeric tract were 
merged to reflect the complete amino acid sequence for appropriate genes regardless of 
phase variation (Table 3.8). The merging of such CDSs was not undertaken in the 
original annotation. The merging of CDSs with an intersecting homopolymeric tract 
allows a better representation of phase-variable CDSs within the C. jejuni NCTC11168 
genome.  
 
Table 3.8. Merged phase-variable CDSs in C. jejuni NCTC11168 re-annotation. 
 
 
 
3.2.5 Additional genome data 
In addition to CDS updates, novel features were also added to the re-annotation. CRISPR 
regions have been shown to provide acquired immunity against viruses and plasmids by 
targeting nucleic acid in a sequence in a sequence-specific manner (Schouls et al., 2003, 
Godde and Bickerton, 2006, Jansen et al., 2002, Bolotin et al., 2005, Horvath and 
CDS Number Product 
Re-annotation 
CDS 
Effect 
Cj0031/Cj0032 
putative type IIS 
restriction/modification 
enzyme 
Cj0031 Merged 
Cj0170/Cj0171 hypothetical protein Cj0170 Cj0170 Merged 
Cj0628/Cj0629 putative lipoprotein Cj0628 Merged 
Cj1144/Cj1145 
hypothetical protein 
Cj1144c 
Cj1144 Merged 
Cj1325/Cj1326 putative methyltransferase Cj1325 Merged 
Cj1335/Cj1336 
motility accessory factor 
(function unknown) 
Cj1335 Merged 
Cj1677/Cj1678 putative lipoprotein Cj1677 Merged 
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Barrangou, 2010, Marraffini and Sontheimer, 2010). To date, there has only been one 
identified CRISPR region within C. jejuni NCTC11168 and this has now been 
incorporated within this re-annotation (PMID: 12517820). As a result one CDS (Cj1520) 
has been removed. This CDS was previously annotated as having five repeat regions. In 
addition, three CDSs (Cj1521c, Cj1522c and Cj1523c) adjacent to the CRISPR repeats 
were re-annotated as CRISPR associated proteins and this concurs with existing CRISPR 
structures (Schouls et al., 2003, Godde and Bickerton, 2006, Jansen et al., 2002).  
  
RFAM databases investigating non-coding RNAs (Griffiths-Jones et al., 2003) were 
performed and identified two new non-coding RNA structures. RFAM RF00169, a 
bacterial signal recognition particle (SRP) RNA, was identified upstream of Cj0046. The 
SRP is a universally conserved ribonucleoprotein involved in the co-translational 
targeting of proteins to membranes (Rosenblad et al., 2003, Regalia et al., 2002). RFAM 
RF00059, a thiamin pyrophosphate riboswitch, was identified upstream of Cj0453 
(thiamin biosynthesis protein ThiC). This RFAM motif is a conserved structure involved 
in thiamin-regulation (Rodionov et al., 2002).  
 
One of the major advantages of performing a manual annotation or re-annotation is the 
potential inclusion of the advice from experts on the organism being annotated. This was 
the case for this re-annotation whereby experts contributed product functions and 
descriptive information for the four main glyco-structure loci in the C. jejuni 
NCTC11168 genome. The N-linked glycosylation locus was reviewed by Dr. Christine 
Szymanski. The O-linked glycosylation locus was reviewed by Dr. Susan Logan. The 
LOS locus was reviewed by Dr. Michel Gilbert and the capsule locus was reviewed by 
Prof. Andrey Karlyshev.  
 
The final step of the re-annotation process was the incorporation of Gene Ontology (GO) 
annotation. GO annotation attempts to link three structured, controlled vocabularies 
(ontologies) that describe gene products in terms of their associated biological processes, 
cellular components and molecular functions in a species-independent manner 
(Ashburner et al., 2000). There are currently two different versions of the GO annotation. 
The EMBL genome file created by EBI carries a GOA link that lists the GO annotation 
created automatically by EBI. GeneDB maintains an alternative list of GO annotations 
created automatically by performing a reciprocal FASTA of the C. jejuni NCTC11168 
genome against C. jejuni RM1221. GO annotation is a valuable feature in current 
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annotation techniques that can expedite systems biology approaches to genome analysis 
(Ashburner et al., 2000). 
 
3.3 Further C. jejuni genome analysis since re-annotation 
Further studies have been performed since the re-annotation was published in 2007. The 
number and type of predicted pseudogenes within C. jejuni NCTC11168 and C. jejuni 
RM1221 were analysed (Table 3.9). The table displays the genomes in synteny. Hence, 
identical pseudogenes are on the same row. This was to ensure that variation in product 
function naming did not exclude identical pseudogenes.  
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Table 3.9. Comparison of predicted pseudogenes in C. jejuni NCTC11168 and C. jejuni 
RM1221. Table represents the genomes in synteny. A cell which is grey in colour 
denotes a pseudogene. Hence, identical pseudogenes are on the same row. A parallel 
italicised white cell can have the pseudogene represented as an intact CDS (present), not 
have the CDS (absent) or have the CDS but mis-annotated (should be a pseudogene). 
 
 
NCTC11168 RM1221* 
CDS Number Product CDS Number Product 
 
mis-annotated as a CDS 
(should be a pseudogene) 
in NCTC11168 
CJE0013 
membrane protein, 
putative 
Cj0046 
pseudogene (putative 
sodium:sulfate 
transmembrane 
transport protein) 
CJE0046 
C4-dicarboxylate 
transporter 
Cj0072c 
pseudogene (putative 
iron-binding protein) 
CJE0068 
conserved hypothetical 
protein 
 present as intact CDS CJE0196 citrate transporter 
Cj0223 
pseudogene (putative IgA 
protease family protein) 
 
mis-annotated as a CDS 
(should be a pseudogene) 
in RM1221 
 absent CJE0274 pathogenicity protein 
 absent CJE0292 
conserved hypothetical 
protein 
 present as intact CDS CJE0297 
conserved hypothetical 
protein 
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Cj0292c 
pseudogene (putative 
glycerol-3-phosphate 
transporter) 
CJE0338 
glycerol-3-phosphate 
transporter 
Cj0444 
pseudogene (putative 
TonB-denpendent outer 
membrane receptor) 
CJE0496 TonB-dependent receptor 
 
mis-annotated as a CDS 
(should be a pseudogene) 
in NCTC11168 
CJE0533 altronate hydrolase 
Cj0501 
pseudogene (ammonium 
transporter) 
CJE0609 ammonium transporter 
Cj0565 
pseudogene (conserved 
hypothetical protein) 
 absent 
 present as intact CDS CJE0665 
MATE efflux family 
protein 
 present as intact CDS CJE0673 
conserved hypothetical 
protein 
 
mis-annotated as a CDS 
(should be a pseudogene) 
in NCTC11168 
CJE0720 hypothetical protein 
Cj0654c 
pseudogene (putative 
transmembrane 
transport protein) 
CJE0758 peptide transporter 
Cj0676 
pseudogene (potassium-
transporting ATPase A 
chain) 
CJE0774 
potassium-transporting 
ATPase, A subunit 
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 present as intact CDS CJE0775 
 
potassium-transporting 
ATPase, B subunit 
 
Cj0678 
pseudogene (potassium-
transporting ATPase C 
chain) 
 present as intact CDS 
Cj0742 
 
pseudogene (putative 
outer membrane protein) 
 
 absent 
 present as intact CDS CJE0777 
sensor histidine kinase 
KdpD 
 present as intact CDS CJE0803 
conserved hypothetical 
protein 
 present as intact CDS CJE0836 
conserved hypothetical 
protein 
Cj0752 
pseudogene (IS element 
transposase) 
CJE0844 transposase 
Cj0866 
pseudogene 
(arylsulfatase) 
CJE0953 
arylsulfate 
sulfotransferase 
 present as intact CDS CJE0955 
cytochrome c family 
protein 
 present as intact CDS CJE1032 
membrane protein, 
putative 
 present as intact CDS CJE1047 
conserved hypothetical 
protein 
 present as intact CDS CJE1056 
conserved hypothetical 
protein 
 absent CJE1121 DNA primase TraC 
 absent CJE1140 hypothetical protein 
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 absent CJE1175 
conserved hypothetical 
protein 
Cj0969 
pseudogene (putative 
periplasmic protein) 
 present as intact CDS 
Cj1064 
pseudogene 
(nitroreductase) 
CJE1208 
nitroreducatase family 
protein 
 
mis-annotated as a CDS 
(should be a pseudogene) 
in NCTC11168 
CJE1294 
conserved hypothetical 
protein 
 
 
present as intact CDS 
 
CJE1393 
multidrug resistance 
efflux transporter 
 
 
present as intact CDS 
 
CJE1544 
enterochelin ABC 
transporter 
 
 
absent 
 
CJE1549 
vacuolating cytotoxin, 
putative 
Cj1389 
pseudogene (putative C4-
dicarboxylate anaerobic 
carrier) 
CJE1580 
cryptic C4-dicarboxylate 
transporter 
Cj1395 
pseudogene (putative 
MmgE/PrpD family 
protein) 
 present as intact CDS 
Cj1470c 
pseudogene (type II 
protein secretion system 
F protein) 
 present as intact CDS 
 present as intact CDS CJE1585 
ferrous iron transport 
protein B 
 
 
present as intact CDS 
 
CJE1697 
CRISPR-associated 
protein 
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Cj1528 
pseudogene (putative C4-
dicarboxylate anaerobic 
carrier) 
CJE1699 
cryptic C4-dicarboxylate 
transporter 
 
 
absent 
 
CJE1718 
outer membrane 
lipoprotein Blc 
 
 
absent 
 
CJE1720 
type I restriction-
modification system, R 
subunit 
 
 
absent 
 
CJE1722 
type I restriction-
modification system, S 
subunit 
 
 
present as intact CDS 
 
CJE1729 
conserved hypothetical 
protein 
 
 
present as intact CDS 
 
CJE1734 
transcriptional regulator, 
putative 
 
 
present as intact CDS 
 
CJE1759 
proline/betaine 
transporter, putative 
 
 
 
 
present as intact CDS 
 
 
CJE1790 
conserved hypothetical 
protein 
 present as intact CDS CJE1802 
TonB-dependent 
receptor, putative 
 
* C. jejuni RM1221 was predicted to have 47 pseudogenes and 35 of these were noted as 
genes in C. jejuni NCTC11168 (Fouts et al., 2005). However, the RM1221 genome 
sequence obtained from the WTSI only contained 46 pseudogenes. Thus, the above 35 
“non-pseudogenes” in C. jejuni NCTC11168 are 34 in number. RM1221 genes are 
represented as ‘CJE’. 
 
Publication of further C. jejuni genome sequences has allowed analysis between different 
genomes. To further investigate the number of pseudogenes in different C. jejuni strains 
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and also to analyse genome features in greater detail, a further four C. jejuni strains were 
analysed (Table 3.10).  
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Table 3.10. Genome features of five C. jejuni genomes.  
 
Trait Strains 
 
Strain 
 
NCTC11168 RM1221 81-176 81116 CG8486 
Serotype HS:2 HS:53 HS:23/36 HS:6 HS:4 
MLSTa ST-21 (43) ST-354 (354) ST-42 (913) ST-283 (267) unknown 
Origin Clinical Chicken Clinical Clinical Clinical 
Genome size 
(Mb) b 
1.64 1.77 1.62 1.63 1.60 
GC content 
(%) 
30.55 30.31 30.62 30.54 30.43 
Predicted 
CDS numbers 
1654 (1643)e 1835 1568 1626 1588 
Pseudogenes 20(19)e 47 0c 1c 3c 
Poly G/C 
tractsd 
29 (22) 25 (8) 19 17 23 
Plasmids 0 0 2 0 0 
References 
(Parkhill et 
al., 2000) 
(Fouts et al., 
2005) 
(Hofreuter et 
al., 2006) 
(Pearson et 
al., 2007) 
(Poly et al., 
2007) 
 
Legend. a ST represents clonal complex. () indicates sequence type. b indicates genome 
size made by approximation. CG8486 genome sequence is currently in 19 contigs. c 
indicates approximate number of pseudogenes. d Poly G/C tracts represent total found. () 
indicate tracts greater than seven or more nucleotides in length and have been shown to 
vary during sequencing project. e () indicates number after NCTC11168 re-annotation.  
 
3.4 Rationale for the selection of predicted CDSs for further characterisation 
Following the re-annotation of the C. jejuni NCTC11168 genome, 15 CDSs were 
selected for further characterisation (Table 3.11). Selection was primarily based on new 
motif and literature information not available at the time of the original annotation. 
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Selected CDSs were grouped into either putative virulence-associated, signal 
transduction or regulation of gene expression (Table 3.11). Defined isogenic C. jejuni 
11168H mutants were successfully constructed for 8 of the selected CDSs. Following a 
number of preliminary phenotypic assays such as growth kinetics, motility, interaction 
and invasion assays on all successfully constructed mutants, the Cj0248 and Cj1556 
mutants displayed the most interesting phenotypic results and were selected for further 
investigation to characterise each CDS function in detail. The characterisation of the 
Cj1556 and Cj0248 mutants are described in Chapters 4 and 5 respectively.  
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Table 3.11. CDSs selected for further study after re-annotation of the NCTC11168 
genome sequence. CDSs were selected in three main categories; regulation of gene 
expression, signal transduction and virulence-associated. 
 
CDS number Product function 
Mutant 
created 
Function category 
Cj0394c putative transcriptional activator No 
Broad regulatory 
function 
Cj0883c putative transcriptional regulator No 
Broad regulatory 
function 
Cj1546 putative transcriptional regulator No 
Broad regulatory 
function 
Cj1556 putative transcriptional regulator Yes 
Broad regulatory 
function 
Cj0144* 
putative methyl-accepting 
chemotaxis signal transduction 
protein 
No Signal transduction 
Cj0145 
putative TAT (Twin-Arginine 
Translocation) pathway signal 
sequence domain protein 
Yes Signal transduction 
Cj0262c* 
putative methyl-accepting 
chemotaxis signal transduction 
protein 
Yes Signal transduction 
Cj1505c 
putative two-component response 
regulator (SirA-like protein) 
No Signal transduction 
Cj1506c* 
putative MCP-type signal 
transduction protein 
Yes Signal transduction 
Cj1507c putative regulatory protein No Signal transduction 
Cj0248 hypothetical protein Cj0248 Yes 
Virulence-
associated 
Cj0619 
putative MATE family transport 
protein 
Yes 
Virulence-
associated 
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Cj0737 
putative haemagglutination 
activity domain containing protein 
Yes 
Virulence-
associated 
Cj0952 
putative HAMP containing 
membrane protein 
Yes 
Virulence-
associated 
Cj0977 hypothetical protein Cj0977 No 
Virulence-
associated 
 
* Denotes product function was identified in 2000. 
 
3.5 Discussion 
Existing genome sequences from model strains should ideally be re-annotated 
continuously to incorporate the maximum information available and to maintain the 
genome sequence as a useful resource. This is important as many aspects of research in 
the 21st century depend on genome sequence data. Global access to genome information 
has made it vital that up-to-date information is provided for each CDS. Using outdated 
CDS data could result in a waste of resources and affect strategic planning of research 
projects. Examples where up-to-date sequence data is important are microarray and 
proteomic studies where throughout the analysis pipeline, genomic data is used in 
conjunction with appropriate software. In addition, the use of up-to-date sequence data 
for next-generation sequencing techniques is also important. Whether the application is 
de novo sequencing, transcriptomics, interactomics or any other related application, 
annotated genome data is the baseline information that can have a strong influence on the 
interpretation of data analysis. 
 
The re-annotation of the C. jejuni NCTC11168 genome sequence led to 299 of product 
functions being updated and 1489 of CDSs having new information added to the note 
qualifier. The number of CDSs in the ‘Unknown and other’ category was reduced from 
389 to 267 (a reduction of 122). This category includes functional classifications such as 
‘IS elements’, ‘plasmid related functions’, ‘antibiotic resistance’, ‘conserved 
hypothetical proteins’ and ‘unknown’ (where no motifs were identified). This decrease is 
predominantly due to novel motifs being identified within a given CDS allowing the 
CDS to be placed into different functional category. There remains 267 CDSs in this 
‘Unknown and other’ category that required further investigation to pinpoint the 
functionality of these CDSs. The number of CDSs in the ‘Miscellaneous’ category has 
risen from 75 to 152 (an increase of 77). CDSs in this category contained a motif, 
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however there were no clear indications as to what functional classification the CDS 
belongs to. The fact that a number of CDSs have new information relating to a product 
function from uncharacterised motifs has led to the increase in CDSs within this 
particular category. This motif identification may not provide the ultimate product 
characterisation, however the designation of such motifs will assist in the future 
characterisation of the CDS in question, especially when a function is associated with the 
currently undefined motif. 
 
The re-annotation of the C. jejuni NCTC11168 genome was performed manually in 
collaboration with WTSI staff. Most genome sequencing projects now use automated 
annotation due to time and cost restraints. So it is rare for a re-annotation to be 
performed by a manual annotator. It is clear that researchers performing a re-annotation 
project can still offer a greater level of insight compared to automated approaches. 
However it is also clear that better automated annotation methods are needed to cope 
with the deluge of genome sequence data generated by next-generation sequencing. 
Automated tools need to be able to incorporate information from wider sources, such as 
literature searches. Searches should include a wide range of motif databases and be able 
to use this information to describe a product function. This of course is extremely 
challenging and requires a high level of programming and computing power. Currently 
automated searches rely primarily on results from similarity searches. This in itself can 
be highly misleading as an incorrectly assigned product function could result in the 
propagation of false designations across genome annotations for many different bacterial 
species and beyond.  
 
This re-annotation has attempted to incorporate data from a number of additional sources 
to allow for a more accurate product function designation. In addition to the classical 
motif databases of PFAM and Prosite, membrane and ribosomal motif databases were 
also searched. One of the most advantageous aspects of manual annotation is the 
incorporation of additional data from publicly available literature. Researchers may also 
have contacts or even information within their own laboratory that can be used to add 
further information to the file. Indeed this was the case with this re-annotation of the C. 
jejuni NCTC11168 genome sequence where a number of experts contributed to the 
updated annotation. 
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An important feature of the current re-annotation project (and indeed annotation projects 
in general) is the improved designation of pseudogenes and phase-variable genes. 
Pseudogenes are difficult to pinpoint due to sections of the full CDS residing on different 
reading frames of the forward or reverse strands. An example of the difficulty and 
complexity associated with pseudogene designation is observed when analysing the 
CDSs Cj0522, Cj0523 and Cj0524 in the C. jejuni NCTC11168 genome (Figure 3.3). 
These three CDSs are represented as one whole CDS on a single frame within C. jejuni 
RM1221 (Cje0628). The three CDSs are large enough to be represented as individual 
CDSs and were represented on more than one reading frame in the original C. jejuni 
NCTC11168 annotation. Do these CDSs represent a pseudogene in C. jejuni 
NCTC11168, which are intact in C. jejuni RM1221? Given the fact that in C. jejuni 
RM1221 Cje0628 does code for a putative product (a putative Na/Pi-co-transporter), it is 
most likely that these three CDSs represent a pseudogene in C. jejuni NCTC11168. In 
this re-annotation, a re-analysis of annotated pseudogenes was performed. However on 
the advice of WTSI staff, the elucidation of new pseudogenes was not undertaken. In this 
particular case, the potential for a pseudogene was noted in the ‘note’ qualifier. 
 
  
  
1
3
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Figure 3.3. Artemis genome viewer with upper panel illustrating CDSs Cj0522, Cj0523 and Cj0524 from the original NCTC11168 genome 
annotation. Lower panel illustrates CDS layout from the RM1221 genome annotation illustrating Cje0628. This figure illustrates the likelihood that 
the three NCTC11168 CDSs (upper panel) should actually be represented as a pseudogene due to the presence of stop codons between Cj0523 and 
Cj0524, and also the presence of a frame-shift for Cj0522. In this re-annotation, a re-analysis of pseudogenes was performed. However the 
elucidation of new pseudogenes was not undertaken. In this particular example, the potential for a pseudogene was noted in the ‘note’ qualifier.  
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The frequency and importance of pseudogene formation in microorganisms has attained 
increased significance in recent years with the development of genome reduction theories 
and the demonstration of enhanced virulence through pathoadaptive mutations (Harrison 
and Gerstein, 2002, Ochman and Davalos, 2006). Recent studies for example in Yersinia 
species have suggested that ever increasing non-functional CDSs are being identified 
within microorganisms and in particular are more common in genomes of recently 
evolved pathogens than in their benign relatives (Tong et al., 2005, Lerat and Ochman, 
2005). It should be noted that sequencing errors are also a factor in the pseudogene 
designation process and that re-sequencing is common to ensure mis-annotation has not 
occurred. Based on guidelines from the WTSI, this re-annotation did not attempt to 
identify novel pseudogenes, but did edit them to better illustrate the non-functional CDS. 
The number and type of predicted pseudogenes within C. jejuni NCTC11168 and C. 
jejuni RM1221 are compared in Table 3.9. After this re-annotation, C. jejuni 
NCTC11168 is predicted to contain at least 19 pseudogenes. 12/19 (63%) of the 
pseudogenes from C. jejuni NCTC11168 were also present in RM1221 as pseudogenes. 
Of the remaining seven pseudogenes, four were present as intact CDSs in RM1221, two 
were absent and one was mis-annotated and should have been designated a pseudogene 
in RM1221 (Table 3.9). C. jejuni RM1221 was predicted to contain 47 pseudogenes 
(Fouts et al., 2005). 12 pseudogenes are shared with NCTC11168 as noted above. Of the 
remaining 35 pseudogenes, 21 were present as intact CDSs in NCTC11168, 9 were 
absent and 4 were mis-annotated and should have been designated a pseudogene in 
NCTC11168 (Table 3.9). The mis-annotated CDSs are represented as two or more CDSs 
in C. jejuni NCTC11168 and were also noted to be putative pseudogenes.  
 
Assuming these are genuine pseudogenes, there is a possibility that C. jejuni 
NCTC11168 (isolated in 1977 from a UK patient with severe gastroenteritis and 
sequenced in 1999 (Parkhill et al., 2000, Skirrow, 1977)) and C. jejuni RM1221 (isolated 
in 2000 from a chicken isolate in the U.S and sequenced in 2004 (Miller et al., 2000, 
Fouts et al., 2005)) share a set of identical pseudogenes. However the sequenced strains 
only represent a single isolated clone and there is scope for significant adaptation from 
the original isolation date and sequence date. Both C. jejuni strains were likely to be 
passaged a number of times and may be laboratory variants with significant 
modifications in genome content compared to the original isolated strain. In addition, 
there is no evidence to date that shows C. jejuni RM1221 to be pathogenic in humans 
(see Section 1.12 – Table 1.1). The number of pseudogenes identified within these two 
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strains can also be attributed to putative pathoadaptive mutations, where a greater 
number of pseudogenes are being identified in recently evolved pathogens. The C. jejuni 
strain RM1221 was isolated from the skin of a supermarket chicken and contains 47 
pseudogenes, whereas C. jejuni NCTC11168 was a human isolate and contains 19 
pseudogenes. This may indicate a more rapidly evolving genome for RM1221 especially 
given the number of C. jejuni present, for example in a poultry farming environment. 
The increased number of pseudogenes identified within C. jejuni RM1221 may be due to 
these CDSs not being necessary as functional copies, as the strain was isolated from 
chicken. Clearly analysing only two genomes is insufficient to make such conclusions 
and a greater sample pool would be required to investigate this question further. 
 
Pseudogenes numbers were analysed in C. jejuni 81-176, RM1221 and NCTC11168 
(Table 3.10) (Hofreuter et al., 2006, Fouts et al., 2005). The annotation of C. jejuni 81-
176 identified  no designated pseudogenes (Hofreuter et al., 2006). A total of 37 CDSs in 
81-176 that are absent or are pseudogenes in NCTC11168 and RM1221 were identified, 
such as kdpA, kdpB, and kdpC, which encode a potassium-transporting ATPase and are 
pseudogenes in the two latter strains (Hofreuter et al., 2006). A total of 51 CDSs were 
identified that were present in NCTC11168, but absent in 81-176 (Hofreuter et al., 
2006). This kind of analysis allows the identification of non-functional CDSs within 
specific strains and thus may lead to identification of potential reasons for phenotypic 
strain variations. 
 
The significance of pseudogenes in early genome annotations were frequently ignored, 
as these were considered sequencing artefacts. However, given the recent realisation of 
the importance of pseudogenes in pathoadaptive mutations, a greater significance is 
placed on their identification (Lerat and Ochman, 2004, Homma et al., 2002). An 
example of this is the re-analysis of the Escherichia coli strain K-12 genome sequence, 
which predicted an additional 160 pseudogenes in comparison to the single pseudogene 
identified in the original annotation (Ochman and Davalos, 2006). The same study also 
indicated pseudogenes are continually generated, with existing pseudogenes being 
eliminated over a period of time (Ochman and Davalos, 2006). Pseudogenes can 
accumulate in the genomes of some bacterial species, especially those undergoing 
processes like niche adaptation or host specialisation (Mira and Pushker, 2005). Analysis 
of further Campylobacter strains and species along with additional epsilon proteobacteria 
species will aid our understanding on this emerging research area. Also, greater 
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understanding of pseudogene dynamics and in particular innovative pseudogene 
identification techniques will yield more information about the actual number and 
purpose of these entities within microorganisms. 
 
Phase-variable CDSs containing hypervariable regions were also analysed. The initial 
annotation correctly identified for the first time a number of hypervariable sequences 
found within the C. jejuni genomic shotgun sequence (Parkhill et al., 2000). These 
hypervariable sequences are scattered throughout the genome, however there are notable 
clusters present within the O-linked glycosylation, CPS and LOS loci. Further research 
on these loci has illustrated the impact of phase-variation on C. jejuni pathogenicity 
(Linton et al., 2001, Karlyshev et al., 2002, Szymanski et al., 2003b). A comparison of 
the number of phase-variable CDSs (i.e. those with an intersecting homopolymeric tract) 
was performed between C. jejuni NCTC11168, RM1221, 81-176, 81116 and CG8486 
strains and all strains were identified as possessing a large number of homopolymeric 
tracts (polyG/C), thus denoting the importance of phase-variable CDSs within C. jejuni 
genomes (Table 3.10). It should also be noted that sequencing errors are also a factor in 
not only the identification of homopolymeric tracts, but also to show whether the phase-
variable CDS are in frame or not (Karlyshev et al., 2002). This is even more pertinent 
with next-generation sequencing as certain methodologies (i.e. 454/pyrosequencing) 
have been noted to have difficulties identifying homopolymeric regions. 
 
The selection of 15 CDSs for further characterisation was based predominantly on 
identification of novel motifs and literature searches. These CDSs were grouped into 
either putative virulence-associated, signal transduction or regulation of gene expression 
(Table 3.11). Table 3.11 lists the selected mutants and indicates where defined isogenic 
C. jejuni 11168H mutants were successfully prepared. Although cloned CDS fragments 
with KmR cassettes were constructed for all 15 CDSs, it is interesting to note that seven 
of these had no KmR transformants identified suggesting that some or all of these 
mutations were lethal to the host. This suggests the selection strategy for the 
identification of CDSs with putative functions linked to roles in virulence, signal 
transduction or regulation of gene expression was accurate as it is possible a number of 
the mutants which could not be constructed were important to the host. 
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3.6 Conclusion 
The re-annotation of the C. jejuni NCTC11168 genome sequence was completed in 2007 
and is arguably already out of date. Novel studies such as C. jejuni RNA-Seq data should 
be incorporated into future re-annotations (van Vliet, 2010). In this re-annotation, 18.2% 
of product functions were updated and 90.0% of CDSs had their note qualifier updated. 
The re-annotated genome sequence has been made publicly available with an updated 
EMBL file and a supporting publication (Gundogdu. et al, 2007/Appendix 5). The 
manuscript has allowed detailed genomic information to be made available regarding the 
evolution of our understanding of this genome. This re-annotation has been a useful 
resource for the Campylobacter research community, allowing up-to-date information to 
be accessible for not only this particular strain, but also related species. This updated 
genome sequence has also been used in third-party software such as microarray and 
proteomic genome annotations. The re-annotation process identified 20 additional CDSs 
linked to ‘small molecule metabolism’, six additional CDSs linked to ‘broad regulatory 
functions’, 26 additional CDSs linked to ‘cell process’ and 77 CDSs linked to 
‘miscellaneous’ functions. The latter function relates to CDSs with new motifs that have 
not yet been linked to a specific function. Interestingly, 122 CDSs were removed from 
the ‘unknown and other’ category mainly due to the assignment of CDSs with new 
motifs. Significant updates were made within the four loci encoding the N- and O-linked 
glycosylation systems, CPS and LOS bioysthesis. Over the last decade, the CDSs within 
these loci have been characterised and this has greatly enhanced our understanding of the 
pathogenesis for this bacterium. In addition, novel CDSs such as regulators and the 
further refinement of many CDS product functions have allowed a greater understanding 
of the genome, mainly due to the availability of new motifs. All of these updates have, 
and will continue to be used in Campylobacter research. 
The manual re-annotation of the genome identified a set of CDSs yet to be fully 
characterised, that may have putative roles in virulence, signal transduction or regulation 
of gene expression. As a result of this re-annotation, the functions of Cj1556 and Cj0248 
were investigated as reported in Chapters 4 and 5 respectively. 
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Chapter 4: Cj1556 encodes a putative transcriptional regulator 
which has a role in oxidative and aerobic (O2) stress response 
along with bacterial survival in vivo 
 
4.1 Introduction 
Re-annotation of the NCTC11168 genome sequence resulted in the identification of 15 
CDSs for further study (see Section 3.4). The selection of these 15 CDSs was based on a 
number of different criteria such as newly identified motifs along with literature 
searches. The function of each CDS was unknown, however putative functions were 
linked to roles in virulence, signal transduction or regulation of gene expression. 
Following the successful construction of eight defined isogenic C. jejuni 11168H 
mutants, a number of preliminary phenotypic assays such as stress tests, motility, 
interaction and invasion assays were performed. Two mutants were chosen for further 
characterisation and this chapter details the characterisation of the 11168H Cj1556 
mutant. 
 
4.1.1 Aims 
- Construct a defined isogenic C. jejuni 11168H Cj1556 mutant 
- Construct a 11168H Cj1556 complement  
- Characterise the 11168H Cj1556 mutant 
 
4.2 Construction and characterisation of the 11168H Cj1556 mutant 
 
4.2.1 Bioinformatic analysis of Cj1556 
The 333 nucleotide predicted CDS of Cj1556 was originally annotated as a hypothetical 
protein in the genome sequence of C. jejuni NCTC11168. Following the re-annotation of 
the C. jejuni NCTC11168 genome sequence performed in this study (see Chapter 3), the 
updated product function indicated Cj1556 as a putative transcriptional regulator based 
on the identification of a new Pfam motif (PF01638), defined as an HxlR-like helix-turn-
helix motif. The HxlR-like helix-turn-helix motif is located 45 nucleotides into the CDS 
and encompasses the remainder of the CDS. The HxlR-like helix-turn-helix motif is part 
of the MarR family of transcriptional regulators that includes proteins that control 
virulence factor production, bacterial responses to both antibiotics and oxidative stress 
and also catabolism of environmental aromatic compounds (Wösten et al., 2008, 
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Wilkinson and Grove, 2004).  In addition to Cj1556, the C. jejuni NCTC11168 genome 
contained one other CDS (Cj1546) with the MarR family motif. Cj1546 was also re-
annotated as a putative transcriptional regulator with 43.6% identity and 58.4% similarity 
to Cj1556. (Figure 4.1).  
 
 
1556    ATGAAAAAATATCATTCTCTTTGTCCTATTGAAAC---CACGCTTAATTTGA---TAGGA 54 
1546    ATGACTAAAGAGAATTCTCCGTGCAATTTCGAAGAATGTGGATTTAACTATACTCTAGCA 60 
        ****  *** *  ******  **   * * ***          **** *  *   *** * 
 
1556 --AATAAATGGAAAATTTTAATTATTCGAGATTTGTTGCAAGGGACTAAAAGATTTGGAG 112 
1546 TTAATTAATGGAAAATATAAAATGAGTATTTTATACTGCTTATTTCGCTATGAAATCGTG 120 
   *** ********** * ** *        * *  ***      *   * **  * * * 
 
1556 AGTTAAGAAAAAGCATTTCATTTACAAAAAATCAAAACATCTCTCAAAATGTCCTTACAC 172 
1546 CGTTATAATGAACTCAAACGCTTTTTAAGCTCCA---TATCTTTTAAAA--CTTTAACCA 175 
  ****  *  **      *  **   **    **    **** * ****     * **   
 
1556 AAAATTTACGAGAATTAGAAGAAGCAAAACTGATCAAACGCAAAGTTTATGCAGAAGTTC 232 
1546 ATACCTTAAGAGAACTAGAAAACGATGGTTTAATTATCAGAAAAGAATACGCTCAAATTC 235 
 * *  *** ***** ***** * *      * ** *   * ****  ** **  ** *** 
 
1556 CTCCAAAGGTTGAGTACTCACTTA--CATCTTTAGGCAATAGTTTAGAATCCATCTTAAA 290 
1546 CACCCAAGGTAGAATA-TAGCTTATCCAAACGTGGACAA-AGTTTAATTCCCATTTTACA 293 
 * ** ***** ** ** *  ****  **    * * *** ******    **** *** * 
 
1556 AAGTCTTGAGAATTGGGGAAATAGCTATAAAAATATCGTTTAA------------ 333 
1546 AGCTATGAGCAAATGGGGCAAGAAAGACAAAAAAGGGAAAAAATGCTTGAATTAA 348 
 *  * *    ** ***** ** *   * *****        **             
 
Figure 4.1. ClustalW alignment comparison of Cj1556 and Cj1546 nucleotide sequences. 
Star indicates identical match. Dash indicates insertion site. ClustalW tool was used at - 
http://www.ebi.ac.uk/Tools/clustalw2/help.html. Underline indicates location of HxlR-
like helix-turn-helix motif. 
 
The predicted function of Cj1556 was investigated further using the Campylobacter 
Protein Interaction Database (Parrish et al., 2007) and putative interactions with Ctb 
(Cj0465c) were identified. Ctb is a group III truncated haemoglobin and characterisation 
studies in C. jejuni have already shown Ctb to be part of the nitrosative stress response 
regulon (Monk et al., 2008) (Appendix 6). Ctb has also been linked with moderating 
oxygen metabolism within C. jejuni (Monk et al., 2008). The Campylobacter Protein 
Interaction Database was also used to investigate Cj1546. A number of common 
interactions e.g. CheA, were identified for both Cj1546 and Cj1556 (Appendix 7), 
however interactions relating to nitrosative stress were only identified for Cj1556.  
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Protein Blast search results surprisingly identified this CDS to be present in relatively 
few strains/species of Campylobacter (Table 4.1). Homologues with relatively high 
identity and expect scores were present in C. jejuni strains CF93-6, 84-25 and 81-176, 
along with the species C. fetus 82-40. The significance of this CDS not being present in 
all C. jejuni strains is unclear, although one of the most commonly used laboratory 
strains, C. jejuni 81-176, a highly pathogenic strain does have the CDS (Hofreuter et al., 
2006). Apart from C. jejuni, other related epsilon proteobacteria with Cj1556 
homologues included Helicobacter bilis ATCC 43879, H. pullorum MIT 98-5489 and H. 
hepaticus ATCC 51449. The homologue was also found in unrelated bacterium such as 
Clostridium leptum. Search results identified Campylobacter species and related 
organisms harbouring homologues named as either a ‘hypothetical protein’ or a 
regulatory/transcription designation based on the presence of the motif. No homologue 
has been characterised as yet. Considering all the bioinformatic analysis, Cj1556 was 
hypothesised to have a role as a stress response regulator.  
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Table 4.1. BlastP results for Cj1556. Campylobacter strains/species indicated below. 
 
Species / Strain 
Identities 
score 
Expect 
score 
Campylobacter jejuni subsp. jejuni NCTC11168 
 
110/110 
 
6e-56 
 
Campylobacter jejuni subsp. jejuni CF93-6 
 
110/110 
 
6e-56 
 
Campylobacter jejuni subsp. jejuni 84-25 
 
110/110 
 
6e-56 
 
Campylobacter jejuni subsp. jejuni 81-176 
 
110/110 
 
6e-56 
 
Helicobacter bilis ATCC 43879 
 
85/109 
 
1e-43 
 
Campylobacter fetus subsp. fetus 82-40 
 
84/108 
 
4e-43 
 
Campylobacter fetus subsp. Venerealis str. Azul-94 
 
84/108 
 
4e-43 
 
Helicobacter pullorum MIT 98-5489 
 
86/108 
 
7e-43 
 
Helicobacter hepaticus ATCC 51449 
 
84/107 
 
2e-42 
 
Anaerofustis stercorihominis DSM 17244 
 
72/110 
 
1e-33 
 
Clostridium leptum DSM 753 
 
8e-31 
 
64/100 
 
 
 
4.2.2 Construction of 11168H Cj1556 mutant and complement 
The mutagenesis strategy and all techniques used to create a defined isogenic 11168H 
Cj1556 mutant and a 11168H Cj1556 complement are described in Chapter 2. Briefly, 
primers were designed for PCR amplification and detection of a Cj1556 CDS fragment 
were performed using Cj1556-F and Cj1556-R (see Section 2.2.5). A vector construct 
(cam25a2 - 1489074..1490567) containing the Cj1556 CDS was selected from the C. 
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jejuni NCTC11168 genome sequence pUC library. This vector construct is 1.49 kb in 
size and includes the CDSs Cj1555c – Cj1560. The vector construct was named pUC-
Cj1556. Digestion with BclI was followed by ligation with the aph-3 (aminoglycoside 
3’-phosphotransferase) kanamycin resistance cassette (KmR) (Trieu-Cuot et al., 1985) 
and transformed into XL-2 cells. The KmR cassette was derived from pJMK30 which 
does not contain a transcriptional terminator. The allows the formation of multicistronic 
mRNA as the KmR can be inserted in the same orientation as the CDS of interest, hence 
removing the potential to form polar effects (van Vliet et al., 1998). Transformants were 
screened by PCR using Cj1556 specific and KmR specific primers; KmR forward-out and 
KmR reverse-out (see Section 2.2.5). pUC-Cj1556-KmR plasmids with the KmR cassette 
in the same orientation as the Cj1556 CDS were selected and electroporated into 11168H 
wild-type as described previously (Jones et al., 2004, Karlyshev et al., 2002). 
Electroporated C. jejuni were plated onto blood agar plates and incubated at 37°C under 
microaerobic conditions for 2 days. Cells were harvested and resuspended in 0.5 ml PBS. 
200 μl of this suspension was spread onto blood agar plates containing kanamycin. 
Putative Cj1556 mutants were screened using PCR and sequencing (Figure 4.2). 
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Figure 4.2. Confirmation of Cj1556 constructs and 11168H Cj1556 mutant using PCR 
with Cj1556 specific primers.  
 
Lane 1 – 1 kb ladder / Lane 2 – pUC-Cj1556 plasmid DNA amplified with Cj1556 
specific primers (0.33 kb) / Lane 3 – pUC-Cj1556-KmR plasmid DNA amplified with 
Cj1556 specific primers (1.76 kb) / Lane 4 – C. jejuni 11168H genomic DNA amplified 
with Cj1556 specific primer (0.33 kb) / Lane 5 – C. jejuni Cj1556 mutant genomic DNA 
amplified with Cj1556 specific primer (1.76 kb) / Lane 6 – C. jejuni Cj1556 complement 
genomic DNA amplified with Cj1556 specific primer (0.33 kb and 1.76 kb) / Lane 7 – 
Negative control 
 
Insertion of a copy of the Cj1556 CDS into the Cj1556 mutant chromosome for 
complementation purposes was achieved using pDENNIS, a C. jejuni 11168H 
complementation vector allowing the insertion of a functional Cj1556 CDS into the 
pseudogene Cj0223 (Hitchen et al., 2010). The coding region for Cj1556 was amplified 
by PCR using primers; Comp-Cj1556-F and Comp-Cj1556-R, which introduced an NcoI 
site at the 5’ end and an NheI site at the 3’ end as well as the native ribosome binding site 
of Cj1556 (Svensson et al., 2008, Wosten et al., 1998). Following digestion with NheI 
and NcoI, this PCR product was ligated into the pDENNIS vector. The construct was 
sequenced to ensure there were no mutations in the Cj1556 nucleotide sequence. This 
construct was electroporated into the Cj1556 mutant strain and grown on blood agar 
plates. Putative mutants were restreaked onto blood agar plates containing kanamycin 
1 2 3 4 5 6 7 
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and chloramphenicol. Positive clones were confirmed by PCR checking for the correct 
distance between Cj1556 and the inserted KmR cassette (Cj1556-F and KmR forward-
out). This confirmed the presence of the mutated CDS with the KmR cassette in the 
correct orientation. PCR was also used to confirm the presence of an intact CDS 
(Cj1556-F and Cj1556-R). In addition, sequencing was also used to further confirm 
positive mutants 
 
4.2.3 The 11168H Cj1556 mutant exhibits increased sensitivity to oxidative but not 
nitrosative stress 
Data from the Campylobacter Protein Interaction Database identified putative 
interactions between Cj1556 and Ctb. Ctb, a truncated haemoglobin encoded by 
Cj0465c, along with Cgb, a single domain haemoglobin encoded by Cj1586, are part of 
the C. jejuni nitrosative stress regulon (Wainwright et al., 2006, Wainwright et al., 2005, 
Elvers et al., 2005, Elvers et al., 2004). The regulon is under the control of NssR 
(encoded by Cj0466). Previous studies have implicated Ctb with a role in oxygen 
metabolism (detoxification, sequestration or transfer of oxygen) within C. jejuni 
(Wainwright et al., 2005, Wainwright et al., 2006). Identification of Cj1556 as a member 
of the MarR family of transcriptional regulators and the link to Ctb through the Protein 
Interaction Database searches suggested a role in the C. jejuni nitrosative stress response. 
Nitrosative stress assays were performed using acidified NaNO2 (10 mM / 75 mins). No 
differences between the survival of the Cj1556 mutant and the 11168H wild-type strain 
were observed under nitrosative stress (Figure 4.4). However, MarR family proteins have 
been shown to be involved in oxidative stress (Wilkinson and Grove, 2004) and even 
though Ctb is part of the nitrosative stress regulon, it has also been shown to be involved 
in oxygen delivery (Wainwright et al., 2005, Wainwright et al., 2006). Oxidative stress 
assays were performed using H2O2. The Cj1556 mutant exhibited increased sensitivity to 
H2O2 (10 mM / 15 mins) compared to the 11168H wild-type strain (Figures 4.5 and 4.6). 
In addition, the Cj1556 complement restored the 11168H wild-type strain H2O2 
sensitivity phenotype. The increased resistance to H2O2 observed for the Cj1556 
complement compared to the 11168H wild-type strain may be due to the Cj1556 
expression being controlled by the constitutively expressed chloramphenicol promoter on 
the complementation vector instead of the native Cj1556 promoter.   
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Figure 4.4. Nitrosative stress assays on C. jejuni 11168H wild-type strain, Cj1556 mutant 
and the Cj1556 complement (Cj1556 comp). C. jejuni were grown on blood agar plates 
for 24 h at 37°C under microaerobic conditions. A bacterial suspension with an OD600 of 
1.0 was prepared and incubated with 10 mM NaNO2 for 75 minutes under microaerobic 
conditions. Serial dilutions (10-1 - 10-6) were performed and 10 μl volumes were spotted 
onto blood agar plates. The plates were incubated at 37°C under microaerobic conditions 
for 48 h. All experimental data is represented using the average of at least three 
biological replicates performed in triplicate. Error bars represent the standard error of 
mean.  
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Figure 4.5. Oxidative stress assays on C. jejuni 11168H wild-type strain, Cj1556 mutant 
and the Cj1556 complement (Cj1556 comp). C. jejuni were grown on blood agar plates 
for 24 h at 37°C under microaerobic conditions. A bacterial suspension with an OD600 of 
1.0 was prepared and incubated with 10 mM H2O2 for 15 minutes under microaerobic 
conditions. Serial dilutions (10-1 - 10-6) were performed and 10 μl volumes were spotted 
onto blood agar plates. The plates were incubated at 37°C under microaerobic conditions 
for 48 h. An example is shown of one of three biological replicates performed in 
triplicate. 
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Figure 4.6. Oxidative stress assays on C. jejuni 11168H wild-type strain, Cj1556 mutant 
and the Cj1556 complement (Cj1556 comp). C. jejuni were grown on blood agar plates 
for 24 h at 37°C under microaerobic conditions. A bacterial suspension with an OD600 of 
1.0 was prepared and incubated with 10 mM H2O2 for 15 minutes under microaerobic 
conditions. Serial dilutions (10-1 - 10-6) were performed and 10 μl volumes were spotted 
onto blood agar plates. The plates were incubated at 37°C under microaerobic conditions 
for 48 h. Figure shows the viable counts in terms of CFU per ml. The asterisk denotes a 
statistically significant difference (* = p <0.05) for Cj1556 mutant compared to the 
11168H wild-type strain. All experimental data is represented using the average of at 
least three biological replicates performed in triplicate. Error bars represent the standard 
error of mean. Variables were compared for significance using a student’s t-test with one 
star (*) indicating p = 0.01 - 0.05 and two stars (**) indicating p = 0.001- 0.01. 
 
4.2.4 The 11168H Cj1556 mutant reveals unaltered growth kinetics during growth 
inhibition studies  
As a result of the oxidative stress assay, a number of growth inhibition studies were 
performed to ascertain whether any modification in growth kinetics was observed due to 
the addition of specific inhibitory compounds. Growth inhibition studies were performed 
using conditions to represent both oxidative and nitrosative inhibition. No differences 
were observed between the Cj1556 mutant and the 11168H wild-type strain for oxidative 
(Figure 4.7) and nitrosative (Figure 4.8) inhibition. Recently Cj1556 was shown to be 2.8 
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fold up-regulated in the presence of 0.1% (w/v) sDOC (Malik-Kale et al., 2008). Growth 
analysis of the Cj1556 mutant in broth supplemented with 0.1% (w/v) sDOC showed no 
difference compared to the 11168H wild-type strain (Figure 4.9). In addition, no 
differences were observed between Cj1556 mutant and the 11168H wild-type strain 
during growth in broth supplemented with the iron chelator deferoxamine (Figure 4.10).  
 
 
 
Figure 4.7. Oxidative stress growth inhibition assays on C. jejuni 11168H wild-type 
strain and Cj1556 mutant. C. jejuni were grown in the presence of 1 mM H2O2. Flasks 
were incubated at 37°C under microaerobic conditions, shaking at 75 rpm. OD600 
readings were recorded at 6, 24 and 48 h. All experimental data is represented using the 
average of at least three biological replicates performed in triplicate. Error bars represent 
the standard error of mean.  
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Figure 4.8. Nitrosative stress growth inhibition assays on C. jejuni 11168H wild-type 
strain and Cj1556 mutant. C. jejuni were grown in the presence of 0.1 mM NaNO2 at pH 
5. Flasks were incubated at 37°C under microaerobic conditions, shaking at 75 rpm. 
OD600 readings were recorded at 6, 24 and 48 h. All experimental data is represented 
using the average of at least three biological replicates performed in triplicate. Error bars 
represent the standard error of mean.  
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Figure 4.9. Bile stress growth inhibition assays on C. jejuni 11168H wild-type strain and 
Cj1556 mutant. C. jejuni were grown in the presence of 0.1% sDOC. Flasks were 
incubated at 37°C under microaerobic conditions, shaking at 75 rpm. OD600 readings 
were recorded at 6, 24 and 48 h.  All experimental data is represented using the average 
of at least three biological replicates performed in triplicate. Error bars represent the 
standard error of mean.  
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Figure 4.10. Iron limitation growth inhibition assays on C. jejuni 11168H wild-type 
strain and Cj1556 mutant. C. jejuni were grown in the presence of 1 mM deferoxamine. 
Flasks were incubated at 37°C under microaerobic conditions, shaking at 75 rpm. OD600 
readings were recorded at 6, 24 and 48 h. All experimental data is represented using the 
average of at least three biological replicates performed in triplicate. Error bars represent 
the standard error of mean.  
 
4.2.5 The 11168H Cj1556 mutant exhibits increased sensitivity to heat stress  
Previous research has suggested a link between aerobic and heat stress  (Lin et al., 2009, 
Andersen et al., 2005, Brondsted et al., 2005, Phongsisay et al., 2007). The HtrA 
protease and HspR regulator have already been described as playing a role in aerobic 
(O2) stress, however their primary role is related to heat tolerance (Brondsted et al., 
2005). The microarray data identified hspR as being 2.07 fold down-regulated in the 
Cj1556 mutant compared to the 11168H wild-type strain. In order to investigate this 
further, a range of heat stress experiments were performed. No significant differences in 
survival were observed at 42°C / 60 mins or 55°C / 15 mins. However the Cj1556 mutant 
displayed increased sensitivity compared to the 11168H wild-type strain at 60°C / 5 
minutes and the Cj1556 complement restored the 11168H wild-type strain phenotype 
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(Figure 4.3). Heat stress above 55°C has been noted to accelerate the spiral-to-coccoid 
transition and result in cell death (Nguyen et al., 2006).  
 
 
 
Figure 4.3. Heat stress assays on C. jejuni 11168H wild-type strain, Cj1556 mutant and 
Cj1556 complement. C. jejuni grown overnight had OD600 adjusted to 1.0 and were 
exposed to 60°C for 5 minutes. Serial dilutions were performed and 200 μl volumes were 
spotted onto blood agar plates. The plates were incubated at 37°C under microaerobic 
conditions for 48 h. All experimental data is represented using the average of at least 
three biological replicates performed in triplicate. Error bars represent the standard error 
of mean. Variables were compared for significance using a student’s t-test with one star 
(*) indicating p = 0.01 - 0.05. 
 
4.2.6 The 11168H Cj1556 mutant displays a reduced ability to interact with and 
invade Caco-2 intestinal epithelial cells  
In order to investigate the colonisation potential of the Cj1556 mutant, interaction 
(adhesion and invasion) and invasion assays were performed using co-culture 
experiments with Caco-2 cells and the 11168H wild-type strain, Cj1556 mutant and 
Cj1556 complement. No significant differences were observed when comparing the 
levels of interaction at either 3 h or 6 h, however the Cj1556 mutant displayed a reduced 
ability to interact with Caco-2 cells after 24 h co-culture compared with the 11168H 
wild-type strain and Cj1556 complement (Figure 4.11A). The Cj1556 mutant also 
displayed a reduced ability to invade Caco-2 cells after 24 h co-culture compared with 
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the 11168H wild-type strain and Cj1556 complement (Figure 4.11B). No significant 
differences were observed when comparing the levels of invasion at either 3 h or 6 h. 
 
A) 
 
B)  
  
 
Figure 4.11. Interaction (adhesion and invasion) and invasion assays on 11168H wild-
type strain, Cj1556 mutant and Cj1556 complement (Cj1556 comp). C. jejuni were co-
cultured with Caco-2 IECs for 3, 6 or 24 h. Caco-2 cells were either lysed and numbers 
of interacting bacteria assessed (A) or incubated with gentamicin (150 μg/ml) for 2 h to 
kill extracellular bacteria, then lysed and numbers of intracellular bacteria assessed (B). 
All experimental data is represented using the average of at least three biological 
replicates performed in triplicate. Error bars represent the standard error of mean. 
Variables were compared for significance using a student’s t-test with one star (*) 
indicating p = 0.01 - 0.05, two stars (**) indicating p = 0.001- 0.01 and three stars (***) 
p < 0.001.  
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4.2.7 The 11168H Cj1556 mutant exhibits reduced intracellular survival in Caco-2 
intestinal epithelial cells  
In order to investigate the ability of C. jejuni to survive when exposed to intracellular 
stress such as ROS, a modification of the interaction and invasion assays was used to 
analyse the level of intracellular survival in Caco-2 IECs (Naito et al., 2010). Here, C. 
jejuni were co-cultured with Caco-2 cells for 3 h, extracellular C. jejuni were removed 
and intracellular bacteria were maintained for 19 h. The results indicated a decrease in 
the level of intracellular survival of the Cj1556 mutant compared to the 11168H wild-
type strain and Cj1556 complement (Figure 4.12). 
 
 
 
 
Figure 4.12. Intracellular survival assays on 11168H wild-type strain, Cj1556 mutant and 
Cj1556 complement (Cj1556 comp). C. jejuni were co-cultured with Caco-2 IECs for 3 
h, then incubated with gentamicin (150 μg/ml) for 2 h to kill extracellular bacteria, 
followed by further incubation with gentamicin (10 μg/ml) for 19 h. Cells were lysed and 
numbers of intracellular bacteria assessed. All experimental data is represented using the 
average of at least three biological replicates performed in triplicate. Error bars represent 
the standard error of mean. Variables were compared for significance using a student’s t-
test with one star (*) indicating p = 0.01 - 0.05.  
 
To ascertain whether the above results were due to a genuine Cj1556 mutant phenotype 
and not to increased sensitivity to Triton X-100, stress assays were performed on all 
three strains with 0.2% (v/v) Triton X-100. No difference in the level of sensitivity to 
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Triton X-100 was observed between 11168H wild-type strain, Cj1556 mutant and the 
Cj1556 complement (Figure 4.13). 
 
 
 
 
Figure 4.13. 0.2% (v/v) Triton X-100 stress assay on C. jejuni 11168H wild-type strain, 
Cj1556 mutant and the Cj1556 complement (Cj1556 comp). C. jejuni were grown on 
blood agar plates for 24 h at 37°C under microaerobic conditions. A bacterial suspension 
with an OD600 of 1.0 was prepared and incubated with 0.2% (v/v) Triton X-100 for 15 
minutes under microaerobic conditions. Serial dilutions (10-1 - 10-6) were performed and 
10 μl volumes were spotted onto blood agar plates. The plates were incubated at 37°C 
under microaerobic conditions for 48 h. All experimental data is represented using the 
average of at least three biological replicates performed in triplicate. Error bars represent 
the standard error of mean.  
 
4.2.8 The 11168H Cj1556 mutant exhibits reduced survival in co-culture media  
A further experiment was performed to compare the number of C. jejuni present in the 
tissue culture medium from supernatant after 24 hours co-culture with Caco-2 cells. 
There was a statistically significant decrease in the number of viable bacterial cells 
obtained from the supernatant after 24 hours co-culture with Caco-2 cells when 
comparing the Cj1556 mutant to the 11168H wild-type strain and Cj1556 complement 
(Figure 4.14). 
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Figure 4.14. Survival assays on 11168H wild-type strain, Cj1556 mutant and the Cj1556 
complement (Cj1556 comp). C. jejuni were co-cultured with Caco-2 IECs for 24 h 
followed by assessing the number of bacteria in the co-culture media. All experimental 
data is represented using the average of at least three biological replicates performed in 
triplicate. Error bars represent the standard error of mean. Variables were compared for 
significance using a student’s t-test with one star (*) indicating p = 0.01 - 0.05.  
 
4.2.9 The 11168H Cj1556 mutant exhibits reduced intracellular survival in J774A.1 
macrophage cells 
Intracellular survival assays using J774A.1 mouse macrophages cells were also 
performed to further investigate the survival rates of the 11168H wild-type strain, 
Cj1556 mutant and the Cj1556 complement strains. Macrophages internalise and destroy 
C. jejuni with previous studies showing that C. jejuni are killed within 24 h of 
internalisation (Watson and Galan, 2008). There was a statistically significant reduction 
in the level of intracellular survival of the Cj1556 mutant compared to the 11168H wild-
type strain and Cj1556 complement (Figure 4.15).  
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Figure 4.15. Intracellular survival assays on 11168H wild-type strain, Cj1556 mutant and 
the Cj1556 complement (Cj1556 comp). C. jejuni were co-cultured with J774A.1 mouse 
macrophages for 3 h, then incubated with gentamicin (150 μg/ml) for 2 h to kill 
extracellular bacteria, followed by further incubation with gentamicin (10 μg/ml) for 4 
and 16 h. Cells were lysed and numbers of intracellular bacteria assessed. All 
experimental data is represented using the average of at least three biological replicates 
performed in triplicate. Error bars represent the standard error of mean. Variables were 
compared for significance using a student’s t-test with one star (*) indicating p = 0.01 - 
0.05.  
 
4.2.10 The 11168H Cj1556 mutant exhibits reduced survival in an aerobic 
environment   
Following the identification of significant differences between the 11168H wild-type 
strain and Cj1556 mutant in response to oxidative stress and intracellular survival, 
further investigations on the ability of these strains to survive aerobic (O2) stress were 
performed. The difference in the level of Cj1556 mutant survival between the interaction 
and intracellular assays suggested that additional stresses might affect C. jejuni during 
these assays. Survival assays using the 11168H wild-type strain, Cj1556 mutant, and 
Cj1556 complement were performed under either microaerobic or aerobic conditions in 
either Brucella broth or tissue culture media with no shaking to replicate the conditions 
for the co-culture assays. A reduction in the number of viable bacterial cells with the 
Cj1556 mutant compared to the 11168H wild-type strain in both types of media were 
observed after 24 h incubation under aerobic conditions (Figure 4.16C and D), but not 
under microaerobic conditions (Figure 4.16A and B).  
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(A)  (B)   
 
 
(C)  (D) 
 
 
Figure 4.16. Aerobic (O2) stress assays on 11168H wild-type strain, Cj1556 mutant and 
the Cj1556 complement (Cj1556 comp). C. jejuni were grown under microaerobic (A 
and B) and aerobic conditions (C and D) in Brucella broth (A and C) or tissue culture 
media (B and D), then numbers of viable bacteria assessed. All experimental data is 
represented using the average of at least three biological replicates performed in 
triplicate. Error bars represent the standard error of mean. Variables were compared for 
significance using a student’s t-test with one star (*) indicating p = 0.01 - 0.05.    
 
4.2.11 The 11168H Cj1556 mutant induces a reduced IL-6 response from T84 cells 
Following on from the co-culture studies investigating the interaction and invasion 
properties of the Cj1556 mutant, further co-culture investigations were performed 
analysing the host innate immune response. To analyse the host innate immune response, 
IL6 and IL8 were selected. IL-6 is an interleukin that acts as both a pro-inflammatory 
and anti-inflammatory cytokine and has been shown to be important for epithelial cell 
integrity (Friis et al., 2009). IL-6 is typically associated with an acute phase response 
(Heinrich et al., 1990). Interleukin-8 is a chemokine produced by macrophages and other 
cell types such as epithelial cells. Both are well-characterised markers denoting a host 
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innate immune response against pathogens (Wolff et al., 1998, Oppenheim et al., 1991). 
To investigate any differences between the level of IL-6 and IL-8 induced by the Cj1556 
mutant compared to the 11168H wild-type strain, co-culture experiments with two 
different cell lines were performed. Only minimal secretion of IL-6 and IL-8 was 
detected when the 11168H wild-type strain and Cj1556 mutant were co-cultured with 
Caco-2 cells (data not shown). However using the T84 cell line, significant levels of 
induction of both IL-6 and IL-8 by the 11168H wild-type strain and Cj1556 mutant were 
observed (Figure 4.17). There was no significant difference in the level of IL-8 induction 
by the Cj1556 mutant compared to that by the 11168H wild-type strain (Figure 4.17A), 
however a significant reduction in the level of IL-6 induction by the Cj1556 mutant was 
observed (Figure 4.17B). 
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A) 
 
B) 
   
 
Figure 4.17. Analysis of the host innate immune response during 11168H wild-type 
strain, Cj1556 mutant and the Cj1556 complement (Cj1556 comp) infection. C. jejuni 
were co-cultured with T84 IECs for 24 h and the levels of IL-8 and IL-6 secreted were 
quantified using either a human IL-8 ELISA (A) or IL-6 ELISA (B). All experimental 
data is represented using the average of at least three biological replicates performed in 
triplicate. Error bars represent the standard error of mean. Variables were compared for 
significance using a student’s t-test with one star (*) indicating p = 0.01 - 0.05.  
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4.2.12 Microarray analysis of gene expression differences between Cj1556 mutant 
and 11168H wild-type strain suggest negative autoregulation of Cj1556 
To analyse the gene expression profile of the Cj1556 mutant compared to the 11168H 
wild-type strain, microarray experiments were performed using total RNA samples 
isolated from C. jejuni grown to late-log phase (16 h). Microarray experiments were 
performed with three biological replicates, each with one technical replicate. Statistically 
significant up- and down-regulated genes were selected when comparing gene 
expression from mutant test arrays against 11168H control arrays using ANOVA 
(ANalysis Of VAriance) (Bacon et al., 2004, Corcionivoschi et al., 2009). ANOVA was 
performed using a Benjamini and Hochberg False Discovery Rate as the Multiple 
Testing Correction within the GeneSpring software (v7.3). A total of 91 genes were 
differentially expressed in the Cj1556 mutant compared to the 11168H wild-type strain 
based on an ANOVA selection methodology. A total of 73 genes, including Cj1556 were 
up-regulated in the Cj1556 mutant, whilst 18 genes were down-regulated compared to 
the 11168H wild-type strain (Appendix 8 and 9). As most of the genes were up-regulated 
(73), this suggests a putative role for Cj1556 as a transcriptional repressor and thus the 
inactivation of this CDS results in the transcription of many different genes that would 
be repressed under these conditions in the 11168H wild-type strain. Changes in 
expression of genes linked to the C. jejuni oxidative and aerobic (O2) stress responses in 
the Cj1556 mutant compared to the 11168H wild-type strain are shown in Table 4.2. The 
genes listed in Table 4.2 do not appear in the significant ANOVA selection (Appendix 8 
and 9), however some genes would be significant if a more classical selection method 
was adopted e.g. 2-fold up/down. In this scenario, genes such as katA (5.13), perR (5.05) 
and hspR (2.07) would be identified as down-regulated. Table 4.2 is only used to display 
expression changes of important oxidative and aerobic (O2) stress genes for further 
discussion. Cj1556 was identified with the highest fold up-regulation (10.4 fold). 
Sequence analysis of the Cj1556 reporter element used on the arrays showed that this 
particular sequence was present upstream of the KmR cassette in the Cj1556 mutant (data 
not shown). Typically the mutated gene in a defined mutant would be expected to be 
significantly down-regulated, however the microarray data indicates that in the absence 
of the Cj1556 protein, Cj1556 gene expression is dramatically increased. This suggests 
that Cj1556 represses further expression of the Cj1556 gene, acting as a negative 
autoregulation system. 
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Table 4.2. Changes in expression of genes linked to the C. jejuni oxidative and aerobic 
(O2) stress responses in the Cj1556 mutant compared to the 11168H wild-type strain. 
 
Gene Name Fold Change Product function 
spoT +1.26 
putative guanosine-3',5'-bis(diphosphate) 3'-
pyrophosphohydrolase 
sodB +1.24 superoxide dismutase (Fe) 
htrA +1.21 serine protease (protease DO) 
fdxA +1.07 ferredoxin 
dcuA -1.17 anaerobic C4-dicarboxylate transporter 
ahpC -1.27 alkyl hydroperoxide reductase 
dps -1.36 putative bacterioferritin 
hspR -2.07 heat shock transcriptional regulator 
perR -5.05 peroxide stress regulator 
katA -5.13 catalase 
htrB No hybridisation 
putative lipid A biosynthesis lauroyl 
acyltransferase 
 
 
4.2.13 Cj1556 promoter analysis reveals similar promoter sequences to ctb 
In silico analysis of Cj1556 was performed using BPROM to predict the presence of 
bacterial σ70 promoters (http://linux1.softberry.com/berry.phtml?topic=bprom). 300 
nucleotides upstream and 50 nucleotides downstream of Cj1556 were analysed. Both a -
10 (ataaat) and -35 (tgttataat) promoter site were identified. In addition, a number of 
other transcription factor binding sites were identified (Appendix 10). To investigate 
links between Cj1556 and ctb, promoter sequences upstream of ctb were also searched in 
the database. Two -35 boxes, three lrp (attttttt) sequences and a lexA (ttttttta) sequence 
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was identified. Both lrp and lexA sequences were also present in the original Cj1556 
search result and indicate possible common promoters for both Cj1556 and ctb. In 
addition, analysis of C. jejuni katA, perR and hspR promoter sequences identified the 
presence of these promoter sequences upstream of Cj1556 (Appendix 10). This suggests 
Cj1556 has the potential to bind to the promoter regions of katA, perR and hspR. 
 
4.2.14 The 11168H Cj1556 mutant reveals unaltered motility   
In response to microarray data described in Section 4.2.12 where a number of flagella 
related genes (Cj0041, Cj0195, Cj0335, Cj0320) were up-regulated in the Cj1556 
mutant, motility assays were performed on the Cj1556 mutant and compared to the 
11168H wild-type strain. The results identified no significant difference in the level of 
motility between the strains (Figure 4.18).  
 
 
 
Figure 4.18. Motility assay comparing the Cj1556 mutant to the 11168H wild-type strain 
and Cj1556 complement (Cj1556 comp) on semi-solid surfaces. C. jejuni from an 
overnight culture was adjusted to an OD600 of 1.0. 5 µl of this suspension was pipetted 
into the centre of the motility plate using a Gilson pipette (P10). Plates were incubated at 
37°C using microaerobic conditions. Plate images were recorded at 24, 48 and 72 h. 
Motility was assessed by measuring the diameter of the halo on the plate. All 
experimental data is represented using the average of at least three biological replicates 
performed in triplicate. Error bars represent the standard error of mean.  
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4.2.15 The 11168H Cj1556 mutant reveals unaltered autoagglutination levels  
Autoagglutination or self-association has been linked with virulence in some Gram-
negative bacteria (Roggenkamp et al., 1995, Bieber et al., 1998, Brondsted et al., 2005). 
Here, the autoagglutination ability of the Cj1556 mutant was compared to the C. jejuni 
11168H wild-type strain. No difference in the level of autoagglutination ability was 
observed between the strains (Figure 4.19). An rpoN mutant was used as a 
autoagglutination negative control. Inactivation of RpoN (σ54) renders the bacterium 
non-motile and without flagella (Jagannathan et al., 2001).   
 
 
 
Figure 4.19. Autoagglutination of the 11168H wild-type strain, Cj1556 mutant and 
Cj1556 complement (Cj1556 comp). C. jejuni that were grown on blood agar plates for 
24 h at 37°C under microaerobic conditions were used to inoculate 10 ml PBS to an 
OD600 of 1.0. Cultures were incubated for 24 h at 37°C under microaerobic conditions. 
The OD600 was measured using 1 ml taken from the middle of a 24 h incubated culture. 
All experimental data is represented using the average of at least three biological 
replicates performed in triplicate. Error bars represent the standard error of mean.  
 
4.2.16 The 11168H Cj1556 mutant exhibits reduced biofilm formation  
Biofilms are commonly defined as matrix-enclosed bacterial populations adherent to 
each other and/or to surfaces of interfaces (Costerton et al., 1995). Studies have shown 
that C. jejuni can form biofilms (Joshua et al., 2006) and that this is an important factor 
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in the survival of C. jejuni in the environment (Reuter et al., 2010). Recent studies have 
also shown biofilm formation increased under aerobic (O2) stress conditions (Reuter et 
al., 2010). The microarray data identified cprS as being 2.0 fold up-regulated in the 
Cj1556 mutant compared to the 11168H wild-type strain. A cprS mutant has been shown 
to have enhanced and accelerated biofilm formation (Svensson et al., 2009). Therefore 
an increase in CprS production in the Cj1556 mutant was predicted to result in a decrease 
in biofilm formation. Analysis of the ability to form biofilms when grown for 72 h under 
microaerobic conditions indicated a significant reduction when comparing the Cj1556 
mutant and the 11168H wild-type strain (Figure 4.20).  
  
 
 
Figure 4.20. Biofilm assay on 11168H wild-type strain, Cj1556 mutant and Cj1556 
complement (Cj1556 comp). C. jejuni were grown with a starting OD600 of 0.1, in culture 
for 72 h at 37°C under microaerobic conditions shaking at 75 rpm followed by crystal 
violet staining. All experimental data is represented using the average of at least three 
biological replicates performed in triplicate. Error bars represent the standard error of 
mean. Variables were compared for significance using a student’s t-test with two stars 
(**) indicating p = 0.001- 0.01.  
 
4.2.17 Galleria mellonella larvae exhibit increased survival after infection with the 
11168H Cj1556 mutant 
G. mellonella larvae have recently been used as a model to study infection by C. jejuni 
and other enteric pathogens (Champion et al., 2009). Insect larvae such as G. mellonella 
are favorable to use as non-mammalian infection models as they can be infected at 37°C 
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and possess specialized phagocytic cells, termed haemocytes (Mylonakis et al., 2007, 
Bergin et al., 2005). Haemocytes mimic the functions of phagocytic cells in mammals 
and are able to degrade bacterial pathogens and also generate bactericidal compounds 
such as superoxide via a respiratory burst (Bergin et al., 2005, Lavine and Strand, 2002). 
Infection with the Cj1556 mutant resulted in increased survival of G. mellonella larvae 
compared to infection with the 11168H wild-type strain (Figure 4.21). This suggests the 
Cj1556 mutant is more susceptible to the host immune mechanisms resulting in 
increased survival of G. mellonella. 
 
 
 
 
Figure 4.21. G. mellonella survival assay on 11168H wild-type strain, Cj1556 mutant 
and Cj1556 complement (Cj1556 comp). G. mellonella larvae were injected with a 10 l 
inoculum of a 24 h C. jejuni culture diluted to OD600 0.1 by micro-injection in the right 
foremost leg, giving an infectious dose of ≈ 106 CFU. Larvae were incubated at 37°C 
with survival and appearance recorded at 24 h intervals. All experimental data is 
represented using the average of at least three biological replicates performed in 
triplicate. Error bars represent the standard error of mean. Variables were compared for 
significance using a student’s t-test with one star (*) indicating p = 0.01 - 0.05.  
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4.3 Discussion 
C. jejuni survival is based upon the ability to sense and respond to the many different 
environments and yet the C. jejuni compact genome appears to have limited capacity for 
transcriptional control (Parkhill et al., 2000). Following re-annotation of the C. jejuni 
NCTC11168 genome sequence (see Chapter 3), Cj1556 was identified as a putative 
transcriptional regulator. Based on motif and protein interaction data, Cj1556 was 
hypothesized to be an important C. jejuni stress response regulator and therefore 
investigations into the ability of the 11168H Cj1556 mutant to survive different stresses 
and further explore the role of Cj1556 during host-pathogen interactions were performed. 
 
The human intestinal pathogen C. jejuni must survive diverse conditions in several 
different hosts and also in the environment. Even though C. jejuni is a microaerophilic 
organism, one of the great mysteries regarding this pathogen is the bacterium’s ability to 
be found ubiquitously within the environment. Fundamental to the survival of C. jejuni is 
the ability to survive both aerobic (O2) and oxidative stress conditions. Even though C. 
jejuni is microaerophilic, the bacterium has clearly adapted to survive when exposed to 
aerobic (O2) stress by inhabiting conditions where atmospheric levels of oxygen are 
present. C. jejuni produces proteins which are directly involved combating both aerobic 
(O2) and oxidative stress conditions. Important proteins identified within C. jejuni to 
counteract aerobic (O2) stress are the heat response proteins HtrA and HspR; the latter 
encoding a regulator important for short-term aerobic tolerance (Brondsted et al., 2005). 
The fdxA gene encoding a ferrodoxin has been noted for being important for 
aerotolerance (van Vliet et al., 2001). In addition SpoT was found to be important for 
low CO2 growth and aerobic survival (Gaynor et al., 2005). Oxidative stress is an 
important type of stress given that C. jejuni is a microaerophilic organism. ROS 
including superoxide, hydrogen peroxide (H2O2) and halogenated O2 molecules form as 
a result of aerobic respiration both inside and outside the host and form a major 
defensive barrier against the bacterium. Often, oxygen is converted into ROS including 
superoxide radicals (Park, 2005). A number of proteins are synthesized by C. jejuni to 
counteract such harmful molecules and these can be grouped into i) the O2
− (superoxide) 
stress proteins and ii) the peroxide stress proteins (van Vliet et al., 1999, Farr and 
Kogoma, 1991). The superoxide dismutase (SOD) for example catalyses the breakdown 
of superoxide to H2O2 and O2 and is classed as a O2
− stress proteins (Purdy and Park, 
1994, Pesci et al., 1994). This enzyme plays a key role in the defence against oxidative 
stress and aerotolerance as SOD-deficient C. jejuni strains are less able to survive in the 
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air (Purdy et al., 1999, Stead and Park, 2000). C. jejuni also contains the catalase KatA 
which converts H2O2 to H2O and O2. C. jejuni contains an alkyl hydroperoxide reductase 
encoded by ahpC which gives resistance to cumene hydroperoxide and aerobic (O2) 
stress (Baillon et al., 1999). KatA and AhpC are classed as peroxide stress proteins. As 
noted above, C. jejuni lacks OxyR which is typically a regulator of ahpC and katA 
expression in response to oxidative stress in E. coli (Cabiscol et al., 2000). Most Gram-
negative bacteria possess a recognition and response mechanism to oxidative stress via 
SoxRS and OxyR which recognise superoxide and peroxide molecules (Park, 2005). 
These are not present in C. jejuni, but a partial homologue PerR, which was noted as a 
functional but non-homologous version of OxyR, is present (van Vliet et al., 1999, 
Palyada et al., 2009). Research in E. coli has shown that the SoxRS system regulates the 
superoxide regulon (Amabile-Cuevas and Demple, 1991) and mutations in soxR or soxS 
fail to induce the members of their regulon (Farr and Kogoma, 1991). OxyR regulates 
the OxyR regulon, which is part of the peroxide stress regulon. The OxyR protein is a 
transcription factor that senses oxidative stress through disulfide bond formation and 
under conditions of oxidative stress, transcription of its regulon is induced following a 
change in OxyR conformation due to this disulfide bond formation (Storz et al., 1990, 
Toledano et al., 1994, Zheng et al., 1998). OxyR is considered a global regulator and H. 
influenzae oxyR mutants are unable to respond to oxidative stress (Maciver and Hansen, 
1996).  
 
Bioinformatics analysis of Cj1556 identified the presence of a helix-turn-helix motif and 
this suggested a role for this protein as a transcriptional activator. This motif is part of 
the MarR family of transcriptional regulators, which includes proteins that control 
virulence factor production, bacterial responses to antibiotics and oxidative stresses 
(Wilkinson and Grove, 2004). Using the search results from the Campylobacter Protein 
Interaction Database, a putative link between Cj1556 and Ctb was identified. Ctb is a 
truncated haemoglobin encoded by Cj0465c and is part of the C. jejuni nitrosative stress 
response regulon with Cgb (encoded by Cj1586), which are both under the control of 
NssR (encoded by Cj0466), a NO-sensitive regulator (Monk et al., 2008). No differences 
in bacterial survival were observed during nitrosative stress assays with the Cj1556 
mutant compared to the 11168H wild-type strain. However Ctb has also been shown to 
be involved in oxygen delivery (Wainwright et al., 2005, Wainwright et al., 2006). 
Oxidative stress assays showed that the Cj1556 mutant has increased sensitivity 
compared to the 11168H wild-type strain and that the wild-type level of sensitivity to 
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oxidative stress was fully restored with complementation of the Cj1556 mutation. In fact, 
the Cj1556 complement demonstrated even greater resistance to H2O2 than the 11168H 
wild-type strain, possibly due to the strength of the promoter as the complementation 
vector utilises the constitutive chloramphenicol cassette promoter to express the Cj1556 
CDS and not the native Cj1556 promoter. In addition, microarray data suggests that 
expression of Cj1556 is negatively autoregulated. Thus, the wild-type Cj1556 CDS 
would not be expected to be constitutively expressed as is the case in the Cj1556 
complement. This would be a possible explanation as to why the Cj1556 complement 
demonstrated even greater resistance to H2O2 than the 11168H wild-type strain, due to 
overexpression of Cj1556. 
 
The ability of the Cj1556 mutant to interact with (adhere and invade) and invade Caco-2 
cells was investigated over a 24 h time period. No significant difference in the ability of 
the Cj1556 mutant to interact with or invade Caco-2 cells was observed at either 3 or 6 h 
post infections. However significant difference in both interaction and invasion was 
observed at 24 h post-infection. This suggests the Cj1556 mutant does not have any 
defect in the ability to adhere to or invade Caco-2 cells, but may have a reduced ability to 
survive contact with host cells over longer periods of time. To further investigate long 
term survival of the Cj1556 mutant, intracellular survival assays were performed. These 
assays indicated that the Cj1556 mutant has a reduced ability to survive within Caco-2 
cells compared to the 11168H wild-type strain. The difference in the level of survival 
between the Cj1556 mutant and the 11168H wild-type strain in the intracellular survival 
assay at 24 h post-infection was approximately 0.5 log (Figure 4.12), very similar to the 
difference between the numbers of invasive bacteria for the Cj1556 mutant compared to 
the 11168H wild-type strain 24 h post-infection (Figure 4.11B). However, the difference 
in the number of interacting bacteria between the Cj1556 mutant and the 11168H wild-
type strain 24 h post-infection was approximately 1.5 log (Figure 4.11A). This suggests 
that in addition to a reduced ability for intracellular survival, the Cj1556 mutant was also 
more susceptible to extracellular stresses when compared to the 11168H wild-type strain. 
The Cj1556 mutant also exhibited increased sensitivity to H2O2 in vitro, so it is 
reasonable to suggest ROS released by Caco-2 cells during these experiments will have 
an effect on C. jejuni survival. Standard co-culture assays will not only result in exposure 
of C. jejuni to ROS released by Caco-2 cells, but also to aerobic (O2) stress as the assays 
are performed in a CO2 incubator. The approximate atmospheric O2 and CO2 levels are 
around 21% and 0.04% respectively. During co-culture experiments, the level of CO2 
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will be around 5% and so the O2 level will be around 16-18%. Based on the relative 
levels of survival between the interaction, invasion and intracellular survival assays, the 
greater level of sensitivity exhibited by the Cj1556 mutant during the interaction assay 
may be in part due to increased exposure of extracellular C. jejuni to aerobic (O2) stress.  
 
As such aerobic survival assays were performed to replicate the conditions during the 
interaction, invasion and intracellular survival assays by incubating C. jejuni in tissue 
culture media but in the absence of Caco-2 cells. A reduction in survival was observed 
for the Cj1556 mutant compared to the 11168H wild-type strain under aerobic 
conditions, but not under microaerobic conditions. C. jejuni typically loses viability 
within IECs over 24 h with no evidence of intracellular replication (Konkel et al., 
1992a). Recent evidence suggests that C. jejuni reside in membrane bound compartments 
termed C. jejuni containing vacuole (CCV), avoiding fusion with lysosomes (Watson and 
Galán, 2008). C. jejuni engulfed by macrophages must resist a combination of 
bacteriocidal stresses such as ROS. There are contradictory reports regarding the ability 
of C. jejuni to survive within macrophages, depending on the macrophage cell type and 
C. jejuni strain used (Day et al., 2000, Wassenaar et al., 1997). In this study, the Cj1556 
mutant was eliminated quicker when compared to the 11168H wild-type within the 
mouse macrophage J774A.1 cell line. Taken together, this data indicates that Cj1556 
plays a multi-factorial role in bacterial survival during adhesion to and invasion of 
human IECs. 
 
Following on from the interaction, invasion and survival studies, host innate immune 
responses was assessed by co-culturing C. jejuni strains with IECs and assessing IL-6 
and IL-8 induction. Minimal IL-6 and IL-8 was detected when the 11168H wild-type 
strain and Cj1556 mutant were co-cultured with Caco-2 cells (data not shown). This 
concurs with research demonstrating the poor chemokine/cytokine induction ability of 
Caco-2 cells when co-cultured with C. jejuni (MacCallum et al., 2006). However using a 
T84 cell line, significant levels of induction of both IL-6 and IL-8 by the 11168H wild-
type strain and Cj1556 mutant were observed. Previous reports have demonstrated 
ELISA experiments using T84 cells to detect levels of IL-8 and IL-6 over 1000 pg/ml 
when co-cultured with C. jejuni (MacCallum et al., 2006). In this study, these levels 
were not achieved most likely due to a number of factors, i) the use of 24-well plates 
rather than 12-well plates, ii) using an MOI of approximately 20:1 rather than 100:1, iii) 
variations in C. jejuni strains, iv) variation in T84 cell line e.g. passage number. In 
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addition, results from ELISA experiments using Caco-2 IECs produced IL-8 and IL-6 
levels detected at approximately 0-20 pg/ml when co-cultured with C. jejuni strains (data 
not shown). Thus, the trends observed in this study using T84 cells would most likely be 
consistent if the increased level of chemokine/cytokine induction was achieved by 
modifications to the experimental protocol. 
 
In this study, there was no significant difference in the level of IL-8 induction by the 
Cj1556 mutant compared to the 11168H wild-type strain, however a significant 
reduction in the level of IL-6 induction by the Cj1556 mutant compared to the 11168H 
wild-type strain was observed. IL-8 acts as a chemoattractant allowing the recruitment of 
lymphocytes and neutrophils (Hobbie et al., 1997, Philpott et al., 2000), whereas IL-6 is 
believed to be important for epithelial cell integrity (Friis et al., 2009). It is possible that 
less IL-6 was induced when T84 cells were co-cultured with Cj1556 mutant compared to 
the 11168H wild-type strain possibly due to the decreased survival characteristic of the 
Cj1556 mutant strain. Based on data from this study, co-culturing the Cj1556 mutant 
strain for 24 h in a 37°C CO2 incubator would result in decreased survival of the Cj1556 
mutant based on the increased sensitivity of this strain compared to the 11168H wild-
type strain. This may be a possible reason for the decreased IL-6 production. This result 
also suggests that IL-8 may be important for an extracellular response as both Cj1556 
mutant and the 11168H wild-type strain elicited similar levels of IL-8 from T84 IECs. 
However, IL-6 may be more important for an intracellular response as the Cj1556 mutant 
was shown to invade less compared to the 11168H wild-type strain and so elicited less 
IL-6 from T84 IECs. 
 
Transcriptional analysis of the Cj1556 mutant compared to the 11168H wild-type strain 
identified Cj1556 as the most up-regulated CDS (10.4 fold). This result was somewhat of 
a surprise as mutated strains traditionally display a reduced transcriptional level 
compared to the wild-type strain. Analysis of the Cj1556 nucleotide sequence upstream 
of the KmR cassette in the Cj1556 mutant confirmed that this was the sequence printed 
on the oligonucleotide spotted array, leading to the hypothesis that expression of Cj1556 
is controlled by a negative autoregulation feedback mechanism. In the 11168H wild-type 
strain, basal levels of Cj1556 would block off further expression of Cj1556 by inhibiting 
the binding of RNA polymerase to the Cj1556 promoter site. However in the absence of 
Cj1556 in the Cj1556 mutant, expression of Cj1556 can continue. This kind of negative 
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autoregulation is a feature of the MarR family of transcriptional regulators (Wilkinson 
and Grove, 2004).  
 
The role of Cj1556 as a putative transcriptional regulator would suggest that when 
expressed, Cj1556 also binds to other areas of the genome and controls expression of 
other proteins. The microarray data indicated down-regulation of katA (5.13), perR 
(5.05) and hspR (2.07) in the Cj1556 mutant (Table 4.2). These genes are also involved 
in oxidative/aerobic (O2) stress response in C. jejuni. It is possible Cj1556 interacts with 
these genes and controls their expression. To analyse this further, the promoter regions 
upstream of Cj1556 were searched and identified in C. jejuni katA, perR and hspR 
(Appendix 10). The C. jejuni katA encodes a catalase which converts H2O2 to H2O and 
O2. As noted before, C. jejuni lacks OxyR which is typically a regulator of AhpC and 
KatA in response to oxidative stress in E. coli (Cabiscol et al., 2000). A Cj1556 mutant 
may have directly or indirectly affected the expression of katA. Further studies would be 
useful for investigating the global binding of Cj1556 using methods such as ChIP-Seq or 
ChIP-ChIP (Ren et al., 2000, Bulyk et al., 1999, Uzzau et al., 2001). 
 
As described earlier, a number of proteins are synthesized by C. jejuni to counteract 
aerobic (O2) and oxidative stress inducing molecules and these can be grouped into, i) 
the O2
− (superoxide) stress proteins and, ii) the peroxide stress proteins (van Vliet et al., 
1999, Farr and Kogoma, 1991). C. jejuni does not possess the typical recognition and 
response mechanism to oxidative stress via SoxRS and OxyR which recognise 
superoxide and peroxide molecules (Park, 2005). However, a partial homologue PerR, 
which was noted as a functional but non-homologous version of OxyR, is present (van 
Vliet et al., 1999, Palyada et al., 2009). Mutation of Cj1556 may have directly or 
indirectly affected the expression of perR. Reduced expression of katA and perR would 
provide one explanation for the increased sensitivity of the Cj1556 mutant to oxidative 
and aerobic (O2) stress observed in this study, however further experiments are required 
to confirm this predicted function.   
 
The ability of C. jejuni to form biofilms goes some way to explain how a bacterium with 
such fastidious growth requirements remains ubiquitous in the environment (Buswell et 
al., 1998, Joshua et al., 2006). C. jejuni can form three distinct forms of biofilm: cell-cell 
aggregates, pellicles at the air-liquid interface and glass-attached flocs (Joshua et al., 
2006). Our understanding of the specific mechanisms underlying biofilm formation in C. 
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jejuni are still limited (Svensson et al., 2008). C. jejuni lacks the classical 2CRSs 
involved in biofilm formation that are present in other bacteria such as GacSA in 
Pseudomonas aeruginosa (Parkins et al., 2001). Genes involved in biofilm formation 
have been linked to responses to oxidative and aerobic (O2) stress and C. jejuni biofilm 
formation is increased under aerobic conditions (Reuter et al., 2010). A C. jejuni spoT 
mutant has been found to overproduce a novel calcofluor white reactive 
exoploysaccharide and demonstrate enhanced biofilm formation (McLennan et al., 
2008). Interestingly a C. jejuni cprS mutant has been shown to display growth defects, 
enhanced and accelerated biofilm formation and also to exhibit decreased oxidative 
stress tolerance (Svensson et al., 2009). The microarray data identified cprS as being 2.0 
fold up-regulated in the Cj1556 mutant compared to the 11168H wild-type strain. 
Therefore an increase in CprS production in the Cj1556 mutant was predicted to result in 
a decrease in biofilm formation. Analysis of the 11168H wild-type and Cj1556 mutant 
strains indicated a significant reduction in relative biofilm formation by the Cj1556 
mutant (Fig. 6). Recent studies have also shown increased biofilm formation under 
aerobic (O2) stress conditions (Reuter et al., 2010). This suggests a possible role for 
Cj1556 in biofilm formation either directly or indirectly.  
 
C. jejuni proteins associated with heat stress responses such as HspR have also been 
linked to oxidative and aerobic (O2) stress (Andersen et al., 2005). The Cj1556 mutant 
showed a greater level of sensitivity to 60°C stress compared to the 11168H wild-type 
strain. Heat stress above 55°C has been noted to accelerate the spiral-to-coccoid 
transition and result in cell death (Nguyen et al., 2006). Previous studies have identified 
numerous C. jejuni genes involved in heat shock response and HtrA and HspR also have 
been shown to have roles in aerobic survival, host cell adherence and invasion 
(Brondsted et al., 2005). Transcriptional analysis identified hspR as being approximately 
2.0 fold down-regulated in the Cj1556 mutant compared to the 11168H wild-type strain. 
In addition, analysis of C. jejuni hspR promoter sequences identified the presence of 
these promoter sequences upstream of Cj1556 (Appendix 10). It is interesting to note 
that the Cj1556 mutant has increased sensitivity to heat stress and this may be due to 
Cj1556 interacting with HspR. Even though no protein-protein interactions between the 
two were identified in the Campylobacter Protein Interaction Database, there may still 
exist a connection between the heat shock response and aerobic tolerance (Andersen et 
al., 2005, Brondsted et al., 2005).  
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The G. mellonella insect model was used to investigate pathogenicity of the Cj1556 
mutant. The G. mellonella insect model is suitable for identification of C. jejuni 
virulence determinants and the larvae possess specialised phagocytic cells, termed 
haemocytes (Bergin et al., 2005). The insect immune system is subdivided into humoral 
and cellular defence responses. Humoral defences include the production of 
antimicrobial peptides (Meister et al., 2000), reactive intermediates of oxygen or 
nitrogen (Bogdan et al., 2000) and the complex enzymatic cascades that regulate 
coagulation or melanisation of haemolymph (Muta and Iwanaga, 1996). Cellular defence 
refers to haemocyte-mediated immune responses like phagocytosis, nodulation and 
encapsulation (Strand and Pech, 1995, Schmidt et al., 2001). Haemocytes perform many 
of the functions of phagocytic cells in mammals, are capable of ingesting bacterial 
pathogens and generating bactericidal compounds such as superoxide via a respiratory 
burst (Bergin et al., 2005, Champion et al., 2009). Studies have shown that after 
infection of G. mellonella with Yersinia pseudotuberculosis, the bacteria accumulates in 
haemocytes, thus suggesting that G. mellonella may be useful for the identification of 
other genes associated with intracellular survival (Champion et al., 2009). Infection with 
the Cj1556 mutant resulted in increased survival of G. mellonella larvae compared to 
survival after infection with the 11168H wild-type strain at 24 h post-infection. This 
suggests the Cj1556 mutant is more susceptible to the host immune mechanisms 
resulting in reduced bacterial survival within G. mellonella. At least six types of 
haemocytes have been identified in insects such as G. mellonella with plasmatocytes and 
granulocytes the most abundant (Boman and Hultmark, 1987). Production of ROS has 
also been detected in haemocytes with evidence of both oxygen radicals and H2O2 both 
found in plasmatocytes of G. mellonella (Slepneva et al., 1999). This data links the 
increased sensitivity of the Cj1556 mutant to H2O2 stress in vitro with an attenuation of 
virulence in vivo using the G. mellonella model of infection. 
 
The digestive secretion bile consists of around 50% bile salts, such as cholates and 
deoxycholates. Bile salts exhibit potent antibacterial properties, acting as detergents to 
disrupt cell membranes and as DNA-damaging agents (Begley et al., 2005). Although 
bacteria inhabiting the gastrointestinal tract are able to resist the antimicrobial effects of 
bile, a number of studies have also shown that bile increases the virulence potential of 
enteric pathogens (Begley et al., 2005). The bile salt sDOC has been shown to increase 
the virulence of C. jejuni, enhancing bacterial ability to invade epithelial cells (Malik-
Kale et al., 2008). Growing C. jejuni in the presence of a physiologically relevant 
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concentration of sDOC (0.1% w/v) changes the invasion kinetics such that maximal 
invasion of INT 407 cells occur in under 30 minutes compared to 3 h for C. jejuni grown 
in the absence of sDOC (Malik-Kale et al., 2008). Microarray analysis has shown that a 
number of C. jejuni virulence factors are up-regulated in the presence of 0.1% (w/v) 
sDOC, including ciaB, cmeABC, dccR and tlyA (Malik-Kale et al., 2008). Interestingly, 
Cj1556 was also up-regulated in the presence of sDOC, with transcription increasing 2.8 
fold (Malik-Kale et al., 2008). The transcriptional response of E. coli O157:H7 to bile 
treatment has also been investigated using microarrays and has identified bile-induced 
changes in transcription for genes encoding proteins affecting membrane structure and 
permeability, bile resistance, adhesion and virulence potential (Hamner et al., 2010). 
Most interestingly this data indicates that bile induces expression of the marRAB operon, 
by binding to the repressor protein MarR and thus preventing binding of MarR to the 
marRAB promoter site (Hamner et al., 2010). Cj1556 is a member of the MarR family of 
transcriptional regulators and further studies will be required to confirm whether bile can 
bind to the Cj1556 protein and thus prevent binding to the Cj1556 promoter site, 
resulting in the up-regulation of Cj1556 in the presence of bile observed previously 
(Malik-Kale et al., 2008). 
 
In addition to Cj1556, the C. jejuni NCTC11168 genome contained one other CDS with 
the MarR family motif; Cj1546. Cj1546 was also re-annotated as a putative 
transcriptional regulator with 43.6% identity and 58.4% similarity to Cj1556. (Figure 
4.1). Protein Blast search results for Cj1556 identified this CDS to be present in 
relatively few strains/species of Campylobacter (Table 4.1). Homologues with relatively 
high identity and expect scores were present in C. jejuni strains CF93-6, 84-25 and 81-
176, along with the species C. fetus 82-40. Protein Blast search results for Cj1546 
identified this CDS in all C. jejuni strains with a significant level of identity and 
similarity (data not shown). Even though no standout aerobic (O2) and/or oxidative stress 
protein-protein interactions were identified for Cj1546 using the Campylobacter Protein 
Interaction database, one hypothesis as to the function of these MarR motif containing 
proteins is that they both perform similar roles in relation to aerobic (O2) and oxidative 
stress. It is tempting to speculate that whilst all C. jejuni strains express Cj1546, strains 
such as C. jejuni NCTC11168 and 81-176 that also express Cj1556 may have a greater 
chance of survival within the human host for example due to greater resistance to 
oxidative stresses. Further experiments will be required to confirm this hypothesis. 
During this study, it was not possible to construct a 11168H Cj1546 mutant. These initial 
  
 180 
attempts at constructing a Cj1546 mutant may have proved unsuccessful due to the small 
size of the CDS (345 nucleotides) or because mutation of Cj1546 is a lethal mutation. 
Adopting a similar strategy used in the construction of a Cj1556 mutant by using larger 
pUC library clones from the original genome sequencing project harbouring the gene of 
interest may prove more efficient.  
  
4.4 Conclusion 
In summary, a cornerstone of C. jejuni survival is based upon the ability to sense and 
respond to the different environments the bacterium encounters within and outside hosts. 
This data indicates that the Cj1556 protein is involved in the regulation of both the C. 
jejuni oxidative and aerobic (O2) stress responses and also plays a role in bacterial 
survival in vivo. As such the Cj1556 putative transcriptional regulator has been 
designated as CosR (Campylobacter oxidative stress Regulator). 
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Chapter 5: Cj0248 encodes a putative phosphohydrolase which 
has a role in both motility and virulence  
 
5.1 Introduction 
Re-annotation of the C. jejuni NCTC11168 genome sequence resulted in the 
identification of 15 CDSs for further study (see Section 3.4). The selection of these 15 
CDSs was based on a number of different criteria such as newly identified motifs along 
with literature searches. The function of each CDS was unknown, however putative 
functions were linked to roles in virulence, signal transduction or regulation of gene 
expression. Following the successful construction of eight defined isogenic C. jejuni 
11168H mutants, a number of preliminary phenotypic assays such as growth kinetics, 
motility, interaction and invasion assays were performed. Two mutants were chosen for 
further characterisation and this chapter details the characterisation of the 11168H 
Cj0248 mutant. 
 
5.1.1 Aims  
- Construct a defined isogenic C. jejuni 11168H Cj0248 mutant 
- Construct a 11168H Cj0248 complement  
- Characterise the 11168H Cj0248 mutant 
 
5.2 Constructions and characterisation of the C. jejuni 11168H Cj0248 mutant 
 
5.2.1 Literature search results  
Using in vitro transposition of C. jejuni chromosomal DNA followed by natural 
transformation of the transposed DNA, large random transposon mutant libraries were 
prepared in wild-type strain 81-176 allowing up to 16,000 mutants to be generated 
(Hendrixson et al., 2001). Subsequent screening identified 28 mutants with motility 
defects (Hendrixson et al., 2001). One such CDS was Cj0248. To further investigate 
caecal colonisation by C. jejuni, signature-tagged transposon mutagenesis was 
performed, generating 1550 C. jejuni 81-176 mutants of which 29 mutants (representing 
22 different genes) were found to be required for wild-type levels of caecal colonisation 
(Hendrixson and DiRita, 2004). As such, a C. jejuni 81-176 Cj0248 mutant was shown to 
have reduced motility (Hendrixson et al., 2001) and a 100- to 10,000- fold reduction in 
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colonisation using a chick caecal colonisation model (Hendrixson and DiRita, 2004). In 
addition the crystal structure of Cj0248 has been elucidated (Xu et al., 2006). Cj0248 
contains a HD motif (PF08668), indicating a function as a possible phosphohydrolase or 
a signal transduction protein. Enzymes known to possess phosphohydrolase activity may 
be involved in nucleic acid metabolism, signal transduction and possibly other functions 
in bacteria (Aravind and Koonin, 1998). Cj0248 was predicted to contain a HD motif 
indicating a function as a possible phosphohydrolase, however structural analysis 
indicated that Cj0248 does not function as a metal-dependent phosphohydrolase (Xu et 
al., 2006). Thus, Cj0248 would appear to have a role in signal transduction linked to 
motility and colonisation. No specific function has as yet been designated. Importantly, 
all previous work was performed on the C. jejuni 81-176 strain.  
 
5.2.2 Bioinformatic analysis of Cj0248  
BlastP search results of the Cj0248 protein sequence identified the presence of this CDS 
in a number of C. jejuni strains and Campylobacter species albeit with significantly 
lower similarity scores (Table 5.1). In addition, homologues are also present in other 
genus from the epsilon proteobacterium class such as Helicobacter, Wolinella and 
Sulfurospirillum. Homologues of this CDS are annotated as “hypothetical protein” or a 
function based on the HD motif. No homologue has been characterised as yet. 
Comparison of the protein sequences of C. jejuni NCTC11168 and 81-176 strains 
identified only five amino acids that were different between the two strains. Three of 
these amino acid differences were conserved and one was a semi-conserved substitution. 
Only one of the five different amino acids was a non-conserved substitution (Figure 5.1). 
This suggests no functional differences between the two strains. No links were identified 
between the Cj0248 protein and any other protein in the Campylobacter Protein 
Interaction Database (Parrish et al., 2007). 
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Table 5.1. BlastP search results for Cj0248 protein sequence. 
 
Species / Strain Identity score Expect score 
Campylobacter jejuni subsp. jejuni NCTC11168 285/285 2e-163 
Campylobacter jejuni subsp. jejuni 84-25 285/285 2e-163 
Campylobacter jejuni subsp. jejuni CF93-6 285/285 2e-163 
Campylobacter jejuni subsp. jejuni CG8486 285/285 8e-163 
Campylobacter jejuni RM1221 284/285 4e-163 
Campylobacter jejuni subsp. jejuni CG8421 284/285 2e-163 
Campylobacter jejuni subsp. jejuni HB93-13 283/285 2e-162 
Campylobacter jejuni subsp. jejuni 81-176 280/285 4e-161 
Campylobacter jejuni subsp. jejuni 260.94 279/285 9e-161 
Campylobacter jejuni subsp. doylei 269.97 278/285 5e-160 
Campylobacter jejuni subsp. jejuni 81116 277/285 6e-160 
Campylobacter coli RM2228 197/286 2e-118 
Campylobacter upsaliensis RM3195 197/282 7e-110 
Campylobacter showae RM3277 74/230 3e-33 
Campylobacter fetus subsp. fetus 82-40 70/230 1e-32 
Campylobacter curvus 525.92 74/231 2e-32 
Campylobacter rectus RM3267 71/230 1e-30 
Campylobacter concisus 13826 71/230 1e-29 
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11168H MIGDMNELLLKSVEVLPPLPDTVSKLRKYVSEANSNIETMKVAEIISSDPLMTAKLLQLA 60 
81-176 MIGDMNELLLKSVEVLPPLPDTVSKLRKYVSEANSNIETMKVAEIISSDPLMTAKLLQLA 60 
       ************************************************************ 
 
11168H NSPYYGFTREITTINQVITLLGVGNIINIVMADSIRDNFKIDVSPYGLNTQNFLKTCNEE 120 
81-176 NSPYYGFTREITTINQVITLLGVGNIINIVTADSIRDNFKIDVSPYGLNTQNFLKTCNEE 120 
       ****************************** ***************************** 
 
11168H ATFIANWLNDEDKKLSHLLVPCAMLLRLGIVIFSNFLIQNHKDKDFLAFLNKNENLALAE 180 
81-176 ATFITNWLNDEDKKLSHLLVPCAMLLRLGIVIFSNFLIQNHKDKDFLAFLNKNENLALAE 180 
       ****:******************************************************* 
 
11168H NEFLGVDHISFLGFLLHRWNFDDVLIESICFVRTPHAAREKVKKSAYALAITDHLFAPHD 240 
81-176 NEFLGVDHISFLGFLLHRWNFDDVLIESICFVRTPHAAREEVKKSAYALAITDHLFAPHD 240 
       ****************************************:******************* 
 
11168H GSSPFNAKAAVALLKEAKTQGINFDLNNLLSKLPNKAKENLNKED 285 
81-176 GSSPFNAKAAVALLEEAKTQGINFDLNNLLSKLPSKAKENLNKED 285 
       **************:*******************.********** 
 
 
Figure 5.1. ClustalW alignment of C. jejuni NCTC11168 and 81-176 protein sequences. 
Based on a colour legend from EBI – (http://www.ebi.ac.uk/Tools/clustalw2/help.html). 
‘*’ indicate identical matches, ‘:’ indicates conserved substitutions, "." indicates semi-
conserved substitutions and a ‘space’ indicates a non-conserved substitution. Underlined 
sequence indicates location of HD motif (PF08668). 
 
5.2.3 Construction of 11168H Cj0248 mutant 
The mutagenesis strategy and techniques used to create a defined isogenic 11168H 
Cj0248 mutant are described in Chapter 2. Briefly, primers were designed for PCR 
amplification and detection of a Cj0248 CDS fragment (0.84 kb) using Cj0248-F and 
Cj0248-R (see Section 2.2.5). A Cj0248 CDS fragment was amplified from C. jejuni 
11168H genomic DNA and ligated with the pGEM-T Easy vector (Promega), forming 
the construct pGEM-Cj0248. This construct was transformed into XL-2 cells. Screening 
for positive clones was performed using PCR and sequencing. Identification of positive 
clones containing the Cj0248 CDS fragment was followed by growing putative positive 
transformants overnight in culture and isolating plasmid DNA using a QIAprep Miniprep 
Kit (Qiagen). To insert a unique restriction site (BamHI) within the cloned Cj0248 CDS 
fragment, IPCRM was performed. Briefly, IPCR amplification of the purified plasmid 
was performed using Cj0248-IPCR-F and Cj0248-IPCR-R primers (see Section 2.2.5). 
The IPCRM product was digested with BglII and DpnI, followed by ligation with the 
aph-3 (aminoglycoside 3’-phosphotransferase) kanamycin resistance cassette (KmR) 
(Trieu-Cuot et al., 1985) and transformation into XL-2 cells. The KmR cassette was 
derived from pJMK30 and does not contain a transcriptional terminator. This allows the 
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formation of multicistronic mRNA as the KmR can be positioned in the same orientation 
as the CDS of interest, hence reducing the potential for polar effects (van Vliet et al., 
1998). Kanamycin-resistant transformants were screened by PCR using Cj0248 specific 
and two KmR specific primers; KmR forward-out and KmR reverse-out (see Section 
2.2.5). pUC-Cj0248-KmR plasmids with the KmR cassette in the same orientation as the 
Cj0248 CDS were selected and electroporated into 11168H wild-type as described 
previously (Jones et al., 2004, Karlyshev et al., 2002). Electroporated C. jejuni were 
plated onto blood agar plates and incubated at 37°C under microaerobic conditions for 2 
days. Cells were harvested and resuspended in 0.5 ml PBS. 200 μl of this suspension was 
spread onto blood agar plates containing kanamycin. Putative Cj0248 mutants were 
restreaked and screened using PCR (Figure 5.2) and sequencing.  
 
 
 
 
Figure 5.2. Confirmation of Cj0248 constructs and 11168H Cj0248 mutant using PCR 
with Cj0248 specific primers. Lane 1 – 1 kb ladder / Lane 2 – pGEM-Cj0248 plasmid 
DNA amplified with Cj0248 specific primers (0.84 kb) / Lane 3 – pGEM-Cj0248-KmR 
plasmid DNA amplified with Cj0248 specific primers (2.26 kb) / Lane 4 – C. jejuni 
11168H wild-type strain genomic DNA amplified with Cj0248 specific primers (0.86 kb) 
/ Lane 5 – C. jejuni 11168H Cj0248 mutant genomic DNA amplified with Cj0248 
specific primers (2.26 kb) / Lane 6 – Negative control. 
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After the successful construction of a Cj0248 mutant and the selection of Cj0248 for 
further study, initial attempts at constructing a Cj0248 complement proved unsuccessful. 
A Cj0248 complement strain was only successfully constructed towards the end of this 
study (see Section 5.2.19). 
 
5.2.4 The 11168H Cj0248 mutant exhibits altered growth kinetics 
To begin characterisation of the 111168H Cj0248 mutant, growth kinetic assays were 
performed comparing the Cj0248 mutant against the 11168H wild-type strain (Figure 
5.3). A significant difference was observed in the growth kinetics of the wild-type strain 
and the Cj0248 mutant at time points 6, 8, 10 and 12 hours. However, further incubation 
showed no significant difference between the Cj0248 mutant and the 11168H wild-type 
strain (data not shown). As all assays were to be performed using C. jejuni strains grown 
for 24 hours, this difference during the early stages of growth was not considered as a 
factor that would need to be taken into account during experimental design and analysis. 
 
 
 
 
Figure 5.3. Growth kinetic assay comparing the 11168H wild-type strain to the Cj0248 
mutant. A secondary broth culture inoculation method was used where C. jejuni grown 
for 16 h was used to inoculate 15 ml preincubated Brucella broth to an OD600 of 0.1. 
Flasks were incubated at 37°C under microaerobic conditions, shaking at 75 rpm. OD600 
readings were performed at selected time points. All experimental data is represented 
using the average of at least three biological replicates performed in triplicate. Error bars 
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represent the standard error of mean. Variables were compared for significance using a 
student’s t-test with one star (*) indicating p = 0.01 - 0.05 and two stars (**) indicating p 
= 0.001- 0.01.   
 
5.2.5 The 11168H Cj0248 mutant exhibits severely reduced motility 
Previous published research had shown that a C. jejuni 81-176 Cj0248 mutant had a 
severely reduced motility phenotype (Hendrixson et al., 2001). Consistent with this 
phenotype, the 11168H Cj0248 mutant also showed a severely reduced phenotype 
(Figure 5.4). The severely reduced motility was statistically significant at 24, 48 and 72 h 
when comparing the Cj0248 mutant to the 11168H wild-type. This data suggests Cj0248 
plays a similar role in C. jejuni 11168H as in 81-176. 
 
 
 
 
Figure 5.4. Motility assay comparing the 11168H wild-type strain and Cj0248 mutant on 
semi-solid surfaces. C. jejuni from an overnight culture was adjusted to an OD600 of 1.0. 
5 µl of this suspension was pipetted into the centre of a motility plate using a Gilson 
pipette (P10). Plates were incubated at 37°C under microaerobic conditions and plate 
images were recorded at 24, 48 and 72 h. Motility was assessed by measuring the 
diameter of the halo on the plate. All experimental data is represented using the average 
of at least three biological replicates performed in triplicate. Error bars represent the 
standard error of mean. Variables were compared for significance using a student’s t-test 
with one star (*) indicating p = 0.01 - 0.05 and two stars (**) indicating p = 0.001- 0.01.  
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5.2.6 The 11168H Cj0248 mutant displays unaltered autoagglutination levels   
Autoagglutination or self-association has been linked with virulence in some Gram-
negative bacteria (Roggenkamp et al., 1995, Bieber et al., 1998, Brondsted et al., 2005). 
Specifically, autoagglutination has been described as a preliminary step in the formation 
of microcolonies (Misawa and Blaser, 2000). Microcolony formation has been identified 
as an important preliminary step in biofilm formation (Haddock et al., 2010). In 
Campylobacter species, autoagglutination has been shown to be mediated by flagella 
(Guerry et al., 2006). The autoagglutination ability of the Cj0248 mutant was compared 
to that of the 11168H wild-type strain. No difference in the level of autoagglutination 
between the two strains was observed (Figure 5.5). A 11168H rpoN mutant was used as a 
autoagglutination negative control. Mutation of rpoN (which encodes the alternative 
sigma factor σ54) renders the bacterium non-motile and without flagella (Jagannathan et 
al., 2001). This data suggests the Cj0248 mutant has a complete or partial flagella 
structure and in conjunction with the motility data may suggest such flagella have 
impaired function.  
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Figure 5.5. Autoagglutination ability of the 11168H wild-type strain and the Cj0248 
mutant. C. jejuni that were grown on blood agar plates for 24 h at 37°C under 
microaerobic conditions were used to inoculate 10 ml PBS to a final OD600 of 1.0. 
Cultures were incubated for 24 h at 37°C under microaerobic conditions with no shaking. 
The OD600 was measured using 1 ml taken from the centre of the 24 h incubated culture. 
A 11168H rpoN mutant was used a negative control which dramatically reduced 
autoagglutinate. All experimental data is represented using the average of at least three 
biological replicates performed in triplicate. Error bars represent the standard error of 
mean.  
 
5.2.7 The 11168H Cj0248 mutant exhibits reduced biofilm formation 
Biofilms are commonly defined as matrix-enclosed bacterial populations adherent to 
each other and/or to surfaces of interfaces (Costerton et al., 1995). Studies have shown 
that C. jejuni can form biofilms (Joshua et al., 2006) and that this is an important factor 
in the survival of Campylobacter in the environment (Reuter et al., 2010). Specifically, 
flagella have an important role in biofilm formation by allowing the survival of this 
microaerophilic organism in water and under other harsh environmental conditions 
(Guerry, 2007). To investigate this further, biofilm assays were performed where C. 
jejuni were grown for 3 days under microaerobic conditions and the level of biofilm 
formation was measured via crystal violet staining. Analysis of the 11168H wild-type 
strain and Cj0248 mutant indicated a significant reduction in the level of biofilm 
  
 190 
formation by the Cj0248 mutant (Figure 5.6). Comparison between the level of biofilm 
formation by the Cj0248 mutant and the Cj1556 mutant strains also revealed differences. 
The level of biofilm formation for the Cj1556 mutant was detected as approximately 
0.15 A595 whereas the level of biofilm detected for the Cj0248 mutant data was 
approximately 0.10 A595. These are relatively small differences however flagella have 
been described as being important for biofilm formation and this data indicates that a 
mutant with putatively altered flagella functionality shows a greater reduction in biofilm 
formation compared to a mutant with increased sensitivity to oxidative and aerobic (O2) 
stress. The motility and autoagglutination data suggested the Cj0248 mutant possesses 
complete or partial flagella, which has impaired function. This data suggests flagella 
with impaired function may result in decreased biofilm formation possibly as a result of 
less microcolony formation, which is an important step in biofilm formation. 
 
 
 
 
Figure 5.6. Biofilm assay on 11168H wild-type strain and Cj0248 mutant. C. jejuni were 
inoculated with a starting OD600 of 0.1 in culture for 72 h at 37°C under microaerobic 
conditions shaking at 75 rpm followed by crystal violet staining. All experimental data is 
represented using the average of at least three biological replicates performed in 
triplicate. Error bars represent the standard error of mean. Variables were compared for 
significance using a student’s t-test with three stars (***) p < 0.001.  
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5.2.8 Transmission electron microscopy reveals the Cj0248 mutant possesses intact 
flagella  
Results from the motility, autoagglutination and biofilm assays suggested Cj0248 mutant 
has complete or partial flagella with impaired function. To investigate this further, TEM 
analysis was performed to ascertain whether the Cj0248 mutant possessed flagella. TEM 
analysis was performed on C. jejuni cultures grown for 16 h at 37°C under microaerobic 
conditions and identified the presence of flagella for Cj0248 mutant (Figure 5.7). This 
result would explain the autoagglutination positive phenotype of the Cj0248 mutant (see 
Section 5.2.6). This result would also suggest that despite the presence of flagella, the 
reduced motility phenotype of the Cj0248 mutant indicates these flagella have impaired 
function. 
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A) 
 
B) 
 
 
Figure 5.7. TEM analysis of the 11168H wild-type strain and Cj0248 mutant. TEM 
analysis was performed on C. jejuni cultures grown for 16 h at 37°C under microaerobic 
conditions. C. jejuni 11168H wild-type (A) and Cj0248 mutant (B) represented by four 
images from three independent experiments. Arrows indicate flagella. Magnification = 
25,000x. Size bar = 500 nm. All experimental data is represented using the average of at 
least three biological replicates performed in triplicate. 
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5.2.9 Microarray analysis reveals changes in expression of genes involved in flagella 
biosynthesis    
To analyse the gene expression profile of the Cj0248 mutant compared to the 11168H 
wild-type strain, microarray experiments were performed using total RNA samples 
isolated from C. jejuni grown to late-log phase (16 h). Microarray experiments were 
performed with three biological replicates, each with one technical replicate. Statistically 
significant up- and down-regulated genes were selected when comparing gene 
expression from mutant test arrays against 11168H control arrays using ANOVA 
(ANalysis Of VAriance) (Bacon et al., 2004, Corcionivoschi et al., 2009). ANOVA was 
performed using a Benjamini and Hochberg False Discovery Rate as the Multiple 
Testing Correction within the GeneSpring software (v7.3). A total of 177 genes were 
differentially expressed in the Cj0248 mutant compared to the 11168H wild-type strain 
based on ANOVA selection methodology. A total of 120 genes were up-regulated and 57 
genes down-regulated (Appendix 11 and 12). A number of differentially expressed genes 
were identified that may cast further light on the phenotype of the Cj0248 mutant (Table 
5.2) and the role of Cj0248.   
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Table 5.2. Selection of significant genes identified from expression studies comparing 
the Cj0248 mutant to the 11168H wild-type. Genes are ordered based on functional 
groups and not fold-change. 
 
Gene name Fold change Product function 
pglA +1.86 GalNAc transferase 
flhA +1.81 Flagella biosynthesis protein 
flgB -1.56 Flagella basal-body rod protein 
flgC -4.48 Flagella basal-body rod protein 
cheA -1.74 Chemotaxis histidine kinase 
cheV -1.60 Chemotaxis protein 
kpsD -1.40 
Capsule polysaccharide export system 
periplasmic protein 
kpsE -2.60 
Capsule polysaccharide export system inner 
membrane protein 
cbrR +1.40 Two-component response regulator 
cmeR -5.16 Transcriptional regulator 
rho -2.43 Transcription termination factor 
   
 
Considering the phenotype of the Cj0248 mutant, changes in expression of genes 
encoding proteins with a role in flagella biosynthesis and chemotaxis were identified (see 
Table 5.2). Expression of flgB and flgC were identified as 1.55 and 4.48 fold down-
regulated, whereas flhA was found to be 1.81 fold up-regulated. FlgB and FlgC are both 
proximal rod proteins in the flagella basal body compartment (Golden and Acheson, 
2002, Konkel et al., 2004, Saijo-Hamano et al., 2004). C. jejuni flgB and flgC mutants 
have been shown to be defective for both motility and secretion (Konkel et al., 2004). 
FlhA is an inner membrane export apparatus protein involved in flagella protein 
secretion (Golden and Acheson, 2002, Miller et al., 1993). FlhA has been associated 
with a role in pathogenesis as a C. jejuni flhA mutant has been shown to affect motility, 
autoagglutination and invasion (Hendrixson and DiRita, 2003, Golden and Acheson, 
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2002). Expression of cheA and cheV were identified as 1.74 and 1.60 fold down-
regulated. CheA and CheV are chemotaxis proteins. CheA is a histidine kinase protein 
part of a two-component regulatory system with the response regulator CheY, which 
controls the chemotaxis response to external stimuli (Chang and Miller, 2006, 
Hendrixson et al., 2001). The binding of the signal ligand is relayed by methyl-
chemotaxis proteins to CheA. Analysis of the C. jejuni NCTC11168 genome sequence 
has identified MCP-like genes which encode Tlps (transducer-like proteins) forming 
receptors which bind to CheA and CheW (Korolik and Ketley, 2008). Diversity in the 
ligand binding domains of the Tlps and notable differences in the complement of 
response regulator domains indicate that the overall mechanism of chemotaxis single 
transduction in C. jejuni is likely to be unique (Korolik and Ketley, 2008). The C. jejuni 
NCTC11168 genome encodes 10 possible Tlp receptor proteins and two aerotaxis 
orthologues that potentially feed signals into the single CheA-CheW-CheY signal 
transduction pathway backbone (Korolik and Ketley, 2008). CheW is also part of this 
complex and CheV has been predicted to have a similar role to CheW as a N-terminal 
CheW domain fused to a C-terminal response regulator domain has been identified 
within CheV (Korolik and Ketley, 2008, Rosario et al., 1994). 
 
5.2.10 Enhanced TEM analysis reveals putative flagella structural differences 
between 11168H wild-type strain and Cj0248 mutant 
Following on from the microarray expression studies described in Section 5.2.9, a 
number of genes with functions relating to flagella basal body biosynthesis were 
identified as differentially expressed. Further analysis was performed using TEM with a 
higher magnification (250,000x as opposed to 25,000x utilised in Section 5.2.8), 
specifically focussing on the flagella basal body region. TEM analysis was performed on 
C. jejuni cultures grown for 16 h at 37°C under microaerobic conditions. Putative 
structural differences in the flagella basal body region were identified when comparing 
the 11168H wild-type strain to the Cj0248 mutant (Figure 5.8). The 11168H wild-type 
strain contains a putative defined layered flagella basal body (Figure 5.8A). The Cj0248 
mutant contains a putative altered flagella basal body region (Figure 5.8B). The locations 
of the proteins encoded by genes identified as differentially regulated in the microarray 
expression study described in Section 5.2.9 (FlhA, FlgB and FlgC) are shown in Figure 
5.9.  
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A)  
  
B) 
 
 
 
Figure 5.8. TEM analysis of 11168H wild-type strain and Cj0248 mutant. TEM analysis 
was performed on C. jejuni culture grown for 16 h at 37°C under microaerobic 
conditions. 11168H wild-type strain (A) and Cj0248 mutant (B) represented by four 
selected images from three independent experiments. A) 11168H wild-type strain with 
putative defined basal body structure, B) Cj0248 mutant with putative altered flagella 
basal body region. Magnification = 250,000x. Size bar = 100 nm. All experimental data 
is represented using the average of at least three biological replicates performed in 
triplicate.  
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Figure 5.9. C. jejuni flagella structure and proteins involved in biosynthesis. Gene 
expression profile analysis of the Cj0248 mutant was compared to the 11168H wild-type 
strain using microarray experiments from total RNA samples isolated from C. jejuni 
grown to late-log phase (16 h). Genes encoding proteins involved in flagella biosynthesis 
with modified expression levels in the Cj0248 mutant are highlighted with colour 
arrows; flhA 1.81 fold up-regulated (red arrow), flgB and flgC 1.56 and 4.48 fold down-
regulated respectively (blue arrows). Image obtained from GeneSpring v7.3.   
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5.2.11 The 11168H Cj0248 mutant does not have a reduced secretion profile 
compared to 11168H wild-type strain   
Following on from the identification of putative alterations in the flagella basal body 
structure and reduced motility results, further investigations were undertaken to ascertain 
whether the secretion profile differed between the 11168H wild-type strain and the 
Cj0248 mutant. Flagella have been shown to be involved in not just motility and 
chemotaxis but also in the putative secretion of virulence proteins (Konkel et al., 2004). 
Thus, it was hypothesised that changes in the basal body structure may cause a possible 
secretion defect. The secretion of Cia proteins is dependent on a functional flagellum, 
indicating that this organelle has a dual function in motility and as a type III secretion 
system (Konkel et al., 2004). Research has described the identification of at least eight 
proteins from the culture supernatant when C. jejuni was grown in the presence of IECs 
(Konkel et al., 2004, Konkel et al., 1999b, Young et al., 1999). The secretion of such 
proteins is further induced in the presence of external compounds such as serum and/or 
bile salts (Guerry, 2007, Konkel et al., 1999b, Rivera-Amill et al., 2001, Malik-Kale et 
al., 2008). C. jejuni strains were grown in the presence of 0.1% (v/v) FCS (serum) and/or 
0.1% (w/v) sDOC (bile constituent). Secretion profile analysis identified no apparent 
differences between the 11168H wild-type strain and Cj0248 mutant when grown in 
culture for 16 h at 37°C under microaerobic conditions (Figure 5.10).  
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Figure 5.10. Coomassie showing secretion profile of C. jejuni 11168H wild-type strain 
and Cj0248 mutant. C. jejuni were grown in culture for 16 h at 37°C under microaerobic 
conditions with a starting OD600 of 0.1. Media supernatants were centrifuged, filter 
sterilised and concentrated. Secretion profiles were analysed by SDS-PAGE then stained 
with Coomassie Blue. Overnight cultures were supplemented with 0.1% (v/v) FCS serum 
(S) or 0.1% (w/v) sDOC (bile constituent) (B) or a combination of both. In order to semi-
quantify any differences in protein secretion between strains, the starting OD600 and 
growth conditions were standardized. 30 l of final sample were analysed by SDS-
PAGE. The data above is representative of experiments with at least three biological 
replicates, performed in triplicate. 
 
5.2.12 The 11168H Cj0248 mutant displays a reduced ability to interact (adhere and 
invade) with Caco-2 intestinal epithelial cells  
A C. jejuni 81-176 Cj0248 mutant had previously been shown to have a 100- to 10,000- 
fold reduction in the ability to colonise a chick caecal colonisation model when 
compared to the 81-176 wild-type strain (Hendrixson and DiRita, 2004). In order to 
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investigate this colonisation defect further, interaction assays were performed using co-
culture experiments with Caco-2 IECs. The Cj0248 mutant displayed a reduced ability to 
interact (adhere and invade) with Caco-2 cells after a 24 h co-culture time period 
compared with the 11168H wild-type strain (Figure 5.11). However no significant 
differences were observed when comparing the levels of interaction at 3 or 6 h. The 
Cj0248 mutant interaction data is similar to the Cj1556 mutant interaction data in that 
both mutants have a reduced ability to interact with Caco-2 cells compared to the 
11168H wild-type strain over 24 h. However the reasons for these low interaction rates 
are probably different. A reason as to why the Cj1556 mutant exhibits reduced 
interaction ability is the increased sensitivity to oxidative and aerobic (O2) stress. In 
contrast, it is probable that the Cj0248 mutant exhibits reduced interaction ability due to 
altered flagella functionality. 
 
 
 
 
Figure 5.11. Interaction assays (adhesion and invasion) on 11168H wild-type strain and 
Cj0248 mutant. C. jejuni were co-cultured with Caco-2 cells for 3, 6 or 24 h. Caco-2 
cells were lysed and numbers of interacting bacteria assessed. The asterisk denotes a 
statistically significant difference (* = p <0.05) in the interaction of the 11168H wild-
type compared to the Cj0248 mutant strain. All experimental data is represented using 
the average of at least three biological replicates performed in triplicate. Error bars 
represent the standard error of mean. Variables were compared for significance using a 
student’s t-test with one star (*) indicating p = 0.01 - 0.05. 
 
  
 201 
 
To ascertain whether the above results were due to a genuine Cj0248 mutant phenotype 
and not due to increased sensitivity to Triton X-100, stress assays were performed with 
0.2% (v/v) Triton X-100. No difference in the level of sensitivity to Triton X-100 was 
observed between 11168H wild-type strain and the Cj0248 mutant (Figure 5.12). 
 
 
 
Figure 5.12. Triton X-100 0.2% (v/v) stress assay on C. jejuni 11168H wild-type strain 
and Cj0248 mutant. C. jejuni were grown on blood agar plates for 24 h at 37°C under 
microaerobic conditions. A bacterial suspension with an OD600 of 1.0 was prepared and 
incubated with 0.2% (v/v) Triton X-100 at 37°C under microaerobic conditions for 15 
minutes. Serial dilutions (10-1 - 10-6) were performed and 10 μl volumes were spotted 
onto blood agar plates. The plates were incubated at 37°C under microaerobic conditions 
for 48 h. All experimental data is represented using the average of at least three 
biological replicates performed in triplicate. Error bars represent the standard error of 
mean.  
 
5.2.13 The 11168H Cj0248 mutant displays a reduced ability to invade Caco-2 
intestinal epithelial cells  
In addition to the interaction assays described in Section 5.2.12, the colonisation ability 
of the 11168H Cj0248 mutant was further analysed by performing invasion assays using 
co-culture experiments with Caco-2 IECs. The Cj0248 mutant displayed a reduced 
ability to invade Caco-2 cells after 3, 6 and 24 h co-culture compared with the 11168H 
wild-type strain (Figure 5.13). The difference in invasion was more significant at time 
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points 6 and 24 h compared to 3 h. Comparison of the Cj0248 mutant invasion results to 
the Cj1556 mutant invasion results showed that the Cj0248 mutant had reduced levels of 
invasion at 3, 6 and 24 h, whereas the Cj1556 mutant only showed reduced invasion at 
24 h. This concurs with the hypothesis that the differences observed specifically at 24 h 
for interaction and invasion of the Cj1556 mutant are more likely due to reduced intra- 
and extracellular survival during co-culture with Caco-2 IECs. The Cj0248 mutant has 
reduced invasion compared to the 11168H wild-type at 3, 6 and 24 h. Previous data 
suggest the Cj0248 mutant has impaired function. The invasion data correlates with the 
motility data confirming the link between the two phenotypes. 
 
 
 
 
Figure 5.13. Invasion assays on 11168H wild-type strain and Cj0248 mutant. C. jejuni 
were co-cultured with Caco-2 cells for 3, 6 or 24 h. Caco-2 cells were then incubated 
with gentamicin (150 μg/ml) for 2 h to kill extracellular bacteria, lysed and numbers of 
intracellular bacteria assessed. All experimental data is represented using the average of 
at least three biological replicates performed in triplicate. Error bars represent the 
standard error of mean. Variables were compared for significance using a student’s t-test 
with one star (*) indicating p = 0.01 - 0.05, two stars (**) indicating p = 0.001- 0.01 and 
three stars (***) p < 0.001.  
 
5.2.14 The 11168H Cj0248 mutant induces a reduced IL-6 response from intestinal 
epithelial cells  
Following on from the co-culture studies investigating the interaction and invasion 
properties of the Cj0248 mutant, further co-culture investigations were performed 
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analysing the host innate immune response. IL-6 is an interleukin that acts as both a pro-
inflammatory and anti-inflammatory cytokine and has been shown to be important for 
epithelial cell integrity (Friis et al., 2009). IL-6 is typically associated with an acute 
phase response (Heinrich et al., 1990). Interleukin-8 is a chemokine produced by 
macrophages and other cell types such as epithelial cells. Both are well-characterised 
markers denoting a host innate immune response against pathogens (Wolff et al., 1998, 
Oppenheim et al., 1991). To investigate any differences between the level of IL-6 and 
IL-8 induced by the Cj0248 mutant compared to the 11168H wild-type strain, co-culture 
experiments with two different cell lines were performed. Only minimal secretion of IL-
6 and IL-8 was detected when the 11168H wild-type strain and Cj0248 mutant were co-
cultured with Caco-2 cells (data not shown). However using a T84 cell line, significant 
levels of induction of both IL-6 and IL-8 by the 11168H wild-type strain and Cj0248 
mutant were observed (Figure 5.14). There was no significant difference in the level of 
IL-8 induction by the Cj0248 mutant compared to the 11168H wild-type strain, however 
a significant reduction in the level of IL-6 induction by the Cj0248 mutant compared to 
the 11168H wild-type strain was observed (Figure 5.14). Comparison between the level 
of IL-8 induction by the Cj0248 mutant and the Cj1556 mutant revealed no difference 
when co-cultured with T84 cells for 24 h. However both mutants induced a reduced IL-6 
secretion compared to the 11168H wild-type strain when co-cultured with T84 cells for 
24 h. The Cj1556 mutant IL-6 induction data was recorded at approximately 70 pg/ml, 
whereas the Cj0248 mutant IL-6 induction data was recorded at approximately 45 pg/ml. 
There may be some biological significance to these results as IL-6 has been shown to be 
important for epithelial cell integrity (Friis et al., 2009). This data suggests, i) that 
bacterial ability to invade and survive within IECs is more important in IL-6 induction 
than IL-8 induction, ii) a Cj0248 mutant with reduced invasion leads to less IL-6 
secretion from host cells when compared to a Cj1556 mutant with reduced survival 
properties. 
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A) 
 
B) 
  
 
Figure 5.14. Analysis of host innate immune response during 11168H wild-type strain 
and Cj0248 mutant infection. C. jejuni were co-cultured with T84 IECs for 24 h and the 
levels of IL-8 and IL-6 secreted were quantified using either a human IL-8 ELISA (A) or 
IL-6 ELISA (B). All experimental data is represented using the average of at least three 
biological replicates performed in triplicate. Error bars represent the standard error of 
mean. Variables were compared for significance using a student’s t-test with one star (*) 
indicating p = 0.01 - 0.05, two stars (**) indicating p = 0.001- 0.01 and three stars (***) 
p < 0.001.  
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5.2.15 Galleria mellonella exhibit decreased survival rates when injected with 
11168H Cj0248 mutant 
G. mellonella larvae have recently been used as a model to study infection by C. jejuni 
and other bacteria (Champion et al., 2009). Insect larvae such as G. mellonella are 
favorable to use as non-mammalian infection models as they can be infected at 37°C and 
possess specialized phagocytic cells, termed haemocytes (Mylonakis et al., 2007, Bergin 
et al., 2005). Haemocytes mimic the functions of phagocytic cells in mammals and are 
able to degrade bacterial pathogens and also generate bactericidal compounds such as 
superoxide via a respiratory burst (Bergin et al., 2005, Lavine and Strand, 2002). When 
G. mellonella were injected with both 11168H wild-type strain and the Cj0248 mutant, 
surprisingly injection with the Cj0248 mutant resulted in decreased survival levels of G. 
mellonella larvae after 24 h infection (Figure 5.15) compared to the 11168H wild-type 
strain. One hypothesis to explain this result is that as C. jejuni is directly injected into the 
G. mellonella larvae, there is essentially no requirement for the bacterium to adhere and 
invade and as such the Cj0248 mutation does not attenuate C. jejuni virulence in this 
model. 
 
 
 
Figure 5.15. G. mellonella survival assay on 11168H wild-type strain and Cj0248 
mutant. G. mellonella larvae were injected with a 10 l inoculum of a 24 h C. jejuni 
culture diluted to OD600 0.1 by micro-injection in the right foremost leg, giving an 
infectious dose of ≈ 106 CFU. Larvae were incubated at 37°C with survival and 
appearance recorded at 24 h intervals. All experimental data is represented using the 
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average of at least three biological replicates performed in triplicate. Error bars represent 
the standard error of mean. Variables were compared for significance using a student’s t-
test with one star (*) indicating p = 0.01 - 0.05.  
 
5.2.16 The 11168H Cj0248 mutant exhibits increased sensitivity to heat stress  
In order to investigate the potential for other phenotypic changes induces by mutation of 
the Cj0248 gene, a number of stress assays were performed. One such assay was heat 
stress. Several C. jejuni heat shock responses have been identified and characterised that 
contribute to maintenance of viability. These include the HtrA protease and the HspR 
regulator that have already been noted as playing a role in aerobic (O2) stress, however 
their primary role is with heat tolerance (Brondsted et al., 2005). C. jejuni also contains 
homologues of well known chaperones and proteases e.g. GroESL, DnaK and HrcA 
(Parkhill et al., 2000). These are also referred to as heat shock proteins. Heat stress above 
55°C has been noted to accelerate the spiral-to-coccoid transition and result in cell death 
(Nguyen et al., 2006). A range of heat stress experiments on the 11168H wild-type strain 
and C. jejuni Cj0248 mutant were performed to explore any potential role of Cj0248 in 
heat response. No differences were observed when using 42°C for 1 h or 55°C for 15 
mins respectively. However the Cj0248 mutant did display increased sensitivity to 60°C 
when exposed for 5 minutes (Figure 5.16). 
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Figure 5.16. Heat stress assay on C. jejuni 11168H wild-type strain and Cj0248 mutant. 
C. jejuni strains were incubated at 60°C for 5 minutes and bacterial survival assessed. All 
experimental data is represented using the average of at least three biological replicates 
performed in triplicate. Error bars represent the standard error of mean. Variables were 
compared for significance using a student’s t-test with one star (*) indicating p = 0.01 - 
0.05.  
 
5.2.17 The 11168H Cj0248 mutant exhibits similar levels of sensitivity to oxidative 
and nitrosative stress 
Oxidative stress assays were performed using H2O2 as described in Section 2.3.4. 
Nitrosative stress assays were performed using acidified NaNO2 as described in Section 
2.3.5. No differences between the survival of the 11168H wild-type strain and Cj0248 
mutant were observed in either stress assay (data not shown).  
 
 5.2.18 The 11168H Cj0248 mutant reveals unaltered growth kinetics during growth 
inhibition studies  
Following on from the stress assays, growth inhibition assays were performed as 
described in Sections 2.3.6-9 to ascertain whether any modification in growth kinetics 
was observed due to the addition of certain compounds. Growth inhibition studies were 
performed using conditions to represent both oxidative and nitrosative inhibition. No 
differences were observed between the 11168H wild-type strain and the Cj0248 mutant 
for oxidative (Figure 5.17) and nitrosative (Figure 5.18) growth inhibition. Growth 
inhibition studies of the Cj0248 mutant in broth supplemented with 0.1% (w/v) sDOC 
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showed no difference compared to the 11168H wild-type strain (Figure 5.19). In 
addition, no differences were observed between the 11168H wild-type strain and Cj0248 
mutant during growth in broth supplemented with the iron chelator deferoxamine (Figure 
5.20). 
 
 
 
Figure 5.17. Oxidative stress growth inhibition assays on C. jejuni 11168H wild-type 
strain and Cj0248 mutant. C. jejuni were grown in the presence of 1 mM H2O2. Flasks 
were incubated at 37°C under microaerobic conditions, shaking at 75 rpm. OD600 
readings were recorded at 6, 24 and 48 h.  All experimental data is represented using the 
average of at least three biological replicates performed in triplicate. Error bars represent 
the standard error of mean.  
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Figure 5.18. Nitrosative stress growth inhibition assays on C. jejuni 11168H wild-type 
strain and Cj0248 mutant. C. jejuni were grown in the presence of 0.1 mM NaNO2 at pH 
5. Flasks were incubated at 37°C under microaerobic conditions, shaking at 75 rpm. 
OD600 readings were recorded at 6, 24 and 48 h. All experimental data is represented 
using the average of at least three biological replicates performed in triplicate. Error bars 
represent the standard error of mean.  
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Figure 5.19. Bile stress growth inhibition assays on C. jejuni 11168H wild-type strain 
and Cj0248 mutant. C. jejuni were grown in the presence of 0.1% sDOC. Flasks were 
incubated at 37°C under microaerobic conditions, shaking at 75 rpm. OD600 readings 
were recorded at 6, 24 and 48 h.  All experimental data is represented using the average 
of at least three biological replicates performed in triplicate. Error bars represent the 
standard error of mean.  
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Figure 5.20. Iron limitation growth inhibition assays on C. jejuni 11168H wild-type 
strain and Cj0248 mutant. C. jejuni were grown in the presence of 1 mM deferoxamine. 
Flasks were incubated at 37°C under microaerobic conditions, shaking at 75 rpm. OD600 
readings were recorded at 6, 24 and 48 h.  All experimental data is represented using the 
average of at least three biological replicates performed in triplicate. Error bars represent 
the standard error of mean.  
 
5.2.19 Complementation of the Cj0248 mutant 
After a number of technical difficulties, complementation of the 11168H Cj0248 mutant 
was successfully achieved. Complementation was performed by inserting a copy of the 
Cj0248 CDS into the 11168H Cj0248 mutant chromosome using pDENNIS, a C. jejuni 
11168H complementation vector allowing the insertion of a functional CDS into the 
Cj0223 pseudogene (Hitchen et al., 2010). The entire coding region for Cj0248 was 
amplified by PCR using primers Comp-Cj0248-F and Comp-Cj0248-R, which 
introduced an NcoI site at the 5’ end and an NheI site at the 3’ end as well as including 
the ribosome binding site of Cj0248 (Svensson et al., 2008, Wosten et al., 1998). 
Following digestion with NheI and NcoI, this PCR product was ligated into the 
pDENNIS vector. This construct was sequenced to ensure there were no mutations in the 
Cj0248 nucleotide sequence. This construct was electroporated into the 11168H Cj0248 
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mutant and grown on blood agar plates. Cells were harvested and resuspended in 0.5 ml 
PBS. 200 μl of this suspension was spread onto blood agar plates containing kanamycin 
and chloramphenicol. Putative clones were restreaked and confirmed by PCR checking 
for the correct distance between Cj0248 and the inserted KmR cassette (Cj0248-F and 
KmR forward-out). This confirmed the presence of the mutated CDS with the KmR 
cassette in the correct orientation. In addition, PCR was used to confirm the presence of 
an intact CDS (Cj0248-F and Cj0248-R). Sequencing was also used to confirm positive 
clones.  
 
Motility assays were performed with the 11168H wild-type strain, Cj0248 mutant and 
Cj0248 complement. Partial resuscitation of the motility phenotype was observed with 
the Cj0248 complement (Figure 5.21). This data gives further evidence that Cj0248 is 
directly involved in flagella functionality and the severely reduced motility phenotype 
observed from the Cj0248 mutant is a direct consequence from inhibiting expression of 
Cj0248.  
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Figure 5.21. Motility assay comparing the 11168H wild-type strain, Cj0248 mutant and 
Cj0248 complement on semi-solid surfaces. C. jejuni from an overnight culture was 
adjusted to an OD600 of 1.0. 5 µl of this suspension was pipetted into the centre of a 
motility plate using a Gilson pipette (P10). Plates were incubated at 37°C under 
microaerobic conditions and plate images were recorded at 24, 48 and 72 h. Motility was 
assessed by measuring the diameter of the halo on the plate. All experimental data is 
represented using the average of at least three biological replicates performed in 
triplicate. Error bars represent the standard error of mean. Variables were compared for 
significance using a student’s t-test with one star (*) indicating p = 0.01 - 0.05 and two 
stars (**) indicating p = 0.001- 0.01.  
 
5.3 Discussion  
Motility is central to the pathogenesis of C. jejuni via active multi-functional flagella that 
allow adhesion to and invasion of IECs. A C. jejuni 81-176 Cj0248 mutant had 
previously been shown to have a severely reduced motility phenotype (Hendrixson et al., 
2001). Cj0248 has thus been implicated with a role in motility, though the function 
remained unknown. The 11168H Cj0248 mutant displayed reduced motility when 
compared to the wild-type strain and this data mirrored the C. jejuni 81-176 data 
observed previously (Hendrixson et al., 2001). To further investigate this phenotype, 
autoagglutination studies were performed. In Campylobacter species, autoagglutination 
has been shown to be mediated by flagella (Guerry et al., 2006). Autoagglutination has 
been described as a preliminary step in the formation of microcolonies (Misawa and 
  
 214 
Blaser, 2000) and  microcolony formation has been identified as an important 
preliminary step in biofilm formation (Haddock et al., 2010). Autoagglutination studies 
were performed and no differences were observed between the 11168H wild-type strain 
and Cj0248 mutant. This data suggests the Cj0248 mutant does possess complete or 
partial flagella and yet the motility data suggests the flagella have impaired function. 
Investigation of biofilm formation showed that the Cj0248 mutant has reduced ability to 
form biofilms compared to the 11168H wild-type strain. Previous research has indicated 
that flagella have an important role in biofilm formation conspiring to facilitate survival 
of this microaerophilic organism in water and under other harsh environmental 
conditions (Guerry, 2007). Taken together, the motility and autoagglutination data 
suggest the Cj0248 mutant has complete or partial flagella, but with impaired function. 
The biofilm data suggests flagella with impaired function may result in decreased 
biofilm formation possibly as a result of less microcolony formation. It is possible 
Cj0248 is directly involved in biofilm formation, though the observed phenotypes are 
more likely due to flagella with impaired function. The presence of flagella was 
confirmed using TEM for both the 11168H wild-type strain and Cj0248 mutant. This 
concurs with the motility, autoagglutination and biofilm data that flagella are present and 
the observed phenotypes are most likely due to a lack of functionality. It remains to be 
proved whether flagella with impaired function result in reduced microcolony formation, 
though it is a possibility as reduced biofilm formation was observed. An important point 
to note is that these biofilm assays were performed in vitro. Any future experiments 
focussing on microcolony or biofilm formation using IECs such as Caco-2 would prove 
negative as C. jejuni does not form biofilms on such tissue culture cells as they do not 
secrete mucin. However, using tissue culture cells such as mucin-secreting HT29 cells or 
ex vivo organ culture assays could be utilised to further investigate this phenotype.  
 
Effective regulation of gene expression in C. jejuni is critical for bacterial survival. The 
C. jejuni genome contains three sigma factors: RpoD (σ70), RpoN (σ54) and FliA (σ28) 
along with 34 transcription factors identified to date (Wösten et al., 2008). RpoD is the 
main sigma factor allowing binding of the RNA polymerase to the majority of C. jejuni 
promoters. RpoN has been noted to have at least 17 putative RpoN promoters in the 
genome (Wösten et al., 2008, Carrillo et al., 2004). The 17 identified RpoN promoters of 
C. jejuni control the transcription of 23 genes, of which 15 encode proteins that are 
involved in the assembly of the flagella (Wösten et al., 2008, Carrillo et al., 2004). FliA 
is a sigma factor that has been found to regulate the activity of at least 10 promoter sites 
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in C. jejuni that direct the transcription of 14 different genes (Wösten et al., 2008, 
Carrillo et al., 2004). These genes encode proteins involved in flagella apparatus 
biosynthesis, proteins involved in the glycosylation of the major flagellin subunits and 
proteins secreted through the flagella (Logan et al., 2002). fliA mutants are non-motile 
but still possess a flagella hook structure (Hendrixson et al., 2001, Jagannathan et al., 
2001).  
 
Flagella have been shown to be involved in not just motility and chemotaxis but also the 
putative secretion of virulence proteins, autoagglutination, microcolony formation and 
avoidance of the innate immune response (Guerry, 2007). Previous studies have 
demonstrated that mutations in genes involved in flagella biosynthesis are non-motile 
and result in reduced intestinal colonisation of animals and humans and for the invasion 
of IECs in vitro (Pavlovskis et al., 1991, Guerry, 2007, Nachamkin et al., 1993). The 
secretion of Cia proteins is also dependent on a functional flagellum, indicating that this 
organelle has a dual function in motility and as a type III secretion system (Konkel et al., 
2004). Cia proteins have been identified from culture supernatant when C. jejuni was 
grown in the presence of IECs (Konkel et al., 2004, Konkel et al., 1999b, Young et al., 
1999). The expression of genes encoding these proteins is further induced in the presence 
of other compounds such as serum and bile salts (Guerry, 2007, Konkel et al., 1999b, 
Rivera-Amill et al., 2001, Malik-Kale et al., 2008). Secretion of Cia proteins were not 
detected in a flhB mutant (defective in inner membrane export apparatus) or in flgBCE 
mutants (defective for the basal body and hook apparatus) (Larson et al., 2008). 
Secretion of Cia proteins occurred in both a flaA mutant and flaB mutant, but not a 
double flaA flaB mutant that completely lacked a flagella filament (Konkel et al., 2004). 
Secretion of Cia proteins requires a functional basal body and hook and at least one of 
the filament proteins (Konkel et al., 2004). The putative role of flagella as a secretory 
apparatus has proved controversial. Watson and Galan argue that there is little evidence 
that any component of the flagella apparatus directly secretes proteins involved in 
invasion when in contact with IECs (Watson and Galán, 2008). These authors argue that 
previous research shows that gene mutations causing a reduced motility phenotype, but 
not affecting the structure of the flagella apparatus, show reduced invasion into host 
IECs (Yao et al., 1994). Their argument is that these mutants, though non-motile, still 
harbour fully secretion positive flagella and so should be able to secrete the proposed 
virulence proteins.  
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The flagellum is a key virulence factor for C. jejuni enabling motility and intestinal 
colonisation (Hendrixson, 2006, Hendrixson and DiRita, 2004). To further investigate 
the reduced motility phenotype, interaction (adhesion and invasion) and invasion assays 
using Caco-2 IECs were performed. No significant difference was observed in the level 
of interaction between the 11168H wild-type and the Cj0248 mutant after 3 and 6 h co-
culture. However, a significant decrease in the level of interaction was observed after 24 
h. Both the Cj0248 mutant and the 11168H wild-type strain exhibit a similar level of 
autoagglutination, however the Cj0248 mutant exhibits a reduced level of biofilm 
formation compared to the 11168H wild-type. It is possible that the reduction in flagella 
functionality in the Cj0248 mutant results in decreased microcolony formation and as 
such the decrease in the level of interaction observed after 24 h when comparing the 
Cj0248 mutant to the 11168H wild-type may be due to this reduction in the ability to 
form microcolonies. Assessing the numbers of viable 11168H wild-type and Cj0248 
mutant present after 24 h co-culture did not reveal any difference and this suggests that 
long term survival is not a factor (data not shown). Comparison between Cj0248 mutant 
and Cj1556 mutant reveal both have a reduction in interaction at 24 h compared to the 
11168H wild-type strain. However it is probable these results are due to different 
reasons. The Cj1556 mutant has been shown to have increased sensitivity to oxidative, 
aerobic (O2) stress and reduced aerobic survival in tissue culture media compared to 
Cj0248 mutant. Thus, the low interaction data for Cj1556 mutant is more likely due to 
less numbers being present after 24 h, rather than a reduction in interaction ability. This 
is in contrast to the Cj0248 mutant which has a reduced motility and potentially reduced 
microcolony formation and thus has a reduced ability to adhere and invade. It is also 
important to remember that this interaction data investigates the numbers of bacteria 
adhered and invaded.  
 
To investigate invasion specifically, invasion assays were performed and identified a 
significant reduction in the level of invasion of the Cj0248 mutant compared to the 
11168H wild-type strain after 3, 6 and 24 h co-culture. The reduction in the level of 
invasion was more significant at time points 6 and 24 h compared to 3 h. The invasion 
results for the Cj0248 mutant show different invasion dynamics when compared to the 
Cj1556 mutant results. The Cj0248 mutant shows reduced invasion at 3, 6 and 24 h, 
whereas the Cj1556 mutant only exhibits reduced invasion at 24 h. This Cj1556 mutant 
invasion data matches the interaction data for the Cj1556 mutant, as significant 
reductions were only observed after 24 h indicating the results are more likely due to 
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reduced survival properties. Given that the Cj0248 mutant has a reduced motility 
phenotype, it is likely the invasion phenotypes observed after 3, 6 and 24 h co-culture are 
linked to flagella with impaired function. Previous studies have demonstrated a 100- to 
10,000- fold reduction in colonisation using a chick caecal colonisation model for the 81-
176 Cj0248 mutant compared to the 81-176 wild-type strain (Hendrixson and DiRita, 
2004). This previous investigation focussed on colonisation ability, whereas these studies 
analysed the interaction and invasion properties over time using IECs.  
   
Based on the reduced motility, biofilm, interaction and invasion phenotypes observed of 
Cj0248 mutant compared to the 11168H wild-type strain, investigation into the host 
innate immune response was performed. IL-6 is an interleukin that acts as both a pro-
inflammatory and anti-inflammatory cytokine and has been shown to be important for 
epithelial cell integrity (Friis et al., 2009). IL-8 acts as a chemoattractant allowing the 
recruitment of lymphocytes and neutrophils (Hobbie et al., 1997, Philpott et al., 2000). 
Both are well-characterised markers denoting a host innate immune response against 
pathogens (Wolff et al., 1998, Oppenheim et al., 1991). Minimal IL-6 and IL-8 was 
detected when the 11168H wild-type strain and Cj0248 mutant were co-cultured with 
Caco-2 cells (data not shown). This concurs with research demonstrating the poor 
chemokine/cytokine induction ability of Caco-2 cells when co-cultured with C. jejuni 
(MacCallum et al., 2006). However using a T84 cell line, significant levels of induction 
of both IL-6 and IL-8 by the 11168H wild-type strain and Cj0248 mutant were observed. 
Previous reports have demonstrated ELISA experiments using T84 cells to detect levels 
of IL-8 and IL-6 over 1000 pg/ml when co-cultured with C. jejuni (MacCallum et al., 
2006). In this study, these levels were not achieved most likely due to a number of 
factors that are discussed in Section 4.3. However, the trends observed in this study using 
T84 cells would most likely be consistent if the increased level of chemokine/cytokine 
induction was achieved by modifications to the experimental protocol. 
 
In this study, there was no significant difference in the level of IL-8 induction by the 
Cj0248 mutant compared to the 11168H wild-type strain, however a significant 
reduction in the level of IL-6 induction by the Cj0248 mutant compared to the 11168H 
wild-type strain was observed. It is possible that the reduced IL-6 induction by the 
Cj0248 mutant when co-cultured with T84 cells is a result of less interaction with IECs 
due to flagella with impaired function. This hypothesis would be supported by the fact 
that reduced invasion has been observed for the Cj0248 mutant when compared to the 
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11168H wild-type strain. Comparison between the level of IL-6 detected from T84 cells 
after co-culture with the Cj0248 and Cj1556 mutants revealed less induction for the 
Cj0248 mutant (45 pg/ml) compared to the Cj1556 mutant (70 pg/ml). This data suggests 
that, i) bacterial ability to invade and survive within IECs are important in IL-6 
induction, ii) a Cj0248 mutant with reduced motility and invasion ability induces less IL-
6 secretion when co-cultured with T84 cells compared to a Cj1556 mutant with increased 
sensitivity to oxidative and aerobic (O2) stress. 
 
The results of the G. mellonella studies identified a decreased survival of G. mellonella 
larvae when infected with Cj0248 mutant compared to infection with the 11168H wild-
type strain. The innate immune system of G. mellonella has a high degree of structural 
and functional homology with the innate immune system of mammals, with the defence 
against bacteria involving both cellular mechanisms such as phagocytosis, nodulization 
and encapsulation, along with humoral mechanisms like melanisation, haemolymph 
clotting and antimicrobial peptide production (Champion et al., 2009). A Cj0248 mutant 
with putative flagella with impaired function may have been assumed to have resulted in 
increased survival of G. mellonella. However, G. mellonella studies identified decreased 
survival when injected with Cj0248 mutant. One hypothesis to explain this result is that 
C. jejuni is directly injected into the G. mellonella and so there is essentially no 
requirement for the bacterium to adhere and invade. One method of analysing if this was 
true would be to feed C. jejuni to the larvae, though the feasibility of this has yet to be 
ascertained. This data would suggest there is actually no reduction in the level of 
virulence and survival of the Cj0248 mutant once internalised.  
  
Based on the reduced motility, interaction and invasion phenotypes of the Cj0248 mutant 
compared to the 11168H wild-type strain, microarray expression analysis was performed 
on the Cj0248 mutant comparing to the 11168H wild-type strain where RNA was 
isolated from bacterial culture grown to the late-log phase (16 h). Up- and down-
regulated genes were identified from the study and flgB (Cj0528c) and flgC (Cj0527c) 
were identified as being 1.55 and 4.48 fold down-regulated in the Cj0248 mutant. Both 
of these down-regulated genes encode part of the rod section of the flagella, part of the 
basal body between the cytoplasm and outer membrane (Konkel et al., 2004, Saijo-
Hamano et al., 2004). C. jejuni flgB or flgC mutants are defective for both motility and 
secretion (Konkel et al., 2004), so the decrease in expression of these genes may be 
significant in understanding why Cj0248 mutant exhibits severely reduced motility and 
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interaction with IECs. The results in this study are in partial agreement with previous 
research where flgB or flgC mutants are defective for both motility and secretion. The 
Cj0248 mutant does have a reduced motility phenotype compared to the 11168H wild-
type strain, however based on the secretion profile study did not identify any differences 
between the Cj0248 mutant and the 11168H wild-type strain. The reduced expression of 
flgB or flgC may or may not be sufficient to give similar phenotypic results as flgB or 
flgC mutants have. Also, given that secretion mechanisms rely on a functional basal body 
(Konkel et al., 2004), it is possible that mutation of Cj0248 has an effect on this 
particular structure and thus not only reducing motility, but also the invasiveness of the 
bacterium by inhibiting protein secretion via the flagella. However, preliminary secretion 
profile analysis identified no apparent differences between the 11168H wild-type strain 
and Cj0248 mutant when grown in culture for 16 h at 37°C under microaerobic 
conditions in vitro. Interestingly, flhA was 1.8 fold up-regulated. flhA encodes a protein 
involved in the biosynthesis of the export component of the flagella system that resides 
in the cytoplasm. FlhA is a key component of the flagella export apparatus which 
belongs to the FHIPEP (flagella/Hr/invasion proteins export pore) family of bacterial 
export proteins involved in flagella assembly and type III secretion (Carrillo et al., 2004, 
Park et al., 2000, Galan et al., 1992). FlhA has been associated with a role in 
pathogenesis as an flhA mutant strain has been shown to affect motility, 
autoagglutination and invasion (Hendrixson and DiRita, 2003, Golden and Acheson, 
2002). Genes encoding flagella proteins have been grouped into three classes based on 
the order of transcription (Carrillo et al., 2004). Class I include genes encoding the 
flagella transport apparatus and have RpoD (σ70) promoters (Petersen et al., 2003). FlhA 
forms part of this flagella transport apparatus. Class II genes with RpoN (σ54) promoters 
are required for the basal body, hook and flagella filament biosynthesis. Class III genes 
with FliA (σ28) promoters include genes required for filament biosynthesis. Mutation of 
flhA inhibits transcription of both class II and class III flagella genes and potential 
virulence factors regulated by FliA (σ28) and RpoN (σ54) (Carrillo et al., 2004). The 
functions of FlgB, FlgC and FlhA all relate to flagella and so a lack of Cj0248 may be 
causing the expression changes observed in this study. This may suggest a compensatory 
effect where the Cj0248 mutant has a reduction in flgB and flgC expression, leading to 
increased expression of flhA to attempt to increase expression of flgB and flgC. Further 
investigate is required to elucidate this potential link.    
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Results from the microarray data led us to focus on the flagella basal body region as 
potentially being important in Cj0248 function. The TEM images were analysed at 
greater magnification and specifically looked at the flagella basal body region. Putative 
structural defects in the flagella basal body region were identified in the Cj0248 mutant 
when compared to the 11168H wild-type strain. The TEM images were replicated using 
a number of different Cj0248 mutant clones and also using different Cj0248 mutants 
produced from newly electroporated constructs. The 11168H wild-type strain contains a 
putative defined layered flagella basal body structure however the Cj0248 mutant 
contains a putative altered flagella basal body region (see figures 5.7 and 5.8). The TEM 
data suggests that the flagella basal body region appears to either not have formed or has 
been altered in the Cj0248 mutant. Interestingly, the altered flagella basal body region 
appears to be varied in structure. This variation was observed on all replicate samples. 
There does not seem to be one specific altered structure, but a varied level of structural 
alteration. No links were identified between the Cj0248 protein and any of the flagella 
associated proteins in the Campylobacter Protein Interaction Database (Parrish et al., 
2007), however flgB and flgC were identified as being down-regulated in the Cj0248 
mutant compared to the 11168H wild-type strain in this study. It is possible that the 
mutation of Cj0248 has affected the expression of basal body encoding genes and thus 
affected flagella functionality specifically. Further studies could focus on the localisation 
of Cj0248 to ascertain whether the protein location is indeed around the bacterial 
membrane region in proximity of the flagella. 
  
Given the putative secretion of Cia proteins is dependent on a functional flagellum 
(Konkel et al., 2004), further investigations into the secretion profile of the 11168H 
wild-type strain and the Cj0248 mutant were performed. Previous studies have shown 
that protein secretion via a functional flagellum was not detected when C. jejuni was 
incubated in the absence of IECs (Konkel et al., 2004). However in this study, in vitro 
conditions were used with the addition of serum (FCS) and/or sDOC to induce increased 
expression of Cia proteins. No differences were observed when analysing the secretion 
profiles of the 11168H wild-type strain and the Cj0248 mutant in the presence of FCS 
and/or sDOC in vitro. The secretion profile data does not suggest any difference in the 
ability of the Cj0248 mutant strain to secrete proteins, however analysis of the coomassie 
stain by eye is insufficient to make this statement. There may be multiple proteins 
present within a single band, thus proteomics analysis would determine the exact protein 
composition. Hence, this data suggests the reduced motility and invasion phenotype of 
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the Cj0248 mutant are a result of a lack of rotational functionality of the flagella rather 
than a lack of secretion ability. This would support the view of Watson and Galan who 
argue that there is little evidence that any component of the flagella apparatus is directly 
secreting proteins involved in invasion when in contact with IECs and that invasion is a 
property of being motile via a functional flagella (Watson and Galán, 2008). Further 
investigation into the secretion profile could be performed by silver-staining to ascertain 
if any proteins are present or absent from the Cj0248 mutant secretion profile. In 
addition, analysis of the secretion profile from C. jejuni co-cultured with IECs could also 
be performed. 
 
Microarray data was analysed to further investigate possible Cj0248 function. CmeR has 
been characterised as the regulator for the CmeABC efflux pump and cmeR expression 
was shown to be 5.16 fold down-regulated in the Cj0248 mutant compared to the 
11168H wild-type. CmeR regulates genes encoding membrane transporters, proteins 
involved in C4-dicarboxylate transport and utilization, enzymes for biosynthesis of CPS, 
and hypothetical proteins with unknown functions (Guo et al., 2008). Deletion of cmeR 
or mutation in the CmeR-binding site impedes the repression and results in 
overexpression of cmeABC (Lin et al., 2005). The CmeABC efflux pump contributes to 
Campylobacter resistance to various antimicrobial agents and bile compounds present in 
the intestinal environment (Lin et al., 2002, Lin et al., 2003). The exact link between 
Cj0248 and CmeR is currently unknown. Finally, cbrR – a Campylobacter bile resistance 
regulator was identified as being 1.40 fold up-regulated. A cbrR mutant strain is unable 
to survive in the presence of bile salts and other detergents and poorly colonizes 
experimentally inoculated chickens (Raphael et al., 2005). Interestingly, both CmeABC 
and CbrR have been associated with bile stress resistance.  
  
In addition to the above, expression of cheA and cheV were identified as 1.74 and 1.60 
fold down-regulated. Both of these proteins are involved in chemotaxis that specifically 
link to the flagella (Korolik and Ketley, 2008). A key element in flagella motility is 
chemotaxis which influences the movement of bacteria toward appropriate 
environmental and host niches that support ideal bacterial growth and away from 
components that are less beneficial for growth or harmful to the organism (Hendrixson, 
2008). A two-component regulatory system, CheAY controls chemotaxis in response to 
environmental stimuli. The binding of the signal ligand is relayed by the MCP to CheA, 
a histidine kinase that forms a complex with the MCP in conjunction with CheW (Chang 
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and Miller, 2006, Hendrixson et al., 2001). CheV is a composite protein that consists of 
an N-terminal CheW domain fused to a C-terminal response regulator domain (Korolik 
and Ketley, 2008, Rosario et al., 1994). CheA autophosphorylates and subsequently 
phosphorylates CheY, the response regulator (Young et al., 2007). Phosphorylated CheY 
interacts with FliM of the flagella motor to initiate movement (Yao et al., 1997). It is 
possible Cj0248 may be affecting flagella biosynthesis indirectly by affecting 
chemotaxis related genes. In addition, C. jejuni lacks a homologue of the phosphatase 
CheZ (which dephosphorylates CheY), but does possess a homologue of the poorly 
understood protein CheV (Marchant et al., 2002, Young et al., 2007, Parkhill et al., 
2000). CheV has an amino terminal CheW-like domain and a carboxyl terminal CheY-
like domain that has been hypothesised to act as a phosphate sink for the chemotaxis 
signal-transduction machinery (Young et al., 2007, Marchant et al., 2002, Pittman et al., 
2001). It is believed this may ameliorate the effect of the absence of a CheZ phosphatase 
on phosphate flow through this signal-transduction pathway (Young et al., 2007, 
Marchant et al., 2002). Given that Cj0248 contains a HD motif and the putative function 
as a possible phosphohydrolase or a signal transduction protein, it is possible Cj0248 has 
a role relating to chemotaxis or even fulfilling the missing role of CheZ? Further studies 
would be to investigate the enzymatic function as a phosphohydrolase and also to 
perform chemotaxis assays comparing the Cj0248 mutant to the 11168H wild-type 
strain. 
 
Movement of C. jejuni is either based on a tumbling mode induced by clockwise-rotating 
dissociated flagella or a smooth, straight swimming mode induced by anti-clockwise 
flagella rotation (Korolik and Ketley, 2008). Tumbling motion is performed to allow 
reorientation, whereas the straight motion is used by the bacterium to swim to a specific 
concentration gradient (Korolik and Ketley, 2008). Importantly, in the absence of 
chemoattractants, autophosphorylation of CheA is inhibited and CheY is not 
phosphorylated (Korolik and Ketley, 2008). The signal transduction pathway is initiated 
by the MCP sensory receptors described above. The interaction between CheY and FliM 
determines the type of movement, as studies in E. coli have shown phosphorylated CheY 
need to occupy at least 70% of the available FliM molecules in the basal body for a 
change of rotational direction to occur (Bren and Eisenbach, 2001). It is predicted that 
when CheY binds to FliM in the flagella motor complex, this leads to a clockwise 
rotation, resulting in tumbling of the cell (Falke et al., 1997, Korolik and Ketley, 2008, 
Bren and Eisenbach, 2001, Spohn and Scarlato, 2001). In contrast, if a chemoattractant is 
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bound to the MCP, this leads to suppression of CheA activity which in turn leads to less 
CheY binding to FliM and hence a return to anti-clockwise rotation leading to swimming 
(Falke et al., 1997, Korolik and Ketley, 2008, Bren and Eisenbach, 2001). Expression of 
cheA has been identified as being 1.74 down-regulated and so there may be a direct or 
indirect role for Cj0248 in terms of the type of movement or even a defective movement 
phenotype, though suppression of CheA has been noted to lead to swimming as opposed 
to tumbling of the bacterium (Colegio et al., 2001, Jahreis et al., 2004). 
 
5.4 Conclusion 
Motility is central to the pathogenesis of C. jejuni via active flagella that allow adhesion 
to and invasion of IECs. This study described the characterisation of a C. jejuni 11168H 
mutant. Cj0248 was previously implicated in flagella functionality and pathogenesis. In 
this study the role of Cj0248 in C. jejuni pathogenesis was further investigated by 
performing a number of phenotypic assays such as growth kinetics, motility, interaction 
and invasion assays to enhance our understanding of this CDS. It is interesting to note 
that Cj0248 homologues are present in almost all strains and species and even related 
species. The Cj0248 mutant produced a severely reduced motility and biofilm formation 
phenotype compared to the 11168H wild-type strain. The Cj0248 mutant also exhibited 
decreased interaction and invasion at specific time points with Caco-2 cells compared to 
the 11168H wild-type strain. TEM analysis identified the presence of flagella, and with 
the aid of microarray expression data, TEM was used to identify putative altered flagella 
basal body structures in the Cj0248 mutant compared to the 11168H wild-type strain. 
The Cj0248 mutant induced a reduced IL-6 response from T84 cells, but not IL-8 when 
compared to 11168H wild-type strain. This data indicates the 11168H Cj0248 protein is 
involved in motility functionality within C. jejuni affecting the ability to adhere and 
invade and thus the pathogenicity of the organism. Further studies are required to 
identify the function of Cj0248 and to add to the understanding of C. jejuni pathogenesis.   
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Chapter 6: Final discussion 
 
6.1 Study objectives 
This investigation sought to perform a re-annotation of the C. jejuni NCTC11168 
genome sequence followed by the selection of CDSs with unknown function with 
putative roles in virulence, signal transduction or regulation of gene expression. Re-
annotation of the NCTC11168 genome sequence resulted in the selection of 15 CDSs for 
further study. The selection of these 15 CDSs was based on a number of different criteria 
such as newly identified motifs along with literature searches. Following the successful 
construction of eight defined isogenic C. jejuni 11168H mutants, a number of 
preliminary phenotypic assays such as growth kinetics, motility, interaction and invasion 
assays were performed. The Cj0248 and Cj1556 mutants displayed the most interesting 
phenotypic results and were selected for further investigation and characterisation.  
 
6.2 Re-annotation of the C. jejuni NCTC11168 genome sequence 
The first goal of this research project was to perform a full re-annotation of the C. jejuni 
NCTC11168 genome sequence. This was performed in collaboration with the WTSI. The 
original annotation was completed in 2000 (Parkhill et al., 2000) and this genome 
sequence rapidly became a valuable resource leading to a renewed impetus on 
Campylobacter research. The re-annotation led to 299 (18.2%) of CDS product functions 
being updated, which is a significant portion of the whole genome. In addition, 1489 
(90.0%) of CDSs had additional information added regarding new motifs or literature 
findings. The re-annotation process identified 20 additional CDSs linked to ‘small 
molecule metabolism’, six additional CDSs linked to ‘broad regulatory functions’, 26 
additional CDSs linked to ‘cell process’ and 77 CDSs linked to ‘miscellaneous’ 
functions. The latter function relates to CDSs with new motifs that have not yet been 
linked to a specific function. Interestingly, 122 CDSs were removed from the ‘unknown 
and other’ category mainly due to the assignment of CDSs with new motifs. Arguably 
the greatest updates have been with the four loci within C. jejuni encoding the N- and O-
linked glycosylation systems, CPS and LOS biosynthesis. Over the last decade, the CDSs 
within these loci have been characterised and this has greatly enhanced our 
understanding of the pathogenesis for this bacterium. In addition, novel CDSs such as 
regulators and the further refinement of many CDS product functions have allowed a 
greater understanding of the genome, mainly due to the availability of new motifs. Thus, 
the re-annotation has significantly added to the information available for a large majority 
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of CDSs within the genome. Since the original annotation, substantial updates on CDSs 
within loci encoding the four main glyco-based virulence determinants have been 
published. In addition, the databases used in the re-annotation process e.g. PFAM and 
PROSITE have been greatly enhanced since the original annotation. This was evident 
during the re-annotation process as supporting information from motif identification was 
a common theme in novel product function designations. The inclusion of additional 
search databases such as RFAM and programs such as TMHMM and SIGNALP further 
increased the usefulness of the re-annotation. The use of research papers for 
characterised genes/proteins was an additional feature of this re-annotation. Interestingly, 
from the 2092 literature citations added during this re-annotation, 1056 (50.5%) had been 
published after the year 2000. Considering there was no literature qualifier in the original 
annotation, this demonstrates the depth of research that has been carried out since 2000 
and further supports the need to make use of this information in the re-annotation. 
  
The re-annotation was completed manually to allow maximum utilisation of current 
annotation tools and incorporation of additional sources of information not available 
using automated methods e.g. information from scientific papers. The advantages of 
carrying out a manual re-annotation outweigh those associated with performing an 
automated process. However manual re-annotation is a labour intensive task and it is 
understandable why so many sequenced genomes receive an automated annotation. The 
resources do not exist for manual annotation of all newly sequenced genomes, let alone 
re-annotations. With the advent of the next-generation sequencing technology, the 
number of genome sequences will increase at a far greater rate than before (Margulies et 
al., 2005). Thus, it seems the best approach to annotation or re-annotation in the future 
will be to improve automated techniques. Priority remains with new sequenced genomes 
and thus manual re-annotation projects will be performed infrequently.  
 
6.2.1 Future studies  
The re-annotation of the C. jejuni NCTC11168 genome sequence has already become 
somewhat outdated. A publication accompanying the genome update was released in 
2007 (Gundogdu et al., 2007) and further research has since been performed not only 
characterising individual CDSs, but also utilising novel genome analysis techniques such 
as RNA-Seq (van Vliet, 2010). What has become clear during this project is that with the 
number of genome sequences currently being generated, the resources simply do not 
exist for all these new genome sequences to be annotated manually. Manual annotation is 
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time consuming and costly, however automated techniques do not yet provide the level 
of detail and accuracy that manual annotation provides. Ideally, an automated annotation 
or re-annotation tool is required which performs at a level of detail and accuracy that 
manual annotation provides. If such a tool was available, a system could be in place 
where automatic annotations and re-annotations could be established at regular time 
points.  
 
6.3 Characterisation of Cj1556  
Despite stringent microaerobic growth requirements, C. jejuni is ubiquitous in the 
aerobic environment and so must possess finely tuned regulatory systems to sense and 
adapt to external stimuli such as oxidative and aerobic (O2) stress. Re-annotation of the 
C. jejuni NCTC11168 genome sequence identified Cj1556 (originally annotated as a 
hypothetical protein) as a MarR family transcriptional regulator and further 
bioinformatic analysis indicated a role in regulating the oxidative stress response. A C. 
jejuni 11168H Cj1556 mutant exhibited increased sensitivity to oxidative and aerobic 
(O2) stress, decreased ability for intracellular survival in both Caco-2 human IECs and 
J774A.1 mouse macrophages and a reduction in virulence in the Galleria mellonella 
infection model. Microarray analysis of gene expression changes in the Cj1556 mutant 
compared to the 11168H wild-type strain indicated negative autoregulation of Cj1556 
expression and down-regulation of genes associated with oxidative and aerobic (O2) 
stress responses, such as katA, perR and hspR. cprS, which encodes a sensor kinase 
involved in the regulation of biofilm formation, was also up-regulated in the Cj1556 
mutant and subsequent studies showed that the Cj1556 mutant had a reduced ability to 
form biofilms. This study has identified a novel C. jejuni transcriptional regulator 
Cj1556 that is involved in oxidative and aerobic (O2) stress responses and is important 
for the survival of C. jejuni in the natural environment and in vivo. This newly identified 
regulator was designated CosR (Campylobacter oxidative stress Regulator). 
 
6.3.1 Future studies  
The characterisation of the 11168H Cj1556 mutant has shown Cj1556 to be involved in 
oxidative/aerobic (O2) stress regulation. However, what has not yet been experimentally 
proven is the ability of Cj1556 to bind DNA as a transcriptional regulator would be 
expected to. Current studies are investigating not only the binding capability of Cj1556, 
but also the location of binding. Specifically, this study has shown the expression of 
Cj1556 to be putatively negatively autoregulated and so Cj1556 would be expected to 
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bind upstream of Cj1556. In addition, microarray studies identified a number of genes 
involved in oxidative/aerobic (O2) stress with modified expression levels in the Cj1556 
mutant when compared to the 11168H wild-type strain. Cj1556 may also bind upstream 
of these genes. Gel-mobility shift assays can be used to identify binding of proteins to 
amplified regions of genomic DNA. In this instance, recombinant Cj1556 can be 
hybridised to amplified fragments of upstream regions from the genes of interest and run 
on a native DNA retardation gel to establish whether a band shift occurs. Alternatively, 
techniques such as ChIP-Seq or ChIP-ChIP whereby the binding capability of Cj1556 is 
assessed on a genome wide scale can be performed. Additional studies should also be 
performed on the putative link between Cj1556 and Cj1546. One hypothesis is that 
Cj1546, found in all C. jejuni strains, is involved in the primary line of defence against 
oxidative/aerobic (O2) stress and that Cj1556, present in only a few C. jejuni strains, 
enhances the ability of these strains to survive these stresses. To test this hypothesis, a 
Cj1546 mutant should be constructed in both C. jejuni 11168H and 81-176, as these 
strains possess both Cj1546 and Cj1556 genes. This would identify whether a 
compensatory role exists between Cj1556 and Cj1546 in the response to aerobic (O2) 
and/or oxidative stress. In addition, a Cj1546 mutant should be constructed in a strain 
lacking Cj1556 such as C. jejuni 81116. This would identify whether Cj1546 has a role 
in aerobic (O2) and/or oxidative stress response. A double Cj1546/Cj1556 mutant should 
also be constructed in either C. jejuni 11168H or 81-176. This would identify whether 
there is any increased sensitivity to aerobic (O2) and/or oxidative stress. Finally, a 
functional copy of Cj1556 should be inserted into the C. jejuni 81116 genome. This 
would identify whether there is indeed any increased resistance to aerobic (O2) and/or 
oxidative stress through the addition of Cj1556 to a Cj1546 background. These mutants 
can be studied using the assays described in this study to test this hypothesis. MarR 
family motifs are also linked to a number of additional roles such as controlling 
virulence factor production and bacterial responses to antibiotics, so a number of 
different assays such as chemotaxis studies or an array of antibiotic stress assays can be 
performed to test these further. In addition, recent data has indicated that bile induces 
expression of the E. coli marRAB operon, by binding to the repressor protein MarR and 
thus preventing binding of MarR to the marRAB promoter site (Hamner et al., 2010). 
Further studies will be required to confirm whether bile can bind to the Cj1556 protein 
and thus prevent binding to the Cj1556 promoter site, resulting in the up-regulation of 
Cj1556 in the presence of bile observed previously (Malik-Kale et al., 2008). 
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It is possible that Cj1556 could be used as a target candidate for the strategic control of 
C. jejuni colonisation in the poultry industry. Blocking the function of Cj1556 would 
result in increased susceptibility to oxidative and aerobic (O2) stresses, making the 
possibility of an interesting control strategy if combined with spraying broiler houses 
with hydrogen peroxide. 
 
6.4 Characterisation of Cj0248   
The ability of C. jejuni to adhere and invade to human IECs is critical in the pathogenesis 
of this ubiquitous bacterium. Central to the survival of C. jejuni is the ability to become 
motile via active flagella that allow adhesion to and invasion of IECs. The flagellum has 
also been implicated as secretory machinery allowing proteins to be secreted that induce 
invasion into IECs. Cj0248 has previously been implicated in flagella functionality and 
pathogenesis. In this study we further investigated the phenotype of a 11168H Cj0248 
mutant by performing an array of assays designed to enhance our understanding of this 
CDS. We confirmed previous findings that mutation of Cj0248 gives a severely reduced 
motility phenotype using a different C. jejuni wild-type strain. The 11168H Cj0248 
mutant also exhibited reduced interaction and invasion when co-cultured with Caco-2 
cells compared to the 11168H wild-type strain. However, TEM analysis identified the 
presence of flagella. Using microarray expression data, TEM was used to identify an 
altered flagella basal body region in the Cj0248 mutant compared to the 11168H wild-
type strain. Subsequent assays demonstrated the Cj0248 mutant had a reduced ability to 
form biofilms compared to the 11168H wild-type strain and also that the Cj0248 mutant 
induced a reduced IL-6 response from T84 cells, but not IL-8 when compared to 11168H 
wild-type strain. Secretion profile analysis identified no differences in the protein profile 
of the Cj0248 mutant compared to the 11168H wild-type strain. The function of Cj0248 
remains unknown.  
  
6.4.1 Future studies  
Further investigation is required to ascertain the function of Cj0248. The phenotypes 
observed in this study must be confirmed by performing assays on the recently 
constructed complemented mutant strain. So far this complemented mutant strain has 
successfully demonstrated the partial resuscitation of the motility phenotype. In addition, 
the functionality of Cj0248 as a putative phosphohydrolase needs to be confirmed 
enzymatically. Analysis of the secretion profile of the 11168H Cj0248 mutant should be 
expanded using silver staining and after co-culture with IECs. It is possible that 
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differences in the secretion profile between Cj0248 mutant and the 11168H wild-type 
strain may be observed when co-culturing C. jejuni in the presence of conditioned media 
for different time periods.  To ascertain the exact composition of the protein profile, 
proteomics analysis should be performed on the bands from the coomassie or silver 
stained gel. The location of Cj0248 within C. jejuni should also be studied by using 
monoclonal or polyclonal antibodies specific for Cj0248 on different bacterial cell 
fractions. This would identify whether Cj0248 is indeed located around the bacterial 
membrane region in proximity of the flagella. Enhanced TEM results identified a 
putative altered flagella basal body region when comparing Cj0248 mutant to the 
11168H wild-type strain. Based on this data, further analysis specifically of the flagella 
apparatus would be required to ascertain if Cj0248 directly interferes with basal body 
formation. A starting point would be to perform enhanced TEM on the complemented 
mutant strain to analyse whether the flagella basal body is structurally similar to the 
11168H wild-type strain. Further experiments should be performed on the 11168H wild-
type strain assessing the role of Cj0248 using monoclonal or polyclonal antibodies 
against this protein. Using microarray data, a number of putative links were made 
between Cj0248 function and chemotaxis. In particular, chemotaxis is heavily linked to 
flagella functionality so there may be a direct role for Cj0248 relating to chemotaxis. 
Investigation of the role of Cj0248 could be performed using monoclonal or polyclonal 
antibodies against Cj0248 on the 11168H wild-type strain in conjuction with assays 
using chemotactic attractants (e.g. mucin) as a possible inducer for the increased 
expression of Cj0248. 
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Appendices 
 
Appendix 1 – Products used in this study 
 
dATP – Promega, Southampton, UK 
dGTP – Promega, Southampton, UK 
dCTP – Promega, Southampton, UK 
dTTP – Promega, Southampton, UK 
MgCl2 - Promega, Southampton, UK 
10X Buffer 
Taq DNA polymerase M166F (2,500 units) Promega, Southampton, UK 
 
ABI Prism Terminator Ready Reaction Mix - Applied Biosystems, Warrington, 
UK 
Agarose      - Sigma-Aldrich, Poole, UK 
Ampicillin      - Sigma-Aldrich, Poole, UK 
Bacto agar      - BD, Oxford, UK 
Bovine Serum Albumin (BSA)   - Sigma-Aldrich, Poole, UK 
Brucella broth      - Fluka, Gillingham, UK 
Campylobacter Selective Supplement (Skirrow)  - Oxoid, Basingstoke, UK 
Columbia Agar     - Fluka, Gillingham, UK 
Dulbecco’s Modified Eagle's Medium (DMEM) - Sigma-Aldrich, Poole, UK 
Ethidium Bromide     - Promega, Southampton, UK 
Foetal Bovine Serum     - Sigma-Aldrich, Poole, UK 
GenElute Gel Extraction Kit    - Sigma-Aldrich, Poole, UK 
Glycerol      - VWR, Lutterworth, UK 
Horse blood in Alsevers - TCS Biosciences, Botolph 
Claydon, UK 
1 Kb Ladder      - Invitrogen, Paisley, UK 
Kanamycin      - Gibco/Invitrogen, Paisley, UK 
Luria Bertani Agar (LB agar)    - Merck, Hoddesdon, UK 
Luria Bertani Broth (LB agar)   - Difco, Northampton, UK 
Lysozyme      - Sigma-Aldrich, Poole, UK 
2 Mercaptoethanol  - Stratagene, Amsterdam, Holland 
MinElute PCR purification Kit   - Qiagen, Crawley, UK 
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Mueller-Hinton Broth (MH)    - Oxoid, Basingstoke, UK 
Non-essential amino acids    - Sigma-Aldrich, Poole, UK 
Oligonuclotide primers    - Sigma-Aldrich, Poole, UK 
Penicillin-Streptomycin solution   - Sigma-Aldrich, Poole, UK 
Phosphate Buffered Saline    - Sigma-Aldrich, Poole, UK 
pGEM-T Easy vector     - Promega, Southampton, UK 
Restriction endonucleases - Promega, Southampton, UK,  
- New England Biolabs, Hitchin, UK  
- Roche, Lewes, UK 
SOC Broth - Fluka, Gillingham, UK 
SCS110 Competent Cells  - Stratagene, Amsterdam, Holland 
T4 DNA Ligase - Promega, Southampton, UK  
T4 DNA Ligase buffer - Promega, Southampton, UK 
Triton X-100      - Sigma-Aldrich, Poole, UK 
0.25 % Trypsin-EDTA    - Sigma-Aldrich, Poole, UK 
QIAquick PCR purification kit   - Qiagen, Crawley, UK 
QIAquick gel extraction kit    - Qiagen, Crawley, UK 
QIAprep Spin Miniprep Kit    - Qiagen, Crawley, UK 
Puregene DNA Purification System - Gentra Systems Inc. - Flowgene, 
Lichfield, UK 
XL-2 Blue MRF’ Competent cells - Stratagene, Amsterdam, Holland 
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Appendix 2 – Media used in this study 
 
Columbia blood agar plates (to make 8-10 plates)* 
Dissolve 12.6 g Columbia agar in 279 ml Milli-RO water. Agar was heated in a 
microwave to a molten level and allowed to cool to approximately 50°C. 7% Horse 
blood in Alsevers (21 ml), Campylobacter Selective Supplement (Skirrow) and any 
antibiotics were added when ready to pour.  
 
LB agar (to make 8-10 plates)* 
Dissolve 9.25 g LB agar in 250 ml Milli-RO water. Agar was heated in a microwave to a 
molten level and allowed to cool to approximately 50°C. Antibiotics were added when 
ready to pour.  
 
LB agar/Ampicillin/IPTG/X-Gal 
LB agar        - 250 ml 
Ampicillin (100 mg/ml)       - 250 μl 
Isopropyl β-D-1-thiogalactopyranoside - IPTG (1 pmol/μl)  - 40 μl 
2% (w/v) X-GAL**        - 500 μl 
** 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside 
 
Motility agar* 
Dissolve 1.0 g Bacto agar in 250 ml Brucella broth to obtain 0.4% semi-solid media. 
 
Overnight Cultures (10 ml)* 
- E. coli 
Dissolve 6.25 g LB broth in 250 ml Milli-RO water. For overnight cultures, use 10 ml 
LB broth with appropriate antibiotics. 
 
- C. jejuni 
Dissolve 7.0 g Brucella broth in 250 ml Milli-RO water. For overnight cultures, use 10 
ml Brucella broth with appropriate antibiotics. 
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Glycerol stock solution*  
- E. coli 
Glycerol stocks should be made from overnight cultures (described above). 1.5 ml 100% 
(v/v) glycerol was added into the 10 ml overnight culture. Mix and then prepare 500 μl 
aliquots into 1.5 ml microcentrifuge tubes. Snap freeze and store at -80°C. 
 
- C. jejuni 
Glycerol stocks should be made from overnight plates (described above). Prepare the C. 
jejuni glycerol solution in a 10 ml Universal as:-  
 
MH broth    - 8 ml 
100% (v/v) FCS    - 1 ml 
100% (v/v) Glycerol  - 1 ml 
 
50X TAE (to make 1 litre)* 
Tris Base    - 242 g  
Acetic acid     - 57.1 ml  
EDTA (0.5 M adjusted to pH 8.0) - 100 ml  
Milli-RO water   - up to 1 litre 
  
1X TAE (to make 20 ml)* 
EDTA 0.5 M pH8.0 - 40 μl 
Tris Base 1 M pH8.0  - 200 μl 
Milli-RO water - 19.7 ml 
 
Agarose gel (300 ml) 
Dissolve 3.15 g agarose in 450 ml Milli-RO water. Agar was heated in a microwave to a 
molten level and allowed to cool to approximately 50°C. Add 0.5 μg/μl Ethidium 
Bromide (22.5 μl) into 450 ml when ready to pour. Mix bottle thoroughly before pouring 
into gel tray. 
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Gel Loading Buffer (20 ml) 
100% (v/v) Glycerol    - 10 ml 
20% (v/v) SDS    - 500 μl  
5% (w/v) Bromothenol blue    - 100 μl 
EDTA (0.5 M)    - 100 μl 
Sterilised Milli-Q water   - up to 20 ml 
 
dNTP 1.25 mM Stock (to make 1 ml total volume) 
dATP (100mM)  - 12.5 μl 
dTTP (100mM)  - 12.5 μl 
dGTP (100mM)  - 12.5 μl  
dCTP (100mM)  - 12.5 μl 
Sterilised Milli-Q water - 950 μl 
 
PCR pre-mix (to make 1 ml total volume) 
10X Buffer     - 100 μl 
dNTPs (1.25mM)    - 168 μl 
MgCl2 (25 mM)   - 60 μl 
Taq polymerase (5 U/μl)   - 6 μl 
Sterilised Milli-Q water  - up to 1000 μl 
 
EBF buffer (100 ml) 
100% (v/v) Glycerol   - 15 ml 
10% (w/v) Sucrose    - 10 ml 
Sterilised Milli-Q water  - up to 100 ml 
     
SOC media components 
Tryptone (20 g/l) 
Yeast extract (5 g/l) 
Sodium Chloride (10 nM) 
Potassium Chloride (2.5 mM) 
Magnesium Chloride (10 mM) 
Magnesium Sulphate (10 mM) 
Glucose  (20mM) 
Final pH 7.0 
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Coomassie staining solution 0.125% (w/v) 
Coomassie     - 0.25 g 
100% (v/v) Methanol     - 150 ml 
100% (v/v) Acetic acid   - 50 ml  
Sterilised Milli-Q water   - up to 500 ml 
 
De-stain solution (500 ml) 
100% (v/v) Methanol     - 150 ml 
100% (v/v) Acetic acid   - 50 ml  
Sterilised Milli-Q water   - up to 500 ml 
 
10X running buffer* 
Tris base     - 30 g 
D-glycine     - 144 g 
Sterilised MilliQ water    - up to 1 litre 
Adjust pH to 8.3 
 
1X running buffer 
10X running buffer    - 100 ml 
10% (v/v) SDS    - 10 ml 
Sterilised MilliQ water   - up to 1000 ml 
 
1X Transfer buffer* 
Tris base     - 3.03 g 
Glycine      - 14.4 g 
100% (v/v) Methanol    - 200 ml 
Sterilised MilliQ water    - up to 1 litre 
 
Equilibration Buffer 
Sodium phosphate (1 M)   - 50 ml 
Sodium chloride (1 M)   - 300 ml 
Sterilised MilliQ water    - up to 1 litre 
Adjust to pH 8.0 
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Wash Buffer 
Sodium phosphate (1 M)   - 50 ml 
Sodium chloride (1 M)   - 300 ml  
Imidazole (1 M)    - 5 ml 
Sterilised MilliQ water    - up to 1 litre 
Adjust to pH 8.0 
 
Elution Buffer 
Sodium phosphate (1 M)   - 50 ml  
Sodium chloride (1 M)   - 300 ml 
Imidazole (1 M)    - 250 ml 
Sterilised MilliQ water    - up to 1 litre 
Adjust to pH 8.0 
 
300 mM sodium chloride 
Sodium chloride     - 17.5 g 
Sterilised MilliQ water    - up to 1 litre 
 
30 mM sodium phosphate 
Sodium chloride     - 4.89 g 
Sterilised MilliQ water    - up to 1 litre 
 
5  mM imidazole 
Sodium chloride     - 0.34 g 
Sterilised MilliQ water    - up to 1 litre 
 
250  mM imidazole 
Sodium chloride     - 1 g 
Sterilised MilliQ water    - up to 1 litre 
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Cell lysis solution (to make 1 ml) 
EDTA (0.5 M)    - 20 μl 
Tris Base (1 M pH8.0 )   - 10 μl 
10% (v/v) Triton X-100   - 2 μl 
Lysozyme (20 mg/ml)   - 50 μl 
Sterilised Milli-Q water   - to 1000 μl 
 
* Denotes solutions/buffers that were sterilised by autoclaving prior to use. 
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Appendix 3 – Different orientations of the KmR cassette 
 
 
 
a) Correct Orientation 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
b) Reverse Orientation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KRO 
KFO GSF 
Ra 
Fa 
.38 kb  
.17 kb 
GSR 
KRO 
KFO GSF 
Ra 
Fa 
.17 kb  
.38 kb 
GSR 
GSF + KFO = Fa + .38 kb 
 
GSR + KRO = Ra + .17 kb 
GSF + KRO = Fa + .17 kb 
 
GSR + KFO = Ra + .38 kb 
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GSF = Gene Specific Forward 
 
GSR = Gene Specific Reverse 
 
KFO = KmR forward-out 
 
KRO = KmR reverse-out 
 
FA = Forward gene size  
 
RA = Reverse gene size 
Oligonucleotide Primer 
Gene Insert 
KmR cassette 
  
 
2
4
0
 
 
Appendix 4 – KmR cassette calculations 
ISF = Insert specific forward primer       
ISR = Insert specific reverse primer       
KFO = KmR forward out primer       
KRO = KmR reverse out primer       
FA = Forward CDS size        
RA = Reverse CDS size        
         
Correct orientation Reverse orientation       
         
GSF + KFO = Fa + .381 kb GSF + KFO = Fa + .173 kb       
GSR + KRO = Ra + .173 kb GSR + KRO = Ra + .381 kb       
         
Kanamycin size = 1.43 kb        
( ) indicate calculation using primers       
CDS CDS Size (kb) CDS+Kan 
Fa 
(kb) 
ISF + 
KFO (kb) 
ISF + 
KRO (kb) 
Ra 
(kb) 
ISR + 
KRO 
(kb) 
ISR + 
KFO (kb) 
Cj1556 1.494 (0.278) 2.92 (1.708) 0.917 1.298 1.030 0.571 0.744 0.952 
Cj0248 0.858 (0.838) 2.284 (2.264) 0.429 0.810 0.602 0.429 0.602 0.810 
  
 241 
Appendix 5 – Re-annotation manuscript 
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Appendix 6 – Cj1556 – Protein Interaction Database Results 
 
/note="Updated (2006) note: Pfam domain PF01638 Transcriptional regulator identified within 
CDS. Product modified to more specific family member based on motif match. No specific 
characterisation has been carried out yet, so putative kept within product function" 
/product="putative transcriptional regulator 
/locus_tag="Cj1556" 
 
"Cj0082","Cj1556","cydB","Cj1556","1","C.jejuni YTH" 
"Cj0465c","Cj1556","Cj0465c","Cj1556","1","C.jejuni YTH" 
"Cj0389","Cj1556","serS","Cj1556","1","C.jejuni YTH" 
"Cj0560","Cj1556","Cj0560","Cj1556","1","C.jejuni YTH" 
"Cj0777","Cj1556","Cj0777","Cj1556","1","C.jejuni YTH" 
"Cj0701","Cj1556","Cj0701","Cj1556","1","C.jejuni YTH" 
"Cj0665c","Cj1556","argG","Cj1556","1","C.jejuni YTH" 
"Cj1059c","Cj1556","gatA","Cj1556","1","C.jejuni YTH" 
"Cj1318","Cj1556","Cj1318","Cj1556","1","C.jejuni YTH" 
"Cj1336","Cj1556","Cj1336","Cj1556","1","C.jejuni YTH" 
"Cj1434c","Cj1556","Cj1434c","Cj1556","1","C.jejuni YTH" 
"Cj1285c","Cj1556","Cj1285c","Cj1556","1","C.jejuni YTH" 
"Cj1489c","Cj1556","ccoO","Cj1556","1","C.jejuni YTH" 
"Cj1422c","Cj1556","Cj1422c","Cj1556","1","C.jejuni YTH" 
"Cj1556","Cj1108","Cj1556","clpA","1","Predictions from E.coli" 
"Cj1556","Cj0759","Cj1556","dnaK","1","Predictions from E.coli" 
"Cj1556","Cj0509c","Cj1556","clpB","1","Predictions from E.coli" 
"Cj1556","Cj0476","Cj1556","rplJ","1","Predictions from E.coli" 
"Cj1556","Cj0284c","Cj1556","cheA","1","Predictions from E.coli" 
 
/note="Updated (2006) note: Pfam domain PF02322 Cytochrome oxidase subunit II identified 
within CDS. Also, nine probable transmembrane helices predicted by TMHMM2.0. Further 
support given to product function. Characterised within Escherichia coli with marginal identity 
score. Putative not added to product function" 
/product="cytochrome bd oxidase subunit II" 
/locus_tag="Cj0082" 
/gene="cydB" 
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/note="Updated (2006) note: Characterised within Escherichia coli with acceptable identity 
score. Putative not added to product function" 
/product="seryl-tRNA synthetase" 
/locus_tag="Cj0389" 
/gene="serS" 
 
/note="Updated (2006) note: Pfam domain PF01152 Bacterial-like globin identified within CDS. 
This family of heme binding proteins are found mainly in bacteria. Characterised within 
Campylobacter jejuni. Ctb protein is shown to be involved in moderating oxygen flux within 
Campylobacter jejuni. NssR (Nitrosative stress sensing Regulator - Cj0466) controls the 
expression of a nitrosative stress-responsive regulon in Campylobacter jejuni which includes ctb 
(Cj0465c) and cgb (Cj1586). Putative not added to product function" 
/product="group III truncated haemoglobin" 
/locus_tag="Cj0465c" 
/gene="ctb" 
 
/note="Updated (2006) note:  Pfam domain PF01554 MatE identified within CDS. Prosite 
domain PS00589 PTS_HPR_SER, Phosphotransferase system, HPr serine phosphorylation site 
also identified. Twelve probable transmembrane helices predicted by TMHMM2.0. 
Characterised members of the Multi Antimicrobial Extrusion (MATE) family function as 
drug/sodium antiporters. These proteins mediate resistance to a wide range of cationic dyes, 
fluroquinolones, aminoglycosides and other structurally diverse antibodies and drugs. MATE 
proteins are found in bacteria, archaea and eukaryotes. These proteins are predicted to have 12 
alpha-helical transmembrane regions (which this one does). Product modified to more specific 
family member due to motif match. No specific characterisation with acceptable identity scores 
has been carried out yet. Putative kept within product function. Literature search identified paper 
giving further clues to product function" 
/product="putative MATE family transport protein" 
/locus_tag="Cj0560" 
/literature="PMID:16048946" 
 
/note="Updated (2006) note: Some characterisation work within Escherichia coli and Rattus 
norvegicus (Rat). Appropriate motifs present. Putative not added to product function" 
/product="argininosuccinate synthase" 
/locus_tag="Cj0665c" 
/gene="argG" 
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/note="Updated (2006) note: Similar to many with marginal identity scores. Putative kept within 
product function" 
/product="putative protease" 
/locus_tag="Cj0701" 
 
/note="Updated (2006) note: Characterisation work carried out within more than one species 
with marginal identity score. Putative kept within product function" 
/product="putative ATP-dependent DNA helicase" 
/locus_tag="Cj0777" 
 
/locus_tag="Cj1059c" 
/gene="gatA" 
/literature="Pfam domain PF01425 Amidase identified within CDS. Further support given to 
product function. Characterised in Bacillus subtilis with acceptable identity score, so putative not 
added to product function" 
/product="Glu-tRNAGln amidotransferase subunit A" 
 
/note="Updated (2006) note: Pfam domains PF02621 Uncharacterized ACR, COG1427 
identified within CDS. Conserved added to product funtion" 
/product="conserved hypothetical protein Cj1285c" 
/locus_tag="Cj1285c" 
  
/note="Updated (2006) note: Pfam domain PF01973 Protein of unknown function DUF115 
identified within CDS. Characterisation work has been carried out within Campylobacter jejuni 
(PMID:11895937). Product function modified to more specific family member. Identifed as part 
of Campylobacter jejuni O-linked glycosylation locus (Cj1293 - Cj1342)" 
/product="motility accessory factor (function unknown)" 
/locus_tag="Cj1318" 
/gene="maf1" 
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/note="Updated (2006) note: Pfam domain PF01973 Protein of unknown function DUF115 
identified within CDS. Some characterisation work has been carried out within Campylobacter 
jejuni. Product funciton updated to more specific family member. Identifed as part of 
Campylobacter jejuni O-linked glycosylation locus (Cj1293 - Cj1342). Coding sequences have 
been merged to reflect the complete amino acid sequence for this gene regardless of phase. 
Previous annotation gave Cj1335 and Cj1336 as seperate CDS. Merging of these CDSs has lead 
to loss of the downstream CDS" 
/product="motility accessory factor (function unknown)" 
/locus_tag="Cj1335" 
/gene="maf4" 
 
/note="Updated (2006) note: No specific characterisation has been carried out yet, so putative 
kept within product function. Literature search identified papers giving further clues to product 
funciton. Identifed as part of Campylobacter jejuni capsule locus (Cj1413c - Cj1448c)" 
/product="putative sugar transferase" 
/locus_tag="Cj1434c" 
 
/note="Updated (2006) note: Prosite PS00221 MIP family signature identified within CDS. No 
specific characterisation has been carried out yet. Putative kept within product function. 
Identified within the Campylobacter jejuni Capsule locus (Cj1413c - Cj1448c)" 
/product="putative sugar transferase" 
/locus_tag="Cj1422c" 
 
/note="Updated (2006) note: PF02433 Cytochrome C oxidase, mono-heme subunit/FixO subunit 
identified within CDS. Further support given to product function. Characterised in Helicobacter 
pylori with acceptable identity score. Putative not added to product function" 
/product="cb-type cytochrome C oxidase subunit II" 
/locus_tag="Cj1489c" 
/gene="ccoO" 
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Appendix 7 – Cj1546 – Protein Interaction Database Results 
 
/note="Updated (2006) note: Pfam domain PF01638 Transcriptional regulator identified within 
CDS. Product modified to more specific family member based on motif match. Putative kept 
within product function" 
/product="putative transcriptional regulator" 
/locus_tag="Cj1546" 
 
"Cj1546","Cj1166c","Cj1546","Cj1166c","1","C.jejuni YTH" 
"Cj1546","Cj1193c","Cj1546","Cj1193c","1","C.jejuni YTH" 
"Cj1546","Cj0865","Cj1546","dsbB","1","C.jejuni YTH" 
"Cj1546","Cj0797c","Cj1546","Cj0797c","1","C.jejuni YTH" 
"Cj1546","Cj0620","Cj1546","Cj0620","1","C.jejuni YTH" 
"Cj1546","Cj0161c","Cj1546","moaA","1","C.jejuni YTH" 
"Cj1546","Cj1108","Cj1546","clpA","1","Predictions from E.coli" 
"Cj1546","Cj0759","Cj1546","dnaK","1","Predictions from E.coli" 
"Cj1546","Cj0509c","Cj1546","clpB","1","Predictions from E.coli" 
"Cj1546","Cj0476","Cj1546","rplJ","1","Predictions from E.coli" 
"Cj1546","Cj0284c","Cj1546","cheA","1","Predictions from E.coli" 
 
/note="Updated (2006) note: Pfam domain PF06738 Protein of unknown function (DUF1212) 
identified within CDS. Five probable transmembrane helices predicted by TMHMM2.0. Further 
support given to product function" 
/product="putative integral membrane protein" 
/locus_tag="Cj1166c" 
 
/note="Original (2000) note: Cj1193c, probable periplasmic protein, len: 268 aa; no Hp match. 
Contains probable N-terminal signal sequence" 
/product="putative periplasmic protein" 
/locus_tag="Cj1193c" 
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/note="Updated (2006) note: Four probable transmembrane helices predicted by TMHMM2.0. 
This CDS has been characterised as DsbB protein (PMID:15632440). It has been demonstrated 
that Cj0865 is indeed a disulfide oxidoreductase. This has been shown via in silico and in vivo 
work in E. coli and also complementation and enzymatic tests in C. jejuni. There is an alignment 
of different DsbB proteins (including Cj0865) with prediction of 5 transmembranehelises (not 4 
as stated in annotation); (P24-A39; F60-I74; S87-L101; F194-A214; F231-G246). There are 
some differences in amino acid sequences between Cj0865 and its orthologue from 81-176 
(CJJ81176_0881). It is stated that its translation starts from the second Met (although the 
predicted N-terminal amino acid sequences of both proteins are identical), there is also an 
insertion of 3 amino acids at the COOH end of protein. Thus, not added to protein function" 
/product="putative disulphide oxidoreductase" 
/locus_tag="Cj0865" 
/gene="dsbB" 
 
/note="Original (2000) note: Cj0797c, unknown, len: 71 aa; weak similarity to TR:O68849 
(EMBL:AF055586) ORF10 in Vibrio cholerae integron InVch (80 aa), fasta scores; opt: 95 z-
score: 151.4 E(): 0.39, 39.2% identity in 51 aa overlap. No Hp match" 
/product="hypothetical protein Cj0797c" 
/locus_tag="Cj0797c" 
 
/note="Updated (2006) note: Pfam domain PF01863 Protein of unknown function DUF45 
identified within CDS. This motif has no known function. Members are found in some 
archaebacteria, as well as Helicobacter pylori (Epsilon Proteobacteria). The proteins are 190-240 
amino acids long, with the C terminus being the most conserved region, containing three 
conserved histidines. This motif is similar to that found in Zinc proteases, suggesting a possible 
role as a protease. Conserved added to product function" 
/product="conserved hypothetical protein Cj0620" 
/locus_tag="Cj0620" 
 
/note="Updated (2006) note: Pfam domains PF06463 Molybdenum Cofactor Synthesis C and 
PF04055 Radical SAM superfamily were identified within CDS. Further support given to 
product funtion. Characterisation work carried out within Escherichia coli with marginal identity 
score. Putative kept within product function" 
/product="putative molybdenum cofactor biosynthesis protein A" 
/locus_tag="Cj0161c" 
/gene="moaA" 
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/note="Updated (2006) note: Pfam domains PF02861 Clp amino terminal domain and PF00004 
ATPase family associated with various cellular activities (AAA) were identified within CDS. 
Further support given to product function. Characterised within Escherichia coli with acceptable 
identity score. Putative not added to product function" 
/product="ATP-dependent Clp protease ATP-binding subunit" 
/locus_tag="Cj1108" 
/gene="clpA" 
 
/note="Updated (2006) note: Characterised within Campylobacter jejuni and others to DnaK 
protein. Putative not added to product function" 
/product="heat shock protein DnaK" 
/locus_tag="Cj0759" 
 
/note="Updated (2006) note: Characterised within Campylobacter jejuni. Putative not added to 
product function" 
/product="ATP-dependent Clp protease ATP-binding subunit" 
/locus_tag="Cj0509c" 
/gene="clpB" 
 
/note="Updated (2006) note: Prosite domain PS01109 RIBOSOMAL_L10, Eubacterial 
ribosomal protein L10 identified within CDS. Further support given to product function. 
Characterised within Escherichia coli with acceptable identity score. Putative not added to 
product function" 
/product="50S ribosomal protein L10" 
/locus_tag="Cj0476" 
/gene="rplJ" 
 
/note="Updated (2006) note: Characterised within Escherichia coli with marginal identity scores. 
Putative not added to product function" 
/product="chemotaxis histidine kinase" 
/locus_tag="Cj0284c" 
/gene="cheA" 
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Appendix 8 – Genes up-regulated in the Cj1556 mutant when compared to 11168H 
wild-type strain using RNA from late-log phase of growth 
 
Gene ID 
Fold 
Change 
Product Function 
Cj1556 10.4 putative transcriptional regulator - Cj1556 (cosR) 
Cj0244 5.392 50s ribosomal protein L35 
Cj0374 5.061 hypothetical protein Cj0374 
Cj1326 3.536 putative methyltransferase Cj1326 - homopolymeric tract 
Cj0767c  3.493 phosphopantetheine adenylyltransferase 
Cj1611 3.381 30S ribosomal protein S20 
Cj0496 3.366 hypothetical protein Cj0496 
Cj1555c  3.058 hypothetical protein Cj1555c 
Cj0487 2.872 putative amidohydrolase 
Cj0628 2.73 putative lipoprotein - homopolymeric tract 
Cj0491 2.578 30S ribosomal protein S12 
Cj0854c  2.125 putative periplasmic protein 
Cj1226c  2.019 putative two-component sensor (histidine kinase) 
Cj0598 1.966 putative membrane protein 
Cj1145c  1.935 hypothetical protein Cj1144c – homopolymeric tract 
Cj0919c  1.887 putative ABC-type amino-acid transporter permease protein 
Cj1423c  1.867 
putative D-glycero-D-manno-heptose 1-phosphate 
guanosyltransferase 
Cj1666c  1.852 putative periplasmic protein 
Cj0310c  1.85 putative efflux protein 
Cj1542 1.767 putative allophanate hydrolase subunit 1 
Cj0694 1.756 putative periplasmic protein 
Cj0301c  1.684 putative molybdenum transport system permease protein 
Cj0944c  1.674 putative periplasmic protein 
Cj1566c  1.649 NADH dehydrogenase I chain N 
Cj0475 1.629 50S ribosomal protein L1 
Cj0357c  1.624 putative integral membrane protein 
Cj0263 1.582 zinc transporter 
Cj1163c  1.58 putative cation transport protein 
Cj0057 1.575 putative periplasmic protein 
Cj0534 1.566 succinyl-coA synthetase alpha chain 
Cj0935c  1.564 putative sodium:amino-acid symporter family protein 
Cj1327 1.563 N-acetylneuraminic acid synthetase 
Cj1438c  1.559 putative sugar transferase 
Cj0099 1.558 putative biotin--[acetyl-CoA-carboxylase] synthetase 
Cj0338c  1.554 DNA polymerase I 
Cj1497c  1.552 hypothetical protein Cj1497c 
Cj1410c  1.551 putative membrane protein 
Cj0041 1.539 putative flagella hook-length control protein 
Cj1655c  1.533 Na(+)/H(+) antiporters 
Cj0856 1.529 signal peptidase I 
Cj0706 1.528 hypothetical protein Cj0706 
C0j272 1.527 hypothetical protein Cj0272 
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Cj1529c  1.511 phosphoribosylformylglycinamidine cyclo-ligase 
Cj0551 1.508 elongation factor P 
Cj0195 1.508 flagellum-specific ATP synthase 
Cj0433c  1.507 phospho-N-acetylmuramoyl-pentapeptide- transferase 
Cj1436c  1.48 Aminotransferase 
Cj1718c  1.461 3-isopropylmalate dehydrogenase 
Cj0928 1.459 putative integral membrane protein (dedA family) 
Cj1241 1.443 
putative MFS (Major Facilitator Superfamily) transporter 
protein 
Cj0343c  1.439 putative integral membrane protein 
Cj0112 1.43 putative TolB precursor protein 
Cj0689 1.427 acetate kinase 
C0j606 1.415 putative secretion protein HlyD 
Cj0693c  1.411 S-adenosyl-methyltransferase 
Cj0853c  1.403 glutamate-1-semialdehyde 2,1-aminomutase 
Cj0056c  1.4 hypothetical protein Cj0056c 
Cj0474 1.397 50S ribosomal protein L11 
Cj0372 1.373 putative glutathionylspermidine synthase 
Cj0345 1.359 putative anthranilate synthase component I 
Cj1426c  1.35 putative methyltransferase family protein 
Cj0574 1.348 acetolactate synthase large subunit 
Cj0335 1.347 flagella biosynthetic protein 
Cj0899c  1.313 
4-methyl-5(beta-hydroxyethyl)-thiazole monophosphate 
synthesis protein 
Cj1568c  1.294 NADH dehydrogenase I chain L 
Cj0320 1.273 putative flagella assembly protein 
Cj1695c  1.273 50S ribosomal protein L5 
Cj0541 1.269 polyprenyl synthetase 
Cj1290c  1.249 biotin carboxylase 
Cj0434 1.232 
2,3-bisphosphoglycerate-independent phosphoglycerate 
mutase 
Cj0860 1.225 probable integral membrane protein 
Cj0069 1.173 hypothetical protein Cj0069 
Cj1625c  1.109 amino acid transporter 
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Appendix 9 – Genes down-regulated in the Cj1556 mutant when compared to 
11168H wild-type strain using RNA from late-log phase of growth 
 
Gene ID 
Fold 
Change 
Product Function 
Cj0461c  1.167 putative MFS (Major Facilitator Superfamily) transport protein 
Cj1690c  1.287 30S ribosomal protein S5 
Cj1273c  1.362 putative DNA-directed RNA polymerase omega chain 
Cj1311 1.364 putative acylneuraminate cytidylyltransferase 
Cj0264c  1.374 molybdopterin-containing oxidoreductase 
Cj0424 1.385 putative acidic periplasmic protein 
Cj1254 1.468 hypothetical protein Cj1254 
Cj0653c  1.541 putative aminopeptidase 
Cj0529c  1.546 putative aminodeoxychorismate lyase family protein 
Cj1053c  1.715 putative integral membrane protein 
Cj1677 1.869 putative lipoprotein (Homopolymeric tract) 
Cj0830 1.89 putative integral membrane protein 
Cj0265c  2.053 putative cytochrome C-type haem-binding periplasmic protein 
Cj0661c  2.268 GTP-binding protein Era homologue 
Cj0623 2.347 hydrogenase isoenzymes formation protein 
Cj0175c  2.387 
putative iron-uptake ABC transport system periplasmic iron-
binding protein 
Cj0564 2.545 putative integral membrane protein 
Cj1086c  4.695 hypothetical protein Cj1086c 
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Appendix 10 – Promoter search results 
 
300 nucleotides upstream and 50 nucleotides of Cj1556 
tttagagctattgcgtacaaaacatactggctctaaatttctttttaaagcttctttgctgatttctttgcctactttaccgcttgcacataa
aattgctattttcataatatctcctttttaagtatttttacataaaaaatgcaatctagaaattataaatatatttactactaaaaatcaagta
gatattattttataatatagtatctattttaggagtattatgttattttagtattttaatgagataaatttttttaaaaaatatgttataattttaaa
aaataaggatttataatgaaaaaatatcattctctttgtcctattgaaaccacgcttaatttgat 
 
> test sequence                                                                  
 Length of sequence - 350 
 Threshold for promoters - 0.20 
 Number of predicted promoters - 1 
 Promoter Pos:    309 LDF- 9.08 
 -10 box at pos.    294 atttataat Score    81 
 -35 box at pos.    273 ttataa    Score    24 
 
 Oligonucleotides from known TF binding sites: 
 
 For promoter at    309: 
        lrp:  ATTTTTTT at position     255 Score -  11 
       lexA:  TTTTTTTA at position     256 Score -  16 
     rpoD17:  TGTTATAA at position     271 Score -  12 
       argR:  TTATAATT at position     273 Score -  14 
        fis:  AAAAATAA at position     284 Score -   9 
     rpoD17:  TTTATAAT at position     295 Score -   9 
 
 
300 nucleotides upstream and 50 nucleotides of ctb (Cj0465c) 
agcaggcatttctgctataaaatttggaggattaaaataatgcaaagtaatttctttatcacttgctgtacttttataaatgcgtatttttc
ccttgagtaaaataaaaaaatttttagcctcttcgccttcataaaataaaatactatttttttgaaatttttttaattttcctacactagataa
aagttctaaataatctttcattatataatatttccattcttaacttatgttaaatttaatttatcttatttttgctatattaacgccataaaattaa
catttaagaaaggcttatatgaaatttgaaacaattaatcaagaaagcatagcaaaactcatggaaat 
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> test sequence                                                                  
 Length of sequence - 351 
 Threshold for promoters - 0.20 
 Number of predicted promoters - 1 
 Promoter Pos:    155 LDF- 11.68 
 -10 box at pos.    136 aaataaaat Score    56 
 -35 box at pos.    117 tagcct    Score    19 
 
 Oligonucleotides from known TF binding sites: 
 
 For promoter at    155: 
     rpoD17:  GAGTAAAA at position      97 Score -   8 
        ihf:  AAATAAAA at position     102 Score -  13 
       arcA:  AATAAAAA at position     103 Score -  12 
       phoB:  TCATAAAA at position     131 Score -  11 
        ihf:  AAATAAAA at position     136 Score -  13 
        ihf:  AATAAAAT at position     137 Score -  10 
        lrp:  TATTTTTT at position     147 Score -  11 
        lrp:  ATTTTTTT at position     148 Score -  11 
        fnr:  TTTTTTGA at position     150 Score -   9 
        lrp:  ATTTTTTT at position     159 Score -  11 
       lexA:  TTTTTTTA at position     160 Score -  16 
       nagC:  TTTAATTT at position     164 Score -   7 
     rpoD18:  TTAATTTT at position     165 Score -   9 
 
 
300 nucleotides upstream and 50 nucleotides of katA (Cj1385) 
aaggaatcggcttgcgattaactctattttcattacgtgcatcccagtgttctatttttttagcacctaaatcatgtaaaacagctctaat
aggagtgatttcatctgcaccaataaccaaaactgacataaattctcctttgtgatttttaaaatatattttgataattattattataatata
aaaaaactaaatttattttgaaatttattatcaataaaatgcaattattcagttaattttaatttttaatagatataatttactaattaataaaa
tttattatttaggagaaaacaatgaaaaaattgactaacgattttggaaacattatagctgataaccaaaat 
 
> test sequence                                                                  
 Length of sequence - 351 
 Threshold for promoters - 0.20 
 Number of predicted promoters - 1 
 Promoter Pos:    270 LDF - 7.57 
 -10 box at pos.    255 agatataat Score    77 
 -35 box at pos.    237 ttaatt    Score    30 
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Oligonucleotides from known TF binding sites: 
 
 For promoter at    270: 
        fnr:  ATCAATAA at position     214 Score -   5 
        ihf:  AATAAAAT at position     217 Score -  10 
     rpoD18:  TTAATTTT at position     237 Score -   9 
       nagC:  TTTAATTT at position     242 Score -   7 
     rpoD18:  TTAATTTT at position     243 Score -   9 
       argR:  AATTAATA at position     269 Score -  11 
        ihf:  AATAAAAT at position     273 Score -  10 
        lrp:  ATTTATTA at position     279 Score -   6 
 
 
300 nucleotides upstream and 50 nucleotides of perR (Cj0322) 
gtaaaatttggtttatttttagtgaaaatgttaaaattggcggtatagaaagtttaattaataattttttacaaaaatatgatttgcatgtaa
aagttgttagctttgaatatgaagacaaatttattgaacatggaaaaacaagtgaggtggaaaaaaatctagaaaaagatgtcaat
agtttgttgacgaaagttttaaaattttatcattaaataataaaaaatattatttaatataaacttcttttaatgaaaattttattattatttttac
ttaaaaaagcaaggaataaataaaatggaattactacaaatgcttaaaaaacatgagttaaaagctactccgcaa 
 
> test sequence                                                                  
 Length of sequence - 351 
 Threshold for promoters - 0.20 
 Number of predicted promoters - 1 
 Promoter Pos:    309 LDF - 7.95 
 -10 box at pos.    294 aaataaaat Score    56 
 -35 box at pos.    272 tttact    Score    42 
 
 Oligonucleotides from known TF binding sites: 
 
 For promoter at    309: 
       deoR:  AATTTTAT at position     257 Score -   8 
     rpoD17:  TTTTACTT at position     271 Score -   8 
     rpoD19:  TACTTAAA at position     274 Score -   8 
     rpoD17:  AATAAATA at position     291 Score -  11 
       lexA:  ATAAATAA at position     292 Score -  14 
       tyrR:  TAAATAAA at position     293 Score -  10 
        ihf:  AAATAAAA at position     294 Score -  13 
        ihf:  AATAAAAT at position     295 Score -  10 
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300 nucleotides upstream and 50 nucleotides of hspR (Cj1230) 
agagaagatgatgatttatatcaaaaggttgatatttctttaaaaactgcactttttggtggaaaaataaatataaaaacactcaaaga
aggcaaggaagaagcaataattaacataacgcctaattcaaaaaataaccaaaaaattcgtttaaaaggctatggtgtgcaaaat
agaaaaagtgatatttatggggatatgtatttgattttaaatgttgttttgccaaatttagatacccttgatgaaaaatttatagaactctt
aaaagaaaaattaccttaaagaaaggaataaaatatggaacagcattatgatgaacctgtatatttaatcagtgttgtggctaaa 
 
> test sequence                                                                  
 Length of sequence - 351 
 Threshold for promoters - 0.20 
 Number of predicted promoters - 1 
 Promoter Pos:     75 LDF - 6.69 
 -10 box at pos.     60 tggaaaaat Score    51 
 -35 box at pos.     39 tttaaa    Score    41 
 
 Oligonucleotides from known TF binding sites: 
 
 For promoter at     75: 
       carP:  CACTTTTT at position      50 Score -   8 
        fis:  AAAAATAA at position      63 Score -   9 
     rpoD17:  AATAAATA at position      66 Score -  11 
        fnr:  ATAAATAT at position      67 Score -   9 
       lexA:  ATATAAAA at position      71 Score -  11 
       lexA:  TAAAAACA at position      74 Score -   7 
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Appendix 11 – Genes up-regulated in the Cj0248 mutant when compared to 11168H 
wild-type strain using RNA from late-log phase of growth 
 
Gene 
ID 
Fold 
Change 
Product Function 
Cj0795c  2.557 UDP-N-acetylmuramoyl-tripeptide D-alanyl-D-alanine ligase 
Cj0848c 2.427 hypothetical protein Cj0848c 
Cj0523 2.41 putative membrane protein 
Cj1131c 2.244 UDP-GlcNAc/Glc 4-epimerase 
Cj0660c 2.237 putative transmembrane protein 
Cj0485 2.054 putative oxidoreductase 
Cj0998c 2.041 putative periplasmic protein 
Cj0816 1.911 hypothetical protein Cj0816 
Cj1718c 1.885 3-isopropylmalate dehydrogenase 
Cj0836 1.866 methylated-DNA--protein-cysteine methyltransferase 
Cj1588c 1.864 putative MFS (Major Facilitator Superfamily) transport protein 
Cj1125c 1.86 GalNAc transferase 
Cj1168c 1.848 putative integral membrane protein (dedA homologue) 
Cj0882c 1.812 flagella biosynthesis protein 
Cj1668c 1.81 putative periplasmic protein 
Cj0823 1.781 hypothetical protein Cj0823 
Cj0500 1.778 putative rhodanese-like domain protein 
Cj0280 1.769 hypothetical protein Cj0280 
Cj1215 1.76 putative peptidase M23 family protein 
Cj1016c 1.754 
branched-chain amino-acid ABC transport system permease 
protein 
Cj1210 1.734 putative integral membrane protein 
Cj0174c 1.729 putative iron-uptake ABC transport system permease protein 
Cj1340c 1.728 hypothetical protein Cj1340c (1318 family) 
Cj1566c 1.69 NADH dehydrogenase I chain N 
Cj1551c 1.689 putative type I restriction enzyme S protein 
Cj1284 1.681 putative K+ uptake protein 
Cj1615 1.673 putative haemin uptake system permease protein 
Cj0535 1.662 OORD subunit of 2-oxoglutarate:acceptor oxidoreductase 
Cj0850c 1.654 putative MFS (Major Facilitator Superfamily) transport protein 
Cj1596 1.654 50S ribosomal protein L17 
Cj1618c 1.654 putative radical SAM domain protein 
Cj1040c 1.652 putative MFS (Major Facilitator Superfamily) transport protein 
Cj1582c 1.642 putative peptide ABC-transport system permease protein 
Cj1163c 1.625 putative cation transport protein 
Cj1089c 1.618 hypothetical protein Cj1089c 
Cj0661c 1.617 GTP-binding protein ERA homologue 
Cj1098 1.614 aspartate carbamoyltransferase 
Cj1555c 1.611 hypothetical protein Cj1555c 
Cj0693c 1.611 S-adenosyl-methyltransferase 
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Cj1091c 1.611 leucyl-tRNA synthetase 
Cj1039 1.606 
putative undecaprenyldiphospho-muramoylpentapeptide b-N-
acetylglucosaminyltransferase 
Cj0590 1.604 putative SAM-dependent methyltransferase 
Cj0821 1.598 UDP-N-acetylglucosamine pyrophosphorylase 
Cj0345 1.594 putative anthranilate synthase component I 
Cj1653c 1.59 probable lipoprotein 
Cj0690c 1.583 possible restriction /modification enzyme 
Cj0179 1.576 biopolymer transport protein 
Cj1253 1.567 polyribonucleotide nucleotidyltransferase 
Cj0984 1.562 hypothetical protein Cj0984 
Cj0308c 1.554 putative dethiobiotin synthetase 
Cj0524 1.551 hypothetical protein Cj0524 
Cj1547 1.55 homologue of BLC protein 
Cj0742 1.541 pseudogene (putative outer membrane protein) 
Cj0305c 1.539 hypothetical protein Cj0305c 
Cj1066 1.539 Nitroreductase 
Cj1442c 1.538 putative sugar transferase 
Cj0091 1.534 putative lipoprotein 
Cj1092c 1.529 protein-export membrane protein 
Cj0437 1.525 succinate dehydrogenase flavoprotein subunit 
Cj1661 1.524 possible ABC transport system permease protein 
Cj0790 1.51 formyltetrahydrofolate deformylase 
Cj1614 1.501 haemin uptake system outer membrane receptor 
Cj0433c 1.493 phospho-N-acetylmuramoyl-pentapeptide- transferase 
Cj1252 1.488 putative periplasmic protein 
Cj1228c 1.486 serine protease (protease DO) 
Cj1601 1.486 
phosphoribosylformimino-5-aminoimidazole carboxamide 
ribotide isomerise 
Cj0646 1.482 putative lipoprotein 
Cj1655c 1.481 Na(+)/H(+) antiporters 
Cj1622 1.479 riboflavin-specific deaminase/reductase 
Cj0947c 1.477 putative carbon-nitrogen hydrolase 
Cj1055c 1.477 putative sulfatase family protein 
Cj1612 1.474 peptide chain release factor 1 
Cj0540 1.467 putative exporting protein 
Cj0861c 1.465 
para-aminobenzoate synthase glutamine amidotransferase 
component II 
Cj0822 1.46 phosphopantothenoylcysteine decarboxylase 
Cj0860 1.451 probable integral membrane protein 
Cj0259 1.437 Dihydroorotase 
Cj0928 1.434 putative integral membrane protein (dedA family) 
Cj0139 1.433 putative endonuclease 
Cj1568c 1.432 NADH dehydrogenase I chain L 
Cj0650 1.432 putative ATP /GTP binding protein 
Cj1200 1.432 putative NLPA family lipoprotein 
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Cj0571 1.427 putative transcriptional regulator 
Cj1093c 1.427 protein-export membrane protein 
Cj1217c 1.421 hypothetical protein Cj1217c 
Cj1453c 1.42 putative tRNA(Ile)-lysidine synthase 
Cj1647 1.418 putative ABC transport system ATP-binding protein 
Cj0866 1.415 pseudogene (arylsulfatase) 
Cj1019c 1.407 
branched-chain amino-acid ABC transport system periplasmic 
binding protein 
Cj0643 1.405 two-component response regulator 
Cj1102 1.405 tRNA pseudouridine synthase B 
Cj0294 1.4 putative MoeB/ThiF family protein 
Cj1137c 1.4 putative glycosyltransferase 
Cj0935c 1.397 putative sodium:amino-acid symporter family protein 
Cj0727 1.397 putative periplasmic solute-binding protein 
Cj0068 1.384 Protease 
Cj1666c 1.383 putative periplasmic protein 
Cj0541 1.376 polyprenyl synthetase 
Cj0338c 1.371 DNA polymerase I 
Cj1319 1.369 putative nucleotide sugar dehydratase 
Cj0075c 1.354 putative oxidoreductase iron-sulfur subunit 
Cj1447c 1.347 capsule polysaccharide export ATP-binding protein 
Cj0491 1.346 30S ribosomal protein S12 
Cj1529c 1.341 phosphoribosylformylglycinamidine cyclo-ligase 
Cj0495 1.338 putative methyltransferase domain protein 
Cj0499 1.331 putative histidine triad (HIT) family protein 
Cj0079c 1.321 cytolethal distending toxin A 
Cj1689c 1.312 50S ribosomal protein L15 
Cj1504c 1.308 putative selenide,water dikinase 
Cj0057 1.302 putative periplasmic protein 
Cj1193c 1.297 putative periplasmic protein 
Cj1422c 1.288 possible sugar transferase 
Cj1320 1.278 putative aminotransferase (degT family) 
Cj0515 1.276 putative periplasmic protein 
Cj0606 1.264 putative secretion protein HlyD 
Cj1185c 1.251 putative ubiquinol-cytochrome C reductase cytochrome B subunit 
Cj0093 1.251 putative periplasmic protein 
Cj1418c 1.166 putative transferase 
Cj0695 1.163 cell division protein ftsA 
Cj1498c 1.163 adenylosuccinate synthetase 
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Appendix 12 – Genes down-regulated in the Cj0248 mutant when compared to 
11168H wild-type strain using RNA from late-log phase of growth 
 
Gene ID 
Fold 
Change 
Product Function 
Cj0396c 1.238 putative lipoprotein 
Cj0363c 1.25 putative oxygen-independent coproporphyrinogen III oxidase 
Cj1401c 1.302 putative triosephosphate isomerase 
Cj0842 1.321 putative lipoprotein 
Cj1175c 1.35 arginyl-tRNA synthetase 
Cj0689 1.399 acetate kinase 
Cj1277c 1.41 putative ABC transporter ATP-binding protein 
Cj1444c 1.412 capsule polysaccharide export system periplasmic protein 
Cj1297 1.418 hypotehtical protein Cj1297 
Cj0952c 1.449 putative HAMP containing membrane protein 
Cj1433c 1.456 hypothetical protein Cj1433c 
Cj1288c 1.464 glutamyl-tRNA synthetase 
Cj1235 1.473 putative peptidase M23 family protein 
Cj0237 1.477 carbonic anyhydrase 
Cj0467 1.477 amino-acid ABC transporter integral membrane protein 
Cj0992c 1.493 oxygen-independent coproporphyrinogen III oxidase 
Cj0314 1.506 diaminopimelate decarboxylase 
Cj0066c 1.511 3-dehydroquinate dehydratase 
Cj0281c 1.517 putative transaldolase 
Cj0895c 1.527 3-phosphoshikimate 1-carboxyvinyltransferase 
Cj0527c 1.555 flagella basal-body rod protein 
Cj0315 1.592 putative HAD-superfamily hydrolase, subfamily IIA 
Cj0285c 1.61 chemotaxis protein 
Cj0327 1.639 putative endoribonuclease L-PSP family protein 
Cj0261c 1.653 putative SAM-dependent methyltransferase 
Cj1451 1.706 dUTPase 
Cj0840c 1.733 fructose-1,6-bisphosphatase 
Cj0284c 1.742 chemotaxis histidine kinase 
Cj1315c 1.767 imidazole glycerol phosphate synthase subunit 
Cj0286c 1.799 hypothetical protein Cj0286c 
Cj0462 1.838 putative radical SAM domain protein 
Cj0529c 1.953 putative aminodeoxychorismate lyase family protein 
Cj1514c 1.957 hypothetical protein Cj1514c 
Cj0854c 1.976 putative periplasmic protein 
Cj0056c 2.004 hypothetical protein Cj0056c 
Cj0922c 2.024 ABC-type amino-acid transporter ATP-binding protein 
Cj0539 2.07 hypothetical protein Cj0539 
Cj0575 2.141 acetolactate synthase small subunit 
Cj1359 2.183 polyphosphate kinase 
Cj0758 2.364 heat shock protein grpE 
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Cj1156 2.433 transcription termination factor 
Cj0874c 2.451 putative cytochrome C 
Cj0757 2.632 putative heat shock regulator 
Cj1445c 2.674 capsule polysaccharide export system inner membrane protein 
Cj0102 2.74 ATP synthase F0 sector B' subunit 
Cj0233c 2.762 putative orotate phosphoribosyltransferase 
Cj0859c 2.924 hypothetical protein Cj0859c 
Cj0977 3.106 hypothetical protein Cj0977 
Cj0981c 3.185 
putative MFS (Major Facilitator Superfamily) transport 
protein 
Cj1656c 3.497 hypothetical protein Cj1656c 
Cj1639 3.559 nifU protein homologue 
Cj0994c 4.255 ornithine carbamoyltransferase 
Cj0528c 4.484 flagella basal-body rod protein 
Cj1465 4.854 hypothetical protein Cj1465 
Cj0368c 5.155 transcriptional regulator CmeR 
Cj0449c 5.556 hypothetical protein Cj0449c 
Cj0370 7.353 30S ribosomal protein S21 
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